学术周报 · IF≥10 或专科旗舰刊

神经内科领域文献阅读汇编

2026年第45周 (2026-11-06) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
收录论文
212
临床研究
114
基础研究
98
IF≥20
25
IF 10-20
147
子领域
41
期刊种类
60
数据日期
2026-11-06

★本周 Top 10 高影响力文献

#论文期刊IF
1Epilepsy: epidemiology, risk factors, classification, pathophysiology, clinical features, diagnosis ...Signal transduction and targeted therapyIF 81.2
2Discontinuation of renin-angiotensin system inhibitors before non-cardiac surgery: a meta-analysis.European heart journalIF 45.3
3Obesity, frail obesity, and outcomes after durable left ventricular assist device implantation: a po...European heart journalIF 45.3
4Impact of Undertreated Antithrombotic Therapy on Adverse Patient Outcomes: A Scientific Statement Fr...CirculationIF 41.3
5Macrotroponin Complexes and Risk of Cardiovascular Events.CirculationIF 41.3
6Transcatheter Aortic Valve Replacement in Pure Aortic Regurgitation: The Randomized SEASON-AR Clinic...CirculationIF 41.3
7PRDM9 Deficiency Drives Mosaic Promoter Deletions in Sporadic Hirschsprung Disease and Supports Bloo...GastroenterologyIF 29.7
8Integration and annotation of spatial multi-omic data with DIRAC.Nature methodsIF 28.3
9Non-invasive oral magnetoelectric vagus nerve neuromodulation for Parkinson's disease therapy.Nature biomedical engineeringIF 26.3
10Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women With Vasomotor Symptoms.JAMA internal medicineIF 26.3

Ŧ期刊分布统计

期刊篇数IF
Stroke28IF 11.1
Ageing research reviews21IF 15.5
Neurology(R) neuroimmunology & neuroinflammation20IF 0.0
Annals of neurology14IF 7.5
Pharmacological research12IF 12.2
Molecular psychiatry12IF 10.4
Redox biology8IF 16.2
Science advances5IF 13.9
Autophagy5IF 18.6
Nature neuroscience5IF 20.3

1痴呆与认知障碍 (55篇)

临床研究 (23篇)

Science advances IF 13.9 2026-11-06 PMID: 42981415
Identifying the neurobiological basis of cognitive vulnerability is essential for preventing Alzheimer's disease (AD). We derived the Alzheimer's Resilience-Vulnerability Connectome (ARC) by contrasting SuperAgers (SA), an extreme phenotype of preserved late-life memory, with AD using resting-state fMRI. ARC distinguished SA from AD in a discovery cohort (N = 290; AUC = 0.85) and replicated independently (N = 143), involving prefrontal, temporal, and insular networks and associating with brain age. Applied to cognitively unimpaired adults (discovery: N = 818; replication: N = 497), ARC-based subtyping revealed SA-like and AD-like subgroups with comparable baseline cognition but divergent longitudinal trajectories. AD-like individuals exhibited faster cognitive decline, greater amyloid-β accumulation, and higher AD conversion risk. Exploratory GWAS nominated CLYBL and FRMD6 as candidate novel loci associated with the subtype difference. These findings suggest that ARC captures a continuous connectomic dimension of cognitive aging spanning SA, cognitively typical aging, and AD, highlighting the potential of functional connectomic variation for early risk stratification in AD.
中文摘要:识别认知脆弱性的神经生物学基础对预防阿尔茨海默病(AD)至关重要。我们利用静息态fMRI,通过对比超级老化者(SuperAgers,SA;晚年记忆保持的极端表型)与AD患者,构建了阿尔茨海默病韧性-脆弱性连接组(ARC)。ARC在发现队列(N=290;AUC=0.85)中区分SA与AD,并在独立队列(N=143)中重复验证,涉及前额叶、颞叶和岛叶网络,并与脑龄相关。将ARC应用于认知未受损成人(发现队列N=818;重复队列N=497),基于ARC的亚型划分显示SA样和AD样亚组,其基线认知相当但纵向轨迹不同。AD样个体表现出更快的认知下降、更大的β-淀粉样蛋白积累和更高的AD转化风险。探索性GWAS提名CLYBL和FRMD6为与亚型差异相关的新候选位点。这些发现提示ARC捕捉了跨越SA、认知正常衰老和AD的连续连接组维度,凸显功能连接组变异在AD早期风险分层中的潜力。
Science translational medicine IF 15.6 2026-11-04 PMID: 42981430
Early-onset Alzheimer's disease (EOAD) and late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau positron emission tomography (PET) burden measured with 18F-flortaucipir and its relationship with clinical variables in amyloid PET-positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer's Disease Study (EOAD; n = 390) and Alzheimer's Disease Neuroimaging Initiative (LOAD; n = 211). Participants with EOAD showed higher baseline tau PET burden, broader neuroanatomical involvement, and stronger associations of tau PET with amyloid PET and global cognition. Higher baseline tau PET burden in EOAD was independently validated in participants with EOAD from ADNI. Longitudinally, tau PET increased more rapidly in EOAD than in LOAD, independent of amyloid PET and clinical stage. We conclude that earlier age of onset in AD is linked to a more aggressive tauopathy, which in turn is a primary driver of clinical decline.
中文摘要:早发性阿尔茨海默病(EOAD)与晚发性AD(LOAD)在临床表现和进展速度上不同。研究比较了来自Longitudinal Early-Onset Alzheimer's Disease Study的 amyloid PET 阳性且认知受损的EOAD参与者(n=390)与来自Alzheimer's Disease Neuroimaging Initiative的LOAD参与者(n=211)中,18F-flortaucipir测量的基线及纵向tau PET负荷,并分析其与临床变量的关系。EOAD参与者基线tau PET负荷更高、神经解剖受累范围更广,tau PET与amyloid PET及整体认知的关联更强。EOAD中较高的基线tau PET负荷在ADNI的EOAD参与者中得到独立验证。纵向来看,EOAD的tau PET增长快于LOAD,且独立于amyloid PET和临床分期。结论是,AD发病年龄越早与更具侵袭性的tau病理相关,而后者是临床衰退的主要驱动因素。
Nature communications IF 18.1 2026-11-03 PMID: 42977753
An age-related neurovascular impairment in nitric oxide (NO)-mediated vasodilation and reciprocal Piezo1-dependent vascular vasoconstriction may precede the accumulation of soluble brain proteins such as amyloid-β (Aβ) and disruption of brain fluid homeostasis in Alzheimer's disease (AD). Preclinical studies suggest that restoring these pathways can enhance neurofluid transport and improve cognitive outcomes. In this study (EudraCT 2021-000625-27), we investigated the effects of sublingual NO and Piezo1-targeted whole-body vibrations (WBVp) in healthy adults (n = 29) using multimodal neuroimaging and blood biomarker analysis. The combined intervention (NO+WBVp) was associated with correlating changes in brain fluid dynamics and increased blood levels of soluble brain-derived proteins (Aβ40&42, GFAP). These effects increased with age and the magnitude of NO-induced hypotension. The interventions were well tolerated under controlled experimental conditions. Overall, the findings are consistent with transient redistribution of brain-derived proteins toward circulation, suggesting a potential non-invasive approach to increase neurofluidic solute efflux in humans. Pre-specified primary endpoints, changes in circulating brain-derived protein concentrations, brain fluid imaging and brain pulsation measures, were met. Secondary outcomes included physiological analyses.
中文摘要:与年龄相关的神经血管损害涉及一氧化氮(NO)介导的血管舒张及与之对应的Piezo1依赖血管收缩功能受损,可能先于阿尔茨海默病(AD)中可溶性脑蛋白如淀粉样β(Aβ)的积聚和脑液体稳态破坏。临床前研究提示,恢复这些通路可增强神经液体转运并改善认知结局。该试验(EudraCT 2021-000625-27)在健康成人(n=29)中采用多模态神经影像和血液生物标志物分析,考察舌下NO与靶向Piezo1的全身振动(WBVp)的作用。联合干预(NO+WBVp)与脑液动力学的相关变化以及血液中可溶性脑源性蛋白(Aβ40和Aβ42、GFAP)水平升高相关。这些效应随年龄和NO诱导的低血压幅度增加而增强。在受控实验条件下,干预耐受良好。这些发现与脑源性蛋白向循环的短暂再分布一致,提示一种潜在的非侵入性方法可增加人体神经液体溶质外排。预设主要终点——循环脑源性蛋白浓度变化、脑液成像和脑搏动指标——均已达到。次要结局包括生理学分析。
JAMA network open IF 11.7 2026-11-02 PMID: 42970288
Older adults with dementia often need nursing home care after hospitalization. To examine whether Black and Hispanic patients have different access to Alzheimer disease special care units (ASCUs) after hospital discharge compared with White patients. This was a retrospective cohort study of 100% Medicare fee-for-service claims from January 2018 to February 2020. Participants were Medicare beneficiaries with a prior diagnosis of dementia who were hospitalized or admitted to nursing homes from January 2018 to August 2019. Data analyses were performed from January to July 2026. The race and ethnicity of a patient. The primary outcome was long-term care admission to a nursing home with an ASCU. An unadjusted logistic regression, an unadjusted 2-level (patient-hospital) model, and a multivariable 2-level model were conducted to assess racial and ethnic differences in long-term care admission to a facility with an ASCU and whether patient and hospital characteristics could explain the differences. Of the 1 428 849 patients, 130 125 (9.11%) were Black, 77 868 (5.45%) were Hispanic, 1 164 829 (81.52%) were non-Hispanic White, 56 027 (3.92%) were of other races (American Indian or Alaska Native, Asian, and Native Hawaiian or Other Pacific Islander), 839 328 (58.74%) were female, and 1 075 171 (75.25%) were aged 75 years or older. A total of 122 654 patients (8.58%) became long-term care residents within 6 months of hospital discharge, and 19 313 patients (1.35%) were admitted to facilities with an ASCU. In the unadjusted logistic model, Black (relative risk [RR], 0.69; 95% CI, 0.65-0.73) and Hispanic (RR, 0.48; 95% CI, 0.44-0.53) patients had lower probabilities of long-term care admission in a facility with ASCU than White patients. After controlling for the clustering of patients in a hospital, the RR substantially increased to 0.94 (95% CI, 0.88-0.99) for Black patients and 0.78 (95% CI, 0.71-0.85) for Hispanic patients. Further controlling for patient and hospital characteristics slightly reduced these RRs. Disparities for Black patients (RR, 0.89; 95% CI, 0.84-0.95), but not Hispanic patients (RR, 0.93; 95% CI, 0.84-1.02), were also observed in the subcohort of Medicare beneficiaries who became long-term care residents. The findings of this cohort study suggest that disparities in access to specialized dementia care occur mostly because patients from minoritized racial and ethnic groups are treated at hospitals with low rates of discharge to ASCUs. Efforts to improve dementia care access should focus on enhancing hospital discharge planning and addressing the extra barriers faced by female patients.
中文摘要:痴呆老年人住院后常需入住养老机构照护。本研究考察黑人及西班牙裔患者在出院后进入阿尔茨海默病特殊照护单元(ASCU)的机会是否不同于白人患者。研究为回顾性队列研究,使用2018年1月至2020年2月100%医疗保险按服务付费理赔数据。研究对象为2018年1月至2019年8月期间住院或入住养老机构、且既往已诊断为痴呆的医疗保险受益人。数据分析于2026年1月至7月完成。暴露因素为患者的种族与族裔。主要结局为入住设有ASCU的养老机构接受长期照护。分析采用未校正logistic回归、未校正两水平(患者-医院)模型及多变量两水平模型,评估入住设有ASCU机构接受长期照护的种族与族裔差异,以及患者和医院特征能否解释这些差异。在1 428 849例患者中,黑人130 125例(9.11%),西班牙裔77 868例(5.45%),非西班牙裔白人1 164 829例(81.52%),其他种族(美洲印第安人或阿拉斯加原住民、亚裔、夏威夷原住民或其他太平洋岛民)56 027例(3.92%);女性839 328例(58.74%),75岁及以上1 075 171例(75.25%)。共122 654例(8.58%)在出院后6个月内成为长期照护居民,其中19 313例(1.35%)入住设有ASCU的机构。未校正logistic模型中,黑人(相对危险度[RR] 0.69,95% CI 0.65-0.73)与西班牙裔(RR 0.48,95% CI 0.44-0.53)患者入住设有ASCU机构接受长期照护的概率低于白人患者。控制患者在医院层面的聚集后,黑人患者RR升至0.94(95% CI 0.88-0.99),西班牙裔患者为0.78(95% CI 0.71-0.85)。进一步控制患者与医院特征后,上述RR略有下降。在已成为长期照护居民的医疗保险受益人子队列中,黑人患者仍存在差异(RR 0.89,95% CI 0.84-0.95),西班牙裔患者则未见差异(RR 0.93,95% CI 0.84-1.02)。该队列研究结果提示,获得专科痴呆照护的差异主要源于少数种族与族裔患者就诊于向ASCU转介率较低的医院。改善痴呆照护可及性的努力应着眼于加强医院出院规划,并解决女性患者面临的额外障碍。
JAMA neurology IF 23.6 2026-11-02 PMID: 42970282
Delirium is a state of acute confusion characterized by deficits in attention that occurs commonly during hospitalization and is associated with adverse outcomes; however, the association of delirium with longitudinal cognitive trajectories is not fully understood. To evaluate the association of delirium during hospitalization with subsequent development of mild cognitive impairment (MCI), dementia, and longitudinal cognitive trajectories. This cohort study used data from participants with hospitalizations in the Mayo Clinic Study of Aging (MCSA) from October 2004 to December 2023. The MCSA is a prospective, population-based longitudinal study of cognitive aging among residents of Olmsted County, Minnesota. Of participants enrolled in the MCSA between 2004 and 2023, individuals who experienced 1 or more hospitalization prior to their last MCSA encounter were included in this study. Participants with dementia at MCSA enrollment or prior to first hospitalization were excluded. Follow-up continued until development of MCI or dementia, last MCSA visit, or the end of the study. Delirium was identified using a validated natural language processing algorithm applied to clinical notes from hospitalizations, associated emergency department visits, and follow-up within 30 days after hospitalization. Delirium status was modeled as a time-dependent exposure. Incident MCI and dementia were assigned through MCSA expert consensus evaluations, including neuropsychological testing performed every 15 months. Association between delirium and development of MCI or dementia was assessed using Cox proportional hazards regression, adjusted for patient age, sex, level of education, and apolipoprotein E (APOE) ε4 allele carrier status; cognitive trajectories were assessed with linear mixed-effects models. Of 7030 participants enrolled in the MCSA, 3542 individuals experienced 1 or more hospitalization prior to their last MCSA encounter and were included, and 41 participants with dementia at enrollment or prior to first hospitalization were excluded. The cohort included 3501 participants with at least 1 hospitalization. Median (IQR) age was 74.1 (66.6-80.9) years, 1676 participants (47.9%) were female, median (IQR) level of education was 14 (12-16) years, and 910 participants (26.0%) were APOE ε4 carriers. During a median (IQR) follow-up of 7.2 (4.1-10.4) years, 75 participants (2.1%) had delirium documented within 30 days of hospitalization. Delirium was associated with increased risk of MCI (adjusted hazard ratio [aHR], 3.67; 95% CI, 2.19-6.15) and dementia (aHR, 5.39; 95% CI, 2.94-9.85) and with accelerated decline in longitudinal cognitive testing. In this cohort study among adults in the MCSA, including those with unimpaired cognition at baseline, delirium during hospitalization was strongly associated with increased risk of MCI and dementia and accelerated cognitive decline in subsequent years.
中文摘要:谵妄是急性意识混乱状态,以注意缺陷为特征,常发生于住院期间,并与不良结局相关;但谵妄与纵向认知轨迹的关系尚未完全明确。评估住院期间谵妄与随后发生轻度认知障碍(MCI)、痴呆及纵向认知轨迹的关系。该队列研究使用2004年10月至2023年12月在Mayo Clinic老化研究(MCSA)中住院参与者的数据。MCSA是一项前瞻性、基于人群的纵向认知老化研究,对象为明尼苏达州Olmsted县居民。2004至2023年纳入MCSA的参与者中,最后一次MCSA访视前有1次或以上住院者纳入本研究。MCSA入组时或首次住院前已患痴呆者排除。随访持续至发生MCI或痴呆、最后一次MCSA访视或研究结束。谵妄通过经验证的自然语言处理算法识别,该算法应用于住院、相关急诊就诊及住院后30天内随访的临床记录。谵妄状态按时间依赖暴露建模。新发MCI和痴呆由MCSA专家共识评估判定,包括每15个月进行的神经心理测试。采用Cox比例风险回归评估谵妄与MCI或痴呆发生的关系,校正年龄、性别、教育水平及载脂蛋白E(APOE)ε4等位基因携带状态;认知轨迹采用线性混合效应模型评估。7030名MCSA入组参与者中,3542人在最后一次MCSA访视前有1次或以上住院并纳入,41人因入组时或首次住院前患痴呆被排除。队列包括3501名至少有1次住院的参与者。中位(IQR)年龄为74.1(66.6-80.9)岁,1676名参与者(47.9%)为女性,中位(IQR)教育年限为14(12-16)年,910名参与者(26.0%)为APOE ε4携带者。中位(IQR)随访7.2(4.1-10.4)年期间,75名参与者(2.1%)记录到住院后30天内谵妄。谵妄与MCI风险升高相关(校正风险比[aHR] 3.67;95% CI 2.19-6.15),与痴呆风险升高相关(aHR 5.39;95% CI 2.94-9.85),并与纵向认知测试加速下降相关。在这项MCSA成人队列研究中,包括基线认知未受损者,住院期间谵妄与随后数年MCI和痴呆风险升高及认知加速下降强相关。
EClinicalMedicine IF 12.8 2026-11 PMID: 42964515
Mild cognitive impairment (MCI) is a clinically heterogeneous syndrome that can represent an early manifestation of neurodegenerative disease. Diagnosis relies on assessments that are difficult to scale, leaving many individuals unidentified. In this cross-sectional study conducted in the United States, Australia, and Spain between May 2022 and October 2024, 638 adults aged ≥ 50 years were classified as cognitively unimpaired (CU; n = 441) or MCI (n = 197) using Petersen/NIA-AA criteria. Participants completed a self-administered, tablet-based assessment (Altoida NeuroMarker Platform) integrating motor, speech, and augmented reality tasks. An XGBoost classifier was trained to distinguish CU from MCI. Diagnostic performance, test-retest reliability, and convergent validity were evaluated. Median assessment time was 13.8 min. Participants reported comfort with digital technology (67%), willingness to engage in cognitive screening (90%), and positive usability. Altoida's NeuroMarker differentiated MCI with ROC-AUC 0.90, 95% CI 0.88-0.92 and comparable performance in an independent cohort (ROC-AUC 0.87, 95% CI 0.80-0.93; n = 75). Cognitive composite and domain scores were lower in MCI than in CU. Classifier agreement across repeated assessments was κ = 0.60, and reliability of composite and domain scores was moderate-to-good (ICC 0.55-0.80). The composite score correlated with the Mini-Mental State Examination (MMSE) (r s = 0.40, p < 0.001) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Index (r s = 0.58, p < 0.001). The platform also showed convergent validity of cognitive domains (|r s| = 0.27-0.50, p < 0.001). A brief, self-administered multimodal assessment identified clinically adjudicated MCI and demonstrated convergent validity, test-retest reliability, and consistent performance in an independent cohort. Prospective studies should evaluate its implementation in real-world workflows. Alzheimer's Drug Discovery Foundation; Altoida Inc.
中文摘要:轻度认知障碍(MCI)是一种临床异质性综合征,可为神经退行性疾病的早期表现。诊断依赖难以规模化开展的评估,导致许多个体未被识别。这项横断面研究在美国、澳大利亚和西班牙于2022年5月至2024年10月开展,638名≥50岁成人依据Petersen/NIA-AA标准被分类为认知正常(CU;n=441)或MCI(n=197)。参与者完成一项自填式平板评估(Altoida NeuroMarker平台),整合运动、言语和增强现实任务。训练XGBoost分类器区分CU与MCI,并评估诊断性能、重测信度和聚合效度。评估时间中位数为13.8分钟。参与者对数字技术感到适应(67%)、愿意参与认知筛查(90%),可用性评价积极。Altoida NeuroMarker区分MCI的ROC-AUC为0.90(95%CI 0.88-0.92),在独立队列中性能相当(ROC-AUC 0.87,95%CI 0.80-0.93;n=75)。MCI的认知复合评分和各域评分低于CU。重复评估间分类器一致性κ=0.60,复合评分与各域评分的信度为中等至良好(ICC 0.55-0.80)。复合评分与简易精神状态检查(MMSE)相关(rs=0.40,p<0.001),与重复性成套神经心理状态测验(RBANS)总分指数相关(rs=0.58,p<0.001)。平台还显示认知域的聚合效度(|rs|=0.27-0.50,p<0.001)。一项简短的自填式多模态评估可识别经临床判定的MCI,并显示聚合效度、重测信度以及在独立队列中的一致性能。前瞻性研究应评估其在真实工作流程中的实施。资助:Alzheimer's Drug Discovery Foundation;Altoida Inc。
Nature neuroscience IF 20.3 2026-11 PMID: 42823476
Aging and Alzheimer's disease (AD) are accompanied by alterations to large-scale communication patterns in the brain, which can be tracked in vivo using functional connectivity. The location, direction and relevance of these changes remain widely debated, although they are rarely studied in the context of whole-cortex communication dynamics. Here, in two independent cohorts (BioFINDER-2, N = 973; Alzheimer's Disease Neuroimaging Initiative, N = 129), we show that functional connectivity changes associated with aging and AD are strongly aligned with separate fundamental axes of hierarchical brain communication. Early accumulation of AD pathology and subsequent cognitive decline are both linked to functional change along the sensory-association axis. Meanwhile, age-related functional changes occur along the representation-executive axis consistently throughout the adult lifespan. These findings together suggest that both AD and aging alter major but orthogonal functional pathways in the brain. More broadly, our findings position whole-brain connectivity dynamics as a unifying framework for interpreting functional changes across the adult lifespan.
中文摘要:衰老与阿尔茨海默病(AD)伴随大脑大规模交流模式的改变,这种改变可通过功能连接在活体追踪。这些变化的位置、方向及意义仍广受争议,且很少在全皮层交流动态的背景下研究。研究者在两个独立队列(BioFINDER-2,N=973;阿尔茨海默病神经影像学计划,N=129)中发现,与衰老和AD相关的功能连接变化分别与层级性脑交流的不同基本轴高度一致。AD病理的早期累积及随后的认知下降均与沿感觉—联合轴的功能变化相关。年龄相关的功能变化则沿表征—执行轴在整个成年生命周期中稳定出现。这些结果提示,AD与衰老改变的是大脑中主要但相互正交的功能通路。这些发现将全脑连接动态定位为解释成年生命周期功能变化的统一框架。
Pharmacological research IF 12.2 2026-11 PMID: 42785536
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive dysfunction. Docosahexaenoic acid (DHA), the most abundant ω-3 polyunsaturated fatty acid (PUFA) in the brain, is essential for neuronal structure and function. Although epidemiological studies generally associate higher DHA intake or blood levels with better cognitive outcomes, clinical findings remain inconsistent, partly because DHA intake is closely linked to healthier dietary patterns and lifestyles. This review summarizes the role of DHA in AD from mechanistic, epidemiological, and clinical perspectives. We first discussed its effects on Aβ and tau pathology, synaptic function, neuroinflammation, oxidative stress, mitochondrial function, and brain lipid homeostasis. We then evaluate epidemiological and clinical evidence, with particular attention to factors contributing to heterogeneous responses, including disease stage, ApoE ε4 genotype, sex difference, intervention exposure, and participant characteristics. We propose that individuals with early and potentially modifiable pathology, together with sufficient cerebral DHA availability, may be more likely to benefit from DHA intervention. Finally, we discussed translational strategies, including combination interventions, brain-targeted delivery, and optimized clinical trial design. Overall, this review develops a conceptual framework linking brain lipid homeostasis, molecular mechanisms, clinical heterogeneity, and individualized intervention, providing a basis for understanding differential responses to DHA and improving its clinical translation.
中文摘要:阿尔茨海默病(AD)是一种以进行性认知功能障碍为特征的神经退行性疾病。DHA是脑内含量最高的ω-3多不饱和脂肪酸(PUFA),对神经元结构和功能必不可少。流行病学研究通常将较高的DHA摄入量或血液水平与更好的认知结局相联系,但临床研究结果并不一致,部分原因在于DHA摄入与更健康的饮食模式和生活方式密切相关。该综述从机制、流行病学和临床角度总结DHA在AD中的作用。先讨论DHA对Aβ和tau病理、突触功能、神经炎症、氧化应激、线粒体功能和脑脂质稳态的影响,随后评估流行病学和临床证据,重点关注导致反应异质性的因素,包括疾病阶段、ApoE ε4基因型、性别差异、干预暴露和受试者特征。文章提出,具有早期且可能可干预病理改变、同时脑内DHA可利用量充足的个体,更可能从DHA干预中获益。最后讨论转化策略,包括联合干预、脑靶向递送和优化临床试验设计。整体上,该综述构建了一个连接脑脂质稳态、分子机制、临床异质性和个体化干预的概念框架,为理解DHA反应差异和改进其临床转化提供基础。
Annals of neurology IF 7.5 2026-11 PMID: 42770547
Apolipoprotein E ε4 (APOE ε4), a robust genetic risk factor for Alzheimer's disease (AD) is associated with functional connectivity deficits and amyloid pathology in brain regions involved in sleep regulation. Thus, alterations in sleep architecture may be one pathway through which ε4 contributes to Alzheimer's disease vulnerability. However, sleep architecture characteristics associated with APOE ε4 remain poorly characterized. This cross-sectional study examined associations between APOE genotype and sleep architecture among adults aged 50-85 years enrolled in the Sleep Heart Health Study (N = 3,081). APOE genotype was classified into ε4 heterozygotes, ε4 homozygotes, ε2 carriers, and ε3 homozygotes (reference group). Sleep architecture was defined using macro-level traits (percentage of time spent in in each sleep stage and wake after sleep onset) and micro-level traits (spindle characteristics [power, density, and frequency], odds ratio product [ORP], and arousal index). Associations between APOE genotype and each sleep metric was evaluated using linear regression. Macroarchitecture was largely comparable across genotypes. However, substantial differences in micro-level traits were identified, including lower spindle power among ε4 homozygotes (β = -2.14, p = 0.02) and a dose-response decrease in spindle frequency at peak power with each ε4 count (βε4 heterozygotes = -0.04, p = 0.04; βε4 homozygote = -0.12, p = 0.065). Both ORP and arousal index decreased in a dose-response pattern with each ε4 count (ORP, βε4-heterozygosity = -0.03, βε4-homozygosity = -0.07, all p < 0.01; arousal index, βε4-heterozygosity = -1.02, p = 0.006, βε4-homozygosity = -1.78, p = 0.07). Between-genotype differences in ORP widened with age. Associations did not vary by sex, race, cognitive status, pTau181, or Aβ42:40 ratio. Abnormal spindle activity observed among ε4 carriers may contribute to their elevated Alzheimer's disease risk. ε4 carriers also showed less sleep fragmentation, which may reflect diminished arousability or electroencephalogram slowing due to neurodegenerative changes. ANN NEUROL 2026;100:1012-1022.
中文摘要:载脂蛋白E ε4(APOE ε4)是阿尔茨海默病(AD)的强遗传风险因素,与睡眠调节相关脑区的功能连接缺陷和淀粉样蛋白病理有关。因此,睡眠结构的改变可能是ε4增加AD易感性的途径之一。然而,与APOE ε4相关的睡眠结构特征仍缺乏充分描述。这项横断面研究分析了睡眠心脏健康研究中50-85岁成年人(N=3,081)APOE基因型与睡眠结构的关系。APOE基因型分为ε4杂合子、ε4纯合子、ε2携带者和ε3纯合子(参照组)。睡眠结构采用宏观层面特征(各睡眠阶段时间百分比和入睡后清醒时间)和微观层面特征(纺锤波特征[功率、密度和频率]、比值比乘积[ORP]和觉醒指数)定义。采用线性回归评估APOE基因型与各睡眠指标的关系。各基因型间宏观结构基本相当。但微观层面特征存在明显差异,包括ε4纯合子纺锤波功率较低(β=-2.14,p=0.02),以及峰值功率处纺锤波频率随ε4等位基因数量呈剂量反应性下降(ε4杂合子β=-0.04,p=0.04;ε4纯合子β=-0.12,p=0.065)。ORP和觉醒指数均随ε4等位基因数量呈剂量反应性下降(ORP,ε4杂合子β=-0.03,ε4纯合子β=-0.07,所有p<0.01;觉醒指数,ε4杂合子β=-1.02,p=0.006,ε4纯合子β=-1.78,p=0.07)。ORP的基因型间差异随年龄增大而扩大。这些关联不受性别、种族、认知状态、pTau181或Aβ42:40比值影响。ε4携带者中观察到的纺锤波活动异常可能促使其AD风险升高。ε4携带者还表现出较少的睡眠碎片化,这可能反映神经退行性改变导致觉醒能力下降或脑电图减慢。ANN NEUROL 2026;100:1012-1022。
Ageing research reviews IF 15.5 2026-11 PMID: 42764107
Alzheimer's disease (AD) remains a major unmet medical challenge despite decades of progress in medicines that target tau and amyloid-β (Aβ) pathology. The clinical benefit of monoclonal antibodies (mAbs) against Aβ is limited, with current data showing only slight slowing of cognitive decline despite encouraging biomarker responses and recent regulatory approval of these drugs. Moreover, their wider clinical use is restricted by dose-dependent toxicities such as amyloid-related imaging abnormalities (ARIA), and by the need for continuous long-term assessment of efficacy and safety in AD patients. The poor penetration of the blood-brain barrier (BBB) by large biologics is a significant but often overlooked factor contributing to this discrepancy. Low-intensity focused ultrasound (LIFU) has emerged as a non-invasive technique for transient localized modification of BBB permeability when paired with intravenously administered microbubbles. This evaluation examines LIFU as a means of delivering anti-tau and anti-amyloid antibodies to AD patients. By integrating data from early-phase clinical research with biological insights, we investigate whether altering the BBB can overcome the pharmacokinetic (PK) limitations of existing immunotherapies. LIFU has biological effects that are critical to the pathophysiology of AD in addition to aiding the mobility of macromolecules, such as enhanced lymphatic clearance and focused neuroimmune activation, which could help treatments based on antibodies. Clinical research to date shows that, in properly chosen AD cohorts, LIFU-mediated BBB opening is practical, reversible, and generally safe; however, there is still a lack of conclusive evidence connecting BBB modulation to elevated intraparenchymal antibody levels or long-term cognitive enhancement. We propose that LIFU should currently be regarded as a promising investigational adjunct to immunotherapy rather than an established therapeutic modality for AD. Biomarker-driven evidence of enhanced cerebral medication distribution and therapeutic effects determines its translational significance; BBB alteration could become a standard Alzheimer's therapeutic strategy if LIFU is successful.
中文摘要:阿尔茨海默病(AD)仍是重大未满足的医学难题,尽管针对tau和淀粉样蛋白β(Aβ)病理的药物研究已有数十年进展。抗Aβ单克隆抗体(mAbs)的临床获益有限,现有数据显示,即便生物标志物反应令人鼓舞且这些药物近期已获监管批准,认知下降也仅轻微减缓。其更广泛的临床使用受剂量依赖性毒性如淀粉样蛋白相关影像学异常(ARIA)限制,也受AD患者需要持续长期评估疗效与安全性的限制。大分子生物制剂对血脑屏障(BBB)的穿透较差,是造成这一差距的重要因素,却常被忽视。低强度聚焦超声(LIFU)与静脉注射微泡联合使用时,已成为一种无创、短暂、局部改变BBB通透性的技术。本评估考察LIFU作为向AD患者递送抗tau和抗淀粉样蛋白抗体的手段。通过整合早期临床研究数据与生物学认识,我们探讨改变BBB能否克服现有免疫治疗的药代动力学(PK)局限。LIFU除帮助大分子移动外,还具有与AD病理生理相关的生物学效应,例如增强淋巴清除和聚焦的神经免疫激活,这些效应可能有助于基于抗体的治疗。迄今的临床研究显示,在适当选择的AD队列中,LIFU介导的BBB开放可行、可逆且总体安全;但仍缺乏确凿证据将BBB调控与脑实质内抗体水平升高或长期认知改善联系起来。我们提出,目前应将LIFU视为免疫治疗中有前景的在研辅助手段,而非AD的成熟治疗方式。生物标志物驱动的脑内药物分布改善与治疗效应证据决定其转化意义;若LIFU取得成功,BBB改变可能成为阿尔茨海默病的标准治疗策略。
Redox biology IF 16.2 2026-11 PMID: 42731289
Growing evidence demonstrates that olfactory dysfunction and disease-related pathology in the olfactory areas occur early in Alzheimer's disease (AD), which is the most common neurodegenerative disorder. Oxidative stress is strongly linked to AD-associated changes in the brain, yet very little is known about redox homeostasis in the peripheral olfactory tissues, and its link to olfactory dysfunction associated with early AD. The olfactory mucosa (OM), located at the rooftop of the nasal cavity is the primary organ for olfaction through odorant detection and transmission of these signals to the brain via the olfactory nerves. This study collected patient-derived biopsies of the OM from cognitively healthy donors, individuals with mild cognitive impairment (MCI) and AD. Shotgun proteomics of the biopsies provided new insights into the molecular mechanisms associated with early AD and olfactory dysfunction, which was assessed by odor identification testing. Furthermore, microRNA sequencing and quantitative analyses of electron carriers, cofactors and glutathione from the biopsy-derived primary cells of the OM were used to link these findings to cellular redox status. The results revealed mitochondrial changes and alterations to cellular defense against oxidative stress, specifically the potentially dampened NRF2 pathway, in MCI and AD OM, which were linked to impairments in odor identification. Understanding the early cellular and molecular changes occurring in the olfactory system and olfaction could aid in the early identification of individuals at risk of developing AD and pathophysiological changes of the OM in AD.
中文摘要:越来越多证据显示,嗅觉功能障碍及嗅区疾病相关病理在阿尔茨海默病(AD)早期即出现,AD是最常见的神经退行性疾病。氧化应激与AD相关脑内改变密切相关,但对外周嗅觉组织中的氧化还原稳态及其与早期AD相关嗅觉功能障碍的联系所知甚少。嗅黏膜(OM)位于鼻腔顶部,是嗅觉的主要器官,通过气味检测并将信号经嗅神经传递至脑。研究采集认知健康供者、轻度认知障碍(MCI)和AD患者的OM活检组织。活检组织的鸟枪蛋白质组学为早期AD及嗅觉功能障碍相关分子机制提供了新认识,嗅觉功能通过气味识别测试评估。研究还对OM活检来源原代细胞进行microRNA测序,并定量分析电子载体、辅因子和谷胱甘肽,以将这些发现与细胞氧化还原状态联系起来。结果显示,MCI和AD的OM存在线粒体改变及抗氧化应激细胞防御的变化,尤其是NRF2通路可能减弱,这些改变与气味识别受损相关。理解嗅觉系统和嗅觉中发生的早期细胞与分子变化,有助于早期识别AD发病风险个体以及OM在AD中的病理生理改变。
Nature neuroscience IF 20.3 2026-11 PMID: 42728376
Memory markedly declines with age, exaggerated in those with Alzheimer's disease, yet the mechanisms are still not resolved. Here we show that frontal lobe tau pathology in humans is associated with impaired en masse unity and cortical traveling propagation of nonrapid eye movement slow waves, linked to impaired memory retention. We elucidate these findings using positron-emission tomography tau brain imaging, and then replicate and extend them using Alzheimer's disease pathology markers derived from cerebrospinal fluid in an independent clinical cohort. Thus, tau-associated memory deficits are not wholly direct but indirectly linked to consequential 'lonely', nontraveling slow-wave events.
中文摘要:记忆随年龄显著下降,在阿尔茨海默病患者中更为突出,但其机制仍未明确。本研究报告,人类额叶tau病理与非快速眼动慢波的群体一致性和皮层传播受损相关,并与记忆保持受损相关。我们利用tau脑正电子发射断层成像阐明这些发现,随后在一个独立临床队列中,使用源自脑脊液的阿尔茨海默病病理标志物进行重复和扩展。因此,tau相关记忆缺陷并非完全直接,而是间接与随之出现的「孤立」、不传播的慢波事件相关。
Ageing research reviews IF 15.5 2026-11 PMID: 42727648
Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which early diagnosis-particularly the accurate prediction of conversion from mild cognitive impairment (MCI) to AD-is essential to enable timely and effective therapeutic interventions. Deep learning (DL) models have demonstrated substantial promise in this domain; however, critical challenges persist, including multiclass staging of disease progression, longitudinal data modeling, and effective multimodal data integration. This systematic review provides a critical appraisal of DL-based approaches for predicting MCI-to-AD conversion, with particular emphasis on these three key challenges. This systematic review was designed and conducted in accordance with the PRISMA guidelines. A comprehensive literature search was performed across PubMed, Scopus, IEEE Xplore, and Web of Science for articles published between January 1, 2019, and February 20, 2026. Following rigorous screening of titles, abstracts, and full texts, 60 studies were included that employed deep learning models for AD stage classification and/or MCI-to-AD conversion prediction. Data were extracted and synthesized regarding study design, datasets, input modalities, DL architectures, and classification tasks. Cross-sectional approaches remained predominant (47 studies), while longitudinal designs were less common (13 studies) and showed heterogeneous but promising performance for MCI-to-AD conversion prediction. Heavy reliance on the ADNI dataset (42 studies) represents a major limitation to generalizability. Multimodal models were used in 24 studies and often reported strong performance, particularly for challenging MCI-related tasks; however, direct cross-study comparisons should be interpreted cautiously because of substantial heterogeneity in datasets, prediction tasks, validation strategies, and methodological quality. Convolutional neural networks (CNNs) dominated neuroimaging-based modeling (21 studies), while recurrent neural networks (RNNs) (4 studies) and transformers (4 studies) have emerged for capturing longitudinal dependencies and global relationships. The binary pMCI vs. sMCI classification proved the most challenging task (accuracy range: 71.71-96.3%), with performance declining as the number of classes increased in multiclass settings. Key limitations across studies include lack of diverse datasets, overfitting, and poor model interpretability. Deep learning models hold considerable potential for predicting MCI-to-AD conversion, yet substantial barriers remain to their translation into routine clinical practice. Greater emphasis on longitudinal analysis, intelligent multimodal fusion, and interpretable architectures is essential for clinical impact. Future research should prioritize the development of diverse, multicenter datasets, advancement of explainable AI (XAI) techniques, and the design of personalized time-to-event models. This review offers a comprehensive roadmap to guide subsequent investigations toward more accurate, reliable, and clinically actionable diagnostic tools in Alzheimer's disease.
中文摘要:阿尔茨海默病(AD)是进展性神经退行性疾病,早期诊断尤其是准确预测轻度认知障碍(MCI)向AD的转化,对及时开展有效治疗干预十分关键。深度学习模型在该领域显示出较大潜力,但疾病进展的多分类分期、纵向数据建模以及多模态数据的有效整合等关键挑战仍然存在。本系统综述对基于深度学习预测MCI向AD转化的方法进行批判性评价,重点关注上述三项挑战。综述按PRISMA指南设计实施,检索PubMed、Scopus、IEEE Xplore与Web of Science于2019年1月1日至2026年2月20日发表的文献,经题目、摘要与全文严格筛选后纳入60项使用深度学习模型进行AD分期分类和/或MCI向AD转化预测的研究,并提取与综合研究设计、数据集、输入模态、深度学习架构及分类任务等信息。横断面研究仍占主导(47项),纵向设计较少(13项),其预测MCI向AD转化的表现存在异质性但具前景。对ADNI数据集的依赖较重(42项),构成推广性的主要限制。24项研究采用多模态模型,常报告较好表现,尤其在具挑战性的MCI相关任务中;但受数据集、预测任务、验证策略与方法学质量高度异质性的影响,跨研究直接比较应谨慎解读。卷积神经网络在神经影像建模中占主导(21项),循环神经网络(4项)与Transformer(4项)已开始用于捕捉纵向依赖与全局关系。进展型MCI与稳定型MCI的二分类是最具挑战性的任务(准确率范围71.71%–96.3%),多分类设置下类别数增加时性能下降。各研究的主要局限包括缺乏多样化数据集、过拟合与模型可解释性差。深度学习模型在预测MCI向AD转化方面潜力可观,但转化为常规临床实践仍面临明显障碍。加强纵向分析、智能多模态融合与可解释架构对产生临床影响十分必要。未来研究应优先构建多样化多中心数据集、推进可解释人工智能技术并设计个体化时间-事件模型。本综述提供全面路线图,引导后续研究开发更准确、可靠且具临床可操作性的阿尔茨海默病诊断工具。
Ageing research reviews IF 15.5 2026-11 PMID: 42722299
Blood phosphorylated tau at threonine 217 (p-tau217) has shown considerable potential for the diagnosis of Alzheimer's disease (AD). For successful implementation in clinical practice, its applicability must be established across representative populations and settings. In this systematic review, we aimed to characterize participants included in p-tau217 research in AD, focusing on study setting, and sociodemographic and clinical features relevant to biomarker interpretation, and to assess how consistently these factors were reported across studies. A systematic review was conducted according to PRISMA guidelines. Observational studies assessing blood p-tau217 in the context of AD research were included. Data on study location, setting, and participant characteristics, including sociodemographic and medical conditions, were extracted. Across the 128 included studies, most participants were recruited from research cohorts (64.1%), primarily in North America (50.0%) and Europe (48.4%). Reporting of sociodemographic and clinical characteristics varied substantially, with several key variables available in only a minority of studies. Cognitively unimpaired participants represented the largest group (44.6%), and most participants were White (77.4%). By contrast, non-White populations, the oldest old, individuals with lower educational attainment, and those with greater clinical complexity were largely underrepresented. Overall, current evidence on p-tau217 is derived mainly from selected populations and may not fully reflect real-world clinical diversity. Differences in representation and in the reporting of clinically relevant factors may affect the biomarker's generalizability and interpretation. Future studies should prioritize more representative cohorts, and standardized reporting of key variables will be essential to strengthen its adoption in clinical practice.
中文摘要:血液苏氨酸217磷酸化tau(p-tau217)在阿尔茨海默病(AD)诊断中显示出较大潜力。要使其顺利进入临床实践,必须确认它在具有代表性的人群和场景中的适用性。本系统综述旨在描述AD领域p-tau217研究纳入参与者的特征,重点关注研究场景,以及与生物标志物解读相关的社会人口学和临床特征,并评估这些因素在各研究中的报告一致性。综述按PRISMA指南开展,纳入在AD研究背景下评估血液p-tau217的观察性研究,提取研究地点、场景和参与者特征(包括社会人口学与医疗状况)数据。128项纳入研究中,多数参与者来自研究队列(64.1%),主要来自北美(50.0%)和欧洲(48.4%)。社会人口学和临床特征的报告差异很大,若干关键变量仅在少数研究中可得。认知未受损参与者占比最大(44.6%),多数参与者为白人(77.4%)。相比之下,非白人人群、高龄老人、受教育程度较低者以及临床复杂性较高者在研究中明显不足。现有p-tau217证据主要来自经过选择的人群,可能无法充分反映真实世界的临床多样性。代表性与临床相关因素报告方面的差异,可能影响该生物标志物的外推性和解读。未来研究应优先纳入更具代表性的人群,并对关键变量进行标准化报告,这对于加强其在临床实践中的应用十分必要。
Ageing research reviews IF 15.5 2026-11 PMID: 42716444
A significant proportion of informal dementia care is provided by male caregivers, however research on their experiences remains limited and with a large focus on spousal relations. Previous scoping reviews exploring male caregiving have not considered how intersectional factors may shape men's experiences. This review synthesises and interprets qualitative research on the experiences of informal male caregivers for people living with dementia (PLwD), extending beyond the anglosphere and applying systematic review methods to assess study quality. The influence of intersecting factors on men's approaches to caregiving was also explored. Seven research databases were searched from inception until 15/07/2025 to identity peer-reviewed qualitative studies. Title/abstract and full texts were screened, and study quality assessed before conducting a qualitative thematic synthesis. 30 papers were included of varying quality. Four main themes were identified: 1) Re-negotiating a masculine caregiver identity, in which men drew upon organisational scripts and protective provider roles; 2) Relational loss and change, including grief, loss of intimacy and isolation; 3) Strategies for managing and personal growth, encompassing emotional containment, task-oriented problem solving, selective help-seeking and pride and personal growth; and 4) Suggestions for support. Across themes, masculinity and gendered ideals shaped men's caregiving approach. Intersectional factors, including the relationship to the PLwD, social class, sexuality and culture shaped experiences, although were rarely discussed in-depth within studies. Results highlight male caregivers expression for support aligned with their coping styles, and interventions should prioritise practical and educational components. Future research should attend to under-reported intersectional experiences of male caregivers to support equitable service provision.
中文摘要:相当比例的非正式痴呆照护由男性照护者承担,但针对其体验的研究仍然有限,且多集中于配偶关系。既往探讨男性照护的范畴综述未考虑交叉性因素如何塑造男性的体验。本综述整合并解释有关痴呆患者非正式男性照护者体验的定性研究,范围超出英语国家,并采用系统综述方法评估研究质量,同时探讨交叉因素对男性照护方式的影响。检索七个研究数据库自建库至2025年7月15日的文献,以识别同行评议的定性研究。经题目与摘要及全文筛选,并在开展定性主题综合前评估研究质量。共纳入30篇质量不一的论文,识别出四个主要主题:1)重新协商男性照护者身份,男性借助组织性脚本与保护性供养者角色;2)关系的丧失与变化,包括悲伤、亲密感丧失与孤立;3)应对管理与个人成长,涵盖情绪克制、任务导向的问题解决、选择性求助以及自豪感与个人成长;4)对照护支持的建议。各主题中,男性气质与性别化理想塑造了男性的照护方式。与痴呆患者的关系、社会阶层、性取向与文化等交叉因素塑造了其体验,但各研究对此少有深入讨论。结果凸显男性照护者希望获得与其应对方式相契合的支持,干预应优先包含实用与教育内容。未来研究应关注男性照护者中报告不足的交叉性体验,以支持公平的服务提供。
Ageing research reviews IF 15.5 2026-11 PMID: 42641765
The introduction of anti-amyloid therapies for Alzheimer's disease challenged current care models, particularly for older adults with frailty. The potential low efficacy of anti-amyloid drugs in these patients may be attributed to chronic inflammation, impaired repair mechanisms, and multisystem dysregulation. Neuropathological studies suggested that the accumulation of common brain pathologies may contribute to progressive physical frailty in older age. At present, there is no certified diagnostic-therapeutic pathway governing the management of patients eligible for anti-amyloid treatment, regardless of the presence of frailty. In the present view point, we argued that frailty should not be treated as an exclusion criterion for anti-amyloid therapies, but as a stratification dimension requiring integrated, multidimensional clinical pathways. Without embedding frailty assessment into eligibility, monitoring, and outcome evaluation, the real-world implementation of disease-modifying therapies risks being ineffective, inequitable, and ethically problematic. Here, we proposed to integrate frailty assessment with biological and neuroimaging criteria to promote ethical, equitable, and clinically-feasible access to disease-modifying treatments in real-world settings.
中文摘要:抗淀粉样蛋白疗法用于阿尔茨海默病,对现有照护模式提出了挑战,对衰弱老年人尤其如此。这类患者中抗淀粉样蛋白药物疗效可能偏低,原因涉及慢性炎症、修复机制受损和多系统调节失衡。神经病理学研究提示,常见脑病理改变的累积可能促进老年期躯体衰弱的进展。目前,无论患者是否存在衰弱,都没有获批的诊断治疗路径来管理适合接受抗淀粉样蛋白治疗的患者。本观点认为,衰弱不应被视为抗淀粉样蛋白治疗的排除标准,而应作为需要整合、多维临床路径的分层维度。若未将衰弱评估纳入适应证判断、监测和结局评价,疾病修饰疗法的真实世界实施可能面临无效、不公平和伦理问题。我们提出将衰弱评估与生物学和神经影像标准整合,以促进真实世界环境中伦理、公平且临床可行的疾病修饰治疗可及性。
Ageing research reviews IF 15.5 2026-11 PMID: 42632461
This systematic review investigates the mediating factors in the relationship between ambient air pollution exposure and cognitive aging. We identified 16 studies examining 72 unique exposure-mediator-outcome associations for six pollutants (PM2.5, PM10, NO2, NOX, black carbon, and PM1 components). The most studied pollutant was PM2.5 (65% of analyses). Cognitive outcomes included memory, cognitive processing speed, and clinically diagnosed conditions such as dementia incidence. Potential mediators spanned mental health outcomes (depression, anxiety, stress), lung function (FEV1, FVC, PEF), vascular diseases (stroke, hypertension), inflammation (CRP), metabolic factors (type 2 diabetes), sleep, and neuroanatomical changes. The quality of mediation analysis reporting was generally good, but most studies had some risk of bias, particularly in outcome assessment and confounding adjustment. Cardio and Cerebro-vascular diseases emerged as a potential key mediator. Mental health outcomes, sleep, and lung function also showed mediating potential, but further research is needed to confirm these findings. This review highlights the need for rigorous causal mediation analyses and standardized reporting to better understand the complex pathways linking air pollution to cognitive aging, in order to identify targeted preventive measures to reduce the negative impact of ambient air pollution on cognitive health.
中文摘要:该系统性综述考察环境空气污染暴露与认知老化关系中的中介因素。共纳入16项研究,涉及六种污染物(PM2.5、PM10、NO2、NOX、黑碳及PM1组分)的72个唯一暴露-中介-结局关联分析。研究最多的污染物是PM2.5,占分析数的65%。认知结局包括记忆、认知加工速度以及痴呆发病等临床诊断状况。潜在中介因素涵盖心理健康结局(抑郁、焦虑、压力)、肺功能(FEV1、FVC、PEF)、血管疾病(卒中、高血压)、炎症(CRP)、代谢因素(2型糖尿病)、睡眠和神经解剖改变。中介分析报告质量总体较好,但多数研究存在一定偏倚风险,尤其在结局评估和混杂调整方面。心脑血管疾病成为潜在关键中介因素。心理健康结局、睡眠和肺功能也显示出中介潜力,仍需进一步研究确认。该综述强调需要严谨的因果中介分析和标准化报告,以更好理解空气污染与认知老化之间的复杂路径,从而识别有针对性的预防措施,减少环境空气污染对认知健康的不良影响。
Annals of neurology IF 7.5 2026-11 PMID: 42601653
Recent studies suggest that combining plasma phosphorylated tau (p-tau) with β-amyloid (Aβ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross-sectional and longitudinal concordance of these markers with Aβ positron emission tomography (PET) positivity remains incompletely understood. This study aimed to evaluate the diagnostic performance of plasma p-tau, alone and in combination with plasma Aβ, in AD. We included 326 participants from the Alzheimer's Disease Neuroimaging Initiative and 357 Chinese older adults from the Greater-Bay-Area Healthy Aging Brain Study who underwent Aβ-PET imaging. Longitudinal data were available for 285 Alzheimer's Disease Neuroimaging Initiative participants. Plasma p-tau181, p-tau217, Aβ42, and Aβ40 were measured on different analytical platforms. Diagnostic performance for Aβ-PET positivity was assessed using a two-cutoff approach. Combining plasma p-tau with Aβ42 or the Aβ42/40 ratio reduced the intermediate zone. Notably, p-tau217/Aβ42 showed stronger agreement with Aβ-PET positivity than p-tau217 alone. Among individuals classified as p-tau217/Aβ42 positive but p-tau217 intermediate, 57.1 to 83.3% were Aβ-PET positive. Longitudinally, most Stable Positive (88.0-96.1%) and Stable Negative (89.4-90.9%) cases defined by p-tau217 or p-tau217/Aβ42 were Aβ-PET positive and Aβ-PET negative, respectively. Critically, 69.7 to 75.8% of Non-positive to Positive cases defined by p-tau217/Aβ42 were Aβ-PET positive. These findings provide novel insights into the cross-sectional and longitudinal diagnostic performance of plasma p-tau217/Aβ42 in AD. To be specific, plasma p-tau217/Aβ42 can reduce the intermediate zone and improve agreement with Aβ-PET positivity, and longitudinal p-tau217/Aβ42 monitoring is particularly informative for identifying Aβ-PET-positive patients who were p-tau217/Aβ42 negative or intermediate at baseline and were misclassified as low risk of AD. ANN NEUROL 2026;100:998-1011.
中文摘要:近期研究提示,将血浆磷酸化tau(p-tau)与β-淀粉样蛋白(Aβ)联合可能提高阿尔茨海默病(AD)的诊断准确性。这些标志物与Aβ正电子发射断层扫描(PET)阳性在横断面和纵向的一致性仍未完全明确。本研究旨在评估血浆p-tau单独及联合血浆Aβ对AD的诊断性能。研究纳入阿尔茨海默病神经影像学倡议的326名参与者和粤港澳大湾区健康老龄化脑研究的357名中国老年人,均接受Aβ-PET成像。285名阿尔茨海默病神经影像学倡议参与者有纵向数据。血浆p-tau181、p-tau217、Aβ42和Aβ40在不同分析平台上测定。采用双截断值方法评估对Aβ-PET阳性的诊断性能。将血浆p-tau与Aβ42或Aβ42/40比值联合可缩小中间区。p-tau217/Aβ42与Aβ-PET阳性的符合程度高于单独p-tau217。在被归类为p-tau217/Aβ42阳性但p-tau217处于中间区的人群中,57.1%至83.3%为Aβ-PET阳性。纵向来看,由p-tau217或p-tau217/Aβ42定义的稳定阳性病例中88.0%至96.1%为Aβ-PET阳性,稳定阴性病例中89.4%至90.9%为Aβ-PET阴性。由p-tau217/Aβ42定义的非阳性转为阳性病例中,69.7%至75.8%为Aβ-PET阳性。这些发现为血浆p-tau217/Aβ42在AD中的横断面和纵向诊断性能提供了新认识。具体而言,血浆p-tau217/Aβ42可缩小中间区并提高与Aβ-PET阳性的符合程度,纵向监测p-tau217/Aβ42尤其有助于识别基线时p-tau217/Aβ42阴性或处于中间区、被误判为AD低风险但实际为Aβ-PET阳性的患者。ANN NEUROL 2026;100:998-1011。
Annals of neurology IF 7.5 2026-11 PMID: 42515850
We aimed to investigate the associations between Alzheimer's disease (AD)-related blood biomarkers and changes in brain volumes and cerebrovascular burden in community-dwelling older adults. We included 361 dementia-free participants with a Mini-Mental State Examination (MMSE) score ≥ 27 and without prior cerebrovascular events from a Swedish population-based study. Blood phosphorylated-tau217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were measured at baseline. Brain magnetic resonance imaging (MRI) was performed at baseline and after 3 and/or 6 years. Linear mixed models were used to examine associations between AD-related blood biomarkers and changes in volumes of total brain tissue (TBTV), lateral ventricles, hippocampus, amygdala, and white matter hyperintensities (WMHs). During the follow-up, higher p-tau217 was associated with faster volume loss in the hippocampus (β*year = -0.047, 95% confidence interval [CI] = -0.077 to -0.018) and in the amygdala (β*year = -0.064, 95% CI = -0.105 to -0.022). Elevated GFAP was linked to faster TBTV decline (β*year = -0.040, 95% CI = -0.059 to -0.021), ventricular enlargement (β*year = 0.028, 95% CI = 0.013 to 0.042), and hippocampal shrinkage (β*year = -0.038, 95% CI = -0.064 to -0.013). Participants with higher NfL showed steeper TBTV decline, ventricular enlargement, hippocampal and amygdala shrinkage, and faster WMH accumulation. Results remained largely consistent after excluding participants with mild cognitive impairment at baseline. In cognitively unimpaired older adults, elevated blood p-tau217 was linked to faster shrinkage in AD-specific brain regions, whereas NfL and GFAP were associated with more widespread atrophy, with NfL also associated with accelerated WMH accumulation. These findings suggest that AD-related blood biomarkers may capture different dementia-related structural brain changes already at early stages. ANN NEUROL 2026;100:987-997.
中文摘要:为探讨阿尔茨海默病(AD)相关血液生物标志物与社区居住老年人脑体积及脑血管负荷变化的关系,研究纳入瑞典一项基于人群的研究中361名无痴呆参与者,其简易精神状态检查(MMSE)评分≥27且既往无脑血管事件。基线检测血液磷酸化tau217(p-tau217)、神经丝轻链(NfL)和胶质纤维酸性蛋白(GFAP)。基线及3年和/或6年后进行脑磁共振成像(MRI)。采用线性混合模型分析AD相关血液生物标志物与全脑组织体积(TBTV)、侧脑室、海马、杏仁核及白质高信号(WMHs)体积变化的关系。随访期间,较高的p-tau217与海马体积下降更快(β×年=-0.047,95%置信区间[CI]=-0.077至-0.018)及杏仁核体积下降更快(β×年=-0.064,95%CI=-0.105至-0.022)相关。GFAP升高与TBTV下降更快(β×年=-0.040,95%CI=-0.059至-0.021)、侧脑室扩大(β×年=0.028,95%CI=0.013至0.042)及海马萎缩(β×年=-0.038,95%CI=-0.064至-0.013)相关。NfL较高者表现为TBTV下降更陡、侧脑室扩大、海马和杏仁核萎缩及WMH积累更快。排除基线轻度认知障碍参与者后,结果基本一致。在认知未受损老年人中,血液p-tau217升高与AD特异性脑区萎缩更快相关,NfL和GFAP与更广泛的脑萎缩相关,NfL还与WMH积累加速相关。这些发现提示AD相关血液生物标志物可能在早期即反映不同的痴呆相关脑结构变化。ANN NEUROL 2026;100:987-997。
Molecular psychiatry IF 10.4 2026-11 PMID: 42399414
Late-onset Alzheimer's disease (LOAD) is the most common cause of dementia in older adults, with specific genomic copy number variants (CNVs) implicated in its pathology. However, the aggregate burden of genome-wide CNVs in dementia and age-related neuropathologies is uncharacterized. This study investigated the association between genome-wide CNV scores (CNV-S) and dementia, as well as LOAD-related neuropathologies, in 1011 elderly participants (mean age 88.06) from two ongoing US-based longitudinal clinical-pathological cohort studies who were initially dementia-free and consented to brain donation upon death. Participants exhibited varying cognitive statuses at death (429 dementia, 258 mild cognitive impairment, 324 cognitively normal). We evaluated effects of (1) eight individual-level CNV-S based on gene loss intolerance and dosage sensitivity; (2) a single nucleotide polymorphism (SNP)-based LOAD polygenic score (PGS-LOAD) calculated using Bayesian continuous shrinkage; and (3) covariates (age, sex, and education). Outcomes included cognitive scores across 19 tests, clinical diagnoses of Alzheimer's disease or mild cognitive impairment, and four LOAD-related neuropathologies assessed postmortem. Analyses identified 4867 CNVs (3918 deletions, 949 duplications) mapped to 3211 genes. Higher deletion CNV-S were significantly associated with increased cerebrovascular pathologies (pLI: β = 0.14, 95% CI [0.08, 0.21]; LOEUF: β = 0.14, 95% CI [0.08, 0.20]; pHI: β = 0.15, 95% CI [0.08, 0.21]; binarized pHI: β = 0.14, 95% CI [0.08, 0.21]). Models predicting cerebral atherosclerosis that included deletion CNV-S significantly outperformed models based on only PGS-LOAD (R2 increase: 0.02). These findings suggest that genome-wide CNV burden, particularly deletions in dosage-sensitive genes, contributes to cerebrovascular pathology in aging. CNV-S may augment existing LOAD genetic risk models by capturing vascular pathways distinct from traditional SNP-based risk.
中文摘要:晚发性阿尔茨海默病(LOAD)是老年人痴呆最常见原因,特定基因组拷贝数变异(CNVs)与其病理有关。全基因组CNVs在痴呆和年龄相关神经病理中的总体负荷尚未明确。本研究纳入美国两项正在进行的纵向临床-病理队列研究中的1011名老年参与者(平均年龄88.06岁),入组时无痴呆并同意死后捐献脑组织,考察全基因组CNV评分(CNV-S)与痴呆及LOAD相关神经病理的关联。参与者死亡时认知状态不同(429例痴呆、258例轻度认知障碍、324例认知正常)。研究评估:(1)基于基因丢失不耐受性和剂量敏感性的8种个体水平CNV-S;(2)用贝叶斯连续收缩法计算的基于单核苷酸多态性(SNP)的LOAD多基因评分(PGS-LOAD);(3)协变量(年龄、性别和教育)。结局包括19项测验的认知评分、阿尔茨海默病或轻度认知障碍的临床诊断,以及死后评估的4种LOAD相关神经病理。分析识别出4867个CNVs(3918个缺失、949个重复),映射到3211个基因。较高的缺失CNV-S与脑血管病理增加显著相关(pLI:β=0.14,95% CI [0.08, 0.21];LOEUF:β=0.14,95% CI [0.08, 0.20];pHI:β=0.15,95% CI [0.08, 0.21];二值化pHI:β=0.14,95% CI [0.08, 0.21])。包含缺失CNV-S的脑动脉粥样硬化预测模型显著优于仅基于PGS-LOAD的模型(R2增加:0.02)。这些发现提示,全基因组CNV负荷,尤其是剂量敏感基因中的缺失,参与衰老过程中的脑血管病理。CNV-S可通过捕捉不同于传统SNP风险的通路,补充现有LOAD遗传风险模型。
Molecular psychiatry IF 10.4 2026-11 PMID: 42362770
Brain atrophy may precede cognitive and functional impairment in Alzheimer's disease (AD), but at this "preclinical" stage, it remains unclear whether atrophy localizes to specific brain networks and whether such localization is associated with clinical outcomes. We investigated cortical thickness in 1778 cognitively unimpaired (CU) older adults with amyloid-β (Aβ) PET from the A4 (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease) and LEARN (Longitudinal Evaluation of Amyloid Risk and Neurodegeneration) studies, with a subset (N = 445) with tau PET. We estimated the networks disrupted by each individual's cortical thinning using a large normative connectome database (N = 1000), and tested whether this preclinical AD atrophy network is associated with clinical manifestations and longitudinal cognitive (PACC) and functional (CDR) trajectories. Distinct networks connected to atrophy patterns were associated with Aβ and regional tau in CU older adults. These networks were similar to a previously published atrophy network for AD dementia (Aβ: r = 0.817, P = 0.006; tau: r = 0.712, P = 0.046). Atrophy connectivity to this preclinical AD network was associated with higher Aβ and tau, independent of total cortical atrophy, and cross-sectionally with lower cognition, greater subjective cognitive decline, and increased anxiety; longitudinally, it predicted faster cognitive and functional decline over ~5 years. After tau adjustment, the functional-decline effect was preserved while the cognitive-slope effect was largely attenuated. Atrophy in preclinical AD localizes to a network resembling AD dementia, and is independently associated with AD pathologies, clinical outcomes, and longitudinal decline. Network-level neurodegeneration is detectable and clinically informative in preclinical AD, supporting future network-based research and therapeutic development.
中文摘要:脑萎缩可能早于阿尔茨海默病(AD)的认知和功能损害,但在「临床前期」,萎缩是否定位于特定脑网络、这种定位是否与临床结局相关仍不清楚。我们分析了A4(抗淀粉样蛋白治疗无症状阿尔茨海默病)和LEARN(淀粉样蛋白风险与神经退行性变的纵向评估)研究中1778名认知正常(CU)且接受淀粉样蛋白β(Aβ)PET检查的老年人的皮质厚度,其中445人同时有tau PET。利用包含1000人的大型标准连接组数据库,我们估计了每个个体皮质变薄所破坏的网络,并检验这一临床前期AD萎缩网络是否与临床表现以及纵向认知(PACC)和功能(CDR)轨迹相关。在CU老年人中,与萎缩模式相连的不同网络与Aβ和区域tau相关。这些网络与既往发表的AD痴呆萎缩网络相似(Aβ:r=0.817,P=0.006;tau:r=0.712,P=0.046)。与该临床前期AD网络的萎缩连接性与更高的Aβ和tau相关,且独立于总皮质萎缩;横断面上,它与较低认知、更明显的主观认知下降和焦虑增加相关;纵向上,它预测约5年内更快的认知和功能下降。校正tau后,功能下降效应仍然存在,而认知斜率效应明显减弱。临床前期AD的萎缩定位于一个类似AD痴呆的网络,并与AD病理、临床结局和纵向下降独立相关。网络水平的神经退行性变在临床前期AD中可被检测并具有临床信息价值,支持未来基于网络的研究和治疗开发。
Molecular psychiatry IF 10.4 2026-11 PMID: 42337011
Accurate prediction of which patients with mild cognitive impairment (MCI) will progress to dementia remains a major challenge. Current biomarkers detect amyloid pathology with high accuracy but offer limited prognostic value for disease progression. We conducted a prospective analysis in the multicentre BALTAZAR cohort, all diagnosed with MCI at baseline and followed for 3 years. Paired cerebrospinal fluid (CSF) and plasma samples were analysed with the NULISA ultrasensitive multiplex platform quantifying more than 120 central nervous system biomarkers. Prognostic performance was assessed using area under the curve (AUC) and hazard ratios (HRs), both for individual markers and for elastic-net-derived biomarker combinations validated by bootstrap and survival analyses. During the 3-year follow-up, 36% of participants converted to dementia. Plasma p-tau biomarkers showed strong accuracy for detecting amyloid positivity (AUC > 0.90) but limited prognostic value for conversion (AUC < 0.75). In CSF, markers of neurodegeneration (tau, NfL) and synaptic dysfunction (NPTX2 encoding the Neuronal Pentraxin 2) predicted conversion with higher accuracy, exceeding p-tau217 performance. The best-performing CSF combination (IL-16, tau, NPTX2) achieved an AUC of 0.86 (95%CI 0.80-0.91) and an HR of 39.8 (95%CI 9.6-165.2). Plasma combinations (p-tau181 or p-tau217 with YWHAG encoding for 14-3-3 protein gamma, a member of the 14-3-3 protein family) provided only modest improvement, likely reflecting the absence of robust synaptic markers in blood. Prognostic assessment of MCI progression to dementia is best achieved through CSF biomarker combinations reflecting neurodegeneration and synaptic dysfunction, complemented by inflammatory markers. These findings emphasize the clinical and pathophysiological relevance of downstream processes beyond amyloid and tau, and support the implementation of multimarker panels for prognosis and therapeutic monitoring.
中文摘要:准确预测哪些轻度认知障碍(MCI)患者会进展为痴呆仍是一项重大挑战。现有生物标志物检测淀粉样蛋白病理的准确性很高,但对疾病进展的预后价值有限。我们在多中心BALTAZAR队列中开展前瞻性分析,所有参与者基线均诊断为MCI,并随访3年。采用NULISA超灵敏多重检测平台分析配对的脑脊液和血浆样本,量化120余种中枢神经系统生物标志物。预后性能通过曲线下面积(AUC)和风险比(HR)评估,既分析单个标志物,也分析弹性网络衍生的标志物组合,并通过bootstrap和生存分析验证。3年随访期间,36%的参与者转化为痴呆。血浆p-tau生物标志物检测淀粉样蛋白阳性准确性较强(AUC>0.90),但对转化的预后价值有限(AUC<0.75)。在脑脊液中,神经退行性变标志物(tau、NfL)和突触功能障碍标志物(NPTX2,编码神经元五聚蛋白2)预测转化的准确性更高,超过p-tau217的表现。表现最佳的脑脊液组合(IL-16、tau、NPTX2)达到AUC 0.86(95%CI 0.80-0.91)和HR 39.8(95%CI 9.6-165.2)。血浆组合(p-tau181或p-tau217联合YWHAG,后者编码14-3-3蛋白家族成员14-3-3蛋白gamma)仅带来有限改善,可能反映血液中缺乏稳健的突触标志物。MCI向痴呆进展的预后评估最适合通过反映神经退行性变和突触功能障碍的脑脊液生物标志物组合来实现,并辅以炎症标志物。这些发现强调淀粉样蛋白和tau之外下游过程的临床与病理生理相关性,并支持采用多标志物panel进行预后评估和治疗监测。
Neurology and therapy IF 4.7 2026-10-30 PMID: 42961631
Lecanemab and donanemab are disease-modifying therapies for early Alzheimer's disease, but their long-term economic value in China remains uncertain. This study evaluated their long-term cost-effectiveness in China. A lifetime Markov model compared lecanemab plus standard of care (SoC), donanemab plus SoC, and SoC alone from the Chinese healthcare system and societal perspectives. Treatment cohorts were stratified by apolipoprotein E ε4 genotype. The model incorporated Chinese real-world costs, treatment-related adverse events, discontinuation, and post-discontinuation benefits. Outcomes included costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way and probabilistic sensitivity analyses assessed parameter uncertainty, while scenario analyses examined drug prices, treatment populations, administration routes, and efficacy assumptions. From the healthcare system perspective, ICERs (in United States dollars [USD]) for lecanemab plus SoC and donanemab plus SoC were USD 309,841.194/QALY and USD 232,793.705/QALY, respectively. Corresponding societal ICERs were USD 300,434.358/QALY and USD 212,256.111/QALY. All estimates exceeded the prespecified willingness-to-pay threshold. The ICER for lecanemab was driven mainly by treatment efficacy and drug price, whereas donanemab was most sensitive to the duration of residual treatment effect. Varying the treatment-eligible population had limited impact on the ICERs. From the healthcare system perspective, ICERs ranged from USD 304,889.902 to USD 310,071.658/QALY for lecanemab and USD 211,226.601 to USD 240,400.661/QALY for donanemab; the corresponding societal ranges were USD 293,467.938-312,810.263/QALY and USD 204,513.613-214,437.087/QALY. At assumed United States prices for subcutaneous lecanemab, intravenous administration had a slightly lower ICER from the healthcare system perspective (USD 309,841.194/QALY versus USD 317,811.454/QALY), whereas all-subcutaneous administration had a slightly lower societal ICER (USD 298,027.332/QALY versus USD 300,434.358/QALY). Neither lecanemab nor donanemab was cost-effective at current Chinese prices. Patient selection had limited impact. The lower ICER for donanemab depended on the assumed residual treatment effect after discontinuation.
中文摘要:lecanemab与donanemab是早期阿尔茨海默病的疾病修饰治疗药物,二者在中国的长期经济价值仍不确定。本研究评估其在中国长期应用的成本效果。采用终身Markov模型,从中国医疗卫生体系与社会两个角度比较lecanemab联合标准治疗(SoC)、donanemab联合SoC与单用SoC。治疗队列按载脂蛋白E ε4基因型分层。模型纳入中国真实世界成本、治疗相关不良事件、停药以及停药后获益。结局指标包括成本、质量调整生命年(QALYs)与增量成本效果比(ICERs)。单因素分析与概率敏感性分析用于评估参数不确定性,情景分析考察药品价格、治疗人群、给药途径与疗效假设。从医疗卫生体系角度,lecanemab联合SoC与donanemab联合SoC的ICER(美元)分别为309,841.194美元/QALY与232,793.705美元/QALY,社会角度相应为300,434.358美元/QALY与212,256.111美元/QALY。所有估计值均超过预设的支付意愿阈值。lecanemab的ICER主要由治疗疗效与药品价格驱动,donanemab对停药后残余疗效持续时间最为敏感。改变符合治疗条件的人群对ICER影响有限。从医疗卫生体系角度,lecanemab的ICER在304,889.902至310,071.658美元/QALY之间,donanemab在211,226.601至240,400.661美元/QALY之间;社会角度相应范围为293,467.938至312,810.263美元/QALY与204,513.613至214,437.087美元/QALY。在假定采用美国皮下给药lecanemab价格的条件下,静脉给药从医疗卫生体系角度ICER略低(309,841.194美元/QALY对317,811.454美元/QALY),全皮下给药从社会角度ICER略低(298,027.332美元/QALY对300,434.358美元/QALY)。按中国当前价格,lecanemab与donanemab均不具备成本效果。患者选择对结果影响有限。donanemab较低的ICER取决于对停药后残余治疗效果的假设。

基础研究 (32篇)

Science advances IF 13.9 2026-11-06 PMID: 42981396
Hibernation demands rapid brain adaptations, involving cycles of reduced metabolic rate during torpor, followed by brief periods of arousal. Previous studies show hibernation induces a drastic increase in Tau hyperphosphorylation, but a mechanistic connection to disease remains unclear. Using single-nucleus RNA sequencing on hippocampi of golden hamsters, we unveil large transcriptional shifts across the hibernation cycle in all cell types, especially glia. Common transcriptional changes in mitochondrial and ribosomal genes are observed in all different cell types. In addition, hibernation triggers an inflammatory-like response in microglia that in part resembles cell states observed in Alzheimer's disease, but here in the absence of Aβ-accumulation and neurodegeneration. These findings reveal brain transformations that might help preserve vital functions under extreme conditions and they suggest that early cellular changes in AD may be a natural adaptive process.
中文摘要:冬眠需要大脑快速适应,涉及深冬眠期代谢率降低的周期,随后是短暂的觉醒期。既往研究显示冬眠诱导Tau超磷酸化大幅增加,但其与疾病的机制联系仍不清楚。对金仓鼠海马进行单核RNA测序,我们揭示了整个冬眠周期中所有细胞类型的大规模转录改变,尤其是胶质细胞。线粒体和核糖体基因的共同转录变化见于所有不同细胞类型。冬眠还在小胶质细胞中触发类炎症反应,部分类似于阿尔茨海默病中观察到的细胞状态,但此处没有Aβ积聚和神经退行性变。这些发现揭示了可能有助于在极端条件下维持重要功能的大脑转化,并提示AD的早期细胞变化可能是一种自然适应过程。
Nature cell biology IF 22.7 2026-11-05 PMID: 42988850
Tauopathies, such as Alzheimer's disease, are neurodegenerative disorders characterized by the accumulation and propagation of toxic extracellular forms of the microtubule-associated protein tau across brain regions. Microglia, the resident macrophages of the brain, are known for clearing and degrading toxic proteins. However, emerging evidence suggests that microglia also enhance tau spreading. To dissect the molecular mechanisms underlying microglial responses to extracellular tau, we use high-resolution imaging and biochemical approaches to assess the trafficking dynamics of different extracellular tau species in human induced pluripotent stem cell-derived microglia. Here we find that tau monomers are internalized by microglia via cell-surface LRP1 receptors but fail to reach terminally degradative lysosomes; instead, they are persistently recycled back to the extracellular space. In contrast, tau fibrils are not internalized and primarily adhere to the cell surface through an HSPG-dependent mechanism, triggering TLR4-mediated microglial activation and the release of pro-inflammatory cytokines. Heparin or anti-tau treatments dampen tau fibril-mediated microglial activation. In addition, disease-associated variants of the Alzheimer's disease-related protein APOE reduce microglia-tau interactions, further reducing tau uptake. Together, these findings demonstrate that microglia fail to efficiently clear extracellular tau monomers and fibrils through mechanistically distinct cellular processes, emphasizing the need for tailored therapeutic strategies to enhance extracellular tau clearance in neurodegenerative diseases.
中文摘要:Tau病,如阿尔茨海默病,是以微管相关蛋白Tau的毒性细胞外形式在脑区之间积聚和传播为特征的神经退行性疾病。小胶质细胞是脑内常驻巨噬细胞,已知可清除和降解毒性蛋白,但新近证据提示小胶质细胞也会促进Tau扩散。为解析小胶质细胞对细胞外Tau应答的分子机制,我们采用高分辨率成像和生化方法,评估不同细胞外Tau种类在人诱导多能干细胞来源小胶质细胞中的转运动态。研究发现,Tau单体经细胞表面LRP1受体内化进入小胶质细胞,却未能到达终末降解溶酶体,而是持续被回收至细胞外空间。相反,Tau纤维不被内化,主要通过HSPG依赖机制黏附于细胞表面,触发TLR4介导的小胶质细胞激活并释放促炎细胞因子。肝素或抗Tau治疗可减弱Tau纤维介导的小胶质细胞激活。阿尔茨海默病相关蛋白APOE的疾病相关变异会减少小胶质细胞与Tau的相互作用,进一步降低Tau摄取。这些发现表明,小胶质细胞通过机制不同的细胞过程均未能有效清除细胞外Tau单体和Tau纤维,提示需要制定量身定制的治疗策略,以增强神经退行性疾病中的细胞外Tau清除。
Pharmacological research IF 12.2 2026-11-05 PMID: 42988190
Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which treatment options remain limited. Extracellular vesicles (EVs) offer a potential cell-free therapeutic approach, but limited brain exposure after systemic administration remains a major obstacle. Mesenchymal stem-like cells derived from human brain organoids (hBO-MSCs) may provide an alternative EV source with a molecular profile shaped by the neural culture environment. This study aimed to generate RDP-modified hBO-MSC-EVs and evaluate their physicochemical characteristics, acute safety, brain-associated biodistribution, and treatment-associated effects in the 5×FAD mouse model of AD. hBO-MSCs were isolated from dorsal forebrain-like human brain organoids and engineered to express an RDP-Lamp2b-HA fusion protein. EV preparations were characterized by morphology, particle measurements, EV-associated protein markers, and relative RDP-Lamp2b-HA abundance. Brain-associated biodistribution and acute safety were assessed in C57BL/6J mice, whereas treatment-associated outcomes were evaluated in 5×FAD mice receiving PBS, unmodified hBO-MSC-EVs, or hBO-MSC-RDP-EVs. Behavioral testing, hippocampal Aβ histopathology, and exploratory transcriptomic profiling were used to assess the response. Following intravenous administration, RDP modification was associated with greater brain-associated fluorescence than unmodified EVs, without evidence of overt acute organ histopathology or a consistent systemic pro-inflammatory response at the tested endpoints. In 5×FAD mice, hBO-MSC-RDP-EV treatment was associated with improvements in selected behavioral measures, most consistently in the Morris water maze, together with reduced histologically detectable hippocampal Aβ plaque burden and changes in inflammation- and neuronal-associated transcripts. These findings warrant further preclinical evaluation of surface-engineered hBO-MSC-EVs as a candidate cell-free approach for AD. Intact-EV blood-brain barrier transport, cargo-dependent mechanisms, source-specific advantages, and long-term safety remain unestablished.
中文摘要:阿尔茨海默病(AD)是一种进行性神经退行性疾病,治疗选择仍然有限。细胞外囊泡(EVs)提供了一种潜在的无细胞治疗途径,但全身给药后脑内暴露有限仍是主要障碍。来源于人脑类器官的间充质干细胞样细胞(hBO-MSCs)可能提供一种替代性EV来源,其分子谱受到神经培养环境塑造。目标是制备RDP修饰的hBO-MSC-EVs,并评估其理化特征、急性安全性、脑相关生物分布以及在5×FAD AD小鼠模型中的治疗相关效应。hBO-MSCs分离自背侧前脑样人脑类器官,并被工程化表达RDP-Lamp2b-HA融合蛋白。EV制品通过形态、颗粒测量、EV相关蛋白标志物以及RDP-Lamp2b-HA相对丰度进行表征。在C57BL/6J小鼠中评估脑相关生物分布和急性安全性,在5×FAD小鼠中评估治疗相关结局,小鼠分别接受PBS、未修饰hBO-MSC-EVs或hBO-MSC-RDP-EVs。采用行为学测试、海马Aβ组织病理学和探索性转录组分析评估反应。静脉给药后,RDP修饰与未修饰EVs相比伴随更高的脑相关荧光,未见明显急性器官组织病理学证据,也未在所测试终点观察到一致的全身促炎反应。在5×FAD小鼠中,hBO-MSC-RDP-EV治疗与部分行为学指标改善相关,最一致地体现在Morris水迷宫,同时海马组织学可检测的Aβ斑块负荷降低,炎症和神经元相关转录本发生变化。这些发现支持进一步开展临床前评价,将表面工程化hBO-MSC-EVs作为AD的候选无细胞方法。完整EV的血脑屏障转运、货物依赖机制、来源特异性优势及长期安全性仍未确立。
ACS sensors IF 10.9 2026-11-05 PMID: 42986928
Electrochemiluminescence (ECL) biosensors are widely used for ultrasensitive bioanalysis; however, their practical application is often limited by insufficient interface stability under complex detection conditions. Herein, an integrated hydrogel-AAO membrane (HAM) as a novel composite ion-exchange membrane is developed for constructing stable ECL biosensing interfaces. In the HAM architecture, the agarose hydrogel provides a three-dimensional, biocompatible matrix for antibody immobilization and target recognition, while the highly ordered AAO nanochannels serve as an efficient ion-transport and signal transduction pathway. The composite membrane enables effective coupling between interfacial biorecognition events and ECL signal modulation while physically separating the recognition layer from the ECL reaction region. Using glial fibrillary acidic protein (GFAP), a clinically relevant biomarker for Alzheimer's disease, as the model analyte, the proposed sensor achieved a detection limit of 191.6 fg/mL with a linear range from 1 pg/mL to 100 ng/mL. The sensor further demonstrated reliable quantification of GFAP in human serum samples, showing good agreement with a commercial ELISA kit. This work establishes the HAM as a versatile composite ion-exchange membrane for ECL biosensing and provides a general design framework for developing stable and sensitive ECL biosensors for clinical analysis.
中文摘要:电化学发光(ECL)生物传感器广泛用于超灵敏生物分析,但在复杂检测条件下界面稳定性不足常限制其实际应用。构建了一种由琼脂糖水凝胶与阳极氧化铝(AAO)纳米通道膜组成的复合离子交换膜(HAM),用于建立稳定的ECL生物传感界面。在HAM结构中,琼脂糖水凝胶提供三维、生物相容的基质,用于固定抗体并识别目标物;高度有序的AAO纳米通道则作为离子传输和信号转导通路。该复合膜使界面生物识别事件与ECL信号调制有效耦合,同时在物理上分隔识别层与ECL反应区域。以阿尔茨海默病临床相关生物标志物胶质纤维酸性蛋白(GFAP)为模型分析物,传感器检出限为191.6 fg/mL,线性范围为1 pg/mL至100 ng/mL。该传感器还实现了人血清样本中GFAP的可靠定量,结果与商业化ELISA试剂盒具有良好一致性。该工作确立HAM作为用于ECL生物传感的多功能复合离子交换膜,并为开发稳定、灵敏的临床分析ECL生物传感器提供通用设计框架。
Cell death & disease IF 12.2 2026-11-04 PMID: 42982811
While the accumulation of Aβ peptides, derived by proteolytic cleavage from the amyloid precursor protein APP, constitutes a hallmark of Alzheimer's disease, the question of whether endogenous, physiological APP processing serves an essential role for normal brain function(s) has remained elusive. Here, we modified the mouse APP locus to delete the endogenous α- and β-secretase sites (APP residues S592-G621) while preserving the transmembrane topology and the APP C-terminus. These novel knockin mice (termed APPΔS622) lack APPsα, APPβ, and Aβ production and show only minimal soluble APPs shedding. These APPΔS622 mice provide a unique model to distinguish between functions mediated by unprocessed cell surface APP involved in synaptic adhesion or by proteolytic fragments. Strikingly, APPΔS622 mice exhibit pronounced impairments in both long-term potentiation (LTP) and homeostatic forms of synaptic plasticity. Extracellular field recordings revealed significant deficits in hippocampal LTP, associated with a reduced density of mature spines and reduced spine head size. LTP deficits could be restored by APPsα application, suggesting a requirement for non-amyloidogenic APP processing for LTP. In addition, APPΔS622 mice lacking endogenous Aβ displayed a lack of homeostatic synaptic scaling in response to network impairment that could be specifically rescued by exogenous Aβ. Importantly, these deficits in different forms of synaptic plasticity also led to impairments in cognitive behavior. In summary, our findings reveal an essential role of physiological APP processing products to differentially regulate complementary forms of synaptic plasticity that are critical for network stability, normal brain function and cognition.
中文摘要:Aβ肽由淀粉样前体蛋白APP经蛋白水解切割产生,其积聚是阿尔茨海默病的标志;内源性生理性APP加工是否对正常脑功能具有必需作用,一直未明。我们修饰小鼠APP基因座,删除内源性α-和β-分泌酶切割位点(APP残基S592-G621),同时保留跨膜拓扑结构和APP C端。这些新型敲入小鼠(称为APPΔS622)不产生APPsα、APPβ和Aβ,仅有极少量可溶性APPs脱落。APPΔS622小鼠为区分未加工细胞表面APP介导的突触黏附功能与蛋白水解片段功能提供了独特模型。APPΔS622小鼠在长时程增强(LTP)和稳态突触可塑性方面均表现出明显损伤。细胞外场电位记录显示海马LTP显著缺陷,并伴有成熟树突棘密度降低和树突棘头部大小减小。给予APPsα可恢复LTP缺陷,提示非淀粉样途径APP加工对LTP是必需的。缺乏内源性Aβ的APPΔS622小鼠在网络受损时缺乏稳态突触缩放,外源性Aβ可特异性挽救这一缺陷。不同形式突触可塑性的这些缺陷也导致认知行为受损。这些发现揭示生理性APP加工产物对互补形式突触可塑性具有差异性调节作用,而这些可塑性对网络稳定性、正常脑功能和认知至关重要。
Neuron IF 16.9 2026-11-04 PMID: 42982039
P2X purinoreceptor 7 (P2RX7), an ATP-gated ion channel, contributes to Alzheimer's disease (AD) progression, but its molecular mechanisms remain unclear. Here, we show that genetic disruption of P2rx7 mitigates brain atrophy, tau accumulation, and cognitive impairment in PS19 mice. Microglia-specific, but not astrocyte-specific, deletion of P2rx7 suppresses tau propagation. Single-cell RNA sequencing identifies a previously unrecognized first-responding microglial state (FRM) with prominent P2rx7 expression. P2RX7 promotes the transition from FRM to an inflammatory microglial state enriched in extracellular vesicle (EV) biogenesis. P2RX7 increases EV loading of tau and of mitochondrial proteins and DNA, which activate cytosolic DNA sensing and interferon signaling in recipient microglia. Tau-containing microglial EVs disrupt neuronal endolysosomal integrity and facilitate endosomal tau escape and phosphorylation. Thus, P2RX7 regulates the FRM branch point, driving inflammatory microglial transition and EV-mediated spread of tau and toxic mitochondrial molecules and highlighting the P2RX7-EV axis as a therapeutic target in AD.
中文摘要:P2X嘌呤受体7(P2RX7)是一种ATP门控离子通道,参与阿尔茨海默病(AD)进展,但其分子机制仍不清楚。研究显示,遗传性破坏P2rx7可减轻PS19小鼠的脑萎缩、tau积累和认知障碍。小胶质细胞特异性而非星形胶质细胞特异性缺失P2rx7可抑制tau传播。单细胞RNA测序识别出一种此前未被认识的首批反应小胶质细胞状态(FRM),其P2rx7表达突出。P2RX7促进FRM向富集细胞外囊泡(EV)生物发生的炎症性小胶质细胞状态转变。P2RX7增加EV对tau以及线粒体蛋白和DNA的装载,这些成分激活受体小胶质细胞中的胞质DNA感知和干扰素信号。含tau的小胶质细胞EV破坏神经元内溶酶体完整性,并促进内体tau逃逸和磷酸化。因此,P2RX7调控FRM分支点,驱动炎症性小胶质细胞转变以及EV介导的tau和毒性线粒体分子传播,并突出P2RX7-EV轴作为AD治疗靶点。
MedComm IF 14.1 2026-11 PMID: 42985466
Alzheimer's disease (AD) is a devastating neurodegenerative condition accompanied by widespread central nervous system damage and complex networked pathogenesis spanning molecular, cellular, and systemic dimensions. Existing studies tend to focus on individual pathological cascades or monotherapeutic approaches, while overlooking the intrinsic crosstalk among protein pathology, neuroinflammation, metabolic dysfunction, and gut-brain axis imbalance, with insufficient systematic integration of nonpharmacological strategies and multifunctional nanoplatforms. Driven by intertwined molecular aberrations, glial dysregulation and systemic metabolic disorders, AD presents profound pathological complexity. Correspondingly, multitarget pharmacotherapy integrated with hierarchical nonpharmacological and nanotherapeutic interventions has achieved substantial progress, exerting synergistic effects on alleviating AD pathological cascades and optimizing overall therapeutic regimens. We comprehensively review current evidence to delineate the mechanistic landscape of AD and update therapeutic advances, including pharmacological agents, multimodal nonpharmacological interventions, and brain-targeted nanosystems for blood-brain barrier penetration, protein modulation, microenvironment remodeling, and gene editing delivery. This study underscores major research limitations and translational obstacles in therapeutic efficacy, biosafety, and nanomedicine applications. This work emphasizes biomarker-based early stratification and staged combined interventions, providing novel integrated insights into AD pathogenesis and prospective targeted therapeutic development.
中文摘要:阿尔茨海默病(AD)是一种破坏性神经退行性疾病,伴随广泛的中枢神经系统损伤,其发病机制呈复杂网络化,跨越分子、细胞和系统层面。现有研究多聚焦单一病理级联或单一治疗方式,忽略蛋白质病理、神经炎症、代谢功能障碍与肠脑轴失衡之间的内在交互,对非药物策略与多功能纳米平台的系统整合也不充分。在相互交织的分子异常、胶质细胞失调和系统性代谢紊乱驱动下,AD表现出显著的病理复杂性。与之相应,多靶点药物治疗联合分层非药物干预和纳米治疗干预已取得实质进展,在减轻AD病理级联和优化整体治疗方案方面产生协同效应。我们全面梳理现有证据,勾勒AD机制图景并更新治疗进展,涵盖药物、多模式非药物干预以及脑靶向纳米系统在跨越血脑屏障、调控蛋白质、重塑微环境和递送基因编辑方面的应用。本工作强调疗效、生物安全性和纳米医学应用中的主要研究局限与转化障碍,并突出基于生物标志物的早期分层与分期联合干预,为AD发病机制及未来靶向治疗开发提供新的整合性认识。
Advanced healthcare materials IF 11.0 2026-11-02 PMID: 42971925
This study examined anti-transferrin receptor (TfR) nanobody-functionalized bacterial outer membrane vesicles (OMVs) as an engineered platform for improving Alzheimer's disease (AD)-like neuronal injury. Escherichia coli-derived OMVs were characterized for morphology, size distribution, surface charge, protein features, nanobody loading, residual endotoxin levels, endotoxin-associated inflammatory responses, and repeated-exposure immune-safety readouts, and were evaluated in neuronal-related cells and APP/PS1 mice. Engineered OMVs showed receptor-associated uptake and preferential brain-delivery signals, increased HT-22 cell viability, reduced apoptosis, and elevated mitophagy-associated markers including LC3-II, PINK1, and Parkin. OMV treatment also reduced cytosolic mtDNA abundance, DNA/cGAS colocalization, phosphorylation of STING/TBK1/IRF3, and inflammatory-marker expression. PINK1 or Parkin knockdown partially weakened OMV-associated mitochondrial and inflammatory readouts, whereas pharmacological autophagy modulation supported a contribution of autophagy-related processes without establishing selective PINK1/Parkin-dependent mitophagy in vivo. In APP/PS1 mice, OMV administration improved Morris water maze and rotarod performance and alleviated neuroinflammatory and histological injury-related changes. Overall, anti-TfR nanobody-modified OMVs were associated with enhanced receptor-related delivery, mitophagy-linked phenotypes, reduced cytosolic mtDNA/cGAS-STING-related inflammatory signaling, and improved AD-like outcomes, supporting further delivery-system optimization and mechanistic validation.
中文摘要:考察了抗转铁蛋白受体(TfR)纳米抗体功能化细菌外膜囊泡(OMVs)作为改善阿尔茨海默病(AD)样神经元损伤的工程化平台。对大肠杆菌来源OMVs的形态、粒径分布、表面电荷、蛋白特征、纳米抗体负载、残留内毒素水平、内毒素相关炎症反应及重复暴露免疫安全性指标进行了表征,并在神经相关细胞和APP/PS1小鼠中评估。工程化OMVs表现出受体相关摄取和优先脑递送信号,提高HT-22细胞活力,减少凋亡,并升高LC3-II、PINK1和Parkin等线粒体自噬相关标志物。OMV处理还降低胞质mtDNA丰度、DNA/cGAS共定位、STING/TBK1/IRF3磷酸化及炎症标志物表达。敲低PINK1或Parkin部分削弱OMV相关的线粒体和炎症读数,药理学自噬调控支持自噬相关过程的贡献,但未在体内确立选择性PINK1/Parkin依赖的线粒体自噬。在APP/PS1小鼠中,OMV给药改善Morris水迷宫和转棒表现,减轻神经炎症及组织学损伤相关改变。总体而言,抗TfR纳米抗体修饰OMVs与增强的受体相关递送、线粒体自噬相关表型、降低的胞质mtDNA/cGAS-STING相关炎症信号及改善的AD样结局相关,支持进一步优化递送系统并开展机制验证。
Autophagy IF 18.6 2026-11-02 PMID: 42912487
Pathological accumulation of MAPT/tau protein is a defining feature of Alzheimer disease (AD) and related tauopathies, highlighting the need to identify druggable regulators of MAPT/tau clearance. Using Drosophila behavioral assays focused on cytoskeletal remodeling pathways dysregulated in AD, we identified genes whose genetic modulation mitigates MAPT/tau-induced behavioral deficits. These modifiers were validated by histopathology and mechanistically examined in human tauopathy cell models to determine their impact on autophagy-dependent MAPT/tau degradation. Autophagic flux, ATG9A trafficking, and autophagosome biogenesis were further analyzed. Across models, reduction of the phosphatase SSH1 consistently lowered steady-state MAPT/tau levels by enhancing autophagic flux through a mechanism distinct from its canonical regulation of CFL1. Mechanistically, SSH1 functions as a negative regulator of early autophagosome formation: SSH1 depletion promotes ATG9A mobilization to the endoplasmic reticulum-phagophore assembly site (ER-PAS), thereby accelerating autophagic vesicle biogenesis. Importantly, the MAPT/tau-lowering effect of Dmssh attenuation was abolished in flies haploinsufficient for DmAtg9, demonstrating that SSH1-mediated MAPT/tau clearance requires ATG9 function. Consistent with a direct regulatory interaction, in vitro phosphatase assays revealed that recombinant SSH1 decreases ATG9A phosphorylation in the presence of actin, identifying an SSH1-ATG9A regulatory axis controlling autophagosome initiation. These findings position SSH1 as a nodal inhibitor of autophagy initiation whose inhibition enhances MAPT/tau proteolysis. Notably, SSH1 haploinsufficiency also reduces SNCA/α-synuclein accumulation in vivo, indicating broader relevance to neurodegenerative proteopathies. By integrating in vivo functional screening with mechanistic studies in human cells, this work identifies SSH1 as a druggable phosphatase that constrains autophagy at the level of ATG9A-dependent vesicle formation.Abbreviations: Aβ: amyloid-beta; AD: Alzheimer disease;AMP-AD: Accelerating Medicines Partnership-Alzheimer's Disease; ANOVA: analysis of variance;ATG9A: autophagy related 9A; BDSC: Bloomington Drosophila stock center; BSA: bovine serum albumin; CFL1: cofilin 1; DIOPT: DRSC Integrative Ortholog Prediction Tool; DmAtg9: Drosophila ortholog of ATG9; DMEM: Dulbecco's modified Eagle medium; DMSO: dimethyl sulfoxide; Dmssh: Drosophila ortholog of SSH1; Dmtsr: Drosophila ortholog of CFL1 and CFL2; ER-PAS: endoplasmic reticulum-phagophore assembly site; ESCRT: endosomal sorting complexes required for transport FC: fold change; FTD: frontotemporal dementia; HeLa: Henrietta Lacks; LIMK: lim domain kinase; MTOR: mechanistic target of rapamycin kinase; ND: neurodegenerative disease; NFE2L2/Nrf2: nuclear factor, erythroid derived 2, like 2; PBS: phosphate-buffered saline PD: Parkinson disease; PFA: paraformaldehyde; PHF-1: paired helical filament 1; RNAi: RNA interference; ROSMAP: The Religious Orders Study and Memory and Aging Project; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; snRNA-seq: single nucleus RNA-sequencing; SQSTM1/p62: sequestosome 1; SS inhibitor: SAR405 + SBI-0206965 inhibitors; SSH1: slingshot protein phosphatase 1; ULK1: unc-51 like kinase 1; WT: wild type.
中文摘要:MAPT/tau蛋白的病理性积聚是阿尔茨海默病(AD)及相关tau蛋白病的标志性特征,因而需要识别可成药调控MAPT/tau清除的因子。利用聚焦于AD中失调的细胞骨架重塑通路的果蝇行为学实验,筛选出遗传调控可减轻MAPT/tau诱导行为缺陷的基因。这些修饰基因经组织病理学验证,并在人tau蛋白病细胞模型中进行机制研究,以确定其对自噬依赖性MAPT/tau降解的影响。进一步分析自噬流、ATG9A转运和自噬体生成。跨模型降低磷酸酶SSH1可一致降低稳态MAPT/tau水平,其增强自噬流的机制不同于对CFL1的经典调控。机制上,SSH1是早期自噬体形成的负调控因子:SSH1缺失促进ATG9A动员至内质网-吞噬泡组装位点(ER-PAS),加速自噬囊泡生成。DmAtg9单倍剂量不足的果蝇中,Dmssh减弱带来的MAPT/tau降低效应消失,表明SSH1介导的MAPT/tau清除需要ATG9功能。与直接调控相互作用一致,体外磷酸酶实验显示,在肌动蛋白存在时重组SSH1降低ATG9A磷酸化,确定了一条控制自噬体起始的SSH1-ATG9A调控轴。这些发现将SSH1定位为自噬起始的关键抑制因子,抑制SSH1可增强MAPT/tau蛋白水解。SSH1单倍剂量不足也在体内减少SNCA/α-突触核蛋白积聚,提示其与更广泛的神经退行性蛋白病相关。通过整合体内功能筛选与人细胞机制研究,这项工作确定SSH1是一种可成药磷酸酶,在ATG9A依赖性囊泡形成层面限制自噬。缩写:Aβ为淀粉样β蛋白;AD为阿尔茨海默病;AMP-AD为加速药物伙伴关系-阿尔茨海默病;ANOVA为方差分析;ATG9A为自噬相关9A;BDSC为Bloomington果蝇库存中心;BSA为牛血清白蛋白;CFL1为肌动蛋白解聚因子1;DIOPT为DRSC整合直系同源预测工具;DmAtg9为ATG9的果蝇直系同源物;DMEM为Dulbecco改良Eagle培养基;DMSO为二甲基亚砜;Dmssh为SSH1的果蝇直系同源物;Dmtsr为CFL1和CFL2的果蝇直系同源物;ER-PAS为内质网-吞噬泡组装位点;ESCRT为转运所需内体分选复合物;FC为倍数变化;FTD为额颞叶痴呆;HeLa为Henrietta Lacks细胞;LIMK为LIM结构域激酶;MTOR为雷帕霉素激酶机制靶点;ND为神经退行性疾病;NFE2L2/Nrf2为核因子红细胞来源2样2;PBS为磷酸盐缓冲液;PD为帕金森病;PFA为多聚甲醛;PHF-1为配对螺旋丝1;RNAi为RNA干扰;ROSMAP为宗教秩序研究与记忆与衰老项目;SDS-PAGE为十二烷基硫酸钠-聚丙烯酰胺凝胶电泳;snRNA-seq为单核RNA测序;SQSTM1/p62为sequestosome 1;SS抑制剂为SAR405+SBI-0206965抑制剂;SSH1为slingshot蛋白磷酸酶1;ULK1为unc-51样激酶1;WT为野生型。
Pharmacological research IF 12.2 2026-11 PMID: 42906650
Synaptic and circuit dysfunction in the hippocampus is an early feature of Alzheimer's disease, involving disturbances at both excitatory and inhibitory synapses. Adenosine receptors (ARs) regulate hippocampal glutamatergic and GABAergic signaling. Caffeine, a non-selective AR antagonist, has well-established neuroprotective actions. We examined whether caffeine attenuates amyloid-β (Aβ)-induced changes in neuronal viability, GABA handling, intrinsic excitability and synaptic excitation/inhibition (E/I) balance, and whether these functional effects occur alongside changes in AR and GABA transporter 1 (GAT-1) protein abundance. Primary mouse hippocampal cultures were exposed to Aβ1-42 (1 nM) and/or caffeine (0.1, 1, 25, and 50 µM) for culture-based assays, whereas acute hippocampal slices were exposed to Aβ1-42 (100 nM) and/or caffeine (25 µM) during whole-cell patch-clamp recordings from CA1 pyramidal neurons. In cultures, Aβ increased neuronal death, confirming previous reports, and caffeine co-treatment attenuated this effect. Total GAT-1, A1R and A2AR protein levels were unchanged, whereas Aβ reduced neuronal A1R immunoreactivity; this reduction was not observed with caffeine co-treatment. Radiometric assays identified treatment-associated differences in 1-h 3H-GABA accumulation and basal 3H-GABA outflow, including a non-significant trend toward increased accumulation after Aβ exposure and reduced accumulation in the Aβ + caffeine condition. In slices, Aβ flattened the frequency-current relationship and transiently reduced the E/I ratio, whereas these changes were not observed during caffeine co-application; subsequent caffeine exposure restored firing output after 30 min of Aβ exposure. Further experiments are required to establish if changes in A1R immunoreactivity or radiometric GABA handling contribute to the electrophysiological effects.
中文摘要:海马突触与环路功能障碍是阿尔茨海默病的早期特征,涉及兴奋性和抑制性突触的异常。腺苷受体(ARs)调节海马谷氨酸能与GABA能信号。咖啡因是非选择性AR拮抗剂,具有明确的神经保护作用。本研究考察咖啡因是否减轻淀粉样β蛋白(Aβ)引起的神经元存活、GABA处理、内在兴奋性和突触兴奋/抑制(E/I)平衡变化,并观察这些功能效应是否伴随AR与GABA转运体1(GAT-1)蛋白丰度改变。原代小鼠海马培养物暴露于Aβ1-42(1 nM)和/或咖啡因(0.1、1、25、50 µM)用于培养实验;急性海马切片在CA1锥体神经元全细胞膜片钳记录期间暴露于Aβ1-42(100 nM)和/或咖啡因(25 µM)。在培养物中,Aβ增加神经元死亡,印证既往报道,咖啡因共处理减轻该效应。总GAT-1、A1R和A2AR蛋白水平未变,Aβ降低神经元A1R免疫反应性;咖啡因共处理时未观察到这一降低。放射测定发现处理相关差异存在于1小时3H-GABA蓄积和基础3H-GABA外流,包括Aβ暴露后蓄积增加的非显著趋势以及Aβ+咖啡因条件下蓄积减少。在切片中,Aβ使频率-电流关系变平并短暂降低E/I比值,咖啡因共施加时未观察到这些变化;Aβ暴露30分钟后给予咖啡因可恢复放电输出。仍需进一步实验确定A1R免疫反应性或放射测定GABA处理的变化是否参与这些电生理效应。
Pharmacological research IF 12.2 2026-11 PMID: 42892457
The "metal ion hypothesis" of Alzheimer's disease (AD) has gained widespread acceptance, but translating this understanding into effective therapies remains elusive. This likely stems from a simplistic understanding of metal homeostasis as merely a matter of "excess and deficiency." This article reviews the context-dependent roles of iron, copper, zinc, aluminum, and manganese in the pathogenesis of AD, with a particular focus on their bidirectional interactions with classic AD pathology (the ferroptosis hypothesis is relatively mature, while emerging hypotheses such as cuproptosis have not been fully elucidated). Metal homeostasis dysregulation can directly promote β-amyloid aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation, and regulated cell death. Conversely, these pathological processes can also alter the binding, storage, transport, and subcellular distribution of metal ions. Dysregulated metal ions function as "context-dependent" modulators of pathological processes. Their functional effects depend on metal species, concentration, binding state, subcellular compartment, and disease stage. Metal homeostasis dysregulation associated with AD may essentially reflect a redistribution between physiological and pathological pools. Ideal interventions should selectively neutralize pathological metal pools while preserving or restoring essential metal-dependent neuronal functions. By integrating the latest advances in the field of metal-targeted therapies (chelators, metabolic modulators, biomarkers, metal imaging, and gene editing), we emphasize that future treatments should shift from nonspecific metal clearance toward precise metal regulation and precision medicine.
中文摘要:阿尔茨海默病的「金属离子假说」已被广泛接受,但将其转化为有效治疗仍很困难。原因可能在于把金属稳态简单理解为「过量与缺乏」。铁、铜、锌、铝、锰在阿尔茨海默病发病中呈情境依赖作用,其与经典阿尔茨海默病病理的双向交互值得关注(铁死亡假说相对成熟,铜死亡等新假说尚未充分阐明)。金属稳态失调可直接促进β-淀粉样蛋白聚集、tau过度磷酸化、氧化应激、神经炎症和调节性细胞死亡。反过来,这些病理过程也会改变金属离子的结合、储存、转运和亚细胞分布。失调的金属离子作为「情境依赖」的病理过程调节因子发挥作用,其功能效应取决于金属种类、浓度、结合状态、亚细胞区室和疾病阶段。阿尔茨海默病相关的金属稳态失调可能本质上反映生理池与病理池之间的再分布。理想干预应选择性中和病理金属池,同时保留或恢复必需的金属依赖神经元功能。结合金属靶向治疗领域的最新进展(螯合剂、代谢调节剂、生物标志物、金属成像和基因编辑),未来治疗应从非特异性金属清除转向精准金属调控和精准医学。
Redox biology IF 16.2 2026-11 PMID: 42748655
Air pollution (AirP) exposure is associated with increased risk of Alzheimer's disease (AD), yet AirP is chemically heterogeneous, complicating identification of shared pathogenic drivers. We compared acute cortical responses to two chemically distinct but metal-rich AirP sources, diesel exhaust particles (DEP) and World Trade Center (WTC) dust, and contrasted them with woodsmoke (WS), a particulate exposure containing substantially lower metal content. Despite major differences in particle composition and size, DEP and WTC elicited highly convergent transcriptomic responses, sharing more than 1200 differentially expressed genes associated with oxidative stress, interferon signaling, ferroptosis, neuronal remodeling, and amyloid processing. These transcriptional changes were accompanied by disrupted glutathione synthesis, altered ferritin-mediated iron storage and heme metabolism, and selective impairment of lipid raft antioxidant defenses, resulting in a 40% increase in lipid raft 4-hydroxynonenal (HNE) with WTC dust with DEP trending similarly, and at least a 65% reduction in phospholipid hydroperoxide detoxification capacity, and 36% increase in the aggregation-prone Aβ42 peptide for both pollution sources. Notably, both exposures produced acute white-matter abnormalities within the corpus callosum despite the absence of bulk brain iron accumulation, indicating that redistribution of bioactive iron rather than total iron burden may be sufficient to promote oxidative injury. In contrast, WS produced a distinct transcriptional profile, lacked coordinated ferroptotic priming, failed to induce lipid peroxidation or Aβ42 accumulation, and showed minimal effects on iron metabolism. Together, these findings identify metal-associated oxidative mechanisms as a convergent pathway linking chemically distinct forms of AirP to ferroptotic vulnerability, amyloidogenic processing, and AD-relevant pathology.
中文摘要:空气污染(AirP)暴露与阿尔茨海默病(AD)风险升高相关,但AirP在化学组成上高度异质,增加了识别共同致病驱动因素的难度。我们比较了两种化学组成不同但均富含金属的AirP来源,即柴油尾气颗粒(DEP)和世界贸易中心(WTC)粉尘,对急性皮层反应的影响,并将其与金属含量明显较低的颗粒物暴露木材烟雾(WS)进行对照。尽管颗粒组成和粒径差异显著,DEP与WTC仍引发高度趋同的转录组反应,共享超过1200个差异表达基因,涉及氧化应激、干扰素信号、铁死亡、神经元重塑和淀粉样蛋白加工。这些转录变化伴随谷胱甘肽合成受扰、铁蛋白介导的铁储存及血红素代谢改变,以及脂筏抗氧化防御的选择性受损,导致WTC粉尘使脂筏中4-羟基壬烯醛(HNE)增加40%,DEP呈相似趋势,磷脂氢过氧化物解毒能力至少降低65%,两种污染源均使易聚集的Aβ42肽增加36%。两种暴露在脑内总体铁蓄积不明显的情况下,均在胼胝体内引起急性白质异常,提示生物活性铁的再分布而非总铁负荷可能足以促进氧化损伤。相比之下,WS产生不同的转录谱,缺乏协同的铁死亡启动,未诱导脂质过氧化或Aβ42积聚,对铁代谢影响很小。这些发现将金属相关氧化机制确定为连接化学组成不同的AirP与铁死亡易感性、淀粉样蛋白生成加工及AD相关病理的趋同通路。
Ageing research reviews IF 15.5 2026-11 PMID: 42735872
Dementia is a progressive neurodegenerative syndrome characterised by cognitive decline, synaptic dysfunction, and neuronal loss. In recent years, growing attention has been given to the role of the gut-brain axis in neurodegenerative disease. Emerging evidence indicates that changes in gut microbiota composition and metabolic activity may affect various systemic processes that contribute to dementia. This review examines the current evidence linking gut microbiota imbalance to dementia through mechanisms involving immune regulation, metabolic signalling, and neuronal stability. Clinical studies have identified distinct microbial changes in patients with cognitive impairment, including decreased microbial diversity and altered abundance of specific bacterial groups. These changes may affect host physiology via several interconnected pathways. Disruption of the intestinal barrier due to dysbiosis can facilitate the translocation of microbial products into the bloodstream, triggering immune activation. Microbial metabolites, such as short-chain fatty acids, bile acids, and tryptophan-derived compounds, can influence metabolic signalling and cellular functions within the nervous system. These pathways have been implicated in processes relevant to dementia, including neuroinflammation, mitochondrial dysfunction, synaptic impairment, and neurovascular alterations. Although most research focuses on Alzheimer's disease, emerging evidence suggests that microbiota-related mechanisms may also be relevant to other dementia types, such as vascular dementia, frontotemporal dementia and dementia with Lewy bodies. Despite these advances, the underlying mechanisms remain underexplored, and further research is needed to investigate molecular pathways and host-microbiome interactions. This knowledge could support the development of novel biomarkers and inform the future development of microbiota-targeted strategies for dementia, although their clinical efficacy and applicability remain to be established.
中文摘要:痴呆是一种以认知下降、突触功能障碍和神经元丢失为特征的进行性神经退行性综合征。近年来,肠脑轴在神经退行性疾病中的作用受到越来越多关注。新出现的证据表明,肠道菌群组成和代谢活动的变化可能影响多种参与痴呆发生的全身过程。本综述考察当前证据,这些证据通过免疫调节、代谢信号传递和神经元稳定性等机制,将肠道菌群失衡与痴呆联系起来。临床研究已发现认知障碍患者存在独特的微生物变化,包括微生物多样性下降和特定细菌类群丰度改变。这些变化可能通过若干相互关联的通路影响宿主生理。菌群失调导致的肠道屏障破坏可促使微生物产物进入血流,触发免疫激活。微生物代谢物,如短链脂肪酸、胆汁酸和色氨酸衍生化合物,可影响神经系统内的代谢信号传递和细胞功能。这些通路涉及与痴呆相关的进程,包括神经炎症、线粒体功能障碍、突触损伤和神经血管改变。尽管多数研究聚焦于阿尔茨海默病,新证据提示微生物相关机制也可能与其他痴呆类型有关,如血管性痴呆、额颞叶痴呆和路易体痴呆。尽管有这些进展,其潜在机制仍未得到充分探索,需要进一步研究分子通路和宿主-微生物组相互作用。这些认识可支持新型生物标志物的开发,并为未来针对微生物群的痴呆策略提供信息,但其临床有效性和适用性仍有待确立。
Ageing research reviews IF 15.5 2026-11 PMID: 42727647
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder in which neuroinflammation, vascular dysfunction, metabolic disturbances, and impaired tissue resilience contribute to disease progression. Aerobic exercise is a widely applicable lifestyle intervention that has been increasingly investigated in AD; however, the mechanisms linking peripheral exercise adaptations to brain outcomes remain incompletely understood. This review evaluates the potential contribution of gut-derived signaling within the broader multisystem response to aerobic exercise, focusing on evidence strength, causal interpretation, and translational limitations. Current evidence suggests that aerobic exercise is associated with alterations in gut microbial features, microbial-derived metabolites, intestinal barrier-related processes, peripheral inflammatory signaling, and brain-relevant responses. Preclinical studies, mainly from AD mouse models, provide biological plausibility that microbiota-related factors may contribute to exercise-associated modulation of neuroinflammation, amyloid-β and tau pathology, and cognitive outcomes. However, microbiota-targeted interventions provide only partial support for causal involvement because of limited specificity and ecological constraints. Human studies support exercise-associated improvements in cognitive, metabolic, inflammatory, and functional outcomes, but direct evidence that gut-derived alterations mediate these benefits remains unavailable. Overall, aerobic exercise should be viewed as a multisystem physiological stimulus rather than an intervention acting through a single gut-mediated pathway. Gut-derived signals represent plausible candidate interfaces that interact with vascular, metabolic, neurotrophic, immune, and neurovascular mechanisms. Future longitudinal and mechanistic studies integrating multi-compartment measurements and pathway-specific perturbation are required to determine whether gut-related alterations represent mediators, consequences, or parallel adaptations of exercise-associated benefits in AD.
中文摘要:阿尔茨海默病(AD)是一种多因素神经退行性疾病,神经炎症、血管功能障碍、代谢紊乱和组织韧性受损共同推动疾病进展。有氧运动是一种适用面广的生活方式干预,在AD中受到越来越多研究;但外周运动适应如何连接至脑结局,其机制仍未完全明确。本综述评估肠源性信号在更广泛的多系统有氧运动反应中的潜在贡献,重点关注证据强度、因果解释和转化局限。现有证据提示,有氧运动与肠道微生物特征、微生物来源代谢物、肠屏障相关过程、外周炎症信号以及脑相关反应的变化有关。临床前研究主要来自AD小鼠模型,提供生物学合理性,即微生物相关因素可能参与运动对神经炎症、淀粉样β蛋白和tau病理以及认知结局的调节。微生物群靶向干预对因果参与仅提供部分支持,原因在于特异性有限和生态学约束。人体研究支持运动相关认知、代谢、炎症和功能结局改善,但尚无直接证据表明肠源性改变介导这些获益。总体而言,有氧运动应被视为一种多系统生理刺激,而非通过单一肠道介导通路起作用的干预。肠源性信号是与血管、代谢、神经营养、免疫和神经血管机制相互作用的合理候选界面。未来需要整合多隔室测量和通路特异性扰动的纵向与机制研究,以判定肠道相关改变在AD运动获益中是介导因素、结果,还是平行适应。
Nature neuroscience IF 20.3 2026-11 PMID: 42711429
Bone marrow-derived macrophages were shown to play an important role in coping with Alzheimer's disease (AD). Boosting their spontaneous recruitment reduces inflammation and disease pathology and slows cognitive decline in mouse models of amyloidosis. However, the factors limiting their spontaneous homing to the diseased brain remain unclear. In this study, we discovered that monocyte development is impaired in mouse models and in patients. In the 5×FAD mouse model, monocyte differentiation was disrupted due to a maladaptive type I interferon (IFN-I)-mediated bone marrow response. A similar phenotype was found in circulating monocytes from patients with AD. Blocking IFN-I signaling with neutralizing antibodies or reconstituting 5×FAD mice with IFN-I receptor-deficient bone marrow restored myelopoiesis, normalized monocyte phenotypes and ameliorated disease pathology. This was accompanied by increased homing of monocyte-derived macrophages to the brain. Our results reveal a dysfunction in bone marrow myelopoiesis in AD and reinforce the concept that AD progression is driven by maladaptive systemic processes.
中文摘要:已有研究表明,骨髓来源巨噬细胞在应对阿尔茨海默病(AD)中发挥重要作用。促进其自发募集可减轻炎症和疾病病理,并延缓淀粉样变小鼠模型的认知下降。然而,限制其自发归巢至病变脑组织的因素仍不清楚。研究发现,小鼠模型和患者中单核细胞发育均受损。在5×FAD小鼠模型中,单核细胞分化因适应不良的I型干扰素(IFN-I)介导的骨髓反应而受阻。AD患者循环单核细胞中可见相似表型。用中和抗体阻断IFN-I信号,或以IFN-I受体缺陷骨髓重建5×FAD小鼠,可恢复髓系生成、使单核细胞表型正常化并改善疾病病理。同时,单核细胞来源巨噬细胞向脑内的归巢增加。结果揭示了AD中骨髓髓系生成功能障碍,并支持AD进展由适应不良的系统性过程驱动的观点。
Ageing research reviews IF 15.5 2026-11 PMID: 42700866
Alzheimer's disease (AD) is an age-dependent neurodegenerative syndrome in which microglial senescence bridges biological ageing and Aβ-tau pathology. Senescent microglia undergo permanent cell-cycle arrest, upregulate p16INK4a and SA-β-gal, and secrete a pro-inflammatory senescence-associated secretory phenotype (SASP) that sustains chronic neuroinflammation. Mitochondria-endoplasmic reticulum contact sites (MERCS) are dynamic physical junctions between the endoplasmic reticulum (ER) and mitochondria, whereas mitochondria-associated membranes (MAM) are biochemically enriched ER subdomains located at MERCS. MERCS coordinate calcium shuttling, mitochondrial dynamics, lipid trafficking and the unfolded protein response (UPR); however, whether their dysfunction drives microglial senescence in vivo remains largely untested. This review critically integrates five MERCS-linked signalling axes that are hypothesised to drive microglial senescence, namely calcium overload, mitochondrial fission-fusion imbalance, inflammatory amplification, lipid dysregulation and unresolved ER stress. We apply a standardized four-tier evidence-grading framework to stratify causal evidence, systematically distinguish dystrophic, disease-associated (DAM) and bona-fide senescent microglia on the basis of transcriptomic and proteomic data from AD models and human tissues, and address underexplored dimensions including APOE/TREM2 crosstalk, mitophagy, epigenetic regulation, peripheral inflammation and senolytic combinations. We stress that inflammatory activation, oxidative stress and mitochondrial dysfunction represent common cellular stress responses that cannot independently define bona-fide microglial senescence. Because more than 90% of current mechanistic evidence is derived from non-microglial models, MERCS dysfunction in microglia remains a compelling hypothesis that requires rigorous in-vivo validation. Notably, MERCS dysfunction and AD-relevant APOE/TREM2 signalling engage in mutually modulatory crosstalk rather than a simple linear upstream-downstream hierarchy. Translational development faces several barriers, including poor blood-brain barrier (BBB) penetration, off-target neurotoxicity, uncharacterised long-term safety and limited generalisability from APP/PS1 models lacking tauopathy. All MERCS-targeted and senolytic combinatorial strategies discussed herein represent prospective pre-clinical research directions rather than mature clinical therapeutic approaches. We propose an experimental roadmap based on conditional knockouts, intravital imaging and bidirectional interventions. Overall, MERCS dysfunction is proposed as a candidate multimodal upstream hub for calcium, mitochondrial, inflammatory, lipid and ER-stress signalling, and rigorous in-vivo validation together with microglia-selective delivery platforms is essential for therapeutic translation.
中文摘要:阿尔茨海默病(AD)是一种年龄依赖性神经退行性综合征,其中小胶质细胞衰老连接生物学衰老与Aβ-tau病理。衰老小胶质细胞发生永久性细胞周期停滞,上调p16INK4a和SA-β-gal,并分泌促炎性衰老相关分泌表型(SASP),维持慢性神经炎症。线粒体-内质网接触位点(MERCS)是内质网与线粒体之间的动态物理连接,而线粒体相关膜(MAM)是位于MERCS的生化富集内质网亚区。MERCS协调钙转运、线粒体动力学、脂质转运和未折叠蛋白反应(UPR);然而,其功能障碍是否在体内驱动小胶质细胞衰老仍基本未经检验。这篇综述批判性整合五条被假设驱动小胶质细胞衰老的MERCS相关信号轴,即钙超载、线粒体分裂-融合失衡、炎症放大、脂质失调和未缓解的内质网应激。我们采用标准化四级证据分级框架对因果证据进行分层,基于AD模型和人体组织的转录组与蛋白质组数据系统区分营养不良性小胶质细胞、疾病相关小胶质细胞(DAM)和真正衰老的小胶质细胞,并讨论未充分探索的维度,包括APOE/TREM2交互、线粒体自噬、表观遗传调控、外周炎症和衰老细胞清除联合方案。我们强调炎症激活、氧化应激和线粒体功能障碍是常见细胞应激反应,不能独立定义真正的小胶质细胞衰老。由于当前90%以上的机制证据来自非小胶质细胞模型,小胶质细胞中的MERCS功能障碍仍是一个有说服力的假说,需要严格的体内验证。需要强调,MERCS功能障碍与AD相关APOE/TREM2信号之间是相互调节的交互,而非简单的线性上下游层级。转化开发面临若干障碍,包括血脑屏障(BBB)穿透差、脱靶神经毒性、长期安全性未明确,以及缺乏tau病理的APP/PS1模型带来的普适性有限。文中讨论的所有靶向MERCS及衰老细胞清除联合策略都是前瞻性临床前研究方向,而非成熟的临床治疗手段。我们提出基于条件性敲除、活体成像和双向干预的实验路线图。整体上,MERCS功能障碍被提出是钙、线粒体、炎症、脂质和内质网应激信号的候选多模式上游枢纽,严格的体内验证连同小胶质细胞选择性递送平台对治疗转化至关重要。
Ageing research reviews IF 15.5 2026-11 PMID: 42697335
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder worldwide. Conventional downstream interventions targeting β-amyloid (Aβ) and tau proteins have repeatedly failed in clinical practice, and mitochondrial functional decline has been identified as the core upstream driver of AD pathogenesis. Focusing on the mitochondrial functional network as the core target, this paper systematically dissects the key molecular mechanisms of mitochondrial dysfunction during AD progression, including oxidative phosphorylation impairment, mitochondrial DNA (mtDNA) mutations and genetic defects, excessive reactive oxygen species (ROS) production, mitochondrial dynamics imbalance, mitophagy dysfunction, calcium homeostasis dysregulation, mitochondrial transport defects, and the bidirectional regulatory pathway of tau pathology, and elucidates the pathological network featured by cascade amplification and reciprocal regulation among these abnormal mechanisms. It also comprehensively summarizes mitochondria-targeted intervention strategies for AD, analyzes the research limitations in this field such as model heterogeneity, lack of specific biomarkers and inefficient drug delivery, and prospects future research directions by integrating cutting-edge technologies including cell reprogramming and artificial intelligence (AI). This study provides a novel interpretation of the aging-related pathogenic mechanisms of AD from a mitochondrial perspective, lays a theoretical foundation for the development of precise and efficient mitochondria-targeted therapeutic strategies for AD, and offers a new paradigm for breaking through the bottlenecks of clinical diagnosis and treatment of AD.
中文摘要:阿尔茨海默病(AD)是全球最常见的神经退行性疾病。针对β-淀粉样蛋白(Aβ)和tau蛋白的传统下游干预在临床实践中反复失败,线粒体功能衰退已被确定为AD发病的核心上游驱动因素。以线粒体功能网络为核心靶点,本文系统剖析AD进展中线粒体功能障碍的关键分子机制,包括氧化磷酸化受损、线粒体DNA(mtDNA)突变与遗传缺陷、活性氧(ROS)生成过多、线粒体动力学失衡、线粒体自噬功能障碍、钙稳态失调、线粒体运输缺陷以及与tau病理的双向调控通路,并阐明这些异常机制之间级联放大和相互调控所构成的病理网络。文章还全面总结针对AD的线粒体靶向干预策略,分析该领域在模型异质性、特异性生物标志物缺乏和药物递送效率低下等方面的研究局限,并结合细胞重编程和人工智能(AI)等前沿技术展望未来研究方向。该研究从线粒体视角对AD的衰老相关致病机制作出新的解释,为开发精准高效的AD线粒体靶向治疗策略奠定理论基础,并为突破AD临床诊疗瓶颈提供新范式。
Nature neuroscience IF 20.3 2026-11 PMID: 42693199
Alzheimer's disease and primary tauopathies are marked by changes in adaptive immunity, with increased brain CD8+ T cells correlating with tau pathology severity. However, how peripheral T cells get primed to enter the brain and contribute to tau-mediated neurodegeneration remains unclear. In different disease conditions, conventional type 1 dendritic cells (cDC1s) cross-present antigens to prime CD8+ T cells into effector cells. We show that tauopathy mice lacking cDC1s or antigen cross-presentation are protected from neurodegeneration, with reduced brain CD8+ T cell infiltration and glial activation. The remaining CD8+ T cells exhibit limited clonal expansion, consistent with impaired priming. We further demonstrate that brain-derived antigens are presented in secondary lymphoid tissues, suggesting a site of T cell activation. Together, these findings establish cDC1-dependent peripheral priming as a key driver of CD8+ T cell accumulation in the brain and tau-mediated neurodegeneration.
中文摘要:阿尔茨海默病和原发性tau蛋白病以适应性免疫改变为特征,脑内CD8+ T细胞增多与tau病理严重程度相关。外周T细胞如何被致敏并进入大脑、参与tau介导的神经退行性变仍不清楚。在不同疾病条件下,经典1型树突状细胞(cDC1)通过交叉呈递抗原使CD8+ T细胞致敏并转变为效应细胞。我们发现,缺乏cDC1或抗原交叉呈递的tau蛋白病小鼠免于神经退行性变,脑内CD8+ T细胞浸润和胶质细胞激活减少。剩余CD8+ T细胞克隆扩增有限,与致敏受损一致。我们进一步证明脑源性抗原在次级淋巴组织中呈递,提示T细胞激活部位。这些结果共同确定cDC1依赖的外周致敏是脑内CD8+ T细胞积聚和tau介导神经退行性变的关键驱动因素。
Ageing research reviews IF 15.5 2026-11 PMID: 42680070
Alzheimer's disease (AD) is a progressive neurodegenerative disorder whose pathological course involves amyloid-β (Aβ) deposition, tau abnormalities, neuroinflammation, and neurovascular dysfunction. Interest in the microbiota-gut-brain axis does not arise because gut dysbiosis has been established as an independent initiating cause of sporadic AD, but because this axis connects modifiable peripheral factors-including diet, medication, ageing, and intestinal physiology-with barrier homeostasis, immunometabolic state, neural afferent signaling, and the brain's response to pathology. Human studies have detected microbiota differences in biomarker-positive preclinical AD and suggest that barrier abnormalities may be associated with subsequent cognitive change; patient-derived microbiota transfer, APOE-dependent tau models, and immune-vagal circuit studies further support phenotype modifiability under defined experimental conditions. This review therefore integrates barrier, immune, metabolic, and neural pathways and emphasizes that diverse microbial alterations may converge on a limited set of measurable functional nodes that could be more informative than individual genera for mechanistic validation, risk stratification, and treatment monitoring. Although clinical intervention evidence remains at an early stage, the peripheral accessibility and modifiability of the microbiota provide a rationale for investigating it as an adjunctive target alongside standard AD therapy. Future work should concurrently evaluate the microbiome, metabolites, both barriers, and immune and neural readouts in longitudinal cohorts and stratified randomized trials to determine which patients, disease stages, and intervention modalities are most likely to benefit.
中文摘要:阿尔茨海默病(AD)是一种进行性神经退行性疾病,其病理过程涉及Aβ沉积、tau异常、神经炎症和神经血管功能障碍。对微生物群-肠-脑轴的兴趣并非源于肠道菌群失调已被确立为散发性AD的独立始动病因,而是因为该轴将可改变的外周因素(包括饮食、用药、衰老和肠道生理)与屏障稳态、免疫代谢状态、神经传入信号以及大脑对病理的反应联系起来。人体研究已在生物标志物阳性的临床前AD中检测到微生物群差异,并提示屏障异常可能与随后的认知变化相关;患者来源微生物群转移、APOE依赖的tau模型和免疫-迷走神经回路研究进一步支持在特定实验条件下表型具有可修饰性。因此,该综述整合屏障、免疫、代谢和神经通路,强调多种微生物改变可能汇聚到有限的可测量功能节点,这些节点在机制验证、风险分层和治疗监测方面可能比单一菌属更具信息价值。尽管临床干预证据仍处于早期阶段,微生物群在外周的可及性和可修饰性为将其作为标准AD治疗之外的辅助靶点进行研究提供了依据。未来工作应在纵向队列和分层随机试验中同步评估微生物组、代谢物、两类屏障以及免疫和神经读出指标,以确定哪些患者、疾病阶段和干预方式最可能获益。
Ageing research reviews IF 15.5 2026-11 PMID: 42668123
Dementia represents a growing global health crisis, yet disease-modifying therapies remain limited. Impaired brain energy metabolism, neuroinflammation, and synaptic dysfunction are some shared pathological features across dementia subtypes that may be amenable to metabolic intervention. Creatine supplementation, through its role in the phosphocreatine/ATP buffering system and proposed neuroprotective properties, has attracted growing scientific and public interest as a candidate intervention for dementia. This scoping review maps the existing evidence on creatine supplementation and dementia-related cognitive outcomes, with attention to intervention characteristics including dose, duration, formulation, route of administration as well as the characteristics of preclinical models. Following the Joanna Briggs Institute (JBI) methodology and Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines, a systematic search of PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) was conducted. No date restrictions were applied to the search; eligibility was limited to English-language reports. Studies were eligible if they evaluated creatine supplementation in older adults or preclinical animal models with dementia and reported at least one cognitive outcome. From 8317 records identified and screened, six studies reported across seven publications, met eligibility criteria comprising one in vitro study, four in vivo animal model studies, and one human pilot trial resulting in two publications. No relevant randomized controlled trials (RCTs) were identified in the search. Evidence was heterogeneous across study design, population, and intervention characteristics. Preclinical studies demonstrated predominantly neuroprotective effects through bioenergetic support and neuroinflammatory modulation, though one rodent study reported worsening spatial memory. A single human pilot trial (n = 20) found that high-dose supplementation (20 g/day for 8 weeks) increased brain total creatine by 11% and was associated with improved fluid cognition. Sex-specific effects were identified in one rodent study, with female animals demonstrating cognitive benefit and males showing a trend toward harm. This was paralleled by sex-divergent bioenergetic responses in the human trial. Current evidence for creatine supplementation in dementia is limited, heterogeneous, and predominantly preclinical. While not supporting a causal inference, preliminary human data does suggest biological plausibility and feasibility, supporting the need for adequately powered, sex-stratified randomized controlled trials in adults with dementia. While preclinical data support a mechanistic rationale for its use, this review identifies critical gaps including the absence of any controlled clinical trials, limited understanding of optimal dosing for brain penetrance, and the need to prospectively examine sex as a biological moderator of treatment response.
中文摘要:痴呆正成为日益严重的全球健康危机,但疾病修饰治疗仍然有限。脑能量代谢受损、神经炎症和突触功能障碍是不同痴呆亚型共有的病理特征,可能适合代谢干预。肌酸补充通过其在磷酸肌酸/ATP缓冲系统中的作用及推测的神经保护特性,作为痴呆候选干预措施受到科学界和公众越来越多的关注。这项范围综述梳理了肌酸补充与痴呆相关认知结局的现有证据,并关注剂量、持续时间、制剂、给药途径等干预特征以及临床前模型特征。研究遵循Joanna Briggs Institute方法学和系统综述与范围综述优先报告条目扩展指南,对PubMed、Embase、Scopus和Cochrane对照试验中心注册库进行了系统检索。检索未设日期限制,资格限于英文报告。若研究评估老年人或痴呆临床前动物模型中的肌酸补充并报告至少一项认知结局,则符合纳入条件。从检索并筛选的8317条记录中,共有6项研究通过7篇出版物报告符合条件,包括1项体外研究、4项体内动物模型研究和1项人体预试验并形成2篇出版物。检索未发现相关随机对照试验。证据在研究设计、人群和干预特征方面存在异质性。临床前研究主要显示通过生物能量学支持和神经炎症调节产生神经保护作用,但一项啮齿类研究报告空间记忆恶化。唯一的人体预试验(n=20)发现高剂量补充(20 g/日,持续8周)使脑总肌酸增加11%,并与流体认知改善相关。一项啮齿类研究发现了性别特异性效应,雌性动物显示认知获益,雄性动物呈损害趋势。人体试验中相应的生物能量学反应也存在性别差异。目前关于肌酸补充用于痴呆的证据有限、异质且以临床前为主。虽不足以支持因果推断,初步人体数据提示生物学合理性和可行性,支持需要在痴呆成人中开展样本量充足、按性别分层的随机对照试验。临床前数据支持其应用的机制依据,但该综述也发现关键空白,包括缺乏受控临床试验、对实现脑穿透的最佳剂量了解有限,以及需要前瞻性检验性别作为治疗反应的生物学调节因素。
Ageing research reviews IF 15.5 2026-11 PMID: 42641766
In vitro cell-line models are essential for investigating the complex, interconnected mechanisms of Alzheimer's disease (AD). While offering high tractability for mechanism-focused screening, their translational utility depends on the precise alignment of the biological inquiry with the appropriate cellular system, induction strategy, and experimental readouts. This systematic review and mechanism-based evidence map searched PubMed (inception to 1 May 2026), capturing 93 original experimental studies across neuronal, glial, endothelial, and higher-fidelity multicellular systems. Extracted data were structured by cellular model, induction paradigm, targeted mechanism, and interpretive scope. The synthesized evidence indicates that AD-relevant in vitro systems are not interchangeable whole-disease models, but mechanism-based tools. SH-SY5Y cells are primarily suited for Aβ-associated neuronal toxicity and general screening. Neuro-2a (N2a) systems are optimized for evaluating APP processing and amyloidogenesis. HT-22 cells specifically model oxidative glutamate toxicity and ferroptosis-related injury, while PC12 cells are strictly reserved for NGF-dependent neurite biology and neuroprotection. While classical cell lines remain essential for initial mechanistic screening, establishing disease-level relevance requires validation through orthogonal readouts and high-fidelity human models, such as multicellular organoids or blood-brain barrier systems.
中文摘要:体外细胞系模型对研究阿尔茨海默病复杂且相互关联的机制具有重要价值。此类模型便于开展以机制为核心的筛选,但其转化价值取决于生物学问题与合适细胞系统、诱导策略及实验读出之间的精确匹配。这项系统综述与基于机制的证据图谱检索了PubMed(建库至2026年5月1日),纳入93项原始实验研究,涵盖神经元、胶质细胞、内皮细胞及更高保真度的多细胞系统。提取数据按细胞模型、诱导范式、靶向机制和解释范围进行结构化整理。综合证据表明,AD相关体外系统并非可互换的完整疾病模型,而是基于机制的研究工具。SH-SY5Y细胞主要适用于Aβ相关神经元毒性和通用筛选。Neuro-2a(N2a)系统针对APP加工和淀粉样蛋白生成评估进行优化。HT-22细胞特异性模拟氧化性谷氨酸毒性和铁死亡相关损伤,PC12细胞则严格用于NGF依赖性神经突起生物学和神经保护研究。经典细胞系仍是初始机制筛选的重要工具,但建立疾病层面的相关性需要借助正交读出和高保真人源模型(如多细胞类器官或血脑屏障系统)进行验证。
Ageing research reviews IF 15.5 2026-11 PMID: 42628846
Population aging is accompanied by a parallel increase in cardiovascular disease (CVD), vascular cognitive impairment (VCI), and dementia, highlighting the urgent need to better understand the complex interactions linking cardiovascular, cognitive, and emotional health. Growing evidence suggests that cardiovascular dysfunction, emotional dysregulation, and cognitive decline are not isolated conditions but interconnected manifestations of shared vascular, inflammatory, neurohumoral, metabolic, and behavioral processes that progressively interact throughout aging. In this review, we examine current evidence supporting the Heart-Brain Axis and expand this concept into an integrated Heart-Brain-Emotion Axis, providing a comprehensive framework to explain the bidirectional relationships among cardiovascular dysfunction, emotional disturbances, and cognitive impairment. We discuss the major mechanisms underlying these interactions, including endothelial dysfunction, cerebral hypoperfusion, chronic low-grade inflammation, oxidative stress, autonomic imbalance, neuroendocrine dysregulation, and psychosocial factors such as depression, anxiety, chronic stress, and social isolation. Attention is given to the reciprocal amplification loops through which dysfunction in one domain may propagate across interconnected biological networks, increasing vulnerability to emotional and cognitive deterioration. Finally, we discuss the clinical implications of this integrated model, emphasizing the importance of early cardiovascular and cognitive screening, multidomain preventive approaches, personalized interventions, and the incorporation of cognitive and emotional assessment into cardiac rehabilitation programs. Recognizing the Heart-Brain-Emotion Axis may facilitate earlier identification of at-risk individuals and support more effective strategies to preserve both cardiovascular and brain health across the aging trajectory. SUMMARY: A growing body of evidence indicates that cardiovascular, emotional, and cognitive alterations should not be considered isolated phenomena but rather interconnected manifestations of a multisystem aging process. Age-related decline appears to arise from reciprocal interactions among cardiovascular, cerebrovascular, neural, and psychosocial mechanisms, whereby dysfunction in one domain propagates through interconnected biological networks, progressively amplifying vulnerability across the others. Shared pathophysiological pathways-including chronic low-grade inflammation, oxidative stress, autonomic dysfunction, neurohumoral imbalance, metabolic disturbances, and adverse lifestyle factors-simultaneously affect cardiovascular, brain, and emotional health, generating self-reinforcing feedback loops that accelerate functional decline. Within this framework, cardiovascular dysfunction contributes to cognitive impairment not only through vascular and neurovascular injury but also by influencing emotional well-being. Conversely, emotional dysregulation, including depression, anxiety, impaired stress adaptation, and reduced emotional resilience, can aggravate cardiovascular dysfunction through behavioral and physiological mechanisms, further compromising cognitive function. These reciprocal relationships support the concept of an integrated Heart-Brain-Emotion Axis, in which cardiovascular dysfunction, emotional dysregulation, and cognitive impairment interact dynamically throughout the aging trajectory. Viewing aging through this integrative framework provides a broader understanding of the mechanisms underlying functional decline and highlights the need for multidomain preventive strategies and personalized interventions. Cardiac rehabilitation may represent an ideal translational model by integrating cardiovascular risk management with cognitive and emotional interventions, thereby promoting healthy brain aging, preserving functional independence, and improving quality of life.
中文摘要:人口老龄化伴随心血管疾病、血管性认知障碍和痴呆的同步增加,迫切需要更好理解心血管、认知与情绪健康之间的复杂相互作用。越来越多证据提示,心血管功能障碍、情绪失调和认知下降并非孤立状况,而是共同血管、炎症、神经体液、代谢和行为过程在衰老过程中逐步相互作用的表现。本综述考察支持心脑轴的现有证据,并将该概念拓展为整合的心-脑-情绪轴,提供一个解释心血管功能障碍、情绪障碍和认知损害之间双向关系的综合框架。我们讨论这些相互作用的主要机制,包括内皮功能障碍、脑灌注不足、慢性低度炎症、氧化应激、自主神经失衡、神经内分泌失调,以及抑郁、焦虑、慢性压力和社会隔离等心理社会因素。关注一个领域的功能障碍如何通过相互连接的生物网络传播并形成相互放大环路,增加情绪和认知恶化的易感性。我们讨论这一整合模型的临床意义,强调早期心血管和认知筛查、多领域预防方法、个体化干预,以及将认知和情绪评估纳入心脏康复项目的重要性。认识心-脑-情绪轴有助于更早识别高危个体,并支持在衰老轨迹中维护心血管和大脑健康的更有效策略。总结:越来越多证据表明,心血管、情绪和认知改变不应被视为孤立现象,而是多系统衰老过程的相互关联表现。年龄相关下降似乎源于心血管、脑血管、神经和心理社会机制之间的相互互动,一个领域的功能障碍通过相互连接的生物网络传播,逐步放大其他领域的易感性。共同病理生理通路,包括慢性低度炎症、氧化应激、自主神经功能障碍、神经体液失衡、代谢紊乱和不良生活方式因素,同时影响心血管、大脑和情绪健康,形成自我强化的反馈环路,加速功能下降。在这一框架内,心血管功能障碍不仅通过血管和神经血管损伤导致认知损害,也通过影响情绪健康起作用。反过来,情绪失调,包括抑郁、焦虑、压力适应受损和情绪韧性降低,可通过行为和心理机制加重心血管功能障碍,进一步损害认知功能。这些相互关系支持整合的心-脑-情绪轴概念,中心血管功能障碍、情绪失调和认知损害在衰老轨迹中动态相互作用。以这一整合框架看待衰老,可以更广泛理解功能下降的机制,并突出多领域预防策略和个体化干预的需要。心脏康复可能是一个理想的转化模型,将心血管风险管理与认知和情绪干预整合,从而促进健康脑衰老、维持功能独立并改善生活质量。
Ageing research reviews IF 15.5 2026-11 PMID: 42617979
Alzheimer's disease (AD) remains one of the most challenging neurodegenerative disorders, primarily due to the lack of reliable tools for its early and non-invasive diagnosis. Exosomes, nanosized extracellular vesicles secreted by neural and peripheral cells, have emerged as promising biomarkers reflecting the molecular alterations associated with AD pathogenesis. Fourier Transform Infrared (FTIR) spectroscopy, with its capacity to capture unique biochemical fingerprints of biomolecules, provides a rapid, label-free, and cost-effective approach for exosome characterization. The recent integration of Artificial Intelligence (AI), particularly machine learning and deep learning algorithms, has significantly advanced the interpretation of complex FTIR spectra, enabling the identification of subtle spectral variations linked to disease progression. This review highlights the synergistic potential of AI-assisted FTIR spectroscopy for exosomal profiling in AD, discussing advances in spectral data analytics, biomarker discovery, and diagnostic modeling. Furthermore, it explores current challenges, technological gaps, and future perspectives toward establishing intelligent, exosome-based diagnostic frameworks for the early detection and personalized management of Alzheimer's disease.
中文摘要:阿尔茨海默病(AD)仍是最具挑战性的神经退行性疾病之一,主要原因在于缺乏可靠的工具来实现早期、无创诊断。外泌体是神经细胞和外周细胞分泌的纳米级细胞外囊泡,已成为有前景的生物标志物,可反映与AD发病机制相关的分子改变。傅里叶变换红外(FTIR)光谱能够捕捉生物分子独特的生化指纹,为外泌体表征提供了快速、无需标记且成本较低的方法。近年来人工智能(AI),尤其是机器学习和深度学习算法的整合,显著提升了对复杂FTIR光谱的解析能力,使识别与疾病进展相关的细微光谱变化成为可能。本综述强调AI辅助FTIR光谱用于AD外泌体谱分析的协同潜力,讨论光谱数据分析、生物标志物发现和诊断建模方面的进展。同时探讨当前挑战、技术缺口和未来方向,以建立基于外泌体的智能诊断框架,用于AD的早期检测和个体化管理。
Medical image analysis IF 14.0 2026-11 PMID: 42585730
Alzheimer's disease (AD) is an irreversible neurodegenerative disorder where early diagnosis serves as the only viable window for effective intervention. While Structural MRI (sMRI) is a primary clinical tool for this purpose, manual diagnosis is heavily constrained by clinician expertise and the difficulty of visually quantifying subtle, diffuse anatomical changes. Deep learning has emerged as a powerful solution to capture these complex patterns. However, the inherent black-box opacity of current models creates a trust deficit that severely impedes their clinical adoption. Furthermore, existing interpretability methods predominantly rely on post-hoc visualizations, which frequently suffer from significant background leakage and lack anatomical coherence. To overcome these barriers, we propose a novel multi-level interpretable framework that inherently integrates diagnostic reasoning into the model architecture. The framework operates through a progressive three-stage trajectory to bridge the gap between pixel-level signals and global pathology. First, to eliminate the ambiguity caused by background leakage, we introduce a voxel discovery module implemented via Hierarchical Evidential Masking (HiEM). By leveraging this iterative optimization strategy, the model actively filters out irrelevant background signals to autonomously discover AD-relevant voxel sets. Subsequently, to bridge the semantic gap between discrete voxels and clinical anatomy, these discovered signals are dynamically aggregated into coherent semantic regions. Finally, recognizing that AD pathology propagates through brain networks, we explicitly model the regional interaction among these defined areas using Graph Attention Network (GAT). This voxel-region-network progression allows the model to transparently zoom out from local cues to global interactions. Validated on the Alzheimer's Disease Neuroimaging Initiative (ADNI) and Australian Imaging, Biomarkers and Lifestyle Study (AIBL) datasets, our method achieves performance comparable to state-of-the-art black-box models while autonomously reconstructing established neuropathological trajectories. Crucially, by extracting high-fidelity pathological signals, it offers a trustworthy tool for precise disease diagnosis and potentially serves as a digital biomarker discovery instrument for localizing subtle prodromal lesions. The source code is publicly available at: https://github.com/k-Jayus/HiEM.
中文摘要:阿尔茨海默病(AD)是不可逆的神经退行性疾病,早期诊断是有效干预唯一可行的窗口。结构MRI(sMRI)是用于该目的的主要临床工具,但人工诊断受临床医生经验水平的限制,且细微、弥漫的解剖改变难以用视觉量化。深度学习已成为捕捉这类复杂模式的有力手段。当前模型固有的黑箱不透明性造成信任缺失,严重阻碍其临床采用。现有可解释性方法多依赖事后可视化,常出现明显的背景泄漏,缺乏解剖学上的一致性。为克服这些障碍,我们提出一种新的多层级可解释框架,把诊断推理内嵌于模型结构之中。该框架通过渐进的三阶段路径运行,连接像素级信号与全局病理。为消除背景泄漏带来的歧义,引入由分层证据掩蔽(HiEM)实现的体素发现模块;借助这一迭代优化策略,模型主动滤除无关背景信号,自主发现与AD相关的体素集合。在此基础上,为弥合离散体素与临床解剖之间的语义鸿沟,所发现的信号被动态聚合为连贯的语义区域。考虑到AD病理沿脑网络传播,模型进一步用图注意力网络(GAT)显式建模这些已定义区域之间的相互作用。这种从体素到区域再到网络的推进,使模型能够透明地从局部线索缩放至全局相互作用。在ADNI与AIBL数据集上验证,本方法性能与最先进的黑箱模型相当,同时能自主重建已被确立的神经病理轨迹。关键在于,通过提取高保真病理信号,它为精确的疾病诊断提供了可信工具,并有望成为定位细微前驱期病灶的数字生物标志物发现工具。源代码公开于:https://github.com/k-Jayus/HiEM。
Nature protocols IF 18.4 2026-11 PMID: 42270887
Late-onset Alzheimer's disease (LOAD) accounts for over 95% of Alzheimer's disease (AD) cases. However, modeling the age-dependent neuropathological hallmarks of LOAD has remained a major challenge. We recently developed a patient-based, three-dimensional (3D) neuronal culture system that endogenously recapitulates key neuropathological features of AD, including extracellular Aβ deposition, tau dysregulation and spontaneous neuronal death. This platform uses high-efficiency, microRNA- and chromatin-based direct somatic reprogramming of fibroblasts from patients with autosomal dominant AD or LOAD to cortical neurons in 3D thin gel (3D-CNs) or self-assembled neuronal spheroids. Here we provide stepwise instructions for generating 3D-CNs and cortical spheroids via neuronal reprogramming of patient fibroblasts, along with methods for analyzing downstream AD neuropathology. Within 3 weeks, fibroblasts are reprogrammed into neurons under either thin-gel or spheroid conditions. By 4 weeks, key AD neuropathology, such as Aβ deposition, tau dysregulation, and neuronal death, can be detected in AD neurons. This system provides an age-relevant, patient-specific neuronal model for investigating molecular events underlying AD-associated neurodegeneration and evaluating compounds or gene targets in the context of potential personalized therapeutic interventions. Successful implementation of this protocol requires prior experience in mammalian cell culture, plasmid preparation, lentiviral production and standard confocal imaging techniques.
中文摘要:晚发性阿尔茨海默病(LOAD)占阿尔茨海默病(AD)病例的95%以上。然而,模拟LOAD的年龄依赖性神经病理标志仍是一大挑战。我们近期开发了基于患者的三维(3D)神经元培养系统,可内源性重现AD的关键神经病理特征,包括细胞外Aβ沉积、tau失调和自发性神经元死亡。该平台利用高效、基于microRNA和染色质的直接体细胞重编程,将常染色体显性AD或LOAD患者的成纤维细胞在3D薄凝胶(3D-CNs)或自组装神经元球体中重编程为皮层神经元。该方案提供通过患者成纤维细胞神经元重编程生成3D-CNs和皮层球体的分步说明,以及分析下游AD神经病理的方法。在3周内,成纤维细胞在薄凝胶或球体条件下被重编程为神经元。到4周时,AD神经元中可检测到Aβ沉积、tau失调和神经元死亡等关键AD神经病理。该系统提供了与年龄相关、患者特异性的神经元模型,用于研究AD相关神经变性背后的分子事件,并在潜在个体化治疗干预背景下评估化合物或基因靶点。成功实施该方案需要具备哺乳动物细胞培养、质粒制备、慢病毒生产和标准共聚焦成像技术的既往经验。
Biosensors & bioelectronics IF 11.8 2026-11-01 PMID: 42251840
Alzheimer's disease (AD) is a progressive neurodegenerative disorder, and early detection of amyloid-beta peptides Aβ42 and Aβ40 is critical for timely intervention. Herein, a novel self-powered photoelectrochemical (SP-PEC) platform was developed for the detection of Aβ42 and Aβ40, using NH2-UiO-66/TAPA-DHNDA-COF (NU66/T-D-COF) as the photocathode and NiCo2S4@ZnIn2S4 (NCS@ZIS) as the photoanode. The NU66/T-D-COF heterojunction was synthesized via Schiff-base reaction to deliver strong cathodic photocurrent and efficient charge separation. CdTe quantum dots (CdTe-QDs) and CdS quantum dots (CdS-QDs) were used as signal probes for Aβ42 and Aβ40, respectively. Under optimal conditions, the SP-PEC platform exhibited a wide linear range from 1 fg/mL to 100 ng/mL, with detection limits of 0.24 fg/mL for Aβ42 and 0.33 fg/mL for Aβ40. The platform showed excellent stability, selectivity, and satisfactory recovery in real biological samples, providing a promising tool for early and sensitive AD biomarker diagnosis.
中文摘要:阿尔茨海默病(AD)是一种进行性神经退行性疾病,早期检测淀粉样β肽Aβ42和Aβ40对及时干预至关重要。构建了一种新型自供能光电化学(SP-PEC)平台,用于检测Aβ42和Aβ40,以NH2-UiO-66/TAPA-DHNDA-COF(NU66/T-D-COF)作为光电阴极,以NiCo2S4@ZnIn2S4(NCS@ZIS)作为光电阳极。NU66/T-D-COF异质结通过席夫碱反应合成,可提供较强的阴极光电流和有效的电荷分离。CdTe量子点(CdTe-QDs)和CdS量子点(CdS-QDs)分别作为Aβ42和Aβ40的信号探针。在优化条件下,该SP-PEC平台表现出1 fg/mL至100 ng/mL的宽线性范围,Aβ42和Aβ40的检出限分别为0.24 fg/mL和0.33 fg/mL。该平台具有优良的稳定性、选择性,并在真实生物样本中获得满意的回收率,为AD生物标志物的早期、灵敏诊断提供了有前景的工具。
Biosensors & bioelectronics IF 11.8 2026-11-01 PMID: 42250351
Plasma neurofilament light chain (NfL) has been identified as a promising early-stage Alzheimer's disease (AD) biomarker, reflecting neuroaxonal degeneration at preclinical stages. However, its extremely low concentration in blood presents a major analytical challenge. Although single-molecule array (Simoa) assays provide exceptional sensitivity, they remain costly, instrumentation-intensive, and difficult to implement in decentralized settings. Here, we report the identification and engineering of high-affinity DNA aptamers against NfL using capillary electrophoresis-SELEX. Solution-phase fluorescence polarization was used to evaluate the binding capability of the aptamer candidates and the effect of aptamer truncation. Molecular modelling provided structural insights into aptamer-protein interactions, thereby supporting the rational optimization of aptamer design. The optimized truncated aptamers were integrated onto microfabricated gold electrodes to construct electrochemical aptasensors, exhibiting a Kd value of 1.67 ± 0.47 nM. To further enhance analytical performance, the aptamers were implemented in ion-gated organic electrochemical transistors (iOECTs), yielding an ultrasensitive and highly selective platform capable of detecting NfL in 0.1 × human serum with an ultralow limit of detection of 9 aM. This work establishes a scalable, minimally invasive, cost-effective alternative to antibody-based assays and provides a versatile biosensing strategy for early neurodegenerative disease diagnostics.
中文摘要:血浆神经丝轻链(NfL)已被视为有前景的阿尔茨海默病早期生物标志物,可反映临床前阶段的神经轴索变性。但其在血液中的浓度极低,给分析检测带来重大挑战。单分子阵列(Simoa)检测虽灵敏度突出,却成本高、依赖复杂仪器,难以在分散化场景中实施。本工作利用毛细管电泳-SELEX筛选并改造针对NfL的高亲和力DNA适配体,采用溶液相荧光偏振评估候选适配体的结合能力及截短影响,并通过分子建模获得适配体-蛋白相互作用的结构信息,为适配体的理性优化设计提供支持。将优化后的截短适配体整合到微加工金电极上构建电化学适配体传感器,其Kd值为1.67 ± 0.47 nM。为进一步提升分析性能,将适配体用于离子门控有机电化学晶体管(iOECTs),形成超灵敏、高选择性的检测平台,可在0.1×人血清中检测NfL,检出限低至9 aM。该工作建立了可规模化、微创、低成本的抗体检测替代方案,并为早期神经退行性疾病诊断提供了通用的生物传感策略。
Trends in pharmacological sciences IF 24.0 2026-11 PMID: 41927413
Abnormal protein aggregation and a dysregulated neuroimmune environment are defining features of many neurodegenerative disorders. In Alzheimer's disease, systemic monoclonal antibodies against amyloid-β provide proof of principle that immunotherapy can modify disease trajectory. However, clinical benefit is limited by low brain exposure, short-lived activity, the need for repeated dosing, and inflammation-linked toxicity. Building on transformative clinical success in oncology, chimeric antigen receptor (CAR) immunotherapies offer a complementary approach to address these limitations, combining the molecular precision of antibody-derived binders with the versatility and persistence of engineered immune cells. These technologies are being explored for central nervous system (CNS) proteinopathies, where they can couple the selective recognition of pathogenic proteoforms to immune programs that are compatible with the CNS's low tolerance for collateral inflammation. Here, we review CAR strategies for aggregate-selective targeting and explore how to incorporate tunable controls and safety mechanisms. Finally, we examine how distinct CAR-engineered effector cell types may modulate key processes in neurodegeneration, from aggregate clearance to immune rebalancing. Together, these advances define CAR design principles for durable, programmable, and targeted immunomodulation in neurodegenerative disease.
中文摘要:异常蛋白聚集和神经免疫环境失调是许多神经退行性疾病的界定性特征。在阿尔茨海默病中,针对β淀粉样蛋白的系统性单克隆抗体提供了免疫治疗可改变疾病轨迹的原理验证。但临床获益受限于脑内暴露低、活性维持时间短、需要反复给药以及与炎症相关的毒性。借鉴肿瘤学中具有变革意义的临床成功,嵌合抗原受体(CAR)免疫治疗为解决这些局限提供了互补路径,将抗体衍生结合分子的分子精确性与工程化免疫细胞的多功能性和持久性结合起来。这些技术正被探索用于中枢神经系统蛋白病,在此类疾病中,它们可将对致病蛋白变体的选择性识别与适合中枢神经系统对附带炎症低耐受性的免疫程序相耦联。综述聚焦用于聚集物选择性靶向的CAR策略,并探讨如何纳入可调控控制与安全机制。同时讨论不同CAR工程化效应细胞类型可能如何调节神经退行性变中的关键过程,从聚集物清除到免疫再平衡。这些进展共同界定了用于神经退行性疾病中持久、可编程和靶向免疫调节的CAR设计原则。
Pharmacological research IF 12.2 2026-10-31 PMID: 42966483
Alzheimer's disease (AD) is one of the leading causes of dementia worldwide. Its pathological features include Aβ deposition, Tau hyperphosphorylation, and impaired neuronal energy metabolism, accompanied by persistent oxidative stress. As a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, sirtuin 1 (SIRT1) is a central regulator of mitochondrial biogenesis. This review systematically examines the emerging roles of SIRT1 in regulating these pathological processes in AD, with a particular focus on its regulation of mitochondrial biogenesis. It also delineates the complex regulatory mechanisms governing SIRT1, including NAD+-metabolism-dependent regulation, protein interaction-dependent regulation, post-translational modifications such as ISGylation and nitrosylation, and non-coding RNA-mediated post-transcriptional regulation. In addition, the coordinated influence of upstream activators and downstream effectors is discussed. Impairment of SIRT1-mediated mitochondrial biogenesis may exacerbate neuronal energy deficits and oxidative stress in AD, thereby increasing susceptibility to neurodegeneration. This review further elucidates the molecular mechanisms underlying the SIRT1-mitochondrial biogenesis axis. By integrating upstream activating signals with downstream effectors, SIRT1 creates a permissive regulatory environment for peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)-driven, mitochondrial transcription factor A (TFAM)-mediated mitochondrial biogenesis, thereby facilitating quality-controlled renewal of the mitochondrial network. In addition, this review discusses the potential value of dynamic biomarker monitoring following therapeutic targeting of the SIRT1 pathway and summarizes current challenges and future intervention strategies. Targeting SIRT1-mediated mitochondrial biogenesis may provide a promising avenue for the development of novel therapeutic strategies for AD.
中文摘要:阿尔茨海默病(AD)是全球痴呆的主要病因之一。其病理特征包括Aβ沉积、Tau过度磷酸化及神经元能量代谢受损,并伴随持续氧化应激。SIRT1作为烟酰胺腺嘌呤二核苷酸(NAD+)依赖性去乙酰化酶,是线粒体生物发生的中枢调控因子。该综述系统梳理SIRT1在AD上述病理过程中的新近作用,重点聚焦其对线粒体生物发生的调控,并阐述SIRT1的复杂调控机制,包括NAD+代谢依赖性调控、蛋白相互作用依赖性调控、ISGylation与亚硝基化等翻译后修饰,以及非编码RNA介导的转录后调控。上游激活因子与下游效应分子的协同影响亦被讨论。SIRT1介导的线粒体生物发生受损可能加重AD中的神经元能量不足与氧化应激,从而提高神经退行性变的易感性。该综述进一步阐明SIRT1-线粒体生物发生轴的分子机制。通过整合上游激活信号与下游效应分子,SIRT1为PGC-1α驱动、TFAM介导的线粒体生物发生创造允许性调控环境,促进线粒体网络的质量控制性更新。该综述还讨论靶向SIRT1通路治疗后动态生物标志物监测的潜在价值,并总结当前挑战与未来干预策略。靶向SIRT1介导的线粒体生物发生可能为AD新型治疗策略开发提供有前景的途径。
Pharmacological research IF 12.2 2026-10-31 PMID: 42966482
Alzheimer's disease (AD) remains one of the most difficult neurodegenerative disorders to treat. Therapeutic failure is driven mainly by two barriers: the multifactorial pathological network of AD and the limited access of most therapeutics to the brain imposed by the blood-brain barrier (BBB). Conventional symptomatic drugs and emerging antibody-based therapies provide clinical benefit, but they do not fully address the interacting processes involving amyloid-β (Aβ) accumulation, Tau pathology, neuroinflammation, mitochondrial dysfunction, oxidative stress, and synaptic impairment. In this review, we discuss nanomedicine as an integrated platform for AD intervention. We summarize the major pathological nodes that provide targets for nanomedicine-based therapy and discuss BBB structure and transport mechanisms. We then compare polymeric, inorganic, carbon-based, lipid-based, protein-based, nucleic acid-based, and biomimetic platforms in terms of delivery function, intrinsic bioactivity, pathological modulation, and translational risk. Assisted brain-delivery strategies are also discussed, including focused ultrasound-mediated BBB modulation and intranasal nose-to-brain delivery. We then review clinical-stage AD nanomedicine candidates and summarize the key barriers to their translation. This review integrates stage-dependent pathology, BBB transport, and nanoplatform properties. It proposes a stage-matched framework for preclinical, mild symptomatic, and moderate-severe AD. At each stage, the framework matches active pathological nodes with feasible BBB transport strategies, carrier features, and administration routes. It may guide the development of mechanistically defined, reproducible, and clinically testable nanomedicines.
中文摘要:阿尔茨海默病(AD)仍是最难治疗的神经退行性疾病之一。治疗失败主要来自两方面障碍:AD的多因素病理网络,以及血脑屏障(BBB)使多数治疗药物难以进入脑内。传统对症药物和新兴抗体疗法可带来临床获益,却未能充分处理Aβ积聚、Tau病理、神经炎症、线粒体功能障碍、氧化应激和突触损伤之间的相互作用。本综述将纳米医学视为AD干预的整合平台,概括可作为纳米药物靶点的主要病理节点,讨论BBB结构与转运机制,并从递送功能、固有生物活性、病理调控和转化风险比较聚合物、无机、碳基、脂质、蛋白、核酸及仿生平台。辅助脑递送策略包括聚焦超声介导的BBB调控和鼻内鼻脑递送。随后回顾临床阶段的AD纳米药物候选物,归纳其转化的关键障碍。综述将分期依赖的病理、BBB转运与纳米平台特性整合起来,提出面向临床前、轻度症状期和中重度AD的分期匹配框架。该框架在各期将活跃病理节点与可行的BBB转运策略、载体特征和给药途径相匹配,可指导机制明确、可重复且可临床检验的纳米药物开发。
Molecular psychiatry IF 10.4 2026-10-30 PMID: 42963367
Mitochondrial complex IV (CIV) is an integral part of the mitochondrial electron transport chain (ETC) and plays a pivotal role in maintaining mitochondrial function. In contrast to the long-standing recognition of its dysfunction in Alzheimer's disease (AD), the exact role of CIV deficit in the pathogenesis of this neurodegenerative disorder remains poorly defined. In this study, by incorporating clinical resources, mouse- and human-based models of AD risk, and a genetic approach to bypass defective CIV via the ectopic expression of alternative oxidase (AOX), we examined whether CIV deficits are a pathogenic driver of or a beneficial adaptation to AD-associated pathologies. Our results showed a clinicopathological association between neuronal CIV dysfunction and pathological characteristics of AD. Further experiments linked defective CIV to the development of mitochondrial dysfunction and synaptic loss in the tested mouse- and human-based models of AD risk. In addition, a reciprocal relationship between CIV dysfunction and amyloid pathology was determined. Lastly, a proteome-wide association study (PWAS) using genetic data from large-scale AD cohorts identified that downregulation of COX11, a crucial CIV assembly factor, confers susceptibility to AD risk. Collectively, our findings suggest that CIV dysfunction is a detrimental pathology contributing to AD-associated mitochondrial and neuronal damage. The dual role of CIV dysfunction, both as a consequence of and a contributor to amyloid toxicity in AD pathogenesis, further justifies the therapeutic potential of strategies targeting CIV deficits to diversify the tools for prevention and treatment of this neurodegenerative disorder.
中文摘要:线粒体复合物IV(CIV)是线粒体电子传递链(ETC)的组成部分,对维持线粒体功能起关键作用。CIV功能障碍在阿尔茨海默病(AD)中已被长期认识,但其在AD发病机制中的确切作用仍不清楚。本研究整合临床资源、基于小鼠和人的AD风险模型,以及通过异位表达交替氧化酶(AOX)绕开缺陷CIV的遗传学策略,检验CIV缺陷是AD相关病理的致病驱动因素还是有益适应。结果显示,神经元CIV功能障碍与AD病理特征存在临床病理关联。进一步实验在所用小鼠和人AD风险模型中,将缺陷CIV与线粒体功能障碍及突触丢失联系起来。CIV功能障碍与淀粉样蛋白病理之间呈相互关系。利用大规模AD队列遗传数据开展的全蛋白质组关联研究(PWAS)发现,CIV关键组装因子COX11下调赋予AD风险易感性。这些结果表明,CIV功能障碍是一种有害病理,参与AD相关线粒体和神经元损伤。CIV功能障碍在AD发病中既可是淀粉样蛋白毒性的后果,也可促进淀粉样蛋白毒性,这种双重作用进一步支持靶向CIV缺陷的策略具有治疗潜力,可拓展该神经退行性疾病的预防和治疗工具。
Neuron IF 16.9 2026-10-30 PMID: 42962664
A growing body of evidence implicates the menopausal transition as a neurobiological inflection point in women's brain aging and Alzheimer's disease (AD) vulnerability. Menopause is a midlife neuroendocrine transition characterized by a decline in sex steroid hormones and widespread systemic effects. The brain is not a passive recipient of ovarian hormones but an active endocrine-sensing organ. Menopause, however, does not act in isolation: the ovarian-brain axis is established embryonically, activated at puberty, remodeled during pregnancy and postpartum, and reconfigured during the menopausal transition, with implications for later-life brain aging. This review places menopause within a lifespan neuroendocrine framework, examining mechanisms by which the transition may influence the brain, including altered hormone signaling, bioenergetics, synaptic plasticity, neurovascular function, inflammation, and AD-related pathology. It then reviews evidence linking menopausal timing to neurobiological and AD vulnerability, discusses estrogen therapy, and considers menopause as a biologically plausible window for risk stratification and prevention.
中文摘要:越来越多证据表明,围绝经期是女性脑老化与阿尔茨海默病(AD)易感性的神经生物学转折点。绝经是中年期的一种神经内分泌转变,以性类固醇激素下降及广泛的全身性效应为特征。脑并非卵巢激素的被动接受者,而是主动感知内分泌信号的器官。绝经并非孤立发挥作用:卵巢-脑轴在胚胎期建立,青春期激活,妊娠与产后重塑,并在围绝经期重新配置,对晚年脑老化产生影响。综述将绝经置于毕生神经内分泌框架中,考察这一转变影响脑的机制,包括激素信号改变、生物能量学、突触可塑性、神经血管功能、炎症及AD相关病理。随后回顾将绝经时相与神经生物学改变和AD易感性相联系的证据,讨论雌激素治疗,并把绝经视为风险分层与预防的生物学上合理的窗口。

2脑血管病与卒中 (54篇)

临床研究 (42篇)

European heart journal IF 45.3 2026-11-06 PMID: 40878832
The best management approach for renin-angiotensin system (RAS) inhibitor use before surgery is controversial. Some studies have suggested that continuation could increase the risk of clinically significant peri-operative hypotension and, thus, organ injury. By contrast, others believe that withholding them significantly increases the risk of severe hypertension and heart failure. To determine the most effective strategy, this systematic review and meta-analysis of randomized controlled trials compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgeries. PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched for randomized controlled trials that compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgery. Five randomized controlled trials (n = 10 773 patients; 5388 randomized to discontinuation) were included. Discontinuation of an RAS inhibitor probaby reduced peri-operative hypotension (27.66% vs 34.06%; risk ratio [RR] 0.81, 95% confidence interval [CI] 0.73-0.89; moderate certainty). The evidence is very uncertain about effects on peri-operative hypertension (9.46% vs 8.05%; RR 1.38, 95% CI 0.66-2.89; very low certainty). For major clinical outcomes, discontinuation suggested little to no difference in acute kidney injury (10.45% vs 10.69%; RR 0.98, 95% CI 0.66-1.45; low certainty), acute heart failure (5.38% vs 5.32%; RR 1.00, 95% CI 0.76-1.31; low certainty), myocardial infarction (1.22% vs 1.00%; RR 1.19, 95% CI 0.60-2.39; low certainty), stroke (0.42% vs 0.40%; RR 1.04, 95% CI 0.56-1.93; low certainty), and arrhythmias (1.80% vs 1.40%; RR 1.28, 95% CI 0.69-2.38; low certainty). These findings suggest that discontinuation of RAS inhibitors is likely to reduce peri-operative hypotension in patients undergoing non-cardiac, non-vascular surgery, but the evidence is very uncertain about effects on peri-operative hypertension and major clinical outcomes.
中文摘要:肾素-血管紧张素系统(RAS)抑制剂术前的最佳管理方式仍有争议。有研究提示继续用药可能增加有临床意义的围术期低血压,从而造成器官损伤;另一些观点则认为停药会显著增加严重高血压和心力衰竭风险。为确定更有效策略,本系统综述与荟萃分析纳入随机对照试验,比较接受非心脏、非血管手术患者停用与继续使用RAS抑制剂。检索PubMed、Embase和Cochrane Central Register of Controlled Trials(CENTRAL)数据库,纳入比较非心脏、非血管手术患者停用与继续使用RAS抑制剂的随机对照试验。共纳入5项随机对照试验(n=10773例患者;5388例随机分配至停药组)。停用RAS抑制剂可能降低围术期低血压(27.66% vs 34.06%;风险比[RR] 0.81,95%置信区间[CI] 0.73-0.89;中等确定性)。对围术期高血压的影响证据非常不确定(9.46% vs 8.05%;RR 1.38,95% CI 0.66-2.89;极低确定性)。主要临床结局方面,停药对急性肾损伤(10.45% vs 10.69%;RR 0.98,95% CI 0.66-1.45;低确定性)、急性心力衰竭(5.38% vs 5.32%;RR 1.00,95% CI 0.76-1.31;低确定性)、心肌梗死(1.22% vs 1.00%;RR 1.19,95% CI 0.60-2.39;低确定性)、卒中(0.42% vs 0.40%;RR 1.04,95% CI 0.56-1.93;低确定性)和心律失常(1.80% vs 1.40%;RR 1.28,95% CI 0.69-2.38;低确定性)提示几乎没有差异。这些发现提示,在接受非心脏、非血管手术的患者中停用RAS抑制剂可能降低围术期低血压,但对围术期高血压和主要临床结局的影响证据非常不确定。
European heart journal IF 45.3 2026-11-04 PMID: 42981223
Obesity in patients supported by left ventricular assist devices (LVADs) is linked to excess mortality and haemocompatibility-related events. Whether this association persists with the fully magnetically levitated HeartMate 3 (HM3) pump is unknown. This analysis tested outcomes with obesity and the additive influence of co-existing frailty ('frail obesity') in the contemporary era. The study pooled 2200 HM3 recipients from the MOMENTUM 3 pivotal randomized trial (n = 515) and Continued Access Protocol (n = 1685). Obesity was defined as body mass index (BMI) ≥30 kg/m2 and frailty by a 40-item Rockwood cumulative-deficit frailty index (FI), with clinically relevant frailty defined as FI ≥0.325 (moderate-severe frailty); BMI was excluded from the FI to avoid mathematical coupling. The primary endpoint was survival to transplant, recovery, or 24 months of support free of disabling stroke (modified Rankin score >3) or pump replacement reoperation. Obese patients (n = 887, 40.3%) were younger, less often with ischaemic aetiology, and more frequently women, but more often had diabetes and hypertension, than non-obese patients. Unadjusted 2-year outcomes were similar between groups (freedom from the primary endpoint: 75.1% vs 77.1%, log-rank P = .34; survival: 79.9% vs 81.2%, P = .57). After covariate adjustment, obesity was independently associated with a higher risk of the primary endpoint (hazard ratio [HR] 1.30, 95% confidence interval [CI] 1.07-1.58) and all-cause mortality (HR 1.35, 95% CI 1.10-1.67), as well as heart failure hospitalization, infection, and arrhythmia, but not stroke, bleeding, or early right heart failure. Frailty affected 67.3% of obese recipients (571/849) and was associated with a higher adjusted risk of the primary endpoint (HR 1.51, 95% CI 1.09-2.10), overall mortality and non-haemocompatibilty-related morbidity endpoints. The obesity-by-frailty interaction was not significant for either the primary endpoint (P = .436) or mortality (P = .215), indicating additive rather than synergistic risk; frail-obese patients nonetheless carried the highest absolute risk of any subgroup. Frailty improved by at least one severity class by 6 months in 75.9% of frail-obese patients, and improvement was associated with better survival (adjusted HR 0.14, 95% CI 0.07-0.26). In the HM3 era, obese and non-obese recipients had similar unadjusted 2-year outcomes; however, after adjustment for baseline case-mix, obesity was independently associated with a higher risk of both the primary endpoint and all-cause mortality, together with heart failure hospitalization, infection, and arrhythmia. Frailty was independently associated with adverse outcomes across nearly all endpoints and was highly prevalent among obese recipients; the combination of obesity and frailty was additive but not synergistic, with frail-obese patients carrying the highest absolute risk. Frailty, however, proved substantially reversible after LVAD support, and its improvement was associated with markedly better survival. Obesity and frailty should therefore be assessed together, rather than through BMI thresholds alone, with recognition that frailty status is dynamic after implantation and that improvement in frailty is associated with markedly better survival.
中文摘要:接受左心室辅助装置(LVAD)支持的患者中,肥胖与超额死亡及血液相容性相关事件有关。在完全磁悬浮的HeartMate 3(HM3)泵中这一关联是否仍然存在尚不清楚。本分析检验了当代背景下肥胖的结局以及合并衰弱的附加影响(「衰弱性肥胖」)。研究汇总了MOMENTUM 3关键随机试验(n=515)与继续准入方案(n=1685)中的2200例HM3受体。肥胖定义为体重指数(BMI)≥30 kg/m2,衰弱采用40项Rockwood累积缺陷衰弱指数(FI)评估,临床相关衰弱定义为FI≥0.325(中重度衰弱);为避免数学耦合,FI中排除BMI。主要终点为存活至移植、心肌恢复或支持满24个月,且无致残性卒中(改良Rankin评分>3)或泵更换再手术。肥胖患者(n=887,40.3%)较非肥胖患者更年轻、缺血性病因更少、女性更多,但糖尿病和高血压更常见。未校正的2年结局两组相似(主要终点无事件率75.1%对77.1%,log-rank P=0.34;生存率79.9%对81.2%,P=0.57)。校正协变量后,肥胖与主要终点风险升高独立相关(风险比[HR]1.30,95%置信区间[CI]1.07-1.58)及全因死亡(HR 1.35,95% CI 1.10-1.67),并与心力衰竭住院、感染和心律失常相关,但与卒中、出血或早期右心衰无关。衰弱见于67.3%的肥胖受体(571/849),与主要终点校正后风险升高相关(HR 1.51,95% CI 1.09-2.10),也与总死亡率及非血液相容性相关疾病终点相关。肥胖与衰弱的交互作用对主要终点(P=0.436)或死亡(P=0.215)均不显著,提示风险为相加而非协同;但衰弱性肥胖患者的绝对风险在各亚组中最高。75.9%的衰弱性肥胖患者在6个月时衰弱严重程度至少改善一个等级,且改善与更好的生存相关(校正HR 0.14,95% CI 0.07-0.26)。在HM3时代,肥胖与非肥胖受体的未校正2年结局相似;但校正基线病例构成后,肥胖与主要终点及全因死亡风险升高独立相关,也与心衰住院、感染和心律失常相关。衰弱在几乎所有终点上均与不良结局独立相关,且在肥胖受体中高度常见;肥胖与衰弱的组合为相加而非协同,衰弱性肥胖患者的绝对风险最高。衰弱在LVAD支持后具有明显可逆性,其改善与显著更好的生存相关。因此肥胖与衰弱应一并评估,而非仅凭BMI阈值判断,并应认识到植入后衰弱状态是动态变化的,衰弱改善与显著更好的生存相关。
Stroke IF 11.1 2026-11-04 PMID: 42979715
Identifying the intensity and frequency of physical activity associated with early independent walking in nonambulatory patients with subacute stroke may inform daily physical activity promotion during hospitalization, which was the aim of the present study. This multicenter prospective cohort study was conducted at 11 facilities. Baseline was defined as admission to a subacute rehabilitation ward, with subacute referring to the phase after completion of acute stroke treatment. Patients with subacute stroke and a Functional Ambulation Category of 1 to 2 at admission were included. Physical activity was measured using an accelerometer for 1 week at baseline. The outcome was achievement of independent walking at 1 month from baseline (Functional Ambulation Category ≥4). To examine the intensity of physical activity associated with the outcome, modified Poisson regression was used to evaluate time spent in low -intensity physical activity (LPA; low-LPA, 1.6-1.9 metabolic equivalents [METs]), high-LPA (2.0-2.9 METs), and moderate-to-vigorous intensity physical activity (≥3.0 METs). Furthermore, to assess frequency associated with activity intensity, bouts of physical activity at or above the intensity level (≥1.6, ≥2.0, or ≥3.0 METs) were calculated as short-bouts (≥5 to <10 minutes) and long-bouts (≥10 minutes), and their associations with the outcome were examined. Of 389 participants (mean age, 68.1 years; 45.0% female), 113 achieved independent walking during follow-up. Time spent in high-LPA was associated with independent walking when expressed per 5 min/d (risk ratio, 1.067 [95% CI, 1.010-1.131]), whereas low-LPA and moderate-to-vigorous intensity physical activity were not. The number of short-bouts at ≥2.0 METs was associated with independent walking (risk ratio, 1.208 [95% CI, 1.060-1.375]), whereas long-bouts were not relevant. Accumulation of high-LPA and short-bouts at ≥2.0 METs was associated with early independent walking. These findings may help characterize activity intensity and bout frequency associated with walking independence in nonambulatory patients with subacute stroke during inpatient rehabilitation. URL: https://www.umin.ac.jp/ctr; Unique identifier: UMIN000058526.
中文摘要:明确亚急性卒中不能独立行走患者中与早期独立行走相关的身体活动强度和频率,可为住院期间身体活动促进提供依据。这项多中心前瞻性队列研究在11家机构开展。基线定义为入住亚急性康复病房,亚急性期指急性卒中治疗完成后的阶段。纳入入住时功能性步行分类(FAC)为1至2级的亚急性卒中患者。基线时使用加速度计测量1周身体活动。结局为基线后1个月达到独立行走(FAC≥4级)。为分析身体活动强度与结局的关系,采用改良Poisson回归评估低强度身体活动(LPA;低LPA,1.6-1.9代谢当量[METs])、高LPA(2.0-2.9 METs)和中高强度身体活动(≥3.0 METs)的时间。为分析活动强度对应的频率,将至少达到某一强度(≥1.6、≥2.0或≥3.0 METs)的身体活动片段分为短片段(≥5且<10分钟)和长片段(≥10分钟),并分析其与结局的关系。389名参与者(平均年龄68.1岁;45.0%为女性)中,113人在随访期间达到独立行走。高LPA时间与独立行走相关,按每5分钟/天计算的风险比为1.067(95% CI,1.010-1.131),低LPA和中高强度身体活动则无此关联。≥2.0 METs的短片段数量与独立行走相关(风险比1.208[95% CI,1.060-1.375]),长片段无相关性。高LPA和≥2.0 METs短片段的累积与早期独立行走相关。这些发现有助于描述亚急性卒中不能独立行走患者在住院康复期间与步行独立相关的活动强度和片段频率。URL: https://www.umin.ac.jp/ctr;唯一标识符:UMIN000058526。
Stroke IF 11.1 2026-11-03 PMID: 42974709
Stroke recovery is highly heterogeneous, and predictive neurophysiological markers of motor outcome are still needed. Although transcranial magnetic stimulation-derived motor evoked potentials (MEPs) are widely used to assess corticospinal integrity, their trial-to-trial variability remains poorly explored and has largely been interpreted as noise rather than a source of clinically relevant information. In this prospective longitudinal observational study, we investigated MEP peak-to-peak amplitude and amplitude variability in 77 patients with subacute stroke assessed at baseline (T0, early subacute phase) and after a 2-month high-intensity daily rehabilitation program (T1), alongside 10 age- and sex-matched healthy controls. MEPs were recorded from both hemispheres at rest. Clinical outcomes were evaluated using the Fugl-Meyer Upper Extremity scale and a Motor Recovery Index. Seventy-seven patients with subacute stroke (mean age, 68.5±12.7 years; 41.6% women) and 10 age- and sex-matched healthy controls (mean age, 73.9±4.3 years; 40.0% women) were included. At T0, MEP amplitude was lower in the affected than in the unaffected hemisphere (0.16±0.02 versus 0.38±0.01 mV; P=5.42×10-10), as was MEP variance (0.013±0.002 versus 0.038±0.003 mV2; P=8.43×10-12). Regarding T1, MEP amplitude increased over time in the affected hemisphere (0.21±0.02 mV; P=0.01), whereas MEP variance remained unchanged (P=0.55). Importantly, baseline MEP amplitude was strongly associated with motor status at follow-up (Fugl-Meyer Upper Extremity scale at T1; P=9.52×10-9), but not with the degree of recovery. In contrast, baseline MEP variability was significantly associated with both motor outcome (Fugl-Meyer Upper Extremity scale at T1; P=2.76×10-7) and the Motor Recovery Index (P=0.009), indicating a specific link with recovery potential. These findings reveal a dissociation between MEP amplitude and variability, suggesting that they capture complementary aspects of corticospinal function. Although amplitude reflects the current functional state of motor pathways, variability appears to index network flexibility and adaptive capacity. MEP variability may, therefore, represent a novel neurophysiological biomarker for predicting motor recovery and guiding personalized rehabilitation strategies after stroke.
中文摘要:卒中恢复异质性很大,仍需要预测运动结局的神经生理标志物。经颅磁刺激衍生的运动诱发电位(MEP)广泛用于评估皮质脊髓束完整性,但其试次间变异性研究不足,多被视为噪声而非临床相关信息来源。在这项前瞻性纵向观察研究中,我们评估了77例亚急性卒中患者在基线(T0,早期亚急性期)和2个月高强度每日康复方案后(T1)的MEP峰峰值波幅及波幅变异性,并纳入10名年龄和性别匹配的健康对照。静息状态下记录双侧半球MEP。临床结局采用Fugl-Meyer上肢量表和运动恢复指数评估。共纳入77例亚急性卒中患者(平均年龄68.5±12.7岁;女性41.6%)和10名年龄性别匹配健康对照(平均年龄73.9±4.3岁;女性40.0%)。T0时,患侧半球MEP波幅低于健侧(0.16±0.02对0.38±0.01 mV;P=5.42×10⁻¹⁰),MEP方差亦较低(0.013±0.002对0.038±0.003 mV²;P=8.43×10⁻¹²)。T1时,患侧半球MEP波幅随时间增加(0.21±0.02 mV;P=0.01),MEP方差未变(P=0.55)。基线MEP波幅与随访时运动状态强相关(T1 Fugl-Meyer上肢量表;P=9.52×10⁻⁹),但与恢复程度无关。基线MEP变异性与运动结局(T1 Fugl-Meyer上肢量表;P=2.76×10⁻⁷)及运动恢复指数(P=0.009)均显著相关,提示其与恢复潜力存在特定联系。这些发现显示MEP波幅与变异性分离,提示二者反映皮质脊髓功能的互补方面。波幅反映运动通路当前功能状态,变异性似乎指示网络灵活性和适应能力。因此,MEP变异性可能成为预测运动恢复并指导卒中后个体化康复策略的新型神经生理生物标志物。
Stroke IF 11.1 2026-11-03 PMID: 42974688
Vascular geometry may impede catheter navigation during mechanical thrombectomy. We evaluated whether cervical curvature predicts recanalization success. This is a retrospective single-center cohort of 160 anterior large vessel occlusion patients treated with mechanical thrombectomy at a comprehensive stroke center (Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO) from May 2019 to February 2021. Cervical curvature was computed using 3-dimensional vessel centerlines derived from preprocedural computed tomography angiography. Primary outcomes were successful recanalization (final modified Thrombolysis in Cerebral Infarction score ≥2b) and intracranial access time (puncture→first pass). Associations were evaluated with multivariable linear or logistic regression, adjusting for age, National Institutes of Health Stroke Scale, first-line device, and access route. Random Forest and Gradient Boosting models with Gini Importance and Shapley Additive Explanation explained feature importance. Mean age was 67±15 years; median National Institutes of Health Stroke Scale 16; mean total curvature was 9.80±2.85. Median intracranial access time was 24 minutes (interquartile range, 17-32), with no correlation to cervical curvature (ρ=0.054; adjusted β=0.20 min/unit [95% CI, -0.75, 1.15]; P=0.676). Successful recanalization occurred in 86% and varied across curvature tertiles (low 91%, mid 93%, high 75%; P=0.017). Per-unit curvature increase was associated with recanalization failure (adjusted odds ratio, 1.21 [95% CI, 1.02-1.43]; P=0.028). Receiver operating characteristic-derived curvature threshold (>11.54) identified a high-risk group (adjusted odds ratio, 5.10 [95% CI, 1.88-13.84]; P=0.001). Machine learning confirmed cervical curvature as the dominant predictor, with a Shapley Additive Explanation peak effect at 11.65. Cervical curvature independently predicts mechanical thrombectomy recanalization failure, with a threshold effect near 11.6 units. Preprocedural curvature assessment derived from routine computed tomography angiography may improve risk stratification and inform mechanical thrombectomy strategy.
中文摘要:血管几何形态可能妨碍机械取栓中的导管导航。评估颈部血管弯曲度是否预测再通成功。回顾性单中心队列纳入2019年5月至2021年2月在综合卒中中心(Barnes-Jewish医院/华盛顿大学医学院,美国密苏里州圣路易斯)接受机械取栓的160例前循环大血管闭塞患者。颈部血管弯曲度基于术前计算机断层扫描血管成像获得的三维血管中心线计算。主要结局为成功再通(最终改良脑梗死溶栓评分≥2b)和颅内到位时间(穿刺至首次通过)。采用多变量线性或逻辑回归评估关联,校正年龄、美国国立卫生研究院卒中量表评分、一线取栓装置和入路。随机森林和梯度提升模型结合基尼重要性和Shapley加性解释分析特征重要性。平均年龄67±15岁;美国国立卫生研究院卒中量表评分中位数16;平均总弯曲度9.80±2.85。颅内到位时间中位数24分钟(四分位距17-32),与颈部血管弯曲度无相关性(ρ=0.054;校正β=0.20分钟/单位[95% CI,-0.75,1.15];P=0.676)。成功再通率为86%,并随弯曲度三分位组变化(低91%,中93%,高75%;P=0.017)。弯曲度每增加1单位与再通失败相关(校正比值比1.21[95% CI,1.02-1.43];P=0.028)。受试者工作特征曲线得出的弯曲度阈值(>11.54)识别出高风险组(校正比值比5.10[95% CI,1.88-13.84];P=0.001)。机器学习确认颈部血管弯曲度是主要预测因素,Shapley加性解释峰值效应位于11.65。颈部血管弯曲度独立预测机械取栓再通失败,阈值效应接近11.6单位。基于常规计算机断层扫描血管成像的术前弯曲度评估可能改善风险分层并指导机械取栓策略。
Circulation IF 41.3 2026-11-03 PMID: 42817881
Antithrombotic therapy undertreatment includes omission, nonadherence, underdosing, and clinical circumstances that result in subtherapeutic antithrombotic levels. Antithrombotic undertreatment has profound implications for patient safety, public health, and healthcare costs. Due to deviation from evidence-based clinical practice, misperceptions of bleeding versus thrombotic risk, and inequities in healthcare access, many patients with atrial fibrillation, venous thromboembolism, or peripheral artery disease remain untreated or receive suboptimal anticoagulant dosing. Antithrombotic undertreatment has been shown to increase rates of ischemic stroke, systemic embolism, recurrent thrombosis, and mortality. Real-world data continue to highlight substantial gaps in care, which appear to be magnified in patients with inequity in social determinants of health. The emergence of antithrombotic stewardship, in concert with growing bodies of literature on antithrombotic agent underdosing, represents a transformative opportunity to address these gaps through structured, interprofessional, and evidence-based approaches. Through interdisciplinary collaboration, healthcare professionals are well positioned to enhance patient health and safety by recognizing and recommitting to reducing antithrombotic undertreatment.
中文摘要:抗血栓治疗不足涵盖漏用、不依从、剂量偏低,以及导致抗血栓水平低于治疗剂量的临床情形。抗血栓治疗不足对患者安全、公共卫生和医疗费用影响深远。由于偏离循证临床实践、对出血风险与血栓风险的误解以及医疗可及性方面的不公平,许多心房颤动、静脉血栓栓塞症或外周动脉疾病患者仍未接受治疗,或抗凝剂量未达理想水平。已有证据显示,抗血栓治疗不足会增加缺血性卒中、系统性栓塞、复发性血栓形成及死亡的发生率。真实世界数据不断显示诊疗存在明显差距,在健康社会决定因素处于不利状况的患者中,这一差距似乎更为突出。抗血栓药物规范化管理(stewardship)的出现,与关于抗血栓药物剂量不足的文献日益增多相呼应,为通过结构化、跨专业、循证的方法弥补这些差距提供了变革性契机。通过跨学科协作,医疗卫生专业人员能够识别抗血栓治疗不足并重新致力于减少这一现象,从而促进患者健康与安全。
JAMA network open IF 11.7 2026-11-02 PMID: 42981091
Although external validation of machine learning (ML)-based delirium risk models is a key stage in the model development pipeline, few published reports exist. Moreover, ML-based delirium risk models commonly degrade in performance during external validation. To examine the performance of a fusion multimodal with natural language processing (NLP) delirium risk stratification model in live clinical practice with cross-hospital external validation. This quality improvement study evaluated live clinical deployment of the model among patients 60 years or older who were admitted to non-intensive care units at Mount Sinai Hospital (MSH), with external validation performed at Mount Sinai Morningside Hospital (MSM), from December 1, 2024, to December 31, 2025. Primary outcomes were performance of the risk stratification model, assessed by area under the receiver operating characteristic curve (AUROC), and monthly delirium detection rates. A 2 × 2 confusion matrix was created, and the 4 cells were used to calculate model performance metrics and compare associated diagnostic yield between premodel deployment and active model deployment periods. The overall sample included 33 095 admissions to non-intensive care units at MSM and MSH (mean [SD] age, 74.86 (9.22) years; 15 601 women [47.1%], 17 271 men [52.2%]). A total of 9020 MSM inpatient admissions were assigned a delirium risk score by the risk stratification model during live clinical operations and were compared to 21 186 MSH inpatient admissions that were assigned a risk score by the same model. Age at admission significantly differed between patients at MSM and MSH (MSM: median [IQR] age, 75.79 [68.25-83.88] years vs MSH: 72.62 [66.64-79.65] years; P < .001). Patients from MSM and MSH also significantly differed by sex, race and ethnicity, surgical vs medical primary diagnosis, length of stay, and dementia prevalence rate. Among 11 909 MSM patients, patients in the pre-ML cohort (median [IQR] age, 78.00 [71.00-85.00] years) were significantly older than those in the post-ML cohort (median [IQR] age, 75.79 [68.25-83.88] years) (P < .001). The AUROC of the model was 0.91 (95% CI, 0.90-0.92) for MSM and 0.94 (95% CI, 0.93-0.94) for MSH. The positive predictive value of the model was 25.9% for MSM and 19.4% for MSH. For MSM, the mean monthly delirium detection rate significantly increased from 9.23% (95% CI, 8.07%-10.38%) to 19.59% (95% CI, 17.32%-21.85%) after model deployment (P < .001). In this quality improvement study, an ML-based delirium risk stratification model maintained acceptable discriminative performance during external deployment without retraining and was similar to its performance at the development site without retraining. Model deployment was also associated with increased diagnostic yield but a high false positive rate. These findings provide further evidence of the potential generalizability of the model.
中文摘要:机器学习谵妄风险模型的外部验证是模型开发流程中的关键阶段,但已发表报告很少。基于机器学习的谵妄风险模型在外部验证中常出现性能下降。本研究考察融合多模态与自然语言处理的谵妄风险分层模型在真实临床实践中的表现,并进行跨医院外部验证。这项质量改进研究评估该模型在60岁及以上、入住西奈山医院(MSH)非重症监护病房患者中的实时临床部署,并在西奈山晨边医院(MSM)进行外部验证,时间为2024年12月1日至2025年12月31日。主要结局为风险分层模型性能,以受试者工作特征曲线下面积(AUROC)评估,以及每月谵妄检出率。研究构建2×2混淆矩阵,用4个单元格计算模型性能指标,并比较模型部署前与模型 active 部署期间的诊断产出。总样本包括MSM和MSH非重症监护病房的33095例入院(平均[SD]年龄74.86[9.22]岁;女性15601例[47.1%],男性17271例[52.2%])。9020例MSM住院患者在实时临床运行中由风险分层模型赋予谵妄风险评分,并与同一模型赋予风险评分的21186例MSH住院患者比较。MSM与MSH患者入院年龄差异显著(MSM:中位[IQR]年龄75.79[68.25-83.88]岁 vs MSH:72.62[66.64-79.65]岁;P<.001)。MSM与MSH患者在性别、种族和民族、外科与内科主要诊断、住院时长及痴呆患病率方面也存在显著差异。在11909例MSM患者中,机器学习前队列(中位[IQR]年龄78.00[71.00-85.00]岁)显著年长于机器学习后队列(中位[IQR]年龄75.79[68.25-83.88]岁)(P<.001)。模型在MSM的AUROC为0.91(95%CI,0.90-0.92),在MSH为0.94(95%CI,0.93-0.94)。模型阳性预测值在MSM为25.9%,在MSH为19.4%。MSM模型部署后平均每月谵妄检出率从9.23%(95%CI,8.07%-10.38%)显著升至19.59%(95%CI,17.32%-21.85%)(P<.001)。在这项质量改进研究中,基于机器学习的谵妄风险分层模型在未重新训练的情况下外部部署时保持了可接受的判别性能,并与开发医院未重新训练时的性能相近。模型部署与诊断产出增加相关,但假阳性率较高。这些发现进一步提示该模型具有潜在可推广性。
Neurology research international IF 2.4 2026 PMID: 42969000
Hypertension is one of the primary risk factors for stroke, and nearly 80% of stroke cases can potentially be prevented through increased awareness and early detection. However, previous studies indicate that patients with hypertension often demonstrate inadequate stroke prevention behaviors. Therefore, this study aims to assess knowledge related to early stroke detection among hypertensive patients. This descriptive quantitative study utilized a cross-sectional design, with 236 respondents recruited through consecutive sampling. Data were collected using the Stroke Recognition Questionnaire (SRQ) and analyzed through univariate statistical methods, including frequency, percentage, mean, and standard deviation. Among the 236 respondents, 53.4% demonstrated a moderate level of knowledge, 31.4% had low knowledge, and the remaining respondents showed a high level of knowledge. The average knowledge score was 64.61 (SD = 13.57; range = 26-97). Participants aged 20-44 years had the highest proportion of high knowledge levels (11.4%), whereas older adults aged over 60 years were more commonly classified in the low-knowledge category (36.1%). The greater proportion of low knowledge among older adults highlights a priority population for targeted education. Integrating structured stroke recognition education into routine hypertension care may strengthen preparedness for early symptom recognition and facilitate timely access to emergency stroke services.
中文摘要:高血压是卒中的主要危险因素之一,通过提高认知和早期识别,近80%的卒中可以潜在预防。既往研究提示高血压患者的卒中预防行为常不足。本研究旨在评估高血压患者对卒中早期识别的知识。这项描述性定量研究采用横断面设计,连续抽样纳入236名受访者。数据用卒中识别问卷(SRQ)收集,采用单变量统计方法分析,包括频数、百分比、均数和标准差。236名受访者中,53.4%知识水平中等,31.4%知识水平低,其余为高知识水平。平均知识得分为64.61(SD=13.57;范围26-97)。20-44岁参与者高知识水平比例最高(11.4%),60岁以上老年人更多归入低知识类别(36.1%)。老年人中低知识比例较高,提示其是针对性教育的优先人群。将结构化的卒中识别教育纳入常规高血压管理,可能增强早期症状识别准备,并促进及时获得急诊卒中服务。
JAMA cardiology IF 15.2 2026-11-01 PMID: 42967827
Coronary microvascular dysfunction (CMD) is highly prevalent in patients with angina and nonobstructive coronary arteries (ANOCA). Microvascular resistance reserve (MRR) is a novel index to assess CMD independently of epicardial disease and driving pressures, but the long-term prognostic value of continuous thermodilution-derived MRR in patients with ANOCA is unknown. To assess the prognostic value of continuous thermodilution-derived MRR and its association with clinical outcomes and symptom burden in patients with ANOCA. This prospective, multicenter cohort study within the Netherlands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT) included patients between July 2020 and June 2025 in 4 clinical centers in the Netherlands. Follow-up for clinical events and patient-reported symptoms was completed for up to 3 years. Clinical events were adjudicated by investigators blinded to CFT results. Consecutive patients with ANOCA who underwent continuous thermodilution were included. Abnormal MRR (CMD) was defined as less than 2.1, gray zone as 2.1 to 2.7, and normal microvascular function as 2.7 or greater. The primary clinical outcome was a composite of all-cause death, acute coronary syndrome, stroke, clinically indicated revascularization, repeat angiography without intervention, and unplanned hospital admittance or emergency department visit due to angina or heart failure. Secondary outcomes included angina at baseline and follow-up. Symptoms were assessed using the patient-reported Seattle Angina Questionnaire (SAQ) scores. Among 553 included patients (mean [SD] age, 59.1 [9.6] years; 459 female [83.0%]) with a mean (SD) follow-up of 27.5 (16.1) months, CMD was observed in 94 patients (17.0%). The main composite outcome did not differ across the 3 MRR categories (18 of 94 patients with abnormal [19.1%] vs 21 of 98 patients with gray zone [21.4%] vs 76 of 361 patients with normal [21.1%] MRR; log-rank P = .85). Individual outcomes did not differ between groups. There was no overall longitudinal interaction between MRR and SAQ summary scores. While low MRR (abnormal vs normal groups) was not associated with an increased symptom burden at baseline, it was associated with worse angina at follow-up (mean [SD] SAQ summary score, 53.0 [16.7] vs 60.1 [16.6]; P = .04) and less clinically relevant improvement (9 of 30 patients [30.0%] vs 52 of 88 patients [59.1%]; P = .02). In this study, CMD assessed by continuous thermodilution-derived MRR was not associated with clinical outcomes.
中文摘要:冠状动脉微血管功能障碍(CMD)在有心绞痛及非阻塞性冠状动脉(ANOCA)患者中较常见。微血管阻力储备(MRR)是评估CMD的新指标,不依赖心外膜疾病和驱动压,但连续热稀释法测得的MRR在ANOCA患者中的长期预后价值尚不清楚。评估连续热稀释法MRR的预后价值及其与临床结局和症状负担的关系。这项前瞻性多中心队列研究属于荷兰有创冠状动脉血管运动功能检测注册研究(NL-CFT),纳入2020年7月至2025年6月荷兰4个临床中心的患者。临床事件和患者报告症状随访至3年。临床事件由对CFT结果设盲的研究者判定。连续纳入接受连续热稀释法检查的ANOCA患者。异常MRR(CMD)定义为小于2.1,灰色区为2.1至2.7,微血管功能正常为2.7或以上。主要临床结局为全因死亡、急性冠脉综合征、卒中、有临床指征的血运重建、无干预的重复造影、因心绞痛或心力衰竭导致的非计划住院或急诊就诊的复合终点。次要结局包括基线和随访时的心绞痛。症状采用患者报告的西雅图心绞痛问卷(SAQ)评分评估。共纳入553例患者(平均[SD]年龄59.1[9.6]岁;女性459例[83.0%]),平均(SD)随访27.5(16.1)个月,94例(17.0%)存在CMD。主要复合结局在3个MRR类别间无差异(异常组94例中18例[19.1%] vs 灰色区98例中21例[21.4%] vs 正常组361例中76例[21.1%];log-rank P=.85)。各单项结局在组间无差异。MRR与SAQ总结评分总体无纵向交互作用。低MRR(异常组 vs 正常组)与基线症状负担增加无关,但与随访时更差的心绞痛相关(平均[SD] SAQ总结评分,53.0[16.7] vs 60.1[16.6];P=.04),且临床相关改善较少(30例中9例[30.0%] vs 88例中52例[59.1%];P=.02)。在本研究中,连续热稀释法MRR评估的CMD与临床结局无关。
Stroke IF 11.1 2026-11 PMID: 42932404
Several phase III clinical trials testing cytoprotective approaches have recently been completed, and many of these studies report a clinical benefit. Reviewing the outcomes of these trials in light of their specific designs reveals intriguing results. Trials designed with shorter treatment time windows (≤24 hours) and featuring high rates of recanalization therapies predominantly show neutral outcomes, that is, no therapeutic benefit. Studies using later time points (>24 hours to 14 days) and often enrolling patients in whom recanalization is not or only infrequently established show clear treatment effects. These results challenge our current understanding of cytoprotective approaches, which are believed to primarily target the penumbra as the key to therapeutic success. The reasons for this are unclear. They may include other, potentially unknown mechanisms of action that improve clinical outcome even when applied within longer time windows rather than exerting acute cytoprotection. Here, we discuss such potential mechanisms, to what extent they could explain the results of recent cytoprotection trials, and review consequences for future translational and clinical research.
中文摘要:近期已完成多项检验细胞保护策略的III期临床试验,其中不少报告临床获益。结合各试验的具体设计审视其结果,可见耐人寻味之处。治疗时间窗较短(≤24小时)且再通治疗比例较高的试验大多为中性结果,即无治疗获益。采用较晚时间点(>24小时至14天)、且入组患者多未实现或仅少数实现再通的试验,则显示出明确治疗效应。这些结果对当前认识构成挑战:细胞保护策略通常被认为主要作用于缺血半暗带,并以此作为治疗成功的关键。其原因尚不清楚,可能涉及其他甚至未知的作用机制,在较长时间窗内应用时改善临床结局,而非发挥急性细胞保护作用。本文讨论这些潜在机制、其可在多大程度上解释近期细胞保护试验的结果,并梳理对未来转化研究和临床研究的影响。
MedComm IF 14.1 2026-11 PMID: 42921569
Moyamoya disease (MMD) is a progressive cerebrovascular disease linked to immune dysregulation, yet T-cell metabolic reprogramming and regulatory T-cell (Treg) function remain poorly understood. Here, we integrated multi-omics approaches, including mass cytometry, single-cell RNA sequencing, bulk RNA sequencing, metabolomics, and flow cytometry to characterize T-cell metabolic alterations and Treg dysfunction in MMD, uncovering a key metabolic-immune axis. Compared with healthy controls, MMD patients showed chronic immune activation and broad suppression of amino acid, glycolytic, and fatty acid metabolic pathways. Although Tregs were aberrantly expanded, they displayed metabolic inflexibility, together with impaired intercellular communication. Single-cell transcriptomics indicated Treg-to-Th17 conversion, while flow cytometry confirmed increased IL-17A+ cells within the CD4+FOXP3+ compartment. Besides, these dysfunctional Tregs correlated with advanced Suzuki stages, ischemic stroke, and posterior cerebral artery involvement. Bulk transcriptomic and serum metabolomic analyses further confirmed coordinated immune activation and metabolic suppression at the gene, protein, pathway, and metabolite levels. These findings define a metabolic-immune axis in MMD in which metabolically constrained, functionally unstable Tregs may contribute to neuroinflammation and vascular remodeling, suggesting that restoring Treg metabolic fitness could represent a therapeutic strategy.
中文摘要:烟雾病(MMD)是一种与免疫失调相关的进展性脑血管病,但T细胞代谢重编程及调节性T细胞(Treg)功能仍认识不足。该研究整合质谱流式、单细胞RNA测序、bulk RNA测序、代谢组学和流式细胞术,刻画MMD中T细胞代谢改变与Treg功能障碍,并揭示关键代谢-免疫轴。与健康对照相比,MMD患者表现为慢性免疫激活,氨基酸、糖酵解和脂肪酸代谢通路广泛受抑。Treg虽异常扩增,却呈现代谢不灵活性并伴细胞间通讯受损。单细胞转录组提示Treg向Th17转化,流式细胞术证实CD4+FOXP3+细胞群中IL-17A+细胞增多。这些功能异常Treg与较高Suzuki分期、缺血性卒中及大脑后动脉受累相关。Bulk转录组和血清代谢组分析进一步在基因、蛋白、通路和代谢物层面证实免疫激活与代谢抑制的协同变化。上述发现界定MMD中的代谢-免疫轴,其中受代谢限制、功能不稳定的Treg可能促进神经炎症和血管重塑,提示恢复Treg代谢适应性或可成为治疗策略。
Stroke IF 11.1 2026-11 PMID: 42877955
Health literacy is a critical component of high-quality stroke care. Across the continuum from prevention through recovery, health literacy is strongly associated with functional outcomes and stroke-related morbidity. Despite its importance, it is often overlooked, leaving patients and caregivers overwhelmed by communication demands that exceed their capacity. These mismatches are especially pronounced among individuals with stroke-related cognitive or language impairments, limited English proficiency, socioeconomic disadvantage, or limited digital literacy. This scientific statement synthesizes current evidence on the role of health literacy and communication within stroke systems of care and identifies nurse-led opportunities to advance equity and patient-centered outcomes while recognizing this as a shared interprofessional responsibility. Nurse-led interventions, including teach-back-based education, dyadic psychoeducational programs, and tailored digital support, have demonstrated improvements in stroke knowledge, self-efficacy, quality of life, and caregiver preparedness. However, the literature is marked by methodological heterogeneity. Many studies are underpowered and infrequently use validated health literacy or communication measures. Future directions include standardized assessment of health literacy; literacy-sensitive, nurse-led, and interprofessional care models; workforce training in plain-language and culturally responsive communication; and organizational health literacy principles. Emerging technologies, including telehealth and artificial intelligence, offer promise for improving communication and personalization but require rigorous evaluation to minimize bias and ensure equity and usability.
中文摘要:健康素养是高质量卒中诊疗的关键环节。从预防到康复的整个连续过程中,健康素养与功能结局及卒中相关患病率密切相关。尽管其重要性明确,却常被忽视,患者与照护者被超出自身能力的沟通要求所困扰。在伴有卒中相关认知或语言障碍、英语水平有限、社会经济处境不利或数字素养不足的人群中,这种不匹配尤为突出。本科学声明汇总了卒中诊疗体系中健康素养与沟通作用的现有证据,指出护理主导的可促进公平与以患者为中心结局的机会,同时将其视为跨专业共同承担的责任。护理主导的干预,包括回授法教育、双人心理教育项目与定制化数字支持,已在卒中知识、自我效能、生活质量与照护者准备度方面显示出改善。文献在方法学上存在异质性,许多研究样本量不足,且较少采用经过验证的健康素养或沟通测量工具。未来方向包括健康素养的标准化评估;对素养敏感的护理主导与跨专业照护模式;面向简明语言与文化回应性沟通的人员培训;组织层面的健康素养原则。远程医疗与人工智能等新兴技术有望改善沟通与个性化,但需严格评估以减少偏倚并确保公平性与可用性。
Stroke IF 11.1 2026-11 PMID: 42841198
Subjective social status (SSS) represents self-perceived social position and may affect poststroke recovery. Despite impacting various medical outcomes, SSS remains understudied in stroke. We hypothesized that higher SSS is associated with better stroke recovery at 3- and 12-months poststroke. In this prospective cohort study, patients were enrolled between October 2016 and February 2020. We examined associations between 3-month SSS score and clinician-reported, performance, and patient-reported outcomes at 3- and 12-month study visits. Ordinal multivariable regression analysis evaluated 3-month SSS score as a predictor of 12-month modified Rankin Scale score. The 494 participants had a median age of 63.5 years; 200 (41%) were women, and median (interquartile range) acute National Institutes of Health Stroke Scale score was 4 (2-8). Scores on SSS showed no meaningful associations with performance outcomes and some associations with clinician-reported outcomes (eg, 3-month modified Rankin Scale: ρ, -0.12 [95% CI, -0.21 to -0.03], false discovery rate-adjusted P=0.017; 12-month modified Rankin Scale: ρ12mo, -0.18 [95% CI, -0.27 to -0.09], false discovery rate-adjusted P=0.001). Conversely, higher SSS showed strong, consistent correlations with patient-reported outcomes, including with less psychological distress and higher Stroke Impact Scale-Activities of Daily Living (ρ3mo, 0.18 [95% CI, 0.09-0.26]; ρ12mo, 0.17 [95% CI, 0.07-0.26]; all false discovery rate-adjusted P<0.05). Item-level analyses of Stroke Impact Scale-Activities of Daily Living revealed that SSS remained most strongly and consistently linked to complex Stroke Impact Scale-Activities of Daily Living motor tasks over time. In ordinal multivariable regression adjusted for age, sex, stroke subtype, initial severity, and the selected objective socioeconomic status proxies (eg, educational attainment, employment, and marital status), 3-month SSS score significantly predicted 12-month modified Rankin Scale score (β, 0.14 [95% CI, 0.02-0.26]; P=0.014). In patients with predominantly mild stroke, 3-month SSS score may serve as a significant social determinant of health that is associated with long-term functional recovery, a relationship closely linked with psychological distress. SSS scores at 3 months poststroke may identify vulnerable patients, enabling development, validation, and targeted application of interventions that optimize stroke recovery.
中文摘要:主观社会地位(SSS)反映个体自我感知的社会位置,可能影响卒中后恢复。尽管SSS影响多种医学结局,但在卒中人群中仍研究不足。我们假设较高的SSS与卒中后3个月和12个月更好的恢复相关。在这项前瞻性队列研究中,患者于2016年10月至2020年2月入组。我们检验了3个月SSS评分与3个月和12个月研究访视时临床医生报告结局、功能表现结局和患者报告结局之间的关联。有序多变量回归分析评估3个月SSS评分对12个月改良Rankin量表评分的预测作用。494名参与者中位年龄63.5岁;200名(41%)为女性,急性期美国国立卫生研究院卒中量表评分中位数(四分位距)为4(2-8)。SSS评分与功能表现结局无有意义的关联,与部分临床医生报告结局存在一定关联(例如3个月改良Rankin量表:ρ为-0.12[95% CI,-0.21至-0.03],FDR校正P=0.017;12个月改良Rankin量表:ρ12mo为-0.18[95% CI,-0.27至-0.09],FDR校正P=0.001)。相反,较高的SSS与患者报告结局呈较强且一致的关联,包括较少的心理痛苦和较高的卒中影响量表-日常生活活动能力评分(ρ3mo为0.18[95% CI,0.09-0.26];ρ12mo为0.17[95% CI,0.07-0.26];所有FDR校正P<0.05)。卒中影响量表-日常生活活动能力的条目水平分析显示,SSS随时间推移仍与复杂的卒中影响量表-日常生活活动能力运动任务关联最强且最一致。在调整年龄、性别、卒中亚型、初始严重程度和所选客观社会经济地位替代指标(例如教育程度、就业状况和婚姻状况)的有序多变量回归中,3个月SSS评分显著预测12个月改良Rankin量表评分(β为0.14[95% CI,0.02-0.26];P=0.014)。在以轻型卒中为主的患者中,3个月SSS评分可能作为重要的健康社会决定因素,与长期功能恢复相关,这一关系与心理痛苦密切相关。卒中后3个月的SSS评分可能识别脆弱患者,从而支持开发、验证和针对性应用优化卒中恢复的干预措施。
Stroke IF 11.1 2026-11 PMID: 42817893
Ninety percent of left atrial thrombi in nonvalvular atrial fibrillation arise in the left atrial appendage, which can be occluded percutaneously (left atrial appendage closure [LAAC]). Two 2026 trials (CHAMPION-AF [Watchman Flx Versus Non-Vitamin K Antagonist Oral Anticoagulant for Embolic Protection in the Management of Patients With Non-Valvular Atrial Fibrillation] and CLOSURE-AF [Left Atrial Appendage Closure in Patients With Atrial Fibrillation Compared to Medical Therapy]) more than doubled the available randomized evidence comparing LAAC with oral anticoagulation. We evaluated pooled effects of LAAC on stroke, bleeding, and mortality by bleeding risk, anticoagulation eligibility, and comparator. In this systematic review and meta-analysis, we searched PubMed, Scopus, and Embase from inception to April 15, 2026, for randomized controlled trials comparing percutaneous LAAC with oral anticoagulation in nonvalvular atrial fibrillation. Risk of bias was assessed with the Cochrane Risk of Bias 2 tool. Cumulative-incidence outcomes were pooled as odds ratios using random-effects models, with prediction intervals, prespecified subgroups, and trial sequential analysis. Six randomized controlled trials (2014-2026; 358 sites in North America, Europe, and Asia; 7028 patients) compared LAAC with warfarin (2 trials) or a direct oral anticoagulant (4 trials); populations were predominantly anticoagulation-eligible with low prior-stroke prevalence, plus 2 high-bleeding-risk and 1 postablation trial. Overall stroke rates were similar between arms (odds ratio, 1.10 [95% CI, 0.78-1.56]). Ischemic stroke was more frequent with LAAC (odds ratio, 1.41 [95% CI, 1.07-1.86]) but did not reach the required information size. Nonprocedural bleeding was lower with LAAC (odds ratio, 0.58 [95% CI, 0.35-0.96]), the only outcome reaching a sufficient information size, in standard-risk and postablation but not high-bleeding-risk patients. LAAC is best positioned to reduce nonprocedural bleeding in anticoagulation-eligible patients at standard-to-moderate bleeding risk, rather than as a stroke-equivalent substitute for oral anticoagulation. URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD420261370546.
中文摘要:非瓣膜性心房颤动中约90%的左心房血栓起源于左心耳,左心耳可经皮封堵(LAAC)。两项2026年试验(CHAMPION-AF:Watchman Flx对比非维生素K拮抗剂口服抗凝药在非瓣膜性心房颤动患者栓塞保护管理中的应用;CLOSURE-AF:心房颤动患者左心耳封堵与药物治疗比较)使比较LAAC与口服抗凝药的随机证据增加逾一倍。该系统评价与荟萃分析评估LAAC对卒中、出血和死亡率的汇总效应,并按出血风险、抗凝适用性和对照措施分层。检索PubMed、Scopus和Embase自建库至2026年4月15日的随机对照试验,纳入非瓣膜性心房颤动中经皮LAAC与口服抗凝药比较的研究。偏倚风险采用Cochrane Risk of Bias 2工具评估。累积发生率结局以随机效应模型汇总为比值比,并计算预测区间、预设亚组和试验序贯分析。共6项随机对照试验(2014—2026年;北美、欧洲和亚洲358个中心;7028例患者)比较LAAC与华法林(2项)或直接口服抗凝药(4项);人群以适合抗凝且既往卒中患病率低者为主,另含2项高出血风险和1项消融术后试验。总体卒中率两组相近(比值比1.10,95%CI 0.78—1.56)。LAAC组缺血性卒中更常见(比值比1.41,95%CI 1.07—1.86),但未达到所需信息量。LAAC组非手术相关出血较低(比值比0.58,95%CI 0.35—0.96),是唯一达到足够信息量的结局,见于标准风险及消融术后患者,高出血风险患者中未见此效应。LAAC最适合用于适合抗凝且标准至中度出血风险患者以减少非手术相关出血,而非作为口服抗凝药的卒中等效替代。网址:https://www.crd.york.ac.uk/PROSPERO/;唯一标识:CRD420261370546。
Stroke IF 11.1 2026-11 PMID: 42817886
Contrast-associated acute kidney injury (CA-AKI) after endovascular thrombectomy (EVT) worsens outcomes in acute ischemic stroke, but threshold-based definitions do not capture prognostic information from subthreshold changes. We tested whether early creatinine change within 48 hours of EVT conveys graded prognostic information beyond dichotomous CA-AKI. We performed a secondary analysis of the CAN-REST registry (Contrast-Associated Nephropathy After Endovascular Stroke Treatment), a retrospective multicenter observational cohort study of 6638 EVT-treated adults with acute ischemic stroke enrolled at 73 centers in 16 countries between January 1 and December 31, 2023. Early creatinine change was quantified as the natural logarithm ratio of 48-hour creatinine to baseline creatinine (ln[48-hour/baseline creatinine]), with CA-AKI defined per Kidney Disease: Improving Global Outcomes criteria (≥0.3 mg/dL or ≥1.5× baseline rise within 48 hours). Multivariable logistic regression adjusted for prespecified baseline and periprocedural covariates examined associations with 90-day modified Rankin Scale shift and in-hospital mortality; linear versus restricted cubic spline specification was selected by likelihood ratio testing, and contrasts were estimated at ±10%, ±25%, and ±50%. Greater creatinine worsening within 48 hours of EVT was independently associated with an unfavorable 90-day modified Rankin Scale shift (adjusted common odds ratio per 1-unit log-ratio increase, 1.48 [95% CI, 1.07-2.04]; linear) and in-hospital mortality (nonlinear dose-response, of larger magnitude). A 10% increase in creatinine at 48 hours-well below Kidney Disease: Improving Global Outcomes threshold-was associated with worse functional outcome (adjusted common odds ratio, 1.04 [95% CI, 1.01-1.07]) and death (adjusted odds ratio, 1.22 [95% CI, 1.13-1.32]); a 10% decrease in creatinine at 48 hours was associated with lower odds of both outcomes (adjusted common odds ratio, 0.96 [95% CI, 0.93-0.99]; adjusted odds ratio, 0.74 [95% CI, 0.65-0.86]). The functional-outcome association concentrated at upper modified Rankin Scale cut-points (severe disability, death); effect modification by baseline renal function was not significant. Early creatinine change after EVT conveys graded, outcome-specific prognostic information extending below formal CA-AKI thresholds, with a dose-response detectable at changes as modest as ±10%, complementing binary CA-AKI as a framework for post-EVT renal risk assessment. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06596603.
中文摘要:血管内取栓后对比剂相关急性肾损伤会加重急性缺血性卒中的结局,但基于阈值的定义无法捕捉阈下变化提供的预后信息。该研究检验取栓后48小时内早期肌酐变化是否在二分类对比剂相关急性肾损伤之外提供分级预后信息。研究为CAN-REST登记(血管内卒中治疗后对比剂相关肾病)的二次分析,这是一项回顾性多中心观察性队列研究,纳入2023年1月1日至12月31日期间16个国家73个中心收治的6638例接受血管内取栓治疗的急性缺血性卒中成人。早期肌酐变化以48小时肌酐与基线肌酐比值的自然对数表示(ln[48小时肌酐/基线肌酐]),对比剂相关急性肾损伤按肾脏病改善全球结局标准定义(48小时内肌酐升高≥0.3 mg/dL或≥基线1.5倍)。多变量logistic回归校正预设基线和围术期协变量,分析其与90天改良Rankin量表评分偏移及院内死亡的关联;线性与限制性立方样条设定通过似然比检验选择,并在±10%、±25%和±50%处估计对比效应。取栓后48小时内肌酐恶化程度更高与90天改良Rankin量表评分不良偏移独立相关(每增加1单位对数比值,校正共同比值比1.48,95% CI 1.07-2.04;线性),也与院内死亡相关(非线性剂量反应关系,幅度更大)。48小时肌酐升高10%远低于肾脏病改善全球结局阈值,仍与更差功能结局(校正共同比值比1.04,95% CI 1.01-1.07)和死亡(校正比值比1.22,95% CI 1.13-1.32)相关;48小时肌酐下降10%与两种结局的较低风险相关(校正共同比值比0.96,95% CI 0.93-0.99;校正比值比0.74,95% CI 0.65-0.86)。功能结局关联集中于改良Rankin量表较高切点(严重残疾、死亡);基线肾功能的效应修饰不显著。取栓后早期肌酐变化在正式对比剂相关急性肾损伤阈值以下仍提供分级、结局特异的预后信息,低至±10%的变化即可检测到剂量反应,可作为二分类对比剂相关急性肾损伤框架的补充,用于取栓后肾脏风险评估。URL: https://www.clinicaltrials.gov;唯一标识:NCT06596603。
Redox biology IF 16.2 2026-11 PMID: 42815190
Ambient air pollutants have been associated with increased risks of mortality and chronic diseases; however, population-based evidence on their shared versus pollutant- and outcome-specific molecular mechanisms remains unclear. Leveraging proteomics data from 48,645 participants in the UK Biobank, we characterized proteomic signatures related to overall and individual air pollutants, including particulate matter (PM2.5 and PM10), nitrogen dioxide (NO2) and nitrogen oxides (NOx), and examined their associations with risks of mortality and major chronic diseases. Subsequently, we investigated potential mediating proteins underlying these associations to determine relevant biological mechanisms through functional annotation analyses. Plasma proteins jointly associated with four air pollutants were commonly enriched in immune regulatory pathways, while proteins uniquely associated with PM2.5, PM10, NO2, and NOx were enriched in pollutant-specific pathways of vascular dysfunction, DNA damage, apoptosis signaling, and extracellular matrix remodeling, respectively. Proteomic signatures of air pollutants captured biological processes underlying mortality and major chronic diseases. Mediation analyses and Mendelian randomization identified mediating proteins causally associated with their respective health outcomes, highlighting shared mechanisms of inflammation and immune response as well as outcome-specific pathways such as vascular remodeling for cardiovascular disease, oxidative stress for chronic kidney disease, and cell adhesion for dementia. Specifically, cell-type and tissue enrichment annotation revealed outcome-relevant specificity of advanced glycosylation end product-specific receptor (AGER) for chronic respiratory disease and lung cancer. This study dissects the relationship between ambient air pollutants and adverse health outcomes by revealing both shared and divergent mechanisms and representing potential targets such as AGER for disease prevention and therapeutic intervention.
中文摘要:环境空气污染物与死亡和慢性病风险升高相关,但其共同及污染物和结局特异性分子机制的人群证据仍不清楚。研究利用英国生物银行48645名参与者的蛋白质组学数据,刻画与总体及单项空气污染物(细颗粒物PM2.5和PM10、二氧化氮NO2、氮氧化物NOx)相关的蛋白质组特征,并检验其与死亡和主要慢性病风险的关联。随后分析这些关联的潜在中介蛋白,并通过功能注释分析探讨相关生物学机制。与四种空气污染物共同相关的血浆蛋白通常富集于免疫调节通路,而与PM2.5、PM10、NO2和NOx各自独特相关的蛋白分别富集于血管功能障碍、DNA损伤、凋亡信号和细胞外基质重塑等污染物特异性通路。空气污染物的蛋白质组特征反映了死亡和主要慢性病背后的生物学过程。中介分析和孟德尔随机化识别出与相应健康结局存在因果关联的中介蛋白,凸显炎症和免疫反应的共同机制,以及结局特异性通路,如心血管病的血管重塑、慢性肾病的氧化应激和痴呆的细胞黏附。细胞类型和组织富集注释显示,晚期糖基化终末产物特异性受体AGER对慢性呼吸系统疾病和肺癌具有结局相关特异性。该研究通过揭示共同和分化机制,剖析环境空气污染物与不良健康结局的关系,并提出AGER等用于疾病预防和治疗干预的潜在靶点。
Stroke IF 11.1 2026-11 PMID: 42803010
Periprocedural flat-panel computed tomography (FPCT) may complement real-time decision-making during endovascular treatment for stroke. This study aims to summarize current evidence on diagnostic findings, prognostic associations, and clinical applications of periprocedural FPCT in the angiography suite. A systematic review and meta-analysis was preregistered (URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD420251142156), conducted and reported according to MOOSE guidelines (Meta-Analysis of Observational Studies in Epidemiology). Medline, Embase, and Scopus were searched for studies published between January 2019 and September 2025 reporting on periprocedural FPCT in endovascular treatment patients (noncontrast FPCT, 3-dimensional-digital subtraction angiography/contrast-enhanced FPCT, or FPCT perfusion). Random-effects models were used to calculate pooled prevalences and odds ratios for associations with outcomes, primarily functional status assessed via the 90-day modified Rankin Scale score. Forty studies comprising 4139 patients were included. For noncontrast FPCT, 3 distinct imaging biomarkers were identified. Intraparenchymal hyperattenuations were frequent (pooled prevalence 49% [95% CI, 42%-56%]) and associated with any intracranial hemorrhage (odds ratio, 10.4 [95% CI, 4.5-24.1]), parenchymal hematoma (odds ratio, 4.3 [95% CI, 2.2-8.7]) and lower rates of good outcomes (eg, 90-day modified Rankin Scale score 0-2; odds ratio, 0.35 [95% CI, 0.24-0.50]). Subarachnoid hyperattenuations occurred in 23% (95% CI, 14%-35%) of patients and were associated with distal occlusions, markers of procedural aggressiveness, and lower rates of good outcome (eg, 90-day modified Rankin Scale score 0-2; odds ratio, 0.69 [95% CI, 0.53-0.91]). Intravascular hyperattenuations (distal occlusion tracker sign; pooled prevalence 35%, [95% CI, 24%-49%]) showed high specificity (93%, 95% CI, 87%-96%) for residual distal occlusions after endovascular treatment. Advanced vessel imaging improved thrombus conspicuity and technical efficacy, while postoperative flat-panel computed tomography perfusion shows added value for the detection of residual hypoperfusion, diagnosis of hemodynamic alterations, and prediction of final infarct. There was evidence for selection bias, suggesting slight overreporting of the above imaging signs. Periprocedural FPCT may offer real-time neurovascular and parenchymal assessment when conventional 3-dimensional imaging is unavailable. In our cohort, FPCT findings were associated with clinical outcomes and improved recognition of complications. FPCT may hence assist intraprocedural decision-making regarding adjunctive manoeuvres or drug administrations if further prospective validation can be demonstrated.
中文摘要:围手术期平板CT(FPCT)可在卒中血管内治疗过程中辅助实时决策。本研究汇总血管造影室内围手术期FPCT在诊断发现、预后关联和临床应用方面的现有证据。系统评价与荟萃分析已预注册(网址:https://www.crd.york.ac.uk/PROSPERO/;唯一标识:CRD420251142156),并按照MOOSE指南(流行病学观察性研究的荟萃分析)实施和报告。检索Medline、Embase和Scopus中2019年1月至2025年9月发表、报告血管内治疗患者围手术期FPCT(平扫FPCT、三维数字减影血管造影/增强FPCT或FPCT灌注)的研究。采用随机效应模型计算合并患病率及与结局关联的比值比,主要结局为90天改良Rankin量表评分评估的功能状态。共纳入40项研究、4139例患者。平扫FPCT识别出3种不同的影像生物标志物。脑实质高密度影常见(合并患病率49%[95%CI,42%-56%]),与任何颅内出血(比值比10.4[95%CI,4.5-24.1])、脑实质血肿(比值比4.3[95%CI,2.2-8.7])及较低的良好结局率(如90天改良Rankin量表评分0-2;比值比0.35[95%CI,0.24-0.50])相关。蛛网膜下腔高密度影见于23%(95%CI,14%-35%)的患者,与远端闭塞、手术侵袭性标志物及较低的良好结局率(如90天改良Rankin量表评分0-2;比值比0.69[95%CI,0.53-0.91])相关。血管内高密度影(远端闭塞追踪征;合并患病率35%[95%CI,24%-49%])对血管内治疗后残余远端闭塞具有高特异性(93%,95%CI,87%-96%)。高级血管成像改善了血栓可见性和技术效能,而术后平板CT灌注在检测残余低灌注、诊断血流动力学改变和预测最终梗死方面显示出附加价值。存在选择偏倚证据,提示上述影像征象可能被轻度过度报告。当常规三维成像不可用时,围手术期FPCT可提供实时神经血管和脑实质评估。在本队列中,FPCT表现与临床结局相关,并提高了并发症识别能力。若能进一步前瞻性验证,FPCT或可协助术中关于辅助操作或药物给药的决策。
Stroke IF 11.1 2026-11 PMID: 42803009
Stroke can occur at any age, and the effects can last for the remaining lifetime. To minimize the clinical and economic burden of stroke, we need to develop and test new treatments that have the potential to improve outcomes for people with stroke. Early-phase trials are foundational to testing new treatments in medicine. Early-phase trials encompass dose-ranging, dose-screening, and dose-finding noncomparative designs. A dose-ranging trial aims to establish the safe and tolerable dose range for a given investigational intervention in a target population to progress to a dose-screening or dose-finding trial that systematically identifies an intervention dose(s) in the target population that has signal of efficacy, feasibility, safety, and tolerability. Such designs originated in the oncology field and are gaining prominence in stroke literature. In this article, we first outline the features that differentiate the contribution of early-phase trials from late-phase trials and present a stepwise development program approach to frame our discussion. We then review early-phase trial terminology, discuss the characteristics of early-phase trials and high-quality reporting, and the role, value, and contribution of early-phase trials across the continuum of stroke care using published and ongoing trial examples. Finally, we highlight emerging innovations in early-phase trial design and application to inform future work in stroke.
中文摘要:卒中可发生于任何年龄,其影响可能持续余生。为减轻卒中的临床和经济负担,需要开发和测试有望改善卒中患者结局的新治疗。早期试验是医学中新治疗测试的基础。早期试验包括剂量范围、剂量筛选和剂量探索的非对照设计。剂量范围试验旨在确定目标人群中某一研究性干预的安全且可耐受剂量范围,以便进入剂量筛选或剂量探索试验,系统识别在目标人群中具有疗效信号、可行性、安全性和耐受性的干预剂量。此类设计源于肿瘤学领域,在卒中文献中日益受到重视。文章概述早期试验与后期试验贡献的不同之处,并提出分阶段开发计划方法作为讨论框架。随后回顾早期试验术语,讨论早期试验特征和高质量报告,并结合已发表和正在进行的试验案例,说明早期试验在卒中全程照护中的作用、价值和贡献。文章还强调早期试验设计的新兴创新及其应用,以启发未来卒中研究。
Stroke IF 11.1 2026-11 PMID: 42803008
Microvascular hemodynamic deterioration is a proposed mechanism underlying the no-reflow phenomenon in acute ischemic stroke. Experimental studies suggested that relative heterogeneity of capillary transit time (RTH) is a potential imaging biomarker of microvascular impairment. We investigated the relationship between peri-infarct RTH and infarct growth, measured on immediate post-thrombectomy (PT) perfusion magnetic resonance imaging (MRI), and functional outcomes in patients with acute ischemic stroke with successful reperfusion. In this retrospective case-control study from the University of California, Los Angeles, patients with acute ischemic stroke from 2015 to 2020 were included if they had excellent reperfusion (modified Thrombolysis in Cerebral Infarction score ≥2c) and diffusion- and perfusion-weighted MRIs at baseline, immediately PT, and 24 to 48 hours after thrombectomy. Peri-infarct regions were defined as time to maximum ≥6-second regions on baseline MRI that were not infarcted on immediate PT MRI. Following image coregistration, quantitative values of perfusion parameters, including RTH, were obtained from peri-infarct regions on immediate PT MRI. Two primary outcomes were assessed: (1) infarct growth ≥10 mL and (2) poor functional outcome (90-day modified Rankin Scale score >2). Associations between clinical and imaging parameters and outcomes were evaluated using univariate analysis. Age, sex, and covariates that were significant in univariate analysis were included in logistic regression analyses. Among 47 patients included in the analysis (62% women; mean age, 72±13 years; median National Institutes of Health Stroke Scale score, 14), 20 (43%) patients had substantial infarct growth and poor functional outcome. Peri-infarct RTH was significantly (P=0.005) higher in patients with infarct growth >10 mL than those without and remained as an independent predictor (odds ratio, 1.4 per 10% increase [95% CI, 1.0-2.0]; P=0.04). Similarly, the peri-infarct RTH was significantly higher (P<0.001) in patients with poor functional outcomes than those with good functional outcomes and remained as a significant predictor of poor functional outcome (odds ratio, 1.4 per 10% increase [95% CI, 1.0-1.9]; P=0.03). Increased peri-infarct RTH on immediate PT MRI predicts substantial infarct growth and poor functional outcomes in successfully reperfused patients with acute ischemic stroke. Results highlight the role of microvascular dysfunction depicted by elevated RTH as a potential marker of no-reflow phenomenon despite excellent macrovascular reperfusion.
中文摘要:微血管血流动力学恶化被认为是急性缺血性卒中无复流现象的机制之一。实验研究提示,毛细血管通过时间相对异质性(RTH)可能是微血管损伤的潜在影像生物标志物。研究纳入成功再灌注的急性缺血性卒中患者,分析梗死周围区RTH与血栓切除术后即刻灌注磁共振成像(MRI)所测梗死增长及功能结局之间的关系。这项来自加州大学洛杉矶分校的回顾性病例对照研究纳入2015至2020年的急性缺血性卒中患者,要求再灌注优良(改良脑梗死溶栓评分≥2c),并具备基线、血栓切除术后即刻及术后24至48小时的弥散加权和灌注加权MRI。梗死周围区定义为基线MRI上达峰时间≥6秒且血栓切除术后即刻MRI上未梗死的区域。图像配准后,从术后即刻MRI的梗死周围区获取包括RTH在内的灌注参数定量值。主要结局为梗死增长≥10 mL和功能预后不良(90天改良Rankin量表评分>2)。采用单因素分析评估临床及影像参数与结局的关联,并将年龄、性别及单因素分析中显著的协变量纳入logistic回归。47例患者中(女性62%;平均年龄72±13岁;美国国立卫生研究院卒中量表评分中位数14),20例(43%)出现明显梗死增长和功能预后不良。梗死增长>10 mL者梗死周围区RTH显著更高(P=0.005),且RTH仍为独立预测因素(每增加10%的比值比1.4,95% CI 1.0-2.0;P=0.04)。功能预后不良者梗死周围区RTH也显著更高(P<0.001),RTH仍为功能预后不良的显著预测因素(每增加10%的比值比1.4,95% CI 1.0-1.9;P=0.03)。血栓切除术后即刻MRI上梗死周围区RTH升高可预测成功再灌注的急性缺血性卒中患者出现明显梗死增长和功能预后不良。结果提示,RTH升高所反映的微血管功能障碍可能是大血管再灌注优良情况下无复流现象的潜在标志物。
Stroke IF 11.1 2026-11 PMID: 42751787
Artificial intelligence is increasingly integrated into acute stroke management, demonstrating strong performance in tasks such as large vessel occlusion detection, Alberta Stroke Program Early Computed Tomography Score scoring, and functional outcome prediction. However, concerns persist regarding both the black-box nature of these models and algorithmic bias that may exacerbate disparities in stroke incidence, treatment, and outcomes across racial and socioeconomic subgroups. This review synthesizes the current literature on explainable artificial intelligence and fairness in artificial intelligence applications for acute stroke management, identifies persistent challenges, and outlines recommendations for the development of equitable and trustworthy systems in stroke care. Recent studies have increasingly adopted post hoc explainability methods, though these are limited by approximation and misleading interpretations, especially since explanations are rarely formally tested. Explainability and fairness remain largely disconnected, with fairness evaluation remaining uncommon due to limited demographic metadata, regulatory constraints, and the absence of stroke-specific fairness criteria. Generalizability also remains a concern due to suboptimal data set partitioning strategies and inadequate reporting practices. Responsible artificial intelligence for acute stroke management requires unified evaluation frameworks that jointly assess explainability, fairness, and generalizability.
中文摘要:人工智能正越来越多地融入急性卒中管理,在大血管闭塞检测、Alberta卒中项目早期CT评分以及功能结局预测等任务中表现良好。这类模型的黑箱性质以及算法偏倚仍引发担忧,后者可能加剧不同种族和社会经济亚组在卒中发病率、治疗和结局上的差异。本综述梳理了急性卒中管理中可解释人工智能与人工智能公平性应用的现有文献,指出持续存在的挑战,并提出在卒中诊疗中开发公平且可信系统的建议。近期研究越来越多采用事后可解释性方法,但这些方法受近似性和误导性解释限制,解释本身也很少经过正式检验。可解释性与公平性仍基本相互脱节,受人口学元数据有限、监管限制以及缺乏卒中特异性公平性标准影响,公平性评估仍不常见。数据集划分策略欠佳和报告实践不足也使泛化性继续成为问题。负责任的急性卒中管理人工智能需要统一评估框架,同时评价可解释性、公平性和泛化性。
Stroke IF 11.1 2026-11 PMID: 42751781
Pediatric stroke is a significant cause of long-term disability worldwide, with outcomes influenced by age, stroke subtype, and access to care. Our objective was to define the global burden of pediatric stroke by its impact on mortality and disability. The Global Burden of Disease study uses advanced statistical modeling to analyze health across locations, synthesizing data on mortality, morbidity, and risk factors. We examined 2023 data from the study to assess deaths, years of life lost, and years lived with disability during 3 eras (1990-2001, 2002-2013, and 2014-2023) across high-income and low- and middle-income countries. We stratified the analysis by sex, age group, and stroke subtype. We calculated the proportion of burden attributable to disability (years lived with disability/[years lived with disability+years of life lost]) to assess shifts from fatal to nonfatal disease over time. Between 1990 and 2023, global age-standardized pediatric stroke incidence declined only modestly, whereas age-standardized years of life lost rates declined significantly, indicating that the lower mortality burden reflected better survival rather than a large reduction in disease occurrence. Because years lived with disability rates remained comparatively stable as mortality declined, the proportion of disease burden attributable to disability rose from 14.6% (1990-2001) to 21.7% (2014-2023). This transition was uneven across settings: high-income countries achieved faster mortality declines and reached a higher disability share, whereas low- and middle-income countries retained a higher mortality burden, reflecting a dual burden of ongoing premature death and rising disability. These patterns were consistent across age and sex strata. These data indicate that pediatric stroke is undergoing an epidemiological transition from a mortality-dominant burden to one increasingly driven by disability, reflecting improved survival but with uneven distribution worldwide. Reducing the disability burden, through better stroke recognition education and expanded access to prevention, acute stroke care systems, reperfusion, and rehabilitation, particularly in low- and middle-income countries, should be prioritized alongside efforts to close persistent global inequities in outcomes.
中文摘要:儿童卒中是全球长期残疾的重要原因,结局受年龄、卒中亚型与医疗服务可及性影响。目标是通过死亡与残疾影响界定儿童卒中的全球负担。全球疾病负担研究采用先进统计建模分析各地健康,整合死亡、患病与危险因素数据。我们检查该研究2023年数据,评估1990—2001年、2002—2013年、2014—2023年三个时期高收入国家与低中收入国家的死亡、寿命损失年和残疾生存年,按性别、年龄组与卒中亚型分层。计算残疾所致负担比例(残疾生存年/[残疾生存年+寿命损失年]),评估由致死向非致死疾病的转变。1990至2023年,全球年龄标化儿童卒中发病率仅小幅下降,年龄标化寿命损失年率显著下降,说明死亡负担降低反映生存改善而非疾病发生大幅减少。残疾生存年率在死亡率下降时相对稳定,残疾所致疾病负担比例从14.6%(1990—2001年)升至21.7%(2014—2023年)。这一转变在不同地区不均衡:高收入国家死亡率下降更快、残疾占比更高,低中收入国家仍保留较高死亡负担,呈现过早死亡与残疾上升的双重负担。各年龄和性别分层结果一致。数据表明儿童卒中正经历从死亡主导负担向日益由残疾驱动的流行病学转变,反映生存改善但全球分布不均。减少残疾负担应通过提高卒中识别教育、扩大预防、急性卒中救治体系、再灌注与康复的可及性,尤其在低中收入国家,并与缩小持续存在的全球结局不公平的努力并列优先。
Annals of neurology IF 7.5 2026-11 PMID: 42742287
Intravenous thrombolysis (IVT) failure in acute ischemic stroke (AIS) is frequent, but its causes remain elusive. We investigated whether biologically relevant intrathrombus concentrations of tissue plasminogen activator (tPA) were achieved in failed IVT and whether neutrophil extracellular traps (NETs) contributed to this therapeutic failure. In this monocenter cohort study, 205 thrombi from AIS patients were analyzed. A total of 83 of these thrombi were compared for tPA content and 53 for their susceptibility to ex vivo thrombolysis according to IVT status. An additional subset of 69 AIS thrombi was used to decipher if and how NETs interfere with intrathrombus fibrinolysis. Thrombi from IVT patients contained twice as much tPA than those from no-IVT patients (p < 0.0001). Plasminogen and tPA in AIS thrombi were associated with fibrin, leukocytes, and NETs. Although ex vivo addition of plasminogen did not cause lysis of either no-IVT or IVT thrombi, combining plasminogen with deoxyribonuclease 1 (DNase 1) helped translate the increased tPA content of IVT thrombi into increased thrombolysis. We further show that DNase 1 enables tPA- and plasmin-mediated thrombolysis by eliminating fibrinolysis inhibitors from AIS thrombi. These results indicate that intrathrombus tPA concentrations reached in failed IVT bear a therapeutic potential that is impaired by NETs, which favor intrathrombus retention of fibrinolysis inhibitors and may limit the availability of tPA and plasminogen for fibrinolysis. Our results stress the interest of DNase 1 to enhance the efficacy of current IVT tPA regimens. ANN NEUROL 2026;100:964-978.
中文摘要:急性缺血性卒中(AIS)静脉溶栓(IVT)失败常见,其原因仍不清楚。研究探讨IVT失败时血栓内是否达到生物学相关的组织型纤溶酶原激活剂(tPA)浓度,以及中性粒细胞胞外诱捕网(NETs)是否参与这一治疗失败。该单中心队列研究分析205份AIS患者血栓,其中83份按IVT状态比较tPA含量,53份比较体外溶栓敏感性;另用69份AIS血栓子集分析NETs是否及如何干扰血栓内纤溶。IVT患者血栓中的tPA含量为未接受IVT者的两倍(p < 0.0001)。AIS血栓中的纤溶酶原和tPA与纤维蛋白、白细胞及NETs相关。体外加入纤溶酶原未引起未IVT或IVT血栓溶解,将纤溶酶原与脱氧核糖核酸酶1(DNase 1)联用可促使IVT血栓较高的tPA含量转化为更强的溶栓效果。研究进一步显示,DNase 1通过清除AIS血栓中的纤溶抑制剂,使tPA和纤溶酶介导的溶栓得以实现。这些结果提示,IVT失败时血栓内达到的tPA浓度具有治疗潜力,但该潜力受NETs损害;NETs有利于纤溶抑制剂在血栓内滞留,并可能限制tPA和纤溶酶原用于纤溶。结果强调DNase 1在提高现有IVT tPA方案疗效方面的价值。
Stroke IF 11.1 2026-11 PMID: 42734077
The CREST-2 trial (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial) demonstrated superiority of carotid artery stenting (CAS) over intensive medical management for asymptomatic carotid stenosis, but it did not evaluate transcarotid artery revascularization (TCAR). Herein, we compared ischemic stroke outcomes between TCAR and CAS among patients with asymptomatic carotid stenosis in contemporary real-world practice. We identified adults with asymptomatic carotid stenosis undergoing TCAR versus CAS using the 2016 to 2024 TriNetX database, which is a multicenter federated database of electronic health records. Propensity score matching was performed for demographics, laboratory values, risk factors, comorbidities, and medications. The primary outcome was ischemic stroke within 4 years. Among 7303 identified patients, 2207 patients remained in each group after matching. TCAR did not demonstrate a significantly different stroke risk compared with CAS (hazard ratio, 0.68 [95% CI, 0.44-1.06]). The absolute risk difference was numerically but nonsignificantly lower for patients with TCAR throughout the follow-up period, progressively widening over time: 0.35% at 6 months (0.61% versus 0.96%; P=0.18) to 1.55% at 4 years (3.26% versus 4.81%; P=0.086). TCAR did not significantly lower stroke risk compared with CAS for asymptomatic carotid stenosis. Although nonsignificant trends towards lower stroke risk were observed for TCAR, the widening of absolute risk differences over time suggests residual confounding rather than potential procedural benefit.
中文摘要:CREST-2试验(无症状颈动脉狭窄颈动脉血运重建与药物治疗试验)显示,对无症状颈动脉狭窄,颈动脉支架置入术(CAS)优于强化药物治疗,但未评估经颈动脉血运重建术(TCAR)。本研究在当代真实世界实践中比较无症状颈动脉狭窄患者接受TCAR与CAS的缺血性卒中结局。利用2016至2024年TriNetX数据库(多中心电子健康记录联合数据库)识别接受TCAR或CAS的无症状颈动脉狭窄成人。按人口学、实验室指标、危险因素、合并症和用药进行倾向评分匹配。主要结局为4年内缺血性卒中。共识别7303例患者,匹配后每组各2207例。TCAR与CAS相比卒中风险无显著差异(风险比0.68,95%CI 0.44-1.06)。随访期间TCAR患者的绝对风险差在数值上较低但无统计学意义,并随时间逐渐扩大:6个月时0.35%(0.61%对0.96%,P=0.18),4年时1.55%(3.26%对4.81%,P=0.086)。对无症状颈动脉狭窄,TCAR较CAS未显著降低卒中风险。虽观察到TCAR卒中风险较低的非显著趋势,但绝对风险差随时间扩大提示残余混杂而非操作本身获益。
Stroke IF 11.1 2026-11 PMID: 42734063
Although preclinical studies and limited clinical evidence suggest potential benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) after acute ischemic stroke, their effects in patients with moderate-to-severe acute ischemic stroke requiring endovascular thrombectomy remain unclear. This study aimed to evaluate whether SGLT2i use after endovascular thrombectomy is associated with improved 3-month functional outcomes in diabetic patients with acute ischemic stroke. This retrospective cohort study analyzed prospectively collected data from January 2020 to March 2025 across 4 comprehensive stroke centers in Korea, Italy, and Switzerland. Consecutive adult patients with diabetes were grouped according to whether SGLT2i was used after their endovascular thrombectomy. Propensity score-based methods-including overlap weighting, inverse probability of treatment weighting, and 1:1 propensity score matching-were applied. Outcomes included the shift in 3-month modified Rankin Scale score, favorable (modified Rankin Scale score 0-2), and excellent outcomes (modified Rankin Scale score 0-1) at 3 months. Ordinal and binary logistic regression analyses were performed. Of 429 eligible patients (mean [SD] age, 73.5 [11.1] years; 249 [58.0%] men; median [interquartile range] initial National Institutes of Health Stroke Scale score, 12 [6-18]), 51 (11.9%) received SGLT2i poststroke. Successful recanalization was achieved in 85.3%. In the overlap weighting model (weighted n=37 per group), SGLT2i use was associated with improved 3-month modified Rankin Scale score distribution (common odds ratio, 2.31; [95% CI, 1.30-4.10]) and higher odds of a favorable outcome (odds ratio, 2.26; [95% CI, 1.15-4.43]). Results were consistent across inverse probability of treatment weighting and propensity score matching models, with inverse probability of treatment weighting analyses additionally demonstrating significant associations with excellent outcomes. No significant effect modification was observed across key clinical subgroups. Poststroke SGLT2i therapy after endovascular thrombectomy was associated with improved 3-month functional outcomes in this multicenter retrospective analysis of diabetic patients. These findings suggest a potential therapeutic role for SGLT2i in poststroke diabetes management and support future prospective trials.
中文摘要:尽管临床前研究和有限临床证据提示钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)在急性缺血性卒中后可能获益,但其在需要血管内取栓的中重度急性缺血性卒中患者中的效应仍不清楚。研究旨在评估糖尿病急性缺血性卒中患者取栓后使用SGLT2i是否与3个月功能结局改善相关。这项回顾性队列研究分析2020年1月至2025年3月韩国、意大利和瑞士4家综合卒中中心前瞻性收集的数据。连续成年糖尿病患者按取栓后是否使用SGLT2i分组。采用基于倾向评分的方法,包括重叠权重、逆概率治疗加权和1:1倾向评分匹配。结局包括3个月改良Rankin量表评分位移、良好结局(改良Rankin量表评分0-2)和极佳结局(改良Rankin量表评分0-1)。进行序贯和二元logistic回归分析。429例合格患者(平均[SD]年龄73.5[11.1]岁;249例[58.0%]男性;初始美国国立卫生研究院卒中量表评分中位数[四分位距]12[6-18])中,51例(11.9%)卒中后接受SGLT2i。85.3%实现成功再通。在重叠权重模型(每组加权n=37)中,SGLT2i使用与3个月改良Rankin量表评分分布改善相关(共同比值比2.31;[95%CI,1.30-4.10]),并与良好结局的更高几率相关(比值比2.26;[95%CI,1.15-4.43])。结果在逆概率治疗加权和倾向评分匹配模型中一致,逆概率治疗加权分析还显示与极佳结局显著相关。关键临床亚组中未观察到显著效应修饰。在这项多中心回顾性糖尿病患者的分析中,取栓后卒中后SGLT2i治疗与3个月功能结局改善相关。这些发现提示SGLT2i在卒中后糖尿病管理中可能具有治疗作用,并支持未来开展前瞻性试验。
Stroke IF 11.1 2026-11 PMID: 42725362
Stratification of stroke risk remains challenging, but metabolomic profiling offers the potential to detect new biomarkers and to improve early risk assessment of incident stroke. The objective of this study was to evaluate the association between circulating metabolites and the incidence of stroke in a case-cohort study conducted across several large population-based European cohorts. Following the case-cohort design, a subset of 10 299 individuals, including all individuals with incident stroke, was selected from the original cohort of >70 000 individuals. The case-cohort design used a random subsample of the selected population cohorts, supplemented with cases not sampled in this random subcohort. A total of 141 circulating metabolites were measured from serum samples of the selected individuals, and associations of these metabolites with risk of incident stroke were estimated and compared with those of classic risk factors (sex, age at examination, systolic blood pressure, total cholesterol, body mass index, diabetes, daily smoking status, and antihypertensive treatment). Associations with time to stroke were assessed using weighted Cox proportional hazards models adjusted for the classic risk factors. Hazard ratios (HRs) for the log-transformed metabolites were reported per 1 SD increase. Of the 70 195 individuals in the original cohort, 1516 (2.2%) experienced incident strokes during a median follow-up time of 8.9 years (interquartile range, 4.4-14.7). Median age was 56.8 years (interquartile range, 49.5-62.4), and 39.5% were women. Six of the 141 metabolites (2 diacyl-phosphatidylcholines, 2 lyso-phosphatidylcholines, 1 hydroxysphingomyelin, and glutamic acid) remained significantly associated with incident stroke after correction for multiple comparisons (adjusted HRs [95% CIs] per SD: lyso-phosphatidylcholines a C18:2 HR, 0.88 [95% CI, 0.82-0.93], lyso-phosphatidylcholines a C17:0 HR, 0.88 [95% CI, 0.83-0.94], hydroxysphingomyelin C14:1 HR, 0.90 [95% CI, 0.85-0.94], diacyl-phosphatidylcholines C34:1 HR, 1.10 [95% CI 1.05-1.16], diacyl-phosphatidylcholines C32:1 HR, 1.14 [95% CI, 1.08-1.21], glutamic acid HR, 1.23 [95% CI 1.11-1.37]). The strengths of these associations were similar to those for classic cardiovascular risk factors (C statistics for 10-year prediction ranging from 0.782 to 0.785 for metabolites compared with 0.781 to 0.792 for classic cardiovascular risk factors). Among 10 299 individuals from the general European population, we identified 6 metabolites from 4 different metabolite classes that were associated with future risk of stroke. The application of specific circulating metabolites may improve early stroke risk prediction before the onset of potentially irreversible cerebrovascular pathological processes.
中文摘要:卒中风险分层仍具挑战性,代谢组学分析有望发现新的生物标志物并改善对新发卒中的早期风险评估。本研究在多个人群为基础的大型欧洲队列中开展病例—队列研究,评价循环代谢物与新发卒中之间的关联。按病例—队列设计,从原始7万余人队列中选取10299人的子集,包含全部新发卒中个体;该设计采用所选人群队列的随机子样本,并补充未纳入随机子队列的病例。对所选个体的血清样本测定141种循环代谢物,估计其与新发卒中风险的关联,并与经典危险因素(性别、检查时年龄、收缩压、总胆固醇、体重指数、糖尿病、每日吸烟状况、降压治疗)比较。采用加权Cox比例风险模型评估与卒中发生时间的关联,并校正经典危险因素。对数转换代谢物的风险比按每增加1个标准差报告。原队列70195人中,中位随访8.9年(四分位间距4.4–14.7)期间有1516人(2.2%)发生新发卒中;中位年龄56.8岁(四分位间距49.5–62.4),女性占39.5%。经多重比较校正后,141种代谢物中有6种(2种二酰基磷脂酰胆碱、2种溶血磷脂酰胆碱、1种羟基鞘磷脂和谷氨酸)仍与新发卒中显著相关(校正后每标准差风险比[95%CI]:溶血磷脂酰胆碱a C18:2为0.88[0.82–0.93],溶血磷脂酰胆碱a C17:0为0.88[0.83–0.94],羟基鞘磷脂C14:1为0.90[0.85–0.94],二酰基磷脂酰胆碱C34:1为1.10[1.05–1.16],二酰基磷脂酰胆碱C32:1为1.14[1.08–1.21],谷氨酸为1.23[1.11–1.37])。这些关联的强度与经典心血管危险因素相近(代谢物10年预测的C统计量为0.782–0.785,经典心血管危险因素为0.781–0.792)。在来自欧洲一般人群的10299人中,鉴定出分属4个代谢物类别的6种代谢物与未来卒中风险相关。特定循环代谢物的应用可能在不可逆脑血管病理过程发生之前改善卒中风险的早期预测。
Stroke IF 11.1 2026-11 PMID: 42723634
Acute basilar artery occlusion causes devastating strokes. Despite the benefit of endovascular treatment, the optimal management remains controversial in specific subgroups, particularly patients with mild deficits, and would benefit from robust prognostic tools. Given the dense white matter networks within the posterior fossa, we tested whether quantifying disconnections from acute diffusion-weighted imaging could improve outcome prediction and identify responders to recanalization compared with conventional metrics. We conducted a secondary analysis of a prospective multicenter stroke registry in France, including consecutive patients (2017-2024) with basilar artery occlusion and admission magnetic resonance imaging. Ultra-high-resolution diffusion magnetic resonance imaging was acquired in 2 healthy participants to build normative tractograms with optimized posterior fossa quality. Patient infarcts delineated on diffusion-weighted imaging were projected onto these tractograms to estimate disconnected fiber volume. The primary outcome was 90-day modified Rankin Scale score (0-3 versus 4-6). Predictive performance of disconnected fiber volume was compared with baseline National Institutes of Health Stroke Scale (NIHSS), infarct volume, and posterior circulation Alberta Stroke Program Early Computed Tomography Score using logistic regressions and area under the receiver operating characteristic curves. Ordinal regressions tested associations between dichotomized disconnection status and the full modified Rankin Scale spectrum, stratified by recanalization status. Analyses were repeated in patients with an NIHSS score ≤10. Among 201 patients (median age, 70; NIHSS score, 10), 97 (48.3%) had a poor outcome. Despite a small median infarct volume (4.75 mL), disconnected fiber volume was substantial (median 25.15 mL). Disconnected fiber volume achieved an area under the receiver operating characteristic curves of 0.84, outperforming NIHSS score (0.67; P<0.0001), infarct volume (0.75; P=0.00059), and posterior circulation Alberta Stroke Program Early Computed Tomography Score (0.76; P=0.0127). Patients without significant disconnection had better outcomes across the full modified Rankin Scale spectrum (odds ratio, 0.12 [95% CI, 0.065-0.204]) and derived greater benefit from successful recanalization (odds ratio, 0.33 [95% CI, 0.15-0.70]). In patients with an NIHSS score ≤10 (n=102), disconnected fiber volume remained the strongest predictor (area under the receiver operating characteristic curves of 0.83). Disconnected fiber volume derived indirectly is a robust prognostic marker of basilar artery occlusion outcomes that outperforms conventional predictors and may support future treatment decisions after prospective validation. URL: https://clinicaltrials.gov; Unique identifier: NCT03776877.
中文摘要:急性基底动脉闭塞可导致严重卒中。血管内治疗虽有益,但在特定亚组尤其轻症缺损患者中的最佳管理仍有争议,需要可靠的预后工具。鉴于后颅窝白质网络密集,研究检验能否通过急性弥散加权成像量化断连来改善结局预测,并与传统指标比较识别血管再通获益者。研究为法国前瞻性多中心卒中登记资料的二次分析,连续纳入2017—2024年基底动脉闭塞且入院接受磁共振成像的患者。研究在2名健康参与者中采集超高分辨率弥散磁共振成像,构建后颅窝质量优化的标准化纤维束图。将弥散加权成像上勾画的患者梗死灶投射至这些纤维束图,估算断连纤维体积。主要结局为90天改良Rankin量表评分0—3分与4—6分。采用逻辑回归和受试者工作特征曲线下面积比较断连纤维体积与基线美国国立卫生研究院卒中量表评分、梗死体积及后循环Alberta卒中项目早期CT评分的预测效能。采用序贯回归检验二分类断连状态与完整改良Rankin量表谱的关联,并按血管再通状态分层。分析在美国国立卫生研究院卒中量表评分≤10分的患者中重复。201例患者中位年龄70岁,美国国立卫生研究院卒中量表评分10分,97例(48.3%)结局不良。尽管中位梗死体积较小(4.75 mL),断连纤维体积仍较大(中位25.15 mL)。断连纤维体积的受试者工作特征曲线下面积为0.84,优于美国国立卫生研究院卒中量表评分(0.67;P<0.0001)、梗死体积(0.75;P=0.00059)和后循环Alberta卒中项目早期CT评分(0.76;P=0.0127)。无显著断连的患者在完整改良Rankin量表谱上结局更好(比值比0.12[95% CI 0.065—0.204]),并从成功再通中获得更大获益(比值比0.33[95% CI 0.15—0.70])。在美国国立卫生研究院卒中量表评分≤10分的患者(n=102)中,断连纤维体积仍是最强预测指标(受试者工作特征曲线下面积0.83)。间接得出的断连纤维体积是基底动脉闭塞结局的稳健预后标志物,优于传统预测指标,并可能在前瞻性验证后支持未来治疗决策。URL: https://clinicaltrials.gov;唯一标识:NCT03776877。
Stroke IF 11.1 2026-11 PMID: 42723611
Vessel wall magnetic resonance imaging (VW-MRI) is a promising tool for evaluating intracranial arteriopathies in pediatric non-neonatal arterial ischemic stroke, but its diagnostic and prognostic roles remain underexplored. This study assesses the utility of VW-MRI in identifying arteriopathy subtypes and predicting clinical and radiological outcomes in children. We conducted an ancillary retrospective study using the national KidClot cohort and the stroke database at Necker-Enfants Malades Hospital (Paris). Children with arterial ischemic stroke who underwent VW-MRI within 3 months of onset and follow-up MRI at least 18 months later were included. Stroke causes were assessed according to the Childhood Arterial Ischemic Stroke Standardized Classification and Diagnostic Evaluation, and intracranial arterial vessel wall enhancement (VWE) was evaluated. Analyses focused on the focal cerebral arteriopathy (FCA) subgroup, comparing VWE-positive and VWE-negative patients and assessing correlations with clinical factors, imaging metrics, and outcomes. Categorical variables were compared using the χ2/Fisher exact test, qualitative/ordinal variables using the Mann-Whitney U test, and correlations were assessed using the Spearman rank correlation coefficient (ρ). From 193 children, 67 were included (median age, 4.1 years, interquartile range, 2.0-9.8; 61.1% male). Causes were FCA (42%, 28/67), bilateral cerebral arteriopathy (5%, 3/67), aortic/cervical arteriopathy (12%, 8/67), cardioembolic (7%, 5/67), other (22%, 15/67), and multifactorial (12%, 8/67). In FCA, 75% (21/28) showed concentric VWE, correlating with stenosis severity (ρ=0.31; P=0.001). VWE-positive patients with FCA had a higher initial focal cerebral arteriopathy severity score (median 5 versus 3; P=0.046) than VWE-negative patients, but no statistically significant differences were found in other evaluated factors, including initial Pediatric National Institutes of Health Stroke Scale (median 8.5 versus 8; P=0.5) and 12-month Pediatric Stroke Outcome Measure (median 0.5 versus 1; P=0.8). VW-MRI detects inflammatory arterial changes in pediatric FCA. However, its prognostic value is limited, suggesting enhancement reflects acute inflammation rather than long-term trajectory.
中文摘要:血管壁磁共振成像(VW-MRI)是评估儿童非新生儿动脉性缺血性卒中颅内动脉病的有前景工具,但其诊断和预后作用仍待深入探索。本研究评估VW-MRI在识别动脉病亚型及预测儿童临床与影像学结局中的价值。我们利用全国KidClot队列和巴黎Necker-Enfants Malades医院卒中数据库开展了一项辅助性回顾性研究。纳入发病3个月内接受VW-MRI且至少18个月后接受随访MRI的动脉性缺血性卒中儿童。卒中病因按儿童动脉性缺血性卒中标准化分类与诊断评估体系判定,并评估颅内动脉血管壁强化(VWE)。分析聚焦局灶性脑动脉病(FCA)亚组,比较VWE阳性与阴性患者,并评估其与临床因素、影像学指标及结局的相关性。分类变量采用χ2/Fisher精确检验比较,定性/有序变量采用Mann-Whitney U检验,相关性采用Spearman秩相关系数(ρ)评估。193名儿童中纳入67名(中位年龄4.1岁,四分位距2.0-9.8;男性61.1%)。病因包括FCA(42%,28/67)、双侧脑动脉病(5%,3/67)、主动脉/颈部动脉病(12%,8/67)、心源性栓塞(7%,5/67)、其他(22%,15/67)和多因素(12%,8/67)。FCA中75%(21/28)显示同心性VWE,与狭窄严重程度相关(ρ=0.31;P=0.001)。FCA中VWE阳性患者初始局灶性脑动脉病严重程度评分高于VWE阴性患者(中位5对3;P=0.046),但其他评估因素未见统计学显著差异,包括初始儿童美国国立卫生研究院卒中量表评分(中位8.5对8;P=0.5)和12个月儿童卒中结局测量(中位0.5对1;P=0.8)。VW-MRI可检测儿童FCA中的炎性动脉改变。然而,其预后价值有限,提示强化反映急性炎症而非长期病程轨迹。
British journal of anaesthesia IF 10.3 2026-11 PMID: 42722596
One in four surgical patients carries a drug allergy label, of which an estimated 90% are incorrect. Avoidance of first-choice drug therapies can lead to worse postoperative outcomes. We sought to determine the nature and extent of any association between drug allergy labels and postoperative complications. A multicentre observational study was performed in 21 UK National Health Service hospitals. Eligible patients were ≥18 yr of age and undergoing common surgical procedures: primary hip or knee replacement, internal fixation of closed long bone fracture, colorectal resection, transurethral resection of prostate or bladder tumour, Caesarean delivery, or hysterectomy. Exclusion criteria were the use of antibiotics in the two weeks before surgery or previous participation in the study. The primary outcome was postoperative complications within 30 days after surgery, a composite outcome comprising all postoperative infections, anastomotic leak, acute respiratory distress syndrome, myocardial infarction, postoperative bleeding, pulmonary embolism, stroke, antimicrobial side-effects, and death. Among 13 646 patients, 3924 (29%) carried ≥1 drug allergy label. Labelled patients were more likely to develop postoperative complications (989/3924 [25%] vs 1926/9722 [20%]; odds ratio [OR] 1.21 [1.10-1.34]; P<0.001). They were more likely to develop surgical site infections (337/3924 [9%] vs 760/9722 [8%]; OR 1.19 [1.03-1.38]; P<0.018), and any postoperative infection (750/3924 [19%] vs 1472/9722 [15%]; OR 1.24 [1.11-1.38]; P<0.001). Labelled patients experienced an increased risk of allergic drug reactions (31/3924 [0.01%] vs 29/9722 [<0.01%]; OR 3.00 [1.77-5.09]; P<0.001), but no increase in mortality. Drug allergy labels are common, but often incorrect. Patients with drug allergy labels experience worse postoperative outcomes, including infective and noninfective complications and an increased risk of allergic drug reactions. ISRCTN Registry (ISRCTN15775657).
中文摘要:约四分之一的外科患者带有药物过敏标签,其中估计90%并不正确。回避首选药物治疗可能导致术后结局变差。研究旨在明确药物过敏标签与术后并发症之间关联的性质和程度。在英国21家国民健康服务体系医院开展多中心观察性研究。纳入标准为年龄≥18岁并接受常见外科手术:初次髋或膝关节置换、闭合性长骨骨折内固定、结直肠切除、经尿道前列腺或膀胱肿瘤切除、剖宫产或子宫切除。排除标准为术前两周内使用抗生素或既往参加过该研究。主要结局为术后30天内并发症,为复合结局,包括所有术后感染、吻合口漏、急性呼吸窘迫综合征、心肌梗死、术后出血、肺栓塞、卒中、抗菌药物副作用和死亡。13646例患者中,3924例(29%)带有至少1个药物过敏标签。带标签患者更易发生术后并发症(989/3924[25%] vs 1926/9722[20%];比值比[OR]1.21[1.10-1.34];P<0.001)。他们更易发生手术部位感染(337/3924[9%] vs 760/9722[8%];OR1.19[1.03-1.38];P<0.018)和任何术后感染(750/3924[19%] vs 1472/9722[15%];OR1.24[1.11-1.38];P<0.001)。带标签患者发生过敏性药物反应的风险增加(31/3924[0.01%] vs 29/9722[<0.01%];OR3.00[1.77-5.09];P<0.001),但死亡率未增加。药物过敏标签常见,但常不正确。带有药物过敏标签的患者术后结局更差,包括感染性和非感染性并发症,以及过敏性药物反应风险增加。ISRCTN注册号ISRCTN15775657。
Stroke IF 11.1 2026-11 PMID: 42717910
Intravenous thrombolysis remains the standard treatment for distal and medium vessel occlusion (DMVO) strokes. However, unlike large vessel occlusions, whether tenecteplase achieves higher early successful recanalization rates than alteplase in DMVO strokes remains uncertain. This single-center observational cohort study included consecutive patients with magnetic resonance imaging (MRI)-confirmed DMVO stroke treated at Centre Hospitalier Sud-Francilien, France, according to an institutional thrombolysis protocol specifying alteplase (0.9 mg/kg, 2016-2018) or tenecteplase (0.25 mg/kg, 2018-2023), with follow-up MRI 1 to 2 hours after intravenous thrombolysis. Patients intended for endovascular thrombectomy or without diagnostic-quality follow-up MRI were excluded. Recanalization was blindly assessed using a modified Arterial Occlusion Lesion scale designed for MRI and DMVO. Early successful recanalization was defined as ≥50% recanalization on early follow-up MRI (grade ≥2b), and substantial early infarct growth, assessed using a semiautomatic segmentation technique, was defined as a ≥0.5 mL and ≥20% increase in lesion volume. Propensity-score weighting accounted for baseline imbalances, including age, sex, vascular risk factors, baseline National Institutes of Health Stroke Scale score, occlusion site, and time period (2020-2023 versus 2016-2019). Of the 319 included patients, 159 were treated with tenecteplase and 160 with alteplase. Median baseline National Institutes of Health Stroke Scale was 3 (1-7) in the tenecteplase group versus 4 (1-7.5) in the alteplase group, while M2 occlusions accounted for 54.1% versus 43.8% of cases. Early successful recanalization, assessed at a median postintravenous thrombolysis time of 80 (70-94) minutes, occurred in 72 (45.3%) and 53 (33.1%) patients treated with tenecteplase and alteplase, respectively (propensity-score weighting-odds ratio, 1.59 [95% CI, 1.15-2.20]; P=0.005). Substantial early infarct growth was observed in 42 (26.8%) and 64 (40.5%) patients, respectively (propensity-score weighting-odds ratio, 0.49 [95% CI, 0.35-0.69]; P<0.0001). Compared with alteplase, tenecteplase-treated patients with DMVO had higher early successful recanalization and a lower risk of substantial early infarct growth, supporting its preferential use in this setting. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05635786.
中文摘要:静脉溶栓仍是远端及中等血管闭塞(DMVO)卒中的标准治疗。但与心血管大血管闭塞不同,替奈普酶在DMVO卒中中是否比阿替普酶获得更高的早期成功再通率仍不确定。这项单中心观察性队列研究连续纳入法国Centre Hospitalier Sud-Francilien按院内溶栓方案治疗的经磁共振成像(MRI)确认的DMVO卒中患者,方案规定使用阿替普酶(0.9 mg/kg,2016—2018年)或替奈普酶(0.25 mg/kg,2018—2023年),并在静脉溶栓后1至2小时复查MRI。拟行血管内取栓或缺乏诊断质量随访MRI的患者被排除。再通由盲法评估,采用为MRI与DMVO设计的改良动脉闭塞病灶量表。早期成功再通定义为早期随访MRI上再通≥50%(分级≥2b),早期梗死显著增长采用半自动分割技术评估,定义为病灶体积增加≥0.5 mL且≥20%。倾向评分加权用于校正基线不均衡,包括年龄、性别、血管危险因素、基线美国国立卫生研究院卒中量表评分、闭塞部位及时间段(2020—2023年对比2016—2019年)。319例纳入患者中,159例接受替奈普酶,160例接受阿替普酶。替奈普酶组基线美国国立卫生研究院卒中量表评分中位数为3(1—7),阿替普酶组为4(1—7.5),M2段闭塞分别占54.1%与43.8%。在静脉溶栓后中位80(70—94)分钟评估的早期成功再通分别见于替奈普酶组72例(45.3%)与阿替普酶组53例(33.1%)(倾向评分加权比值比1.59[95% CI,1.15—2.20];P=0.005)。早期梗死显著增长分别见于42例(26.8%)与64例(40.5%)(倾向评分加权比值比0.49[95% CI,0.35—0.69];P<0.0001)。与阿替普酶相比,接受替奈普酶治疗的DMVO患者早期成功再通率更高、早期梗死显著增长风险更低,支持在该情形下优先选用替奈普酶。网址:https://www.clinicaltrials.gov;唯一标识号:NCT05635786。
Stroke IF 11.1 2026-11 PMID: 42717885
Acute ischemic stroke (AIS) survivors are at high risk of major adverse cardiovascular events (MACE), highlighting the need to identify modifiable secondary prevention targets. We assessed whether postacute discharge destination is associated with 1-year MACE risk among AIS survivors. In this retrospective cohort study, adult AIS survivors were identified from the state inpatient and emergency department databases of 5 US states (2016-2019) and categorized by discharge destination: home, inpatient rehabilitation facility (IRF), or skilled nursing facility (SNF). Other destinations were excluded. The primary outcome was 1-year MACE, defined as recurrent stroke, acute myocardial infarction, systemic embolism, or vascular death. Multivariable Cox models, adjusted for demographic and clinical factors, were used to evaluate the association between discharge disposition and MACE risk. Fine-Gray models were used for nonfatal secondary outcomes, and restricted mean survival time analyses were used to estimate absolute risk. Effect modification by age (<65 versus ≥65 years) was examined. Confounder-adjusted number-needed-to-be-exposed was estimated by marginal standardization. Among 213 511 AIS survivors (median age, 71 years), 16 237 (7.6%) experienced MACE within 1-year. MACE incidence was lowest after IRF discharge (6.6%) versus home (7.6%) or SNF (8.3%). In adjusted analyses, IRF discharge was associated with lower MACE risk versus home (adjusted hazard ratio, 0.88 [95% CI, 0.83-0.93]) and SNF (0.84 [95% CI, 0.79-0.89]). The association persisted across age strata but was more pronounced in patients <65 years (Pinteraction=0.014). Restricted mean survival time analyses indicated that IRF discharge was associated with 3.47 and 3.87 additional MACE-free days versus home and SNF discharge, respectively (both P<0.001). Adjusted number-needed-to-be-exposed were 115 (95% CI, 80-207) for IRF versus home and 87 (95% CI, 64-136) for IRF versus SNF. Postacute IRF discharge is associated with a lower 1-year MACE risk after AIS, highlighting the postacute care setting as a potentially modifiable system-level target for secondary prevention of long-term vascular outcomes.
中文摘要:急性缺血性卒中(AIS)存活者发生主要不良心血管事件(MACE)的风险较高,识别可干预的二级预防靶点具有必要性。本研究评估急性期后出院去向是否与AIS存活者1年MACE风险相关。这项回顾性队列研究从美国5个州的住院与急诊数据库(2016—2019年)识别成人AIS存活者,按出院去向分为家庭、住院康复机构(IRF)和熟练护理机构(SNF),排除其他去向。主要结局为1年MACE,定义为复发性卒中、急性心肌梗死、系统性栓塞或血管性死亡。采用多变量Cox模型校正人口学与临床因素,评估出院去向与MACE风险的关联;非致死性次要结局采用Fine-Gray模型,绝对风险采用限制性平均生存时间分析估计。研究检验年龄(<65岁与≥65岁)的效应修饰。通过边际标准化估计校正混杂因素后的需暴露人数。213 511例AIS存活者(中位年龄71岁)中,16 237例(7.6%)在1年内发生MACE。MACE发生率在IRF出院后最低(6.6%),家庭出院为7.6%,SNF出院为8.3%。校正分析中,IRF出院相较家庭出院与更低的MACE风险相关(校正风险比0.88,95% CI 0.83-0.93),相较SNF出院也更低(0.84,95% CI 0.79-0.89)。该关联在各年龄层中持续存在,但在<65岁患者中更明显(交互作用P=0.014)。限制性平均生存时间分析显示,IRF出院相较家庭和SNF出院分别多3.47和3.87个无MACE日(均P<0.001)。校正后的需暴露人数为IRF相较家庭115(95% CI 80-207),IRF相较SNF 87(95% CI 64-136)。AIS后急性期转入IRF与较低的1年MACE风险相关,提示急性期后照护环境可能是长期血管结局二级预防中可干预的系统层面靶点。
Stroke IF 11.1 2026-11 PMID: 42717860
Hemodynamic insufficiency may contribute to the development of neuroimaging signs of cerebral small vessel disease (SVD). The arterial spin labeling (ASL) spatial coefficient of variation (ASL-sCoV) is a proxy marker of arterial transit time and may better capture SVD-related hemodynamic disturbances compared with ASL-derived cerebral blood flow. We investigated ASL-derived hemodynamic indices in relation to cognition and neuroimaging markers of SVD over an 11-year follow-up period. Participants without dementia or stroke were enrolled in the Vanderbilt Memory and Aging Project, a longitudinal observational cohort study in Nashville, TN. Participants underwent serial multimodal 3T brain magnetic resonance imaging to quantify SVD burden and neuropsychological assessment from 2012 to 2024 (4.9±3.5 years mean follow-up). Pseudo-continuous ASL assessed cerebral blood flow and ASL-sCoV in total gray matter. Baseline ASL-sCoV and cerebral blood flow were individually related to the cross-sectional burden and longitudinal trajectory of each SVD neuroimaging marker (white matter hyperintensities, enlarged perivascular spaces, cerebral microbleeds, and lacunar infarcts) and cognitive performances using linear and linear mixed-effects regression models. Models were adjusted for demographics, cognitive status, Framingham Stroke Risk Profile (minus age), apolipoprotein E-ε4 status, intracranial volume (for SVD outcomes), and follow-up time (for longitudinal models). Among participants (n=667, 68±9 years, 18% mild cognitive impairment, 51% female), higher ASL-sCoV was cross-sectionally associated with SVD markers, including white matter hyperintensities and enlarged perivascular spaces (pFDR-values<0.006). Higher baseline ASL-sCoV was associated with a faster longitudinal increase in the burden of white matter hyperintensities (pFDR=0.03) and accelerated decline in executive function, information processing, language, and visuospatial performances (P<0.05). Gray matter cerebral blood flow was not associated with SVD burden or cognition cross-sectionally (pFDR-values>0.05) or longitudinally (pFDR-values>0.06). ASL-sCoV may serve as an important hemodynamic measure for identifying perfusion deficits tied to SVD burden and progression. Readily derived from existing ASL data sets, ASL-sCoV could provide substantial insight into the longitudinal clinical consequences of SVD.
中文摘要:血流动力学不足可能促成脑小血管病(SVD)的神经影像征象。动脉自旋标记(ASL)空间变异系数(ASL-sCoV)是动脉通过时间的替代指标,相较ASL衍生的脑血流量,可能更好反映SVD相关血流动力学紊乱。研究在11年随访期内考察ASL衍生血流动力学指标与认知及SVD神经影像标志物的关系。参与者无痴呆或卒中,来自Vanderbilt Memory and Aging Project,为田纳西州纳什维尔一项纵向观察性队列研究。2012至2024年参与者接受系列多模态3T脑磁共振成像以量化SVD负荷,并接受神经心理评估,平均随访4.9±3.5年。伪连续ASL评估全灰质脑血流量和ASL-sCoV。基线ASL-sCoV与脑血流量分别与各SVD神经影像标志物(白质高信号、血管周围间隙扩大、脑微出血、腔隙性梗死)的横断面负荷和纵向轨迹及认知表现相关,采用线性回归和线性混合效应回归模型。模型校正人口学特征、认知状态、Framingham卒中风险谱(不含年龄)、载脂蛋白E-ε4状态、颅内体积(SVD结局)和随访时间(纵向模型)。参与者共667人,年龄68±9岁,18%为轻度认知障碍,51%为女性。较高ASL-sCoV在横断面上与SVD标志物相关,包括白质高信号和血管周围间隙扩大(pFDR值<0.006)。较高基线ASL-sCoV与白质高信号负荷纵向增长更快(pFDR=0.03)以及执行功能、信息处理、语言和视空间表现加速下降相关(P<0.05)。灰质脑血流量在横断面(pFDR值>0.05)和纵向(pFDR值>0.06)均与SVD负荷或认知无关。ASL-sCoV可能成为识别与SVD负荷和进展相关灌注缺损的重要血流动力学指标。该指标可从现有ASL数据集直接获得,或能为SVD纵向临床后果提供重要认识。
JAMA internal medicine IF 26.3 2026-11-01 PMID: 42709460
Vasomotor symptoms in perimenopause are associated with increased future cardiovascular (CVD) risk. Most clinical trials on menopausal hormone therapy (MHT) and CVD risk have focused on postmenopausal women, with limited study of the perimenopausal period when hormonal fluctuations and symptoms are greatest. Moreover, these trials were not designed to evaluate CVD risk with MHT among women with vasomotor symptoms. To estimate the effect of MHT on CVD risk among perimenopausal and recently postmenopausal women with vasomotor symptoms and assess the extent to which timing of MHT use relative to menopause and race and ethnicity modify this effect. Cohort data from the Study of Women's Health Across the Nation (SWAN, 1997-2017)-a multiethnic, multicenter, longitudinal study of the menopause transition-were used to emulate a sequence of target trials. Eligible participants were women who self-reported any vasomotor symptoms (ie, hot flashes and/or night sweats over the past 2 weeks) and who were CVD-free, with no prior MHT use. Data were analyzed from January 2023 to December 2025. MHT use (systemic estrogen with/without progestogens, verified from medication containers). CVD events (myocardial infarction, stroke, heart failure, and revascularization) were self-reported. CVD-related death was recorded from death certificates. Of 2737 women who reported any vasomotor symptoms, 755 initiated MHT (mean [SD] age, 53.7 [4.6] years) over the 20-year follow-up period, during which 224 fatal and nonfatal CVD events occurred. Overall, the estimated adjusted hazard ratio (aHR) of CVD events for MHT initiation vs noninitiation was 0.78 (95% CI, 0.62-0.98). The estimated aHR was 0.73 (95% CI, 0.58-0.93) and 1.53 (95% CI, 0.66-3.52) among women initiating MHT 10 or fewer years vs more than 10 years from the onset of menopause, respectively (P value for interaction: .02). Race and ethnicity modified the MHT initiation effect, with Black women showing protective effect (aHR, 0.51; 95% CI, 0.33-0.81), while no clear effects were observed in White women or women of other races (P value for interaction = .007). The presented results are pooled from all target trials and found that MHT initiation during perimenopause or recently postmenopausal women with vasomotor symptoms was estimated to reduce CVD risk by 22%. Benefits were more pronounced in Black women and women who initiated MHT within 10 years of menopause onset. However, all estimates warrant caution given the potential for residual confounding. Given the inconsistency of the cardiovascular benefits and the need to consider overall risk-benefit balance, these findings should not be used to support MHT for CVD prevention.
中文摘要:围绝经期血管舒缩症状与未来心血管(CVD)风险升高相关。大多数关于绝经激素治疗(MHT)与CVD风险的临床试验集中于绝经后女性,对激素波动和症状最明显的围绝经期研究有限。这些试验也并非为评估有血管舒缩症状女性中MHT的CVD风险而设计。研究目的是估计围绝经期和近期绝经且有血管舒缩症状女性中MHT对CVD风险的影响,并评估MHT使用相对于绝经的时间以及种族和族裔对该效应的修饰程度。研究使用全国女性健康研究(SWAN,1997-2017)的队列数据模拟一系列目标试验;SWAN是一项多族裔、多中心、纵向绝经过渡研究。合格参与者为自我报告任何血管舒缩症状(即过去2周潮热和/或盗汗)且无CVD、既往未使用MHT的女性。数据分析时间为2023年1月至2025年12月。MHT使用指全身雌激素联合或不联合孕激素,经药物容器核实。CVD事件包括心肌梗死、卒中、心力衰竭和血运重建,为自我报告。CVD相关死亡从死亡证明记录。在2737名报告任何血管舒缩症状的女性中,755名在20年随访期间开始MHT,平均(标准差)年龄53.7(4.6)岁,期间发生224例致死和非致死CVD事件。总体而言,MHT开始与未开始的CVD事件估计调整风险比(aHR)为0.78(95%CI,0.62-0.98)。在绝经开始后10年或以内与超过10年开始MHT的女性中,估计aHR分别为0.73(95%CI,0.58-0.93)和1.53(95%CI,0.66-3.52),交互作用P值=0.02。种族和族裔修饰MHT开始效应,黑人女性显示保护效应(aHR,0.51;95%CI,0.33-0.81),白人女性或其他种族女性未观察到明确效应,交互作用P值=0.007。所呈现结果汇总自所有目标试验,发现围绝经期或近期绝经且有血管舒缩症状的女性开始MHT估计使CVD风险降低22%。黑人女性和绝经开始10年内开始MHT的女性获益更明显。由于潜在残余混杂,所有估计值都需谨慎解读。鉴于心血管获益不一致且需考虑总体风险获益平衡,这些发现不应被用于支持MHT预防CVD。
Annals of neurology IF 7.5 2026-11 PMID: 42708556
In this post hoc analysis of the ANNEXa-I trial (n = 434), we evaluated non-contrast computed tomography (NCCT) markers of hematoma expansion (HE) in factor Xa inhibitor (FXai) -associated intracerebral hemorrhage (ICH). At least one NCCT marker was present in 72.1%, and HE (≥12.5 mL or ≥ 35% increase in hematoma volume) occurred in 31.8%. Heterogeneous density, hypodensity, and the black hole sign were independently associated with HE. The effect of andexanet on HE was generally consistent across NCCT marker subgroups. These findings support the utility of NCCT markers for identifying patients at high risk of HE in FXai-associated ICH. ANN NEUROL 2026;100:979-983.
中文摘要:在这项ANNEXa-I试验的事后分析(n=434)中,我们评估了凝血因子Xa抑制剂(FXai)相关脑出血中用于提示血肿扩大(HE)的非增强计算机断层扫描(NCCT)标志物。72.1%的患者至少存在1项NCCT标志物,31.8%发生HE(血肿体积增加≥12.5 mL或≥35%)。密度不均、低密度和黑洞征与HE独立相关。在不同NCCT标志物亚组中,andexanet对HE的作用总体一致。这些发现支持NCCT标志物用于识别FXai相关脑出血中HE高风险患者。ANN NEUROL 2026;100:979-983。
Stroke IF 11.1 2026-11 PMID: 42695174
Despite increasing incidence of stroke among younger adults, the associations of social determinants of health (SDOH) and stroke among younger adults are not well known. This study investigates the associations between SDOH from early adulthood and stroke in a prospective longitudinal cohort. We studied participants enrolled in the CARDIA study (Coronary Artery Risk Development in Young Adults). Participants aged 18 to 30 years were enrolled in 1985 and followed through 2022. We investigated longitudinal, time-varying measures of SDOH classified into 5 distinct domains: economic (6 measures), education (1 measure), healthcare (4 measures), neighborhood (2 measures), and social/community (5 measures). The outcome was incident stroke or transient ischemic attack. We evaluated associations between individual SDOH and stroke using unadjusted Cox models. We then evaluated whether a greater cumulative number of adverse SDOH domains (each represented by 1 exposure selected by empirical techniques) was associated with stroke risk after adjustment for demographics. Among the 5114 participants (54.5% were female; baseline age, 25 years; and median follow-up, 37.9 years), 146 individuals experienced stroke or transient ischemic attack, all of which occurred <65 years. Household income (hazard ratio [HR], 1.24 per $10 000 lower [95% CI, 1.11-1.39]), education (HR, 0.93 per greater year [95% CI, 0.87-0.99]), neighborhood deprivation (HR, 1.21 [95% CI, 1.02-1.43]), and lacking health insurance (HR, 1.49 [95% CI, 1.05-2.11]) were associated with stroke risk. Those experiencing 2 adverse SDOH domains (HR, 1.65 [95% CI, 0.91-2.97]) or ≥3 adverse domains (HR, 2.00 [95% CI, 1.09-3.66]) had progressively higher stroke risk (Ptrend=0.005). In interaction analyses, the association between income and stroke appeared stronger in Black participants (Pinteraction=0.02) and women (Pinteraction=0.02). In this young cohort followed through midlife, SDOH spanning several domains were associated with stroke risk. We also observed a dose-dependent response with the number of adverse SDOH domains experienced. Our results suggest that SDOH experienced throughout adulthood are relevant to future stroke risk.
中文摘要:尽管年轻成人卒中发病率上升,年轻成人中健康社会决定因素(SDOH)与卒中的关联仍不明确。本研究在前瞻性纵向队列中考察成年早期起的SDOH与卒中的关联。研究对象为CARDIA研究(年轻成人冠状动脉风险发展研究)参与者,1985年入组时年龄18至30岁,随访至2022年。研究分析5个领域的纵向、随时间变化的SDOH指标:经济(6项)、教育(1项)、医疗保健(4项)、社区邻里(2项)、社会/社区(5项)。结局为新发卒中或短暂性脑缺血发作。先用未校正Cox模型评估各SDOH与卒中的关联,再在校正人口学特征后评估累积不利SDOH领域数(每个领域由经验方法选出的1项暴露代表)是否与卒中风险相关。5114名参与者(54.5%女性;基线年龄25岁;中位随访37.9年)中,146人发生卒中或短暂性脑缺血发作,均发生在65岁以前。家庭收入每降低1万美元HR 1.24(95%CI 1.11-1.39)、教育每增加1年HR 0.93(95%CI 0.87-0.99)、邻里剥夺HR 1.21(95%CI 1.02-1.43)、缺乏医疗保险HR 1.49(95%CI 1.05-2.11)与卒中风险相关。经历2个不利SDOH领域者HR 1.65(95%CI 0.91-2.97),经历≥3个不利领域者HR 2.00(95%CI 1.09-3.66),卒中风险逐步升高(P趋势=0.005)。交互分析中,收入与卒中的关联在黑人参与者和女性中似乎更强(交互P分别为0.02和0.02)。在这个随访至中年的年轻队列中,跨多个领域的SDOH与卒中风险相关,且随不利SDOH领域数增加呈剂量依赖反应。结果提示成年期经历的SDOH与未来卒中风险有关。
Stroke IF 11.1 2026-11 PMID: 42695153
The utility-weighted approach to analyzing the modified Rankin Scale (mRS) is increasingly being utilized in acute stroke clinical trials. This analytic approach assigns a patient-centered utility weight-the desirability or value of a health state to patients-to each level of the mRS. The utility-weighted-mRS analysis converts the mRS from a scale reflecting only the rank order of functional outcome after stroke into one that quantifies the value of each poststroke mRS health state from patients' perspectives. The ability of the utility-weighted-mRS analysis to capture the unequal difference in patient health-related quality of life between each level of the mRS makes it an appealing patient-centered end point for acute stroke clinical trials. However, several concerns have historically raised skepticism regarding its value as a trial end point. Unfamiliarity with how utility weights are derived and used poses challenges to its use for shared decision-making between patients and clinicians. There are valid concerns that social, geographic, and demographic factors that differ between countries influence the mRS utility weights, so that use of uniform weights across all settings mildly reduces the precision of utility quantification, particularly in multinational stroke clinical trials. This narrative review aims to provide the clinical and research stroke community with a practical overview of key methodology in the utility-weighted-mRS analysis to aid in its interpretation, considers the advantages and challenges of using the utility-weighted-mRS analysis, and suggests future areas of study.
中文摘要:改良Rankin量表(mRS)的效用加权分析在急性卒中临床试验中的应用日益增多。该方法为mRS每一等级赋予以患者为中心的效用权重,即患者对某一健康状态的偏好或价值判断。效用加权mRS分析将mRS从仅反映卒中后功能结局排序的量表,转变为可量化患者视角下卒中后各mRS健康状态价值的工具。效用加权mRS分析能够体现mRS各等级之间患者健康相关生活质量差异的不均等性,因而成为急性卒中临床试验中颇具吸引力的以患者为中心的终点。长期以来,若干顾虑使其作为试验终点的价值受到质疑。对效用权重如何推导和使用不熟悉,给患者与临床医生共同决策带来困难。有合理担忧认为,国家间社会、地理和人口学因素的差异会影响mRS效用权重,因此在所有场景使用统一权重会轻度降低效用量化的精确性,在多国卒中临床试验中尤为如此。本叙述性综述旨在为卒中临床与研究界提供效用加权mRS分析关键方法的实用概览,以助其解读,讨论使用该分析的优势与挑战,并提出未来研究方向。
Diabetologia IF 10.4 2026-11 PMID: 42542457
Recent awareness that metabolic dysfunction-associated steatotic liver disease (MASLD) is a common liver condition in individuals with type 2 diabetes and carries a significant risk of cirrhosis and extrahepatic disease has called for an examination of its relationship with diabetes-related complications. MASLD, especially at-risk steatohepatitis (metabolic dysfunction-associated steatohepatitis [MASH]) with significant fibrosis ≥F2, shares many metabolic abnormalities with type 2 diabetes, including insulin resistance, gluco- and lipotoxicity, chronic subclinical inflammation and mitochondrial impairment. In addition, many cross-sectional and longitudinal observational studies suggest an association between MASLD and micro- and macrovascular complications of type 1 and type 2 diabetes. However, a causal pathogenic relationship has been difficult to confirm given the overlap of cardiometabolic risk factors (CMRFs) in MASLD and type 2 diabetes. Complicating matters further, most of the available evidence has significant limitations. These include shortcomings in participant selection, heterogeneity in study design, use of diagnostic tools with low sensitivity for liver disease and diabetes-related complications, inadequate control for alcohol consumption or CMRFs, and lack of repeat measurements during longitudinal studies. Nevertheless, current evidence suggests that MASLD is a 'risk enhancer' for both micro- and macrovascular disease in diabetes, rather than an independent risk factor. Here, we review the underlying mechanistic pathways and clinical evidence that appear to link both conditions and identify knowledge gaps in need of future research. Until more robust evidence emerges, we hope that a greater awareness about the link between MASLD and diabetes-related micro- and macrovascular complications will prompt clinicians to educate their patients and peers on the potentially heightened health risks of MASLD and encourage clinicians to take a more proactive approach to risk stratification and intervention.
中文摘要:近期认识到,代谢功能障碍相关脂肪性肝病(MASLD)是2型糖尿病患者中常见的肝脏疾病,并带来肝硬化和肝外疾病的显著风险,这要求审视其与糖尿病相关并发症的关系。MASLD,尤其是伴显著纤维化≥F2的高危脂肪性肝炎(代谢功能障碍相关脂肪性肝炎[MASH]),与2型糖尿病共有许多代谢异常,包括胰岛素抵抗、糖毒性和脂毒性、慢性亚临床炎症及线粒体损伤。此外,许多横断面和纵向观察性研究提示,MASLD与1型和2型糖尿病的微血管和大血管并发症存在关联。然而,鉴于MASLD与2型糖尿病中心血管代谢危险因素(CMRFs)重叠,因果致病关系难以确认。更复杂的是,现有证据大多有明显局限,包括参与者选择缺陷、研究设计异质性、对肝病和糖尿病相关并发症敏感性低的诊断工具、对饮酒或CMRFs控制不足,以及纵向研究缺乏重复测量。尽管如此,当前证据提示MASLD是糖尿病微血管和大血管疾病的「风险增强因素」,而非独立危险因素。综述回顾了似乎连接这两种情况的潜在机制通路和临床证据,并指出未来研究需要填补的知识空白。在更有力证据出现之前,希望提高对MASLD与糖尿病相关微血管和大血管并发症之间联系的认识,促使临床医生向患者和同行说明MASLD可能带来的更高健康风险,并鼓励临床医生在风险分层和干预中采取更主动的方法。
Molecular psychiatry IF 10.4 2026-11 PMID: 42277229
The plasma proteomic signatures of sleep disturbance remain poorly characterized. Using data from 43,709 predominantly European-ancestry, middle-aged and older UK Biobank participants, we depict a large-scale atlas of plasma proteomic signatures of seven self-reported sleep traits (sleep duration, chronotype, insomnia symptoms, daytime napping, daytime sleepiness, snoring, and ease of getting up in the morning) and a derived sleep health score. We identify 935 proteins associated with at least one sleep trait, converging on lipid metabolism, immune function and inflammation, cell adhesion, and neurochemical signaling. Leveraging genomic structural equation modeling to define three latent sleep factors, namely circadian preference, daytime sleep burden, and nighttime sleep adequacy, bidirectional Mendelian randomization (MR) identifies one protein (LTA) with robust cis-instrument and strong colocalization support (PP.H4 = 0.98) for a putative causal effect on nighttime sleep adequacy. Sixteen additional genetically supported candidate proteins rely primarily on trans-pQTL instruments or weaker colocalization. These genetically supported candidates are prospectively associated with incident cardiovascular disease, stroke, type 2 diabetes, dementia, chronic kidney disease, depression, and mortality over a median 13.6-year follow-up, with the strongest per-SD hazard ratio (HR) associations observed for chronic kidney disease (e.g., BTN2A1: HR = 2.33) and type 2 diabetes (e.g., RBP5: HR = 1.58). Collectively, these findings highlight the potential of large-scale proteomics in elucidating sleep pathogenesis, and generate testable hypotheses for validation in independent cohorts and experimental models.
中文摘要:睡眠障碍的血浆蛋白质组特征仍缺乏充分描述。利用43,709名以欧洲血统为主的中老年英国生物银行参与者的数据,我们绘制了七种自报睡眠特征(睡眠时长、昼夜节律类型、失眠症状、日间小睡、日间嗜睡、打鼾、早晨起床难易)及一个派生睡眠健康评分的大规模血浆蛋白质组特征图谱。我们识别出935种与至少一种睡眠特征相关的蛋白质,集中于脂质代谢、免疫功能与炎症、细胞黏附及神经化学信号传导。利用基因组结构方程模型定义三个潜在睡眠因子,即昼夜偏好、日间睡眠负担和夜间睡眠充足性,双向孟德尔随机化识别出一种蛋白质LTA,其对夜间睡眠充足性的推定因果效应具有稳健的顺式工具和强共定位支持(PP.H4=0.98)。另外16种遗传支持的候选蛋白质主要依赖反式pQTL工具或较弱共定位。这些遗传支持的候选蛋白质与中位13.6年随访期间新发心血管疾病、卒中、2型糖尿病、痴呆、慢性肾病、抑郁和死亡前瞻性相关,每标准差风险比最强的关联见于慢性肾病(如BTN2A1:HR=2.33)和2型糖尿病(如RBP5:HR=1.58)。这些发现凸显大规模蛋白质组学在阐明睡眠发病机制方面的潜力,并为在独立队列和实验模型中验证产生可检验的假设。
Circulation IF 41.3 2026-10-31 PMID: 42965504
For patients with severe pure aortic regurgitation (AR) at high surgical risk, guideline-directed medical therapy (GDMT) is often the only available option. Transfemoral transcatheter aortic valve replacement (TAVR) is an established treatment for aortic stenosis and has also been evaluated in patients with pure AR. However, no adequately powered randomized trial has compared TAVR with GDMT alone in this population. We conducted a prospective, investigator-initiated, multicenter, randomized, open-label trial in China. Patients with severe pure AR for whom surgery was considered difficult or unacceptable by the local heart team or who persistently declined surgery were randomly assigned at a 1:1 ratio to receive transfemoral TAVR with the VitaFlow system plus GDMT or GDMT alone. The primary end point was a composite of all-cause death, disabling stroke, or heart failure rehospitalization at 1 year. We assigned 210 patients with severe pure AR to the TAVR group (n=109) or GDMT group (n=101) at 18 centers. At 1-year follow-up, the Kaplan-Meier estimate of the primary end point was significantly lower in the TAVR group than in the GDMT group (8.3% vs 24.8%; hazard ration [HR], 0.31 [95% CI, 0.14-0.66]; P=0.001), driven primarily by a reduction in heart failure rehospitalization (3.7% vs 21.3%; HR, 0.16 [95% CI, 0.06-0.47]; P < 0.001). TAVR was associated with higher rates of major or life-threatening bleeding and new permanent pacemaker implantation, most of which occurred within 30 days after the procedure. Among patients with severe pure AR, TAVR plus GDMT significantly reduced the rate of all-cause death, disabling stroke, or heart failure rehospitalization at 1 year compared with GDMT alone despite higher 30-day rates of major or life-threatening bleeding and new permanent pacemaker implantation. URL: https://www.clinicaltrials.gov; Unique identifier: NCT04864145.
中文摘要:对于外科手术高风险的重度单纯性主动脉瓣反流(AR)患者,指南导向药物治疗(GDMT)常是唯一可选方案。经股动脉经导管主动脉瓣置换术(TAVR)是主动脉瓣狭窄的成熟治疗方式,也已在单纯性AR患者中接受评估。然而,尚无足够把握度的随机试验在该人群中比较TAVR与单独GDMT。我们在中国开展了一项前瞻性、研究者发起、多中心、随机、开放标签试验。对于当地心脏团队认为手术困难或不可接受、或持续拒绝手术的重度单纯性AR患者,按1:1比例随机分配接受VitaFlow系统经股动脉TAVR联合GDMT或单独GDMT。主要终点为1年全因死亡、致残性卒中或心力衰竭再住院的复合终点。我们在18个中心将210例重度单纯性AR患者分配至TAVR组(n=109)或GDMT组(n=101)。1年随访时,TAVR组主要终点的Kaplan-Meier估计值显著低于GDMT组(8.3%对24.8%;风险比[HR],0.31[95% CI,0.14-0.66];P=0.001),主要驱动因素为心力衰竭再住院减少(3.7%对21.3%;HR,0.16[95% CI,0.06-0.47];P<0.001)。TAVR与较高的大出血或危及生命出血及新发永久起搏器植入率相关,其中多数发生在术后30天内。在重度单纯性AR患者中,与单独GDMT相比,TAVR联合GDMT显著降低1年全因死亡、致残性卒中或心力衰竭再住院发生率,尽管30天内大出血或危及生命出血及新发永久起搏器植入率较高。URL:https://www.clinicaltrials.gov;唯一标识符:NCT04864145。
Neurology India IF 0.8 2026-10-30 PMID: 42963853
Cerebral venous thrombosis (CVT) represents an uncommon yet potentially reversible form of stroke, predominantly affecting young adults. Mechanical thrombectomy (MT) is increasingly used in patients with extensive thrombus burden or medically refractory cases. In low- and middle-income countries (LMICs), where repeated neuroimaging may not be readily feasible, transcranial Doppler (TCD) ultrasonography offers a non-invasive, bedside, and low-cost approach to assess cerebral hemodynamics. Its role in CVT remains underexplored. To evaluate the changes in middle cerebral artery (MCA) flow velocities measured by TCD ultrasonography in patients with CVT at baseline, day 1, and day 2 following MT. Fourteen patients (15-60 years) with magnetic resonance venography-confirmed CVT undergoing MT were prospectively studied. Bilateral MCA peak systolic velocity (PSV), mean flow velocity (MFV), end-diastolic velocity (EDV), and pulsatility index (PI) were recorded at baseline and on days 1 and 2 postprocedure. Serial MCA flow parameters across baseline, day 1 and day 2 were compared using repeated-measures analysis of variance, with paired t-tests for pre-specified comparisons against baseline (confirmed by Wilcoxon signed-rank tests); a two-sided P < 0.05 was considered significant. We observed a predominantly young male cohort (57%) of mean age 34.4 ± 11 years. Venous involvement was left (42.8%), right (42.8%), or bilateral (14.2%), with raised intracranial pressure in 78.6%. No significant MCA flow changes occurred on day 1. By day 2, right MCA EDV showed a decreasing trend, though statistically not significant (P = 0.06). Other parameters, such as PSV, MFV, and PI, showed non-significant trends. The left MCA parameters remained stable. TCD assessment of the MCA may have limited sensitivity in detecting early hemodynamic changes following MT in CVT. Larger prospective studies with longer follow-up durations are needed to better define the role of TCD in this setting.
中文摘要:脑静脉血栓形成(CVT)是一种不常见但可能可逆的卒中类型,主要累及年轻成人。机械取栓(MT)越来越多用于血栓负荷大或内科治疗难治的患者。在低收入和中等收入国家(LMICs),重复神经影像检查未必容易实施,经颅多普勒(TCD)超声提供了一种无创、床旁、低成本评估脑血流动力学的方法。其在CVT中的作用仍研究不足。评估CVT患者接受MT前基线及术后第1天、第2天经TCD超声测得的大脑中动脉(MCA)血流速度变化。前瞻性研究14例(15-60岁)经磁共振静脉成像确诊CVT并接受MT的患者。记录基线及术后第1天、第2天双侧MCA收缩期峰值流速(PSV)、平均血流速度(MFV)、舒张末期流速(EDV)和搏动指数(PI)。采用重复测量方差分析比较基线、第1天和第2天系列MCA血流参数,预设与基线的比较采用配对t检验(并用Wilcoxon符号秩检验确认);双侧P < 0.05为显著。队列以年轻男性为主(57%),平均年龄34.4 ± 11岁。静脉受累位于左侧(42.8%)、右侧(42.8%)或双侧(14.2%),78.6%存在颅内压升高。第1天MCA血流无显著变化。至第2天,右侧MCA EDV呈下降趋势,但无统计学意义(P = 0.06)。PSV、MFV和PI等其他参数呈无显著意义的趋势。左侧MCA参数保持稳定。TCD评估MCA在检测CVT患者MT后早期血流动力学变化方面敏感性可能有限。需要更大样本、更长随访的前瞻性研究来更好界定TCD在该场景中的作用。
Neurology India IF 0.8 2026-10-30 PMID: 42963849
Shunt-dependent hydrocephalus (ShDH) remains a source of morbidity after aneurysmal subarachnoid hemorrhage (aSAH). During microsurgical clipping, lamina terminalis (LT) fenestration with basal cisternostomy (BC) and membrane of Liliequist (MoL) fenestration (LTF-BC) can potentially reduce shunt dependency. To evaluate permanent cerebrospinal fluid (CSF) diversion rates and clinical outcomes in patients with aSAH undergoing microsurgical aneurysm occlusion with LTF-BC and MoL fenestration, and to identify factors associated with them. We performed a single-center retrospective cohort study using an institutional registry (2014-2023). Of 381 patients screened, 331 with ruptured aneurysms treated microsurgically with LTF-BC and MoL fenestration were included. Primary outcomes were permanent CSF diversion and 3-year functional outcome (modified Rankin Scale [mRS]). Multivariable logistic regression and Firth regression were performed. An external comparator analysis provided descriptive absolute risk reduction (ARR) and number needed to treat (NNT) estimates. Median age was 55 years; 56.8% were women, 81.3% had Fisher grade III-IV hemorrhage, and 39.6% had acute hydrocephalus. Temporary CSF diversion was required in 50/131 (38.2%) patients with acute hydrocephalus. At 3 years, mRS was available for 326/331 patients; 244/326 (74.8%) had a good outcome (mRS 0-3). Permanent CSF diversion was performed in 9/331 patients (2.7%). Temporary CSF diversion was the only independent predictor of 3-year shunt dependency (odds ratio (OR) 5.08, 95% confidence interval (CI) 1.12-23.18; P = 0.036). Independent predictors of worse 3-year functional outcome were increasing age (OR 0.96 per year, 95% CI 0.94-0.99; P = 0.003), World Federation of Neurosurgical Societies grade ≥3 (OR 0.34, 95% CI 0.19-0.62; P < 0.001), and intraventricular hemorrhage (OR 0.42, 95% CI 0.23-0.75; P = 0.004). In external comparison, permanent CSF diversion was lower than in the nonfenestration cohort (2.7% vs 17.9%; ARR 15.2%; NNT 6.59). LTF-BC with MoL fenestration was associated with a low 3-year permanent CSF diversion rate despite high hemorrhage severity. Temporary CSF diversion identified a subgroup at increased risk for future shunt dependency.
中文摘要:分流依赖性脑积水(ShDH)仍是动脉瘤性蛛网膜下腔出血(aSAH)后致病原因之一。显微外科夹闭术中行终板(LT)开窗联合基底池造瘘(BC)及Liliequist膜(MoL)开窗(LTF-BC)可能降低分流依赖。评估接受显微外科动脉瘤闭塞并LTF-BC及MoL开窗的aSAH患者永久性脑脊液(CSF)分流率及临床结局,并识别相关因素。利用机构登记数据(2014-2023)开展单中心回顾性队列研究。筛查381例,纳入331例接受LTF-BC及MoL开窗显微外科治疗的破裂动脉瘤患者。主要结局为永久性CSF分流及3年功能结局(改良Rankin量表[mRS])。采用多变量logistic回归及Firth回归。外部对照分析提供描述性绝对风险降低(ARR)及需治疗人数(NNT)估计。中位年龄55岁;56.8%为女性,81.3%为Fisher III-IV级出血,39.6%有急性脑积水。131例急性脑积水患者中50例(38.2%)需要临时CSF分流。3年时326/331例有mRS;244/326例(74.8%)结局良好(mRS 0-3)。331例中9例(2.7%)接受永久性CSF分流。临时CSF分流是3年分流依赖的唯一独立预测因素(OR 5.08,95%CI 1.12-23.18;P=0.036)。3年功能结局较差的独立预测因素为年龄增加(每岁OR 0.96,95%CI 0.94-0.99;P=0.003)、世界神经外科医师联盟分级≥3级(OR 0.34,95%CI 0.19-0.62;P<0.001)及脑室内出血(OR 0.42,95%CI 0.23-0.75;P=0.004)。外部比较中,永久性CSF分流率低于未开窗队列(2.7% vs 17.9%;ARR 15.2%;NNT 6.59)。尽管出血严重程度较高,LTF-BC联合MoL开窗与较低的3年永久性CSF分流率相关。临时CSF分流识别出未来分流依赖风险较高的亚组。
Stroke IF 11.1 2026-10-30 PMID: 42961033
Patients with medium or distal vessel occlusion stroke are heterogeneous. Randomized trials show no net benefit of endovascular treatment (EVT) over best medical treatment (BMT) alone, which may mask heterogeneity of treatment effect. We used an externally developed machine learning model to predict excellent early neurological outcome (EENO) with BMT alone and examined whether the effect of EVT differed across predicted risk. A Tabular Prior-Data Fitted Network (TabPFN) model was trained to predict EENO (24-hour National Institutes of Health Stroke Scale [NIHSS] score of 0-2) in patients with medium or distal vessel occlusion treated with BMT alone in a local Bernese Stroke Registry. This model was applied to patients from the DISTAL randomized trial (55 centers and 11 countries), who were randomized to EVT plus BMT or BMT alone. We tested for interaction between predicted EENO and treatment allocation on the primary outcome (90-day modified Rankin Scale shift), repeating this using admission NIHSS alone. In the development cohort (n=257, 42% female, and mean age 70.4±14.8 years), 54% achieved EENO. In the DISTAL cohort (270 BMT alone, 269 EVT plus BMT, 44% female, and mean age 74.9±12.0 years), the model showed moderate external discrimination (area under the receiver operating characteristic curve 0.73). A significant interaction was found between predicted EENO and treatment effect (Pinteraction=0.012): in 152 patients predicted to achieve EENO, EVT was associated with worse 90-day modified Rankin Scale score (common odds ratio, 0.48 [95% CI, 0.27-0.84]), whereas no treatment effect was seen in 387 patients predicted not to achieve EENO (common odds ratio 1.13 [95% CI, 0.79-1.60]). A model using admission NIHSS alone showed comparable discrimination (area under the receiver operating characteristic curve 0.71) and a common odds ratio for EVT of 0.47 (95% CI, 0.25-0.89) in patients with an NIHSS score of ≤4 and a common odds ratio of 1.05 (95% CI, 0.75-1.47) in patients with an NIHSS score of >4 (Pinteraction=0.029). EVT was harmful in patients with medium or distal vessel occlusion predicted to achieve EENO with BMT alone, and an NIHSS-alone model performed comparably to the multivariable model. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05029414.
中文摘要:中等或远端血管闭塞卒中患者具有异质性。随机试验显示血管内治疗(EVT)相较单纯最佳药物治疗(BMT)无净获益,这可能掩盖治疗效应的异质性。研究使用外部开发的机器学习模型预测单纯BMT下的极佳早期神经功能结局(EENO),并检验EVT效应是否随预测风险不同而变化。在本地伯尔尼卒中登记中,以单纯BMT治疗的中等或远端血管闭塞患者训练表格先验数据拟合网络(TabPFN)模型,预测EENO,即24小时美国国立卫生研究院卒中量表(NIHSS)评分0-2分。该模型应用于DISTAL随机试验患者(55个中心、11个国家),这些患者被随机分配至EVT加BMT或单纯BMT。研究检验预测EENO与治疗分配对主要结局(90天改良Rankin量表评分分布偏移)的交互作用,并仅用入院NIHSS重复分析。开发队列257例,女性42%,平均年龄70.4±14.8岁,54%达到EENO。DISTAL队列包括单纯BMT 270例和EVT加BMT 269例,女性44%,平均年龄74.9±12.0岁,模型外部判别能力中等,受试者工作特征曲线下面积0.73。预测EENO与治疗效应存在显著交互作用(Pinteraction=0.012):在预测达到EENO的152例患者中,EVT与更差的90天改良Rankin量表评分相关(共同比值比0.48,95% CI 0.27-0.84),而在预测未达到EENO的387例患者中未见治疗效应(共同比值比1.13,95% CI 0.79-1.60)。仅使用入院NIHSS的模型判别能力相近(受试者工作特征曲线下面积0.71),在NIHSS评分≤4分的患者中EVT的共同比值比为0.47(95% CI 0.25-0.89),在NIHSS评分>4分的患者中为1.05(95% CI 0.75-1.47)(Pinteraction=0.029)。在预测单纯BMT即可达到EENO的中等或远端血管闭塞患者中,EVT有害,仅用NIHSS的模型与多变量模型表现相近。URL: https://www.clinicaltrials.gov;Unique identifier: NCT05029414。
Stroke IF 11.1 2026-10-30 PMID: 42960430
The ABCD2 score is widely used to stratify stroke risk after transient neurological events. We aimed to evaluate the association between the ABCD2 score and the risk of subsequent ischemic stroke among patients with diffusion-weighted imaging (DWI)-positive (DWI+) or DWI-negative (DWI-) findings for the index event. We pooled individual participant data from 3 multicenter cohorts including patients presenting with transient or minor neurological events. Patients presenting with transient neurological symptoms, a normal neurological examination, and available DWI for the index event were included. Associations between the ABCD2 score and 90-day ischemic stroke risk were analyzed separately in the DWI+ and DWI- groups using logistic regression models adjusted for sex, atrial fibrillation, and study source. Among 2014 patients (1143 [56.8%] men; median age 67 years), the median ABCD2 score was 4 (interquartile range, 3-5), and 504 (25.0%) were DWI+. Ischemic stroke occurred within 90 days in 20 patients (4.0%) in the DWI+ group and 33 (2.2%) in the DWI- group. The ABCD2 score was associated with stroke risk in the DWI- group (per 1-point increase, odds ratio, 1.36 [95% CI, 1.04-1.79]), but this relationship was not significant in the DWI+ group (per 1-point increase, odds ratio, 1.08 [95% CI, 0.76-1.53]). When stratified ABCD2 score into 0 to 3, 4 to 5, and 6 to 7, the predicted 90-day stroke risks were 3.2%, 3.9%, and 4.5% in the DWI+ group (per 1-category increase, odds ratio, 1.23 [95% CI, 0.63-2.40]) and 1.0%, 2.3%, and 4.1% in the DWI- group (per 1-category increase, odds ratio, 1.88 [95% CI, 1.11-3.20]), respectively. The ABCD2 score was associated with 90-day stroke risk among patients with DWI- findings. Patients with both a low ABCD2 score and DWI- findings had a particularly low risk of subsequent stroke, which may inform risk stratification and clinical decision-making after transient neurological events.
中文摘要:ABCD2评分广泛用于对短暂性神经系统事件后的卒中风险进行分层。本研究旨在评估在索引事件弥散加权成像(DWI)阳性(DWI+)或阴性(DWI-)的患者中,ABCD2评分与后续缺血性卒中风险之间的关系。我们汇总了3个多中心队列的个体参与者数据,这些队列纳入表现为短暂性或轻微神经系统事件的患者。纳入标准为出现短暂性神经系统症状、神经系统检查正常且索引事件有可用DWI的患者。分别在DWI+组和DWI-组中,使用校正性别、心房颤动和研究来源的logistic回归模型分析ABCD2评分与90天缺血性卒中风险的关系。2014例患者(1143例[56.8%]男性;中位年龄67岁)中,ABCD2评分中位数为4(四分位距3-5),504例(25.0%)为DWI+。90天内缺血性卒中发生于DWI+组20例(4.0%)和DWI-组33例(2.2%)。ABCD2评分与DWI-组卒中风险相关(每增加1分,比值比1.36[95% CI,1.04-1.79]),但在DWI+组中该关系不显著(每增加1分,比值比1.08[95% CI,0.76-1.53])。将ABCD2评分分为0至3分、4至5分和6至7分后,DWI+组预测的90天卒中风险分别为3.2%、3.9%和4.5%(每增加1个类别,比值比1.23[95% CI,0.63-2.40]),DWI-组分别为1.0%、2.3%和4.1%(每增加1个类别,比值比1.88[95% CI,1.11-3.20])。ABCD2评分与DWI-患者的90天卒中风险相关。ABCD2评分低且DWI-的患者后续卒中风险特别低,这可能有助于短暂性神经系统事件后的风险分层和临床决策。

基础研究 (12篇)

Nature methods IF 28.3 2026-11-05 PMID: 42988870
Spatial multi-omic technologies measure multiple molecular layers within intact tissues. Two central challenges are vertical integration, which combines different molecular modalities, and horizontal integration, which aligns cell types across studies. Here we show domain invariant representation through adaptive calibration (DIRAC), a geometric deep learning model that unifies these tasks in a generalized domain adaptation framework. DIRAC learns task-discriminative features that are insensitive to domain shifts caused by batch effects, omic modalities or study sites, enabling a shared embedding space and automated cell-type annotation through label transfer from reference datasets. Across sequencing-based and imaging-based datasets, DIRAC identified a new microvascular proliferation domain in glioblastoma, corrected cortical-layer annotations in severe Alzheimer's disease, resolved subtle structures in mouse embryos and remained robust to missing data and unseen cell types. We generated mouse spleen and thymus Stereo-CITE-seq data and used DIRAC to reveal thymic T cell migration and splenic immune cell interactions. DIRAC is fast and scales to millions of cells.
中文摘要:空间多组学技术在完整组织内测量多个分子层面。两项核心挑战是垂直整合,即合并不同分子模态,以及水平整合,即在研究间对齐细胞类型。我们展示通过自适应校准的域不变表示(DIRAC),这是一种几何深度学习模型,在广义域适应框架中统一上述任务。DIRAC学习对批次效应、组学模态或研究站点引起的域偏移不敏感的任务判别特征,从而实现共享嵌入空间,并通过从参考数据集迁移标签进行自动化细胞类型注释。在基于测序和基于成像的数据集中,DIRAC在胶质母细胞瘤中识别出新的微血管增生域,纠正了重度阿尔茨海默病的皮层分层注释,解析了小鼠胚胎中的细微结构,并对缺失数据和未见细胞类型保持稳健。我们生成了小鼠脾脏和胸腺Stereo-CITE-seq数据,并用DIRAC揭示胸腺T细胞迁移和脾脏免疫细胞相互作用。DIRAC速度快,可扩展到数百万细胞。
Pharmacological research IF 12.2 2026-11 PMID: 42843676
Ischemic stroke (IS) results from an acute interruption of cerebral blood flow and the ensuing collapse of energy metabolism. Although vascular recanalization can salvage the ischemic penumbra, its overall benefit remains constrained by a narrow therapeutic window and reperfusion injury. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, contributes to neuronal injury after IS and can amplify ischemia/reperfusion injury. By integrating energy metabolism, iron homeostasis, and redox balance, mitochondria can shape ferroptosis susceptibility within the energy-depleted, iron-dysregulated, and oxidatively stressed ischemic brain. However, most studies have examined iron metabolism and lipid peroxidation at the whole-cell level, leaving the temporal and interorganelle dimensions of mitochondrial regulation of ferroptosis insufficiently integrated. Here, we organize mitochondria-associated ferroptosis across the pathological course of IS, from metabolic reprogramming and substrate accumulation during ischemia to the reverse electron transport-associated reactive oxygen species burst during early reperfusion and subsequent disruption of mitochondrial quality control. We further examine mitochondrial crosstalk with the endoplasmic reticulum, lysosomes, lipid droplets, and nucleus, compare ferroptosis susceptibility across neurovascular unit cell populations, and map these mechanisms onto pharmacological interventions and mechanistically plausible therapeutic windows. Finally, we assess barriers to the clinical translation of mitochondria-targeted therapies and provide a stage-resolved framework for developing neuroprotective strategies in IS.
中文摘要:缺血性卒中由脑血流急性中断及随之发生的能量代谢崩溃所致。血管再通虽可挽救缺血半暗带,其总体获益仍受治疗时间窗狭窄和再灌注损伤限制。铁死亡是一种由脂质过氧化驱动的铁依赖性调节性细胞死亡,参与缺血性卒中后的神经元损伤,并可放大缺血/再灌注损伤。线粒体整合能量代谢、铁稳态和氧化还原平衡,在能量耗竭、铁调控紊乱和氧化应激的缺血脑组织中影响铁死亡易感性。现有研究多在整细胞水平考察铁代谢和脂质过氧化,线粒体调控铁死亡的时间维度与细胞器间维度仍缺乏整合。文中按缺血性卒中的病理进程梳理线粒体相关铁死亡,从缺血期代谢重编程和底物蓄积,到早期再灌注时反向电子传递相关活性氧爆发及随后线粒体质量控制受损。进一步讨论线粒体与内质网、溶酶体、脂滴和细胞核的交互,比较神经血管单元各细胞群对铁死亡的易感性,并将这些机制对应到药物干预和机制上可行的治疗时间窗。并评估线粒体靶向治疗临床转化的障碍,提出用于缺血性卒中神经保护策略开发的按阶段解析的框架。
Advanced healthcare materials IF 11.0 2026-11 PMID: 42834627
Cerebral ischemia-reperfusion injury (IRI) is a key driver of poor prognosis in ischemic stroke. Idebenone (IDBN) shows promise for mitigating IRI, but its efficacy is limited by poor brain accumulation. Moreover, IDBN cannot be visually tracked, making it difficult to confirm whether it reaches the ischemic brain and exerts therapeutic effects. Here, IDBN functionalized with a reactive oxygen species (ROS)-cleavable bond is grafted onto phosphorothioate-modified DNA strands and co-assembled with ultrasmall superparamagnetic iron oxide (USPIO) to form USPIO-IDBN-SNAs, where SNAs stands for spherical nucleic acids. Exploiting upregulated class A scavenger receptors, USPIO-IDBN-SNAs target the ischemic area without targeting modifications and increase local IDBN concentration. Hydrophobic IDBN inside the SNAs limits water access to USPIO clusters, suppressing their contrast-enhancing ability. Under oxidative stress, IDBN is rapidly released and exerts remarkable protection. This release allows USPIO clusters to re-establish contact with water, activating their contrast-enhancing ability on T2-weighted imaging. Collectively, USPIO-IDBN-SNAs provide significant neuroprotection against IRI and offer a magnetic resonance imaging (MRI)-visible platform to monitor IDBN release in the ischemic brain, presenting a promising theranostic approach for precise, trackable stroke therapy.
中文摘要:脑缺血再灌注损伤(IRI)是缺血性卒中预后不良的关键驱动因素。艾地苯醌(IDBN)在减轻IRI方面具有潜力,但其疗效受脑内蓄积不足限制。IDBN也无法被可视化追踪,难以确认其是否到达缺血脑组织并发挥治疗作用。研究将带有活性氧(ROS)可裂解键的IDBN接枝到硫代磷酸修饰的DNA链上,并与超小超顺磁性氧化铁(USPIO)共组装,形成USPIO-IDBN-SNAs,其中SNAs指球形核酸。利用上调的A类清道夫受体,USPIO-IDBN-SNAs无需靶向修饰即可靶向缺血区域,并提高局部IDBN浓度。SNAs内部的疏水性IDBN限制水接近USPIO簇,抑制其对比增强能力。在氧化应激下,IDBN快速释放并发挥显著保护作用。该释放使USPIO簇重新与水接触,激活其在T2加权成像上的对比增强能力。总体而言,USPIO-IDBN-SNAs对IRI提供显著神经保护,并提供磁共振成像(MRI)可见平台以监测缺血脑内IDBN释放,为精准、可追踪的卒中治疗提供了有前景的诊疗一体化策略。
Ageing research reviews IF 15.5 2026-11 PMID: 42731600
Influenza vaccination may confer benefits that extend well beyond seasonal protection against respiratory infection: reduced cardiovascular morbidity and mortality, lower dementia incidence, fewer cardio-renal complications, improved survival in the very old, and emerging signals in oncology and diabetes. Although vulnerable to confounding and evidence in adults aged ≥ 75-80 years and in frail populations remains scarce, their magnitude, cross-organ consistency and apparent dose-response suggest that protection is not explained solely by prevention of infection, but points to a shared upstream mechanism: modulation of chronic inflammation. Recent single-cell multiomic studies provide a plausible substrate: inactivated influenza vaccine induces persistent epigenetic remodelling in monocytes and myeloid dendritic cells, lasting up to six months,and, consistent with a regulatory recalibration of innate reactivity, termed trained tolerance. This myeloid axis is also central to inflammaging, whose clinical expression in older people is frailty. We review multiomic, preclinical and epidemiological evidence supporting a framework in which influenza vaccination may exert effects beyond pathogen-specific protection. Murine models provide causal evidence that vaccination can modify vascular, neurodegenerative and tumour pathology through systemic immune mechanisms. We position these findings alongside heterologous effects of other vaccines and examine their relevance to chronic inflammation. Although innate immune reprogramming involves pathways shared with inflammaging, a direct effect on chronic low-grade inflammation remains unproven. Key uncertainties including healthy-vaccinee bias, the absence of frailty stratification and the age discordance between mechanistic and clinical evidence are discussed.
中文摘要:流感疫苗接种可能带来远超季节性呼吸道感染防护的益处:降低心血管疾病发病率和死亡率、降低痴呆发生率、减少心肾并发症、改善高龄老人的生存,并在肿瘤学和糖尿病领域出现新信号。相关证据易受混杂影响,且在75—80岁及以上成年人和衰弱人群中证据仍少,但这些效应的幅度、跨器官一致性及明显的剂量反应关系提示,其保护作用不能仅由预防感染解释,而指向一个共同的上游机制:对慢性炎症的调节。近期单细胞多组学研究提供了可能的机制基础:灭活流感疫苗可诱导单核细胞和髓系树突状细胞发生持续的表观遗传重塑,最长可达六个月,并与先天反应性的调控性重校准相一致,被称为训练性耐受。这一髓系轴也是炎性衰老的核心,其在老年人中的临床表现是衰弱。我们综述多组学、临床前和流行病学证据,支持一个框架:流感疫苗接种可能产生超出病原体特异性保护的作用。小鼠模型提供了因果证据,表明接种疫苗可通过全身免疫机制改变血管、神经退行性和肿瘤病理。我们将这些发现与其他疫苗的异源效应并列,并考察其与慢性炎症的相关性。先天免疫重编程涉及与炎性衰老共享的通路,但对慢性低度炎症的直接作用仍未得到证实。文中讨论了若干关键不确定性,包括健康接种者偏倚、缺乏衰弱分层,以及机制证据与临床证据之间的年龄不一致。
Stroke IF 11.1 2026-11 PMID: 42723606
White matter preservation is a rate-limiting factor in neurological recovery after ischemic stroke and depends on efficient clearance of myelin debris by microglia/macrophages. Our prior work demonstrated that microglia/macrophage-specific SIK3 (salt-inducible kinase) knockout (SIK3-mKO) promotes an anti-inflammatory subset, enhances myelin phagocytosis, and limits white matter injury, yet the downstream molecular mechanisms remain undefined. Here, we elucidate a previously unrecognized signaling axis underlying these protective effects. SIK3-mKO mice (SIK3Flox+/+;CX3CR1CreER) were generated via tamoxifen-induced Cre recombination. Transient focal cerebral ischemia was induced by 60-minute transient middle cerebral artery occlusion. Neurological outcomes were assessed via Garcia, rotarod, foot-fault, and adhesive-removal tests. Immunofluorescence, flow cytometry, single-cell RNA sequencing, real-time quantitative polymerase chain reaction, ex vivo myelin phagocytosis assay, magnetic resonance imaging, and compound action potential recordings were used to characterize microglia/macrophage polarization, myelin phagocytic capacity, white matter integrity, and nerve conduction function. In the acute phase poststroke, SIK3-mKO selectively upregulated cluster of differentiation (CD)11c and its upstream complement initiator component 1q in anti-inflammatory microglia/macrophage subsets. Within the 400 to 800 µm peri-infarct zone, SIK3-mKO elevated the proportion of CD11c+ microglia/macrophage by 15.1% and C1q+ microglia/macrophage by 15.8% relative to wild-type controls. This CD11c-component 1q axis enhanced myelin debris clearance by 19.0% while constraining pathological engulfment of intact myelin, representing a balanced functional switch that mitigates severe demyelination. Conversely, myeloid-CD11c silencing using adeno-associated virus (AAV)-Itgax short hairpin RNA partially reversed SIK3-mKO-conferred protection. CD11c knockdown reduced anti-inflammatory microglia/macrophage proportions by 9.7%, attenuated physiological phagocytosis and lowered debris clearance efficiency by 7.5%, reduced MBP (myelin basic protein)-positive myelin preservation by 10.0%, and ultimately impaired white matter preservation and neurological recovery. We identify the SIK3-CD11c-component 1q axis as a novel pathway that orchestrates microglia/macrophage phagocytic homeostasis and preserves white matter integrity after ischemic stroke. These findings clarify SIK3 signaling in microglia/macrophage and highlight the CD11c-centered complement cascade as a promising therapeutic target for restoring white matter integrity in poststroke neurorepair.
中文摘要:缺血性卒中后白质的保留是神经功能恢复的限制因素,其依赖于小胶质细胞/巨噬细胞对髓鞘碎片的有效清除。既往工作显示,小胶质细胞/巨噬细胞特异性SIK3(盐诱导激酶)敲除(SIK3-mKO)可促进抗炎亚群、增强髓鞘吞噬并减轻白质损伤,但下游分子机制尚不明确。本研究报告一条此前未被认识的信号轴,解释上述保护作用。SIK3-mKO小鼠(SIK3Flox+/+;CX3CR1CreER)经他莫昔芬诱导Cre重组构建。采用60分钟短暂大脑中动脉闭塞诱导短暂性局灶性脑缺血。神经功能结局通过Garcia评分、转棒、足错步和粘连去除试验评估。研究使用免疫荧光、流式细胞术、单细胞RNA测序、实时定量聚合酶链反应、离体髓鞘吞噬实验、磁共振成像和复合动作电位记录,刻画小胶质细胞/巨噬细胞的极化状态、髓鞘吞噬能力、白质完整性与神经传导功能。卒中后急性期,SIK3-mKO在抗炎小胶质细胞/巨噬细胞亚群中选择性上调分化簇(CD)11c及其上游补体启动因子成分1q。在梗死周围400至800微米区域内,SIK3-mKO使CD11c+小胶质细胞/巨噬细胞比例较野生型对照升高15.1%,C1q+小胶质细胞/巨噬细胞升高15.8%。该CD11c-成分1q轴使髓鞘碎片清除提高19.0%,同时限制对完整髓鞘的病理性吞噬,构成一种减轻严重脱髓鞘的平衡性功能转换。相反,使用腺相关病毒(AAV)-Itgax短发夹RNA沉默髓系CD11c可部分逆转SIK3-mKO带来的保护。CD11c敲低使抗炎小胶质细胞/巨噬细胞比例下降9.7%,削弱生理性吞噬并使碎片清除效率降低7.5%,MBP(髓鞘碱性蛋白)阳性髓鞘保留减少10.0%,最终损害白质保留与神经功能恢复。研究确认SIK3-CD11c-成分1q轴是协调小胶质细胞/巨噬细胞吞噬稳态、在缺血性卒中后维持白质完整性的新通路。这些结果阐明了小胶质细胞/巨噬细胞中的SIK3信号,并提示以CD11c为中心的补体级联是恢复卒中后神经修复中白质完整性的有前景的治疗靶点。
Medicinal research reviews IF 13.6 2026-11 PMID: 42439295
Mitochondrial F1FO-ATPase is classically viewed as the "splendid" rotary nanomachine that sustains life by converting the proton-motive force (pmf) into ATP. Yet this same complex can adopt a second, context-dependent function that links bioenergetics to cell fate. When oxygen becomes limiting during ischemia, stroke, hypoxia, or anoxia, respiratory chain activity declines, pmf collapses, and the enzyme reverses direction: ATP hydrolysis drives rotor turnover and pumps H+ across the inner mitochondrial membrane to partially restore pmf. This reverse mode can be protective by preserving membrane potential and basic mitochondrial homeostasis, but it also imposes a severe energetic burden on the cell. A key determinant of whether F1FO-ATPase acts as an energy-conserving or energy-dissipating machine is the identity of the catalytic divalent cation. Under physiological conditions, Mg2+ supports efficient, reversible ATP synthesis/hydrolysis. In pathology, mitochondrial Ca2+ overload may replace Mg2+ at catalytic sites, shifting catalysis toward ATP hydrolysis and promoting an ATP-wasting state that triggers mitochondrial permeability transition pore (mPTP) formation and regulated cell death. Thus, ATP hydrolysis by F1FO-ATPase beyond regulation by pmf and inhibitory proteins such as IF1, cation cofactor selection emerges as a decisive switch that repurposes the enzyme from "enzyme of life" to "enzyme of death." Here, this cofactor-dependent reversibility is framed as a moonlighting role of F1FO-ATPase, integrating energy conversion with death signaling. Conceptual questions are outlined to resolve current debate and to exploit this switch for therapeutic insight.
中文摘要:线粒体F1FO-ATPase通常被视为维持生命的「卓越」旋转纳米机器,通过把质子动力势(pmf)转化为ATP。该复合体还能采用第二种依赖情境的功能,把生物能量学与细胞命运联系起来。缺血、卒中、缺氧或无氧时氧受限,呼吸链活性下降,pmf崩溃,酶反向运行:ATP水解驱动转子转动并跨线粒体内膜泵出H+,以部分恢复pmf。反向模式可通过维持膜电位和基本线粒体稳态起保护作用,也给细胞带来严重能量负担。决定F1FO-ATPase是保能还是耗能机器的关键因素,是催化二价阳离子的种类。生理条件下,Mg2+支持高效、可逆的ATP合成与水解。病理状态下,线粒体Ca2+超载可在催化位点取代Mg2+,使催化偏向ATP水解并促进耗ATP状态,触发线粒体通透性转换孔(mPTP)形成和受调控细胞死亡。因此,F1FO-ATPase的ATP水解除受pmf和IF1等抑制蛋白调控外,阳离子辅因子选择成为决定性开关,使该酶从「生命之酶」转变为「死亡之酶」。在此,这种辅因子依赖的可逆性被界定为F1FO-ATPase的兼职功能,将能量转换与死亡信号整合。文中提出概念性问题,以解决当前争论并利用这一开关获得治疗启示。
Biosensors & bioelectronics IF 11.8 2026-11-01 PMID: 42284674
Early and accurate identification of Japanese encephalitis virus (JEV) is vital for effective outbreak control and surveillance. An electrochemical immunosensor was developed for the detection of JEV non-structural protein 1 (NS1). The JEV NS1 antigen was expressed, purified and subsequently refolded in vitro to recover soluble, functional protein. High-affinity monoclonal antibodies (mAbs) were generated through hybridoma technology. To gain molecular-level insights, antibody gene sequences were decoded using next-generation sequencing (NGS), while molecular docking analysis enabled predictive epitope-paratope mapping. To maximize sensitivity, screen-printed carbon electrodes (SPCEs) were modified with a gold nanoflower/MXene (GNF/MXene) nanocomposite, enhancing the electroactive surface area, and electrical conductivity of the sensor. Cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS), and differential pulse voltammetry (DPV) were employed to analyse the electrochemical reactions. The sensor exhibited a low limit of detection (LOD) of 0.35 fM across a broad range concentration range of JEV NS1 (1 fM-1 μM). The immunosensor was further evaluated with clinical samples and sensor showed high specificity (100%), sensitivity (95%), and accuracy (96.66%) with no cross-reactivity to other flavivirus NS1 antigens, with a rapid response of 10 min and maintained excellent stability over 4 weeks.
中文摘要:早期、准确识别日本脑炎病毒(JEV)对有效控制暴发和监测至关重要。研究构建了一种用于检测JEV非结构蛋白1(NS1)的电化学免疫传感器。JEV NS1抗原经表达、纯化并在体外复性,以恢复可溶且具有功能的蛋白。通过杂交瘤技术制备高亲和力单克隆抗体(mAbs)。为获得分子层面信息,利用下一代测序(NGS)解析抗体基因序列,并通过分子对接分析进行预测性表位-互补位映射。为提高灵敏度,采用金纳米花/MXene(GNF/MXene)纳米复合材料修饰丝网印刷碳电极(SPCEs),增强传感器的电活性表面积和导电性。采用循环伏安法(CV)、电化学阻抗谱(EIS)和差分脉冲伏安法(DPV)分析电化学反应。该传感器在JEV NS1的宽浓度范围(1 fM-1 μM)内表现出0.35 fM的低检测限(LOD)。该免疫传感器进一步用临床样本评估,显示出高特异性(100%)、灵敏度(95%)和准确率(96.66%),与其他黄病毒NS1抗原无交叉反应,响应快速为10分钟,并在4周内保持良好稳定性。
Biomaterials IF 13.6 2026-11 PMID: 42134250
Burn wounds are a common traumatic injury that impair cellular function and hinder the healing process, often resulting in significant skin loss. While autologous skin grafting is considered the gold standard for treating burns, its widespread use is limited due to donor site morbidity and the requirement for large amounts of tissue. Traditional wound dressings and treatments often fail to ensure complete recovery. Being initially FDA-approved to treat multiple sclerosis, 4-aminopyridine (4-AP) has also been shown to accelerate burn wound closure by modulating keratinocytes and fibroblasts when administered systemically. However, prolonged systemic use of 4-AP can lead to significant side effects. In this study, we aimed to repurpose 4-AP for treating skin burn wounds by delivering it topically using a laponite-gelatin gel formulation. This method allows for non-invasive and localized drug delivery on the burn wound site. We evaluated the physical properties of the 4-AP gel, including shear thinning behavior, drug release kinetics, cytocompatibility, and functional wound closure (48hr) using a scratch assay (>90%). Moreover, our in vivo experiments showed that the 4-AP loaded gel accelerates wound healing by reducing inflammation, thereby enhancing re-epithelialization and angiogenesis, and promoting the transformation of fibroblasts into myofibroblasts. Burn closure in the 4-AP gel group was consistently higher than the control gel from day 6 through day 21, reaching near-complete healing by day 21, whereas control-treated wounds remained partially open. This enhanced closure correlated with accelerated collagen remodeling, as the 4-AP gel significantly increased collagen type I and III deposition and their ratio compared to controls (438% vs. 267%; 288% vs. 215%; ratio 1.7 vs. 1.2; ∗P < 0.05 to ∗∗∗P < 0.0002), indicating improved matrix maturation during burn healing. This novel application of the 4-AP gel could offer a promising alternative to current burn wound therapies, potentially leading to improved outcomes for burn patients.
中文摘要:烧伤创面是常见创伤,损害细胞功能并阻碍愈合过程,常导致明显皮肤缺损。自体皮肤移植被视为烧伤治疗金标准,但供区并发症和所需组织量大限制其广泛应用。传统伤口敷料和治疗常难以保证完全恢复。4-氨基吡啶(4-AP)最初获FDA批准用于治疗多发性硬化,全身给药时也被证明可通过调节角质形成细胞和成纤维细胞加速烧伤创面闭合。但长期全身使用4-AP可带来明显副作用。为将4-AP重新用于烧伤创面治疗,采用锂皂石-明胶凝胶制剂进行局部递送。该方法可在烧伤创面部位实现无创、局部给药。我们评估了4-AP凝胶的物理性质,包括剪切变稀行为、药物释放动力学、细胞相容性,以及划痕实验中的功能性创面闭合(48小时,>90%)。体内实验显示,载4-AP凝胶通过减轻炎症加速创面愈合,从而增强再上皮化和血管生成,并促进成纤维细胞向肌成纤维细胞转化。从第6天到第21天,4-AP凝胶组烧伤闭合率持续高于对照凝胶,至第21天接近完全愈合,而对照处理创面仍部分开放。这种闭合改善与胶原重塑加快相关:与对照相比,4-AP凝胶显著增加I型和III型胶原沉积及其比值(438% vs. 267%;288% vs. 215%;比值1.7 vs. 1.2;∗P < 0.05至∗∗∗P < 0.0002),提示烧伤愈合过程中基质成熟改善。4-AP凝胶的这一新应用可能为现有烧伤创面治疗提供有前景的替代方案,有望改善烧伤患者结局。
Biomaterials IF 13.6 2026-11 PMID: 42090834
The treatment of intracerebral hemorrhage (ICH) remains highly challenging, primarily due to its dynamic and multifaceted pathologies, which create a hostile microenvironment at the lesion site characterized by a ROS-inflammation-glial scar feedback loop and severely impaired neural regeneration. Herein, a dynamic protein-polysaccharide hydrogel is designed, constructed by a visible light-induced thiol-disulfide exchange reaction as a general strategy, and integrated with a spatiotemporal controlled delivery of chondroitinase ABC (ChABC) and insulin-like growth factor-1 (IGF-1) loaded in mesoporous silica nanoparticles (MSNs). Thiolated gelatin and thiolated hyaluronan were chosen to formulate the hydrogel that mimics brain ECM providing structure support with cell adhesion, infiltration, and tunable degradability, but also presents anti-swelling and pro-coagulant capacities. Importantly, the thiol-disulfide chemistry endowed the hydrogel efficient ROS scavenging and ROS-responsive on-demand release of ChABC, while MSNs loading achieved a sustained release of IGF-1. In vitro studies, the hydrogel is shown to reduce cellular ROS, regulate anti-inflammation polarization of macrophages via the MAPK signaling pathway, and promote neural stem cells (NSCs) proliferation, migration, differentiation and endothelial angiogenesis. Moreover, in an ICH mouse model, the hydrogel is demonstrated not only to enable efficient tissue ROS scavenging, anti-inflammation polarization of microglial/macrophages, and dynamical self-adaptive reduction of glial scar, achieving microenvironment remodeling, but also to regulate behaviors of endogenous NSCs and enhance angiogenesis, providing neural regeneration. Consequently, these effects enhanced neurons and myelin repair, ultimately contributing to synergistic recovery of neurological function. Overall, this dynamic hydrogel represents a promising strategy for simultanously remodeling the lesion site's microenvironment and promoting neural regeneration, thereby improving the treatment efficacy of ICH.
中文摘要:脑出血(ICH)的治疗仍极具挑战,主要源于其动态且多方面的病理过程,在病灶部位形成恶劣微环境,表现为ROS—炎症—胶质瘢痕反馈环路及神经再生严重受损。据此,设计了一种动态蛋白—多糖水凝胶,以可见光诱导的硫醇—二硫键交换反应作为通用构建策略,并整合载于介孔二氧化硅纳米颗粒(MSNs)中的软骨素酶ABC(ChABC)与胰岛素样生长因子-1(IGF-1)的时空可控递送。选用硫醇化明胶与硫醇化透明质酸制备水凝胶,模拟脑细胞外基质,提供结构支撑并支持细胞黏附、浸润和可调降解性,同时具备抗溶胀和促凝血能力。硫醇—二硫键化学使水凝胶具有高效ROS清除能力和ROS响应性按需释放ChABC,MSNs负载则实现IGF-1持续释放。体外研究显示,该水凝胶可降低细胞ROS,经MAPK信号通路调控巨噬细胞抗炎极化,并促进神经干细胞(NSCs)增殖、迁移、分化及内皮血管生成。在ICH小鼠模型中,该水凝胶不仅能有效清除组织ROS、促进小胶质细胞/巨噬细胞抗炎极化、动态自适应减少胶质瘢痕,实现微环境重塑,还能调控内源性NSCs行为并增强血管生成,促进神经再生。这些效应促进神经元和髓鞘修复,最终协同促进神经功能恢复。该动态水凝胶为同时重塑病灶微环境并促进神经再生、提高ICH治疗效果提供了有前景的策略。
Acta biomaterialia IF 10.4 2026-10-30 PMID: 42962843
Proper cerebral artery function is essential for maintaining the brain's microenvironment. The multilayered organization of cellular and extracellular matrix (ECM) constituents enables large cerebral arteries to accommodate pulse pressure and ensure both effective blood distribution and protection of the microcirculation. However, aging and disease induce compositional and structural remodeling in cerebral arteries, such as the middle cerebral artery (MCA), which can alter biomechanical properties and increase susceptibility to cerebrovascular conditions including atherosclerosis and aneurysms, both major contributors to stroke. Understanding how age-related changes in arterial structure and composition influence biomechanical behavior is critical for improving prediction of cerebrovascular risk. In this study, we characterized the age-dependent elastic and viscoelastic properties of human MCAs and related these changes to ECM structure and composition using imaging and biochemical assays. Our results demonstrate that aging is associated with increased stiffness and stress relaxation in MCAs. Biochemical analyses revealed age-related increases in collagen and glycosaminoglycan (GAG) content, both of which correlated with altered mechanical properties. Histological staining further showed denser collagen organization within the adventitia and elevated GAG presence, consistent with mechanical and biochemical findings. Additionally, multiphoton imaging under mechanical loading provided insight into layer-specific collagen reorganization in the adventitia. Collectively, these findings elucidate key age-dependent alterations in the structure-function relationship of human cerebral arteries and provide a mechanistic basis for increased cerebrovascular risk with aging. STATEMENT OF SIGNIFICANCE: Age-related remodeling of the extracellular matrix is a fundamental driver of tissue dysfunction, yet its effects on human cerebral artery mechanics remain poorly understood. In this study, we combine biomechanical testing, biochemical assays, histology, and multiphoton microscopy to characterize structural and functional remodeling of human middle cerebral arteries across a broad age range. We demonstrate that aging is associated with increased arterial stiffness and viscoelastic relaxation, accompanied by elevated collagen and glycosaminoglycan content. By directly linking extracellular matrix composition and organization to biomechanical function, this work provides new insights into the mechanisms governing cerebrovascular aging. These findings establish an important structure function framework for understanding vascular tissue remodeling and have broader implications for age related vascular dysfunction, mechanobiology, and biomaterials research.
中文摘要:脑动脉功能正常对维持脑内微环境至关重要。细胞与细胞外基质成分构成的多层组织使大型脑动脉能够承受脉压,保障有效血液分布并保护微循环。衰老和疾病可引起大脑中动脉等脑动脉的成分与结构重塑,改变生物力学特性,并增加动脉粥样硬化和动脉瘤等脑血管病的易感性,这两类病变均为卒中的重要原因。理解衰老相关的动脉结构与成分变化如何影响生物力学行为,对改进脑血管风险预测十分关键。该研究表征了人脑大脑中动脉随年龄变化的弹性和黏弹性特性,并通过成像和生化检测将这些变化与细胞外基质结构和成分联系起来。结果显示,衰老与大脑中动脉僵硬度增加和应力松弛增强相关。生化分析显示胶原和糖胺聚糖含量随年龄增加,二者均与力学特性改变相关。组织学染色进一步显示外膜内胶原排列更致密、糖胺聚糖存在增加,与力学和生化结果一致。机械加载下的多光子成像为了解外膜中层特异性胶原重组提供了线索。这些发现阐明了人脑动脉结构-功能关系中随年龄出现的关键改变,并为衰老相关脑血管风险增加提供了机制基础。意义说明:细胞外基质的年龄相关重塑是组织功能障碍的基本驱动因素,但其对人脑动脉力学的影响仍知之甚少。该研究结合生物力学测试、生化检测、组织学和多光子显微镜,在较宽年龄范围内表征人脑大脑中动脉的结构与功能重塑。结果显示,衰老与动脉僵硬度增加和黏弹性松弛增强相关,并伴随胶原和糖胺聚糖含量升高。通过将细胞外基质成分和组织方式直接与生物力学功能联系起来,这项工作为理解脑血管衰老机制提供了新认识。这些发现为理解血管组织重塑建立了重要的结构-功能框架,并对年龄相关血管功能障碍、力学生物学和生物材料研究具有更广泛意义。
Stroke IF 11.1 2026-10-30 PMID: 42960431
Recovery after ischemic stroke is limited by persistent cerebrovascular dysfunction, but the mechanisms regulating vascular repair remain poorly understood. Prnd (Prnd/Doppel) is a prion family protein expressed in the cerebrovascular endothelium during development. We tested the hypothesis that endothelial Prnd promotes vascular repair and functional recovery in the adult brain after stroke. Using middle cerebral artery occlusion in mice, we compared wild-type and Prnd-null mice and evaluated endothelial-specific Prnd overexpression. Functional recovery was assessed by behavioral testing, while infarct volume, brain atrophy, vascular architecture, blood-brain barrier integrity, and macrophage/microglia infiltration were evaluated histologically. Vascular signaling and endothelial cell junctional proteins were examined mechanistically. Acute infarct volumes were comparable between wild-type and Prnd-null mice, indicating that Prnd does not substantially affect initial ischemic injury. During recovery, however, Prnd-null mice exhibited disrupted cerebrovascular architecture, increased blood-brain barrier disruption, greater brain atrophy, and increased macrophage/microglial infiltration. Conversely, endothelial Prnd overexpression improved long-term functional recovery without altering acute infarct size and was associated with enhanced blood-brain barrier integrity and vascular remodeling. Mechanistically, Prnd manipulation was associated with enhanced VEGF-A (vascular endothelial growth factor-A) signaling and increased endothelial cell tight junction protein expression. Prnd is dispensable for acute ischemic injury but promotes cerebrovascular remodeling, blood-brain barrier restoration, and functional recovery after stroke. These findings identify endothelial Prnd as a regulator of poststroke vascular repair and a potential therapeutic target for enhancing long-term recovery.
中文摘要:缺血性卒中后的恢复受持续性脑血管功能障碍限制,但调控血管修复的机制仍不清楚。Prnd(Prnd/Doppel)是一种在发育期脑血管内皮表达的朊蛋白家族蛋白。实验检验了内皮Prnd促进成年脑卒中后血管修复和功能恢复的假说。在小鼠大脑中动脉闭塞模型中,比较野生型与Prnd缺失小鼠,并评估内皮特异性Prnd过表达。通过行为学测试评估功能恢复,用组织学评估梗死体积、脑萎缩、血管结构、血脑屏障完整性和巨噬细胞/小胶质细胞浸润。机制上检查血管信号和内皮细胞连接蛋白。野生型与Prnd缺失小鼠急性梗死体积相当,提示Prnd对初始缺血损伤无实质影响。恢复期,Prnd缺失小鼠出现脑血管结构破坏、血脑屏障破坏增加、脑萎缩加重及巨噬细胞/小胶质细胞浸润增加。相反,内皮Prnd过表达改善长期功能恢复而不改变急性梗死面积,并与血脑屏障完整性和血管重塑增强相关。机制上,Prnd干预与VEGF-A信号增强及内皮细胞紧密连接蛋白表达增加相关。Prnd对急性缺血损伤并非必需,但促进卒中后脑血管重塑、血脑屏障恢复和功能恢复。这些发现确定内皮Prnd是卒中后血管修复的调控因子,也是增强长期恢复的潜在治疗靶点。
Acta pharmacologica Sinica IF 10.4 2026-10-30 PMID: 42957749
Diabetes mellitus-associated endothelial dysfunction represents a pivotal early event in diabetic vasculopathy, linking metabolic derangements to vascular injury. Dimethyl fumarate (DMF), an FDA-approved drug for multiple sclerosis and psoriasis, exhibits potent anti-inflammatory and antioxidant properties, yet whether it protects against diabetic endothelial dysfunction and the underlying molecular mechanisms remain unclear. Here, diabetic db/db mice and the non-diabetic db/m+ littermates were treated with DMF (100 mg·kg-1·d-1) or vehicle for 4 weeks, and vascular function in aortic and mesenteric artery rings was assessed by wire myography. Human umbilical vein endothelial cells (HUVECs) and endothelial cell (EC)-specific Tfeb knockout (TfebECKO) mice were employed to investigate the target of DMF in vitro and in vivo. DMF restored the impaired endothelium-dependent relaxations (EDRs) in db/db mouse aortas and insulin-induced relaxations in mesenteric arteries, improved glucose tolerance, reduced aortic endothelial mitochondrial ROS (mito-ROS) accumulation, and lowered the expression of inflammatory markers. IL-1β induced phosphorylation and cytoplasmic retention of TFEB (indicative of TFEB inhibition), mito-ROS production, and inflammatory responses in HUVECs and mouse aortas, all of which were reversed by DMF pretreatment. These protective effects of DMF were largely reversed by TFEB knockdown in HUVECs or in aortas of TfebECKO mice. RNA sequencing data analysis revealed a substantial overlap between DMF-regulated and TFEB-overexpression transcriptional profiles, implicating a role of TFEB in DMF-induced suppression of inflammatory and oxidative pathways. Together, DMF ameliorates endothelial dysfunction in diabetes by inhibiting TFEB phosphorylation and restoring TFEB nuclear activity. Endothelial TFEB represents a critical mediator responsible for the vaso-protective effects of DMF and a promising therapeutic target for the treatment of diabetic vascular complications.
中文摘要:糖尿病相关的内皮功能障碍是糖尿病血管病变的关键早期事件,将代谢紊乱与血管损伤联系起来。富马酸二甲酯(DMF)是FDA批准用于多发性硬化和银屑病的药物,具有强效抗炎和抗氧化特性,但其是否保护糖尿病内皮功能障碍及潜在分子机制仍不清楚。研究使用糖尿病db/db小鼠及非糖尿病db/m+同窝对照,给予DMF(100 mg·kg⁻¹·d⁻¹)或溶媒4周,通过线肌张力描记评估主动脉和肠系膜动脉环的血管功能。采用人脐静脉内皮细胞(HUVECs)和内皮细胞特异性Tfeb敲除(TfebECKO)小鼠在体外和体内探究DMF靶点。DMF恢复db/db小鼠主动脉受损的内皮依赖性舒张(EDRs)和肠系膜动脉胰岛素诱导的舒张,改善糖耐量,减少主动脉内皮线粒体ROS(mito-ROS)积聚,并降低炎症标志物表达。IL-1β诱导HUVECs和小鼠主动脉中TFEB磷酸化及胞质滞留(提示TFEB受抑)、mito-ROS产生和炎症反应,DMF预处理可逆转这些变化。HUVECs中TFEB敲低或TfebECKO小鼠主动脉中,DMF的保护作用大部分被逆转。RNA测序数据分析显示DMF调控与TFEB过表达转录谱显著重叠,提示TFEB参与DMF对炎症和氧化通路的抑制。DMF通过抑制TFEB磷酸化并恢复TFEB核活性,改善糖尿病内皮功能障碍。内皮TFEB是DMF血管保护作用的关键介导者,也是治疗糖尿病血管并发症的有前景靶点。

3多发性硬化与神经免疫 (17篇)

临床研究 (14篇)

Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42912879
Sensitive, minimally invasive biomarkers that reflect functional decline in multiple sclerosis (MS) are still lacking. Untargeted metabolomic profiling allows unbiased discovery of circulating biomarkers and dysregulated biological pathways underlying MS onset and progression. We aimed to identify candidate circulating metabolite signatures correlated with clinical, imaging, and patient-reported outcomes in MS and to characterize the underlying metabolic pathways. We conducted a cross-sectional analysis of untargeted circulating metabolomic profiles from 541 samples of 323 people with multiple sclerosis (PwMS), including both relapsing-remitting and progressive forms, detecting 332 metabolites. Associations between metabolite levels and outcomes, including clinical disability (Expanded Disability Status Scale), functional tests (walking speed, manual dexterity, and processing speed), Neuro-QoL patient-reported domains, optical coherence tomography-derived retinal layer thicknesses, and MRI-derived measures, were assessed using linear mixed-effects models adjusted for age, sex, race, treatment status, and MS subtype. To identify clusters of metabolites jointly linked to outcomes, we applied Hierarchical All-Against-All Association Analysis and weighted correlation network analysis. Pathway enrichment was also performed using Fast Gene Set Enrichment Analysis on ranked effect sizes based on the RaMP database, excluding pathways with fewer than 3 metabolites. We identified multiple metabolites consistently associated with MS severity across clinical, patient-reported, and imaging domains. Metabolites such as p-cresol sulfate, p-cresol glucuronide, phenylacetylglutamine, and carnitine-derived species were linked to greater disease severity, whereas tryptophan betaine, ergothioneine, N-acetylcarnosine, and indolepropionate were associated with more favorable outcomes. Pathway analyses highlighted amino acid transport and metabolism, aromatic and branched-chain amino acid pathways, and solute carrier transporter systems, as well as bile acid, sphingolipid, and carnitine-related pathways linked to MS severity. Comprehensive integration of metabolomic, clinical, and imaging data in PwMS highlights distinct metabolites and metabolic pathways associated with MS severity. These candidate metabolites warrant external validation in independent cohorts and provide a rationale for future biomarker discovery studies aimed at improving disease monitoring and management in MS.
中文摘要:敏感、微创且能反映多发性硬化功能衰退的生物标志物仍然缺乏。未靶向代谢组学分析可在无预设假设下发现循环生物标志物及多发性硬化发病和进展相关的失调生物学通路。目标是识别与多发性硬化临床、影像和患者报告结局相关的候选循环代谢物特征,并刻画其潜在代谢通路。对323名多发性硬化患者的541份样本进行横断面未靶向循环代谢组学分析,涵盖复发缓解型和进展型,共检测332种代谢物。采用线性混合效应模型评估代谢物水平与结局的关联,模型校正年龄、性别、种族、治疗状态和多发性硬化亚型;结局包括临床残疾(Expanded Disability Status Scale)、功能测试(步行速度、手部灵活性和处理速度)、Neuro-QoL患者报告领域、光学相干断层扫描衍生视网膜层厚度和MRI衍生指标。为识别与结局共同相关的代谢物簇,采用Hierarchical All-Against-All Association Analysis和加权相关网络分析。还基于RaMP数据库按效应量排序进行Fast Gene Set Enrichment Analysis通路富集,排除代谢物少于3种的通路。发现多种代谢物在临床、患者报告和影像领域均与多发性硬化严重程度一致相关。对甲酚硫酸盐、对甲酚葡萄糖醛酸苷、苯乙酰谷氨酰胺和肉碱衍生物种与更重疾病严重程度相关,而色氨酸甜菜碱、麦角硫因、N-乙酰肌肽和吲哚丙酸与更有利结局相关。通路分析突出氨基酸转运与代谢、芳香族和支链氨基酸通路、溶质载体转运系统,以及胆汁酸、鞘脂和肉碱相关通路与多发性硬化严重程度相关。在多发性硬化患者中整合代谢组、临床和影像数据,揭示与疾病严重程度相关的特定代谢物和代谢通路。这些候选代谢物需在独立队列中外部验证,并为未来旨在改善多发性硬化疾病监测和管理的生物标志物发现研究提供依据。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42912878
Distinguishing multiple sclerosis (MS) from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can be challenging because of some shared clinical and radiologic features. We aimed to describe adults with clear positive serum MOG antibodies (MOG-Abs) presenting with MS features and rethink their nosological framework. We conducted a retrospective longitudinal study within the French NOMADMUS cohort and included adults from 2015 to 2025 tested clear positive for MOG-Ab in the serum with at least 1 MS-suggestive feature: (1) biological (CSF-specific oligoclonal bands [OCBs] and/or kappa free light chain index [KFLCi] ≥5.7) or (2) radiologic (≥1 lesion among juxtacortical lesion, Dawson finger, or inferior temporal lobe lesion). All MRI scans were reviewed blindly by an expert neuroradiologist. Minimum clinical and radiologic follow-up was 6 months. We classified patients as (1) typical MS when fulfilling 2024 McDonald criteria, with OCB and/or KFLCi ≥5.7 and showing no MOGAD supporting features, or (2) equivocal in all other situations. Among the 78 included patients (65% female, median age: 35 years), 23% were classified as typical MS and 77% as equivocal; all met MOGAD criteria, and 76% met 2024 McDonald criteria, without using central veinous sign or paramagnetic rim lesion, which have been rarely assessed. Myelitis followed by optic neuritis constituted the predominant clinical presentations in the whole cohort (45% and 32%, respectively) and in both groups. For typical MS cases, half of the patients did not receive maintenance therapy after the first MOG-Ab-positive event, 28% relapsed, 55% developed new silent lesions, and none showed lesion resolution (median follow-up: 1.9 years). For equivocal patients, 84% had OCB and 88% had ≥1 MOGAD supporting feature. After the first MOG-Ab-positive event, 72% initiated a maintenance therapy-mostly rituximab-15% relapsed, 46% developed silent new lesions, and 23% showed complete resolution of ≥1 lesion (median follow-up: 3 years). Clear positive MOG-Ab may occur in patients with genuine MS, and their presence may lead to therapeutic inertia. The substantial proportion of equivocal cases highlights current diagnostic limitations and underscores the need for longitudinal clinical and radiologic reassessment.
中文摘要:区分多发性硬化(MS)与髓鞘少突胶质细胞糖蛋白抗体相关疾病(MOGAD)可能较困难,因为两者存在部分共同的临床和影像学特征。研究旨在描述以MS特征就诊、血清MOG抗体(MOG-Abs)明确阳性的成人患者,并重新思考其疾病分类框架。在法国NOMADMUS队列中开展回顾性纵向研究,纳入2015至2025年血清MOG-Ab明确阳性且至少具有1项提示MS特征的成人患者:(1)生物学特征(脑脊液特异性寡克隆带[OCBs]和/或κ游离轻链指数[KFLCi]≥5.7),或(2)影像学特征(近皮质病灶、Dawson手指征或下颞叶病灶中至少1个病灶)。所有MRI扫描由一名专家神经放射科医生盲法复核。临床和影像学随访至少6个月。将患者分为:(1)典型MS:符合2024 McDonald标准,伴OCB和/或KFLCi≥5.7,且无支持MOGAD的特征;(2)其他所有情况为不确定。78例纳入患者(65%女性,中位年龄35岁)中,23%归类为典型MS,77%为不确定;全部符合MOGAD标准,76%符合2024 McDonald标准,未使用中央静脉征或顺磁边缘病灶,因为这些特征很少被评估。整个队列及两组中,脊髓炎后视神经炎是最主要临床表现(分别为45%和32%)。典型MS病例中,半数患者在首次MOG-Ab阳性事件后未接受维持治疗,28%复发,55%出现新的无症状病灶,无一例病灶消退(中位随访1.9年)。不确定患者中,84%有OCB,88%有至少1项支持MOGAD特征。首次MOG-Ab阳性事件后,72%启动维持治疗(多为利妥昔单抗),15%复发,46%出现新的无症状病灶,23%至少1个病灶完全消退(中位随访3年)。血清MOG-Ab明确阳性可见于真正的MS患者,其存在可能导致治疗惰性。不确定病例占比较高,凸显当前诊断局限性,并强调需要纵向临床和影像学再评估。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42905998
Collapsin response-mediator protein 5 (CRMP5)-IgG is an acknowledged biomarker in the International Consortium on Optic Neuritis (ICON) diagnostic criteria for optic neuritis (ON), but these criteria have not been validated in CRMP5-IgG+ON. We evaluated the ICON and Acute Optic Neuritis Network (ACON) criteria for CRMP5-IgG+ON, using patients with late-onset (age ≥50 years) aquaporin-4-IgG-positive (AQP4-IgG+)-ON or myelin-oligodendrocyte glycoprotein antibody (MOG-IgG+)-ON for comparison. We developed the "CRMP score," based on typical CRMP5-IgG+ON clinical features, to guide CRMP5 antibody testing in ON. The study included 17 patients with CRMP5-IgG+, 11 with AQP4-IgG+ON, and 13 with MOG-IgG+ON. Application of ICON criteria yielded no "definite ON" and 1 "probable ON" diagnosis among the 17 CRMP5-IgG+ cases, but definite ON diagnoses for 6 of 11 AQP4-IgG+ (55%, p = 0.003) and 7 of 13 MOG-IgG+ cases (54%, p = 0.001). ACON criteria yielded definite ON diagnoses for 2 (12%) CRMP5-IgG+ON, 10 (91%) of the AQP4-IgG+ON, and 13 (100%) of the MOG-IgG+ON (p < 0.001). A CRMP score ≥1 identified CRMP5-IgG+ON with a sensitivity of 88.2% and a specificity of 87.5%. ICON and ACON criteria for ON diagnosis identified only a minority of CRMP5-IgG+ON cases; thus, we developed the "CRMP" score to aid their identification in clinical practice.
中文摘要:CRMP5-IgG是国际视神经炎联盟(ICON)视神经炎诊断标准中已认可的生物学标志物,但这些标准尚未在CRMP5-IgG阳性视神经炎中验证。本研究评估ICON与急性视神经炎网络(ACON)标准对CRMP5-IgG阳性视神经炎的适用性,并以晚发型(年龄≥50岁)水通道蛋白4-IgG阳性(AQP4-IgG+)视神经炎或髓鞘少突胶质细胞糖蛋白抗体(MOG-IgG+)视神经炎患者作比较。基于CRMP5-IgG阳性视神经炎的典型临床特征,我们开发了CRMP评分,用于指导视神经炎中的CRMP5抗体检测。研究纳入17例CRMP5-IgG+患者、11例AQP4-IgG+视神经炎患者和13例MOG-IgG+视神经炎患者。应用ICON标准,17例CRMP5-IgG+病例中无确定视神经炎诊断,1例为可能视神经炎;AQP4-IgG+组11例中6例(55%,p=0.003)、MOG-IgG+组13例中7例(54%,p=0.001)获确定诊断。ACON标准下,CRMP5-IgG+视神经炎2例(12%)、AQP4-IgG+视神经炎10例(91%)、MOG-IgG+视神经炎13例(100%)获确定诊断(p<0.001)。CRMP评分≥1识别CRMP5-IgG+视神经炎的敏感性为88.2%,特异性为87.5%。ICON与ACON标准仅能识别少数CRMP5-IgG+视神经炎病例;因此我们开发CRMP评分以辅助临床实践中的识别。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42879711
To investigate the association between serum levels of glial-related biomarkers, including glycoprotein nonmetastatic melanoma B (GPNMB), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), galectin-3, serpin peptidase inhibitor clade A member 3 (SERPINA3), chitotriosidase-1 (CHIT1), and chitinase 3-like 1 (CHI3L1) and 2 (CHI3L2), and the presence of paramagnetic rim lesions (PRLs) and the risk of progression independent of relapse activity (PIRA) in patients with a first demyelinating event. PRLs were identified using 3T susceptibility-based imaging. Univariable and multivariable linear regression models assessed the association between biomarker levels and the presence of PRLs at baseline. Univariable and multivariable Cox proportional hazards models investigated the association between biomarker levels and risk of PIRA during follow-up. sTREM2 and CHI3L1 levels were measured using single molecule array assays, whereas levels of the remaining biomarkers were determined using ELISA. We included 135 patients (median age, 34.4 [interquartile range (IQR) 29.2-41.7] years; 98 [72.6%] women; median follow-up, 5.4 [IQR 2.7-9.4] years). PRLs were detected in 59 (43.7%) patients. The presence of ≥1 PRLs at baseline was associated with increased levels of CHI3L1 in univariable (multiplicative effect [ME] = 1.32; 95% CI 1.10-1.58; p = 0.003) and multivariable analyses (ME = 1.31; 95% CI 1.05-1.63; p = 0.01). Thirty (22.2%) patients developed PIRA during follow-up. Doubling of serum galectin-3 levels was associated with an increased risk of PIRA in univariable (hazard ratio [HR] = 1.76; 95% CI 1.06-2.94; p = 0.02) and multivariable analyses (HR = 2.15; 95% CI 1.22-3.80; p = 0.008). Similarly, doubling of serum CHI3L2 levels was associated with an increased risk of PIRA in both univariable (HR = 1.36; 95% CI 1.05-1.76; p = 0.02) and multivariable analyses (HR = 1.36; 95% CI 1.02-1.82; p = 0.03). The combined elevation of galectin-3 and CHI3L2 was associated with an increased risk of PIRA in multivariable analysis (HR = 8.44; 95% CI 3.01-23.70; p < 0.0001). These findings suggest distinct contributions of glial-related biomarkers to radiologic and clinical outcomes in early multiple sclerosis. Validation in independent cohorts will be required before their value as blood prognostic biomarkers can be established.
中文摘要:探讨血清胶质相关生物标志物水平与首次脱髓鞘事件患者顺磁性边缘病灶(PRLs)存在及独立于复发活动的进展(PIRA)风险之间的关系。所测标志物包括非转移性黑色素瘤糖蛋白B(GPNMB)、可溶性髓系细胞触发受体2(sTREM2)、半乳糖凝集素-3、丝氨酸蛋白酶抑制剂A3(SERPINA3)、几丁质酶-1(CHIT1)以及几丁质酶3样蛋白1(CHI3L1)和2(CHI3L2)。PRLs采用3T磁敏感成像识别。单因素与多因素线性回归模型评估基线生物标志物水平与PRLs存在的关联,单因素与多因素Cox比例风险模型分析生物标志物水平与随访期间PIRA风险的关联。sTREM2与CHI3L1采用单分子阵列法测定,其余标志物采用ELISA测定。共纳入135例患者,中位年龄34.4岁(四分位距29.2~41.7岁),女性98例(72.6%),中位随访5.4年(四分位距2.7~9.4年)。59例(43.7%)检出PRLs。基线存在≥1个PRL与CHI3L1水平升高相关,单因素分析的乘积效应为1.32(95% CI 1.10~1.58,p=0.003),多因素分析为1.31(95% CI 1.05~1.63,p=0.01)。随访期间30例(22.2%)出现PIRA。血清半乳糖凝集素-3水平每翻倍,PIRA风险增加,单因素风险比为1.76(95% CI 1.06~2.94,p=0.02),多因素为2.15(95% CI 1.22~3.80,p=0.008)。血清CHI3L2水平每翻倍同样与PIRA风险升高相关,单因素风险比为1.36(95% CI 1.05~1.76,p=0.02),多因素为1.36(95% CI 1.02~1.82,p=0.03)。半乳糖凝集素-3与CHI3L2同时升高者PIRA风险在多因素分析中明显增加(HR=8.44,95% CI 3.01~23.70,p<0.0001)。上述结果提示胶质相关生物标志物对早期多发性硬化的影像学结局与临床结局各有不同贡献。其作为血液预后标志物的价值尚需在独立队列中验证。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42879710
Cognitive impairment affects 40%-70% of patients with multiple sclerosis (MS). Although recent hypothesis-driven and data-driven efforts have identified cognitive phenotypes, functional substrates underlying impairment in such phenotypes are still not clear. Our objective was to identify distinct cognitive phenotypes using clustering in a large cohort of patients with MS and characterize their associated clinical, structural MRI, and resting-state (RS) functional connectivity (FC) features. We conducted an observational, cross-sectional study with right-handed patients with MS and age-matched and sex-matched healthy controls (HCs) who underwent neurologic and neuropsychological evaluation (Brief Repeatable Battery of Neuropsychological tests). Latent profile analysis on cognitive test Z-scores identified MS cognitive phenotypes. 3.0T MRI was used to derive atrophy measures and RS FC within default mode network (DMN I/II), executive control network (ECN), left/right fronto-parietal, language, and salience networks. Linear regression models compared structural MRI and RS FC across cognitive phenotypes and HCs, while polynomial contrasts assessed RS FC patterns across groups. Three hundred and sixty-nine patients with MS and 168 HCs were enrolled. Four cognitive phenotypes were detected: preserved cognition ([PC], n = 67[18.2%]), mild single-domain verbal fluency involvement (MSD-VF, n = 37[10.0%]), mild single-domain attention involvement (MSD-A, n = 197[53.4%]), and severe multidomain (SMD) involvement (SMD, n = 68[18.4%]). At corrected threshold, PC patients showed decreased deep gray matter (GM) volumes (p < 0.001-0.001) and similar RS FC vs HCs, whereas MSD-VF exhibited no significant atrophy and no differences in RS FC vs HCs. MSD-A displayed lower cortical/deep GM volumes vs HCs (p < 0.001-0.005), whereas SMD had worse clinical and atrophy features (p < 0.001-0.04), as well as decreased DMN II RS FC (p = 0.01-0.04) vs other groups. Polynomial contrast analyses revealed significant quadratic patterns with increased RS FC in MSD-VF vs HC/PC groups, followed by decrease in MSD-A and SMD, within DMN II (p = 0.005), ECN (p = 0.005), and language network (p < 0.001). PC exhibited intact RS FC, whereas SMD presented widespread structural and DMN RS FC damage. These findings advance our understanding of cognitive heterogeneity in MS by revealing distinct structural and functional neuroimaging profiles across cognitive phenotypes, encouraging future longitudinal and multimodal investigations to improve disease characterization and prognostic stratification.
中文摘要:认知损害影响40%~70%的多发性硬化(MS)患者。近期基于假设驱动和数据驱动的分析已识别出认知表型,但这些表型所对应损害的功能基础仍不清楚。本研究目标是在大型MS患者队列中通过聚类识别不同认知表型,并描述其相关临床、结构MRI和静息态(RS)功能连接(FC)特征。研究为观察性横断面设计,纳入右手MS患者及年龄、性别匹配的健康对照(HC),均接受神经系统和神经心理学评估(简明可重复神经心理测验组合)。对认知测验Z分数进行潜在剖面分析以识别MS认知表型。采用3.0T MRI获取萎缩指标及默认模式网络(DMN I/II)、执行控制网络(ECN)、左/右额顶网络、语言网络和突显网络内的RS FC。线性回归模型比较各认知表型与HC之间的结构MRI和RS FC,多项式对比评估各组间RS FC模式。共纳入369例MS患者和168名HC。检出四种认知表型:认知保留(PC,n=67[18.2%])、轻度单域言语流畅性受累(MSD-VF,n=37[10.0%])、轻度单域注意力受累(MSD-A,n=197[53.4%])和重度多域受累(SMD,n=68[18.4%])。在校正阈值下,PC患者深部灰质(GM)体积降低(p<0.001~0.001),RS FC与HC相似;MSD-VF未见显著萎缩,RS FC与HC无差异。MSD-A较HC皮质/深部GM体积降低(p<0.001~0.005);SMD临床和萎缩特征更差(p<0.001~0.04),且DMN II的RS FC较其他组降低(p=0.01~0.04)。多项式对比分析显示显著二次型模式:MSD-VF较HC/PC组RS FC升高,随后MSD-A和SMD降低,见于DMN II(p=0.005)、ECN(p=0.005)和语言网络(p<0.001)。PC的RS FC完整,SMD存在广泛结构和DMN RS FC损伤。这些发现通过揭示不同认知表型对应的结构和功能神经影像特征,推进了对MS认知异质性的理解,并支持未来开展纵向和多模态研究以改善疾病刻画和预后分层。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42879709
In multiple sclerosis (MS), new or enlarging brain lesions often suggest disease activity, but infections or tumors may mimic relapse. We report a 35-year-old woman with MS whose enlarging thalamic lesion was ultimately diagnosed as diffuse midline glioma, underscoring the need for prompt evaluation of atypical MRI findings.
中文摘要:在多发性硬化(MS)中,新出现或增大的脑病灶常提示疾病活动,但感染或肿瘤也可能类似复发。我们报告一名35岁女性MS患者,其增大的丘脑病灶最终诊断为弥漫性中线胶质瘤,强调需要对不典型MRI表现及时评估。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42854176
Preliminary data suggest sustained disease control with ocrelizumab (OCR) or rituximab (RTX) in women with multiple sclerosis (MS) after pregnancy suspension; however, the influence of washout duration and cumulative dosing remains unknown. This study investigates disease activity during and after pregnancy in women with relapsing-remitting MS treated with OCR/RTX before pregnancy. In this cohort study, pregnancies of women treated with OCR/RTX documented in the German MS and Pregnancy Registry were stratified by timing of last infusion (≥ or <4 months to last menstrual period [LMP]) and number of cycles (≥ or <2 cycles). Relapses treated with high-dose glucocorticosteroids were analyzed, as was persistent disability (following a relapse) at 1-year postpartum, defined as a ≥2.0-point increase in Expanded Disability Status Scale (EDSS) or new/worsening ambulatory impairment (Severe Relapse Disability Composite Score [SRDCS]). Of 294 pregnancies among 275 women, only 28.6% (n = 84) suspended OCR/RTX ≥4 months before LMP and most (79.3% [n = 233]) received ≥2 cycles. Relapses during pregnancy (2.0%) and within 12 months postpartum (8.5%) were rare. Four women (1.6%) reached the SRDCS postpartum. Neither the time of last infusion nor the number of cycles was associated with a higher relapse risk during pregnancy (time between OCR/RTX and LMP: <4 months adjusted OR: 0.60, CI: 0.09-5.02, p value: 0.60; number of cycles: <2 cycles adjusted OR: 2.23, CI: 0.34-15.5, p value: 0.39) or postpartum (time between OCR/RTX and LMP: <4 months adjusted OR: 0.62, CI: 0.23-1.77, p value: 0.36; number of cycles: <2 cycles adjusted OR: 0.64, CI: 0.16-2.03, p value: 0.48, time of anti-CD20 antibody restart postpartum: >6 weeks adjusted OR: 1.15, CI: 0.37-4.11, p value: 0.82) or with reaching the SRDCS or EDSS worsening postpartum. In women receiving ≥2 cycles and interrupting treatment <4 months before LMP, numerically fewer relapses during pregnancy could be observed (1/163: 0.6% vs 5/131: 3.8%, p value: 0.09). Relapses and disability during and after pregnancy after OCR/RTX interruption are rare and independent of timing and number of cycles. However, potential differences may not be detectable due to the low number of events and should be evaluated in larger studies. In addition, the applicability to ofatumumab, given its different dosing interval, remains unclear.
中文摘要:初步数据显示,多发性硬化女性在妊娠期暂停奥瑞利珠单抗(OCR)或利妥昔单抗(RTX)后仍可维持疾病控制;停药间隔与累积给药的影响尚不清楚。本研究考察妊娠前接受OCR/RTX治疗的复发缓解型多发性硬化女性在妊娠期间及产后的疾病活动。这项队列研究纳入德国多发性硬化与妊娠登记中接受OCR/RTX女性的妊娠,按末次输注距末次月经(LMP)的时间(≥或<4个月)及周期数(≥或<2个周期)分层。分析接受大剂量糖皮质激素治疗的复发,以及产后1年时复发后持续残疾,定义为扩展残疾状态量表(EDSS)增加≥2.0分或新发/加重的行走障碍(严重复发残疾复合评分[SRDCS])。275名女性的294次妊娠中,仅28.6%(n=84)在LMP前≥4个月暂停OCR/RTX,多数(79.3%[n=233])接受≥2个周期。妊娠期复发(2.0%)与产后12个月内复发(8.5%)少见。4名女性(1.6%)在产后达到SRDCS。末次输注时间与周期数均未与妊娠期更高的复发风险相关(OCR/RTX距LMP<4个月:校正OR 0.60,CI 0.09-5.02,p值0.60;周期数<2:校正OR 2.23,CI 0.34-15.5,p值0.39),也未与产后复发风险相关(OCR/RTX距LMP<4个月:校正OR 0.62,CI 0.23-1.77,p值0.36;周期数<2:校正OR 0.64,CI 0.16-2.03,p值0.48;产后重启抗CD20抗体>6周:校正OR 1.15,CI 0.37-4.11,p值0.82),也未与产后达到SRDCS或EDSS恶化相关。在接受≥2个周期且在LMP前<4个月中断治疗的女性中,妊娠期复发在数值上更少(1/163:0.6% 对比 5/131:3.8%,p值0.09)。OCR/RTX中断后妊娠期间及产后复发与残疾少见,且与停药时间和周期数无关。但事件数少可能无法检出潜在差异,需在更大研究中评估。鉴于给药间隔不同,结果对奥法妥木单抗的适用性仍不明确。
Drugs IF 14.7 2026-11 PMID: 42814369
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder of the central nervous system for which more than 20 disease-modifying therapies (DMTs) are currently available. Recent advances in diagnostic criteria, biomarker development, and understanding of disease biology have challenged traditional phenotype-based treatment paradigms and created new opportunities for individualized therapeutic strategies. The 2024 McDonald diagnostic criteria expand the biological definition of MS through incorporation of advanced MRI biomarkers, thereby supporting earlier diagnosis and potentially earlier treatment initiation. Aging influences both disease pathobiology and treatment risk-benefit balance, contributing to reduced focal inflammatory activity, increased progression, diminished regenerative capacity, and greater susceptibility to infections and comorbidities. These observations have important implications for treatment initiation, sequencing, escalation, de-escalation, and discontinuation. Current monitoring strategies remain centered on relapses, disability measures, and MRI lesion activity, but each has important limitations. Emerging imaging and fluid biomarkers, including brain and spinal cord atrophy metrics, neurofilament light chain, glial fibrillary acidic protein, and paramagnetic rim lesions, may improve biological stratification and therapeutic decision making, although further validation is needed. Safety considerations vary substantially across DMT classes. Real-world data have advanced our understanding of long-term risks, particularly with B-cell-depleting therapies. Novel therapeutic approaches in development are intended to more effectively target compartmentalized central nervous system inflammation and progression biology while potentially reducing systemic immunosuppression. As a result of these factors, MS management is evolving.
中文摘要:多发性硬化(MS)是中枢神经系统慢性炎症性和神经退行性疾病,目前已有20多种疾病修饰治疗(DMT)。诊断标准、生物标志物开发及对疾病生物学认识的进展,挑战了传统基于表型的治疗模式,并为个体化治疗策略带来新机会。2024年McDonald诊断标准通过纳入先进MRI生物标志物扩展了MS的生物学定义,从而支持更早诊断并可能更早启动治疗。衰老影响疾病病理生物学和治疗风险获益平衡,导致局灶性炎症活动减少、进展增加、再生能力下降,以及对感染和合并症的易感性增加。这些观察对治疗启动、排序、升级、降级和停药具有重要影响。当前监测策略仍以复发、残疾指标和MRI病灶活动为中心,但各有重要局限。新兴影像和液体生物标志物,包括脑和脊髓萎缩指标、神经丝轻链、胶质纤维酸性蛋白和顺磁性边缘病灶,可能改善生物学分层和治疗决策,但仍需进一步验证。不同DMT类别的安全性考虑差异很大。真实世界数据加深了对长期风险的理解,尤其是B细胞清除治疗。正在开发的新治疗方法旨在更有效靶向中枢神经系统区室化炎症和进展生物学,同时可能减少全身免疫抑制。受这些因素影响,MS管理正在演变。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42809446
Autologous hematopoietic stem cell transplantation (AHSCT) can induce long-lasting immune tolerance and disease quiescence in patients with severe multiple sclerosis (MS), but the underlying mechanisms are not well understood. We hypothesized that AHSCT would induce persistent decreases in inflammatory cytokines, chemokines, and axoglial damage biomarkers in serum and CSF. Longitudinal serum and CSF samples were obtained from 24 participants with severe MS undergoing AHSCT in the HALT-MS trial (NCT00288626), with serum collected at 9 time points from pretreatment through month 60 and CSF collected at 3 time points, including pretreatment, month 24, and month 48. Approximately 50 soluble biomarkers were analyzed to determine treatment-induced changes and associations with disease activity, including clinical and MRI parameters. AHSCT resulted in decreased expression of many proinflammatory cytokines, chemokines, and neuroinflammatory markers for several years in both serum and CSF, including neurofilament light chain (NfL). CSF levels of glial fibrillary acid protein and IL-7, on the contrary, increased after treatment. Expansion of cytomegalovirus and/or Epstein-Barr virus early after AHSCT resulted in transient increases in inflammatory cytokines in serum, but these changes did not persist. Changes in serum were largely distinct from changes in CSF, and concentrations of cytokines and chemokines in serum rarely correlated with concentrations in CSF, except for NfL. These results confirm the hypothesis that AHSCT results in long-lasting reductions in inflammatory cytokines, chemokines, and axoglial damage markers, consistent with persistent disease quiescence. The lack of relationships between biomarkers in serum and CSF suggests that these samples largely reflect distinct immunologic processes and compartments, and that analysis of CSF may be warranted for deeper understanding of disease processes in the CNS despite the challenges associated with performing lumbar punctures. Expression of IL-7 in CSF may be an underappreciated biomarker of the inflammatory state in the CNS and warrants further study.
中文摘要:自体造血干细胞移植(AHSCT)可使重症多发性硬化(MS)患者获得持久的免疫耐受与疾病静止,其机制尚未充分明确。我们假设AHSCT会使血清和脑脊液中的炎性细胞因子、趋化因子及轴突胶质损伤生物标志物持续下降。研究采集了HALT-MS试验(NCT00288626)中24例接受AHSCT的重症MS患者的纵向血清和脑脊液样本,血清自治疗前至第60个月共9个时间点,脑脊液在治疗前、第24个月和第48个月3个时间点采集。检测约50种可溶性生物标志物,分析治疗引起的变化及其与疾病活动度(包括临床和MRI指标)的关联。AHSCT使血清和脑脊液中多种促炎细胞因子、趋化因子及神经炎症标志物的表达在数年内下降,包括神经丝轻链(NfL)。脑脊液中胶质纤维酸性蛋白和IL-7水平在治疗后升高。移植后早期巨细胞病毒和/或EB病毒扩增引起血清炎性细胞因子短暂升高,但这些变化未持续。血清的变化与脑脊液的变化大多不同,除NfL外,血清中细胞因子和趋化因子浓度很少与脑脊液中的浓度相关。这些结果证实了上述假设,即AHSCT带来炎性细胞因子、趋化因子和轴突胶质损伤标志物的长期降低,与疾病持续静止相符。血清与脑脊液生物标志物之间缺乏关联,提示这两种样本主要反映不同的免疫过程和分隔,尽管腰椎穿刺存在困难,分析脑脊液可能有助于更深入理解中枢神经系统内的疾病过程。脑脊液中IL-7的表达可能是中枢神经系统炎症状态中被低估的生物标志物,值得进一步研究。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42809445
PET imaging targeting the 18-kDa translocator protein (TSPO) is a widely used method to detect neuroinflammation in vivo and shows promise for detecting innate inflammatory activity in multiple sclerosis (MS). However, TSPO-PET findings in MS vary substantially across studies. We performed a systematic review and meta-analysis to quantify TSPO-PET signal differences between people with MS (PwMS) and healthy controls (HCs) and to evaluate the impact of methodological factors on study outcomes. A systematic search of Scopus, MEDLINE, Web of Science, and Embase databases was conducted through September 10, 2025. Original TSPO-PET studies in PwMS were included. Standardized mean differences (SMDs) in TSPO-PET signal between PwMS and HC were pooled using random-effects models with cluster robust variances. Heterogeneity was assessed using I2 statistics. Meta-regression and subgroup analyses investigated methodological sources of heterogeneity. Patient-level data were analyzed for associations with clinical and demographic variables. Risk of bias and certainty of evidence were assessed using quality assessment of diagnostic accuracy studies 2 tool and GRADE framework, respectively. Forty-nine studies met inclusion criteria. Overall meta-analysis revealed significantly increased TSPO-PET signal in PwMS vs HC (SMD = 0.44, 95% CI: 0.27-0.61, p = 0.0002, I2: 97.00%). TSPO-PET signal was also significantly higher in progressive MS than in relapsing-remitting MS, indicating discrimination across MS clinical subtypes. Meta-regression attributed study heterogeneity to tracer (11.47%), PET quantification method (15.37%), and region of interest (19.71%) differences. Significant PwMS vs HC differences were most consistently observed with select tracers ([11C]PBR28, [18F]DPA-714, [11C]ER176, and [11C]PK11195) and with distribution volume ratio (DVR), nondisplaceable binding potential (BPND), and standardized uptake value ratio metrics. Significant effects were found in perilesional, thalamic, cortical, hippocampal, normal-appearing white matter, and T2-weighted white matter lesion regions. Patient-level analyses, while limited in power, showed significant associations between TSPO-PET signal (DVR) and disability measures (expanded disability status scale). TSPO-PET effectively distinguishes PwMS from HC and differentiates MS subtypes. However, radiotracer, quantification method, image analysis method, reference tissue, and region of interest significantly impact TSPO-PET outcomes and must be considered when designing and interpreting studies. Methodological standardization and improved reporting will be essential to enhance cross-study comparability and clinical interpretability.
中文摘要:靶向18 kDa转位蛋白(TSPO)的PET成像是在体内检测神经炎症的常用方法,在检测多发性硬化(MS)固有炎症活动方面显示出前景。然而,MS中的TSPO-PET研究结果差异很大。我们开展系统综述和荟萃分析,量化MS患者(PwMS)与健康对照(HC)之间的TSPO-PET信号差异,并评估方法学因素对研究结果的影响。检索Scopus、MEDLINE、Web of Science和Embase至2025年9月10日,纳入PwMS的原始TSPO-PET研究。采用随机效应模型及聚类稳健方差合并PwMS与HC之间TSPO-PET信号的标准化均数差(SMD)。用I2统计量评估异质性。通过荟萃回归和亚组分析探讨异质性来源。分析患者水平数据与临床及人口学变量的关联。分别用QUADAS-2工具和GRADE框架评估偏倚风险与证据确定性。49项研究符合纳入标准。总体荟萃分析显示PwMS较HC的TSPO-PET信号显著升高(SMD=0.44,95%CI:0.27-0.61,p=0.0002,I2:97.00%)。进展型MS的TSPO-PET信号也显著高于复发缓解型MS,提示可区分MS临床亚型。荟萃回归将研究异质性归因于示踪剂(11.47%)、PET定量方法(15.37%)和感兴趣区(19.71%)差异。PwMS与HC的显著差异在使用特定示踪剂([11C]PBR28、[18F]DPA-714、[11C]ER176和[11C]PK11195)以及分布容积比(DVR)、不可置换结合电位(BPND)和标准化摄取值比指标时最一致。在病灶周围、丘脑、皮质、海马、表现正常白质和T2加权白质病灶区域发现显著效应。患者水平分析效力有限,但显示TSPO-PET信号(DVR)与残疾指标(扩展残疾状况量表)显著相关。TSPO-PET能有效区分PwMS与HC,并区分MS亚型。然而,放射性示踪剂、定量方法、图像分析方法、参考组织和感兴趣区显著影响TSPO-PET结果,在设计和解释研究时必须考虑。方法学标准化和报告改进对于提高跨研究可比性和临床可解释性至关重要。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42766812
Paramagnetic rim lesions (PRLs) in multiple sclerosis (MS) indicate chronic, innate immune-mediated inflammation contributing to disease progression. Rim disappearance or attenuation is interpreted as a treatment response; however, it remains uncertain whether reduced susceptibility signal-likely reflecting decreased iron within the rim compartment-represents true resolution of chronic inflammation, natural lesion aging, and/or advanced tissue degeneration. Cross-sectionally, PRLs show variable rim conspicuity, enabling classification as Definite or Probable. We used quantitative MRI (qMRI) to assess underlying tissue destruction in Definite vs Probable PRLs in people with progressive MS (PwPMS). One hundred six PwPMS (34 primary progressive [PP], 72 secondary progressive; age 56 ± 10 years; median Expanded Disability Status Scale [EDSS] 5.5; 44% on disease-modifying therapy) underwent 3D-EPI and multishell diffusion MRI. PRLs (N = 155) were classified as Definite (N = 114) or Probable (N = 41). Prior clinical MRI scans estimated lesion age using an accelerated failure time model accounting for censoring. Whole-lesion, rim, and core regions were segmented; lesion size, quantitative susceptibility mapping, diffusion tensor imaging, Neurite Orientation Dispersions Density Imaging metrics, and T1 signal intensity were compared after multiple comparison correction. In total, 52% of PwPMS had ≥1 PRL; only 33% had Definite PRLs. Probable PRLs were more frequent in secondary vs PP MS (24% vs 9%, p = 0.05). Higher PRL counts were associated with younger age (p < 0.001), and PRLs were more often Definite in younger PwPMS (p < 0.0004). Participants with only Definite PRLs had shorter disease duration than those with ≥1 Probable PRL or no PRLs, and Probable PRLs were significantly older. Definite PRLs showed higher rim susceptibility (22 vs 8 ppb, p < 0.001); Probable PRLs demonstrated greater tissue disruption at qMRI-higher mean diffusivity (MD), axial diffusivity (AD), radial diffusivity (RD), and FISO and lower neurite density index (NDI), and larger lesion size (all p < 0.001). In progressive MS, PRLs with lower rim susceptibility are more likely classified as Probable but may represent older lesions with greater tissue damage. Because chronic active lesions do not require iron pathologically and rims can fade over time, rim disappearance at MRI cannot be interpreted unequivocally as resolving inflammation and may reflect natural lesion evolution. Rim persistence may be a more informative marker of ongoing compartmentalized inflammation than rim disappearance is of its resolution.
中文摘要:多发性硬化(MS)中的顺磁性边缘病灶(PRLs)提示慢性、固有免疫介导的炎症,并促进疾病进展。边缘消失或减弱常被解读为治疗反应,但磁敏感信号降低可能反映边缘区铁减少,其是否代表慢性炎症真正消退、病灶自然老化及/或晚期组织变性仍不确定。横断面上,PRLs的边缘可见度存在差异,可分类为明确或可能。我们采用定量MRI(qMRI)评估进展型MS患者(PwPMS)中明确与可能PRLs的潜在组织破坏。106例PwPMS(34例原发进展型,72例继发进展型;年龄56±10岁;EDSS中位数5.5;44%接受疾病修饰治疗)接受3D-EPI和多壳扩散MRI。155个PRLs分为明确(114个)或可能(41个)。既往临床MRI扫描通过考虑删失的加速失效时间模型估计病灶年龄。分割整个病灶、边缘和核心区域;经多重比较校正后比较病灶大小、定量磁敏感 mapping、扩散张量成像、神经突方向离散度密度成像指标和T1信号强度。52%的PwPMS有至少1个PRL;仅33%有明确PRLs。可能PRLs在继发进展型MS中比原发进展型更常见(24%对9%,p=0.05)。PRL数量较多与较年轻年龄相关(p<0.001),年轻PwPMS中PRLs更常为明确(p<0.0004)。仅有明确PRLs的参与者病程短于有至少1个可能PRL或无PRLs者,可能PRLs显著更老。明确PRLs边缘磁敏感较高(22对8 ppb,p<0.001);可能PRLs在qMRI上显示更明显的组织破坏,平均弥散率(MD)、轴向弥散率(AD)、径向弥散率(RD)和FISO较高,神经突密度指数(NDI)较低,病灶更大(均p<0.001)。在进展型MS中,边缘磁敏感较低的PRLs更可能被归为可能,但可能代表组织损伤更重的较老病灶。慢性活动性病灶在病理上并不需要铁,且边缘可随时间淡出,因此MRI上边缘消失不能明确解释为炎症消退,可能反映病灶自然演变。边缘持续存在可能比边缘消失更能提示持续存在的区室化炎症。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42743451
Late-onset neutropenia (LON) is a rare, transient reduction in absolute neutrophil count (ANC) associated with anti-CD20 therapies. In multiple sclerosis (MS), data regarding severity, infectious outcomes, and predictors remain limited. We aimed to determine the incidence, characteristics, and predictors of LON in rituximab-treated people with MS (pwMS). We conducted a registry-based retrospective multicenter cohort study of pwMS in Sweden exposed to rituximab between 2008 and 2024. Any LON was defined as ANC <1,500 cells/μL occurring at least 30 days after rituximab initiation. Grades 3-4 LON was defined as ANC <1,000 cells/μL, recording infectious complications for these events. Incidence rates (IRs) were calculated per 1,000 person-years, and event times were summarized as medians (interquartile range [IQR]). Predictors of LON events were evaluated using Cox regression with time-varying covariates and binary logistic regression. Among 2,686 rituximab-exposed pwMS, 6.2% (n = 165) experienced ≥1 LON event during a median follow-up of 7.8 years (IQR 5.7-9.8). The IR for any LON (grades 2-4) was 10.1/1,000 person-years (95% CI 8.6-11.8); the median time-to-first event was 360 days (IQR 112-1,017). Most events were mild, 5.3% (grade 2, n = 142). Grades 3-4 LON occurred for 1% (23 individuals; 36 events) and IR 2.1/1,000 person-years (95% CI 1.4-2.9). Ten infections occurred among LON grades 3-4 events, classifying 8 as severe. All individuals with infectious LON grades 3-4 events (48%) recovered after hospitalization, antibiotics/antivirals, and/or granulocyte colony-stimulating factor. Rituximab was rechallenged in 89% (32/36) of grades 3-4 events: 14 recurred and 2 complicated by infections. In time-dependent Cox models, higher accumulated rituximab exposure (HR 0.87, 95% CI 0.81-0.93) and prior injectable therapy (HR 0.66, 95% CI 0.45-0.96) were associated with a lower hazard of any LON. Exploratory binary analyses of LON grades 3-4 showed associations with prior natalizumab (odds ratio [OR] 2.8) and higher body mass index (OR 0.87), not confirmed in time-to-event models. In this large real-world cohort, high-grade LON (grades 3-4) events were rare and frequently complicated by infections. Mild (grade 2) LON events were often fluctuating and generally clinically uneventful. Rechallenge with rituximab was rarely complicated by serious adverse events. Prediction of LON remains challenging, highlighting the relevance of infection vigilance during anti-CD20 therapy.
中文摘要:晚发型中性粒细胞减少症(LON)是与抗CD20治疗相关的罕见、短暂性中性粒细胞绝对计数(ANC)下降。在多发性硬化(MS)中,有关其严重程度、感染结局和预测因素的数据仍有限。研究旨在明确接受利妥昔单抗治疗的MS患者(pwMS)中LON的发生率、特征及预测因素。研究为基于登记资料的回顾性多中心队列研究,纳入2008年至2024年在瑞典接受利妥昔单抗治疗的pwMS。任何LON定义为利妥昔单抗启动至少30天后出现ANC<1,500 cells/μL。3-4级LON定义为ANC<1,000 cells/μL,并记录这些事件的感染性并发症。发生率(IR)按每1,000人年计算,事件时间以中位数(四分位距[IQR])汇总。LON事件的预测因素采用含时变协变量的Cox回归和二元logistic回归评估。在2,686例接受利妥昔单抗治疗的pwMS中,6.2%(n=165)在中位随访7.8年(IQR 5.7-9.8)期间发生至少1次LON事件。任何LON(2-4级)的IR为10.1/1,000人年(95% CI 8.6-11.8);首次事件的中位时间为360天(IQR 112-1,017)。多数事件较轻,5.3%为2级(n=142)。3-4级LON发生于1%(23例;36次事件),IR为2.1/1,000人年(95% CI 1.4-2.9)。3-4级LON事件中发生10次感染,其中8次归类为严重感染。所有发生感染性3-4级LON事件者(48%)经住院、抗生素/抗病毒药物和/或粒细胞集落刺激因子治疗后均恢复。89%(32/36)的3-4级事件再次使用利妥昔单抗:14次复发,2次合并感染。在时间依赖Cox模型中,较高的累积利妥昔单抗暴露(HR 0.87,95% CI 0.81-0.93)和既往注射治疗(HR 0.66,95% CI 0.45-0.96)与任何LON风险降低相关。针对3-4级LON的探索性二元分析显示与既往那他珠单抗(比值比[OR] 2.8)和较高体重指数(OR 0.87)相关,但未在时间至事件模型中得到证实。在这一大型真实世界队列中,高级别LON(3-4级)事件罕见,且常合并感染。轻度(2级)LON事件常呈波动性,临床上通常无明显不良后果。再次使用利妥昔单抗很少合并严重不良事件。LON的预测仍然困难,提示抗CD20治疗期间需警惕感染。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42664474
Although anti-CD20 monoclonal antibodies (anti-CD20s) theoretically represent an ideal treatment option for women with multiple sclerosis (wwMS) planning a pregnancy, the paucity of real-world data still limits their use in this context. Through our Italian registry "CD20-PREGNANCY," we aim to report pregnancy, infant, and maternal outcomes in wwMS treated with anti-CD20s. In this observational study, wwMS having received rituximab (RTX), ocrelizumab (OCR), or ofatumumab (OFA) before and/or during pregnancy (≤12 months for RTX/OCR, ≤6 months for OFA) were included. Considering drug pharmacokinetics and timings of immunoglobulin placental transfer, pregnancies were classified as "exposed" (last administration pre-pregnancy ≤2.3 months for RTX, ≤3 for OCR, ≤1.8 for OFA) and "not-exposed" (last administration beyond these intervals) for comparative analysis. A total of 153 pregnancies (85 "not-exposed," 68 "exposed") across 27 Italian MS centers were collected. The median age at conception was 33.9 years (interquartile range 30.0-37.6) with 39.9% of women older than 35 years. Most pregnancies occurred in patients treated with OCR (77.1%). 80.4% of pregnancies ended in livebirth and 13.1% in spontaneous abortions (SA), without stillbirths/neonatal deaths. There was a significantly higher percentage of SA in "exposed" pregnancies than "not-exposed" (20.6% vs 7.1%, p = 0.014), but with values similar to those reported in general population. One serious perinatal infection ("exposed" group) and 2 major congenital anomalies (MCA) (one per group) were reported. Compared with the 12 months pre-pregnancy, annualized relapse rate remained stable during pregnancy but slightly increased postpregnancy (0.00 vs +0.09) in "not-exposed." Conversely, it decreased in both periods (-0.02 vs -0.13) among "exposed". Compared with pre-pregnancy, postpregnancy combined unique active lesions decreased in both groups (-0.15 in "not-exposed", -0.38 in "exposed"), while 2 confirmed disability worsening were observed ("not-exposed"). In conclusion, a good control of disease activity was observed without an increased risk of MCA or perinatal infections. Percentages of SA were overall in line with those of general population, although with a higher proportion in the "exposed" group. These findings support the use of anti-CD20 therapies in wwMS planning pregnancy, although further data are needed to better define their safety profile in this setting.
中文摘要:抗CD20单克隆抗体(anti-CD20s)理论上可作为计划妊娠的多发性硬化女性(wwMS)的理想治疗选择,但真实世界数据有限,这类药物在该人群中的应用仍受到限制。本研究经意大利「CD20-PREGNANCY」登记研究,报告接受抗CD20治疗的wwMS的妊娠结局、婴儿结局及母亲结局。该观察性研究纳入在妊娠前和/或妊娠期间接受利妥昔单抗(RTX)、奥瑞利珠单抗(OCR)或奥法妥木单抗(OFA)的wwMS,时间窗为RTX、OCR不超过12个月,OFA不超过6个月。根据药物药代动力学和免疫球蛋白胎盘转运时间,将妊娠分为「暴露」和「未暴露」两组进行比较分析:「暴露」指末次给药距妊娠前不超过2.3个月(RTX)、不超过3个月(OCR)或不超过1.8个月(OFA);「未暴露」指末次给药时间超出上述间隔。研究共纳入来自27个意大利多发性硬化中心的153例妊娠,其中85例未暴露、68例暴露。受孕中位年龄为33.9岁(四分位间距30.0~37.6),39.9%的女性年龄超过35岁。多数妊娠发生于接受OCR治疗的患者(77.1%)。80.4%的妊娠以活产结束,13.1%为自然流产(SA),未见死胎或新生儿死亡。暴露组SA比例显著高于未暴露组(20.6% vs 7.1%,p=0.014),但数值与一般人群报道相近。研究报道1例严重围产期感染(暴露组)和2例重大先天畸形(MCA,每组各1例)。与妊娠前12个月相比,未暴露组年化复发率在妊娠期保持稳定,产后轻度升高(0.00 vs +0.09);暴露组在两个时期均下降(-0.02 vs -0.13)。与妊娠前相比,两组的产后联合唯一活动病灶均减少(未暴露组-0.15,暴露组-0.38),未暴露组观察到2例确认的残疾恶化。总体而言,疾病活动控制良好,未见MCA或围产期感染风险增加。SA比例总体与一般人群一致,暴露组比例更高。这些结果支持将抗CD20治疗用于计划妊娠的wwMS,但仍需更多数据以更好界定其在该情境下的安全性。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42647758
Environmental factors are pivotal in determining multiple sclerosis (MS) susceptibility, yet their specific influence on the immune system at the time of diagnosis remains incompletely understood. The aim of this study was to map the systemic effects of modifiable risk factors, specifically smoking, body mass index (BMI), serum vitamin D, UV exposure, and latent viral immunity, on immune function in patients with treatment-naive MS. A multiomics analysis was performed on a monocentric cohort of 96 treatment-naive patients. The study used a combination of bulk transcriptomics across 6 immune cell lineages, serum proteomics, cell-cell communication modeling, and high-dimensional flow cytometry to identify unique immunologic patterns linking environmental exposures to disease pathology. Smoking was found to induce an upregulation of the tissue-homing receptor GPR15 across lineages, particularly in NK cells, which correlated with higher disability levels. Smoking also amplified a proinflammatory milieu (increased CXCL17 and LAMP3). Higher potential UV exposure seemed to counteract these effects by lowering IFI30 and LYZ expression; notably, elevated IFI30 correlated with the presence of gadolinium-enhancing lesions. Regarding metabolic factors, high BMI exerted a linear effect on monocyte metabolism, driving cholesterol biosynthesis (MVD and SQLE) and increasing proinflammatory markers (FABP4 and LEP) associated with blood-brain barrier compromise. These findings elucidate the molecular mechanisms by which modifiable risk factors contribute to MS pathology. The data imply distinct clinical approaches for risk management: while smoking cessation must likely be absolute to reverse pathogenic trafficking signals (such as GPR15 upregulation), the linear effect of BMI suggests that incremental weight loss confers proportional immunologic benefits. These insights strongly support the integration of lifestyle interventions as a core component of early MS management.
中文摘要:环境因素在多发性硬化易感性中起关键作用,但其在诊断时对免疫系统的具体影响仍未完全明确。本研究旨在描绘可改变危险因素,包括吸烟、体重指数、血清维生素D、紫外线暴露和潜伏病毒感染免疫,对未经治疗的多发性硬化患者免疫功能的系统性影响。研究对96例未经治疗患者的单中心队列进行多组学分析,联合6种免疫细胞谱系的批量转录组分析、血清蛋白质组学、细胞间通讯建模和高维流式细胞术,识别将环境暴露与疾病病理联系起来的独特免疫模式。吸烟可诱导各谱系组织归巢受体GPR15上调,尤其在NK细胞中,并与更高残疾水平相关。吸烟还放大了促炎环境,表现为CXCL17和LAMP3升高。较高的潜在紫外线暴露似乎通过降低IFI30和LYZ表达抵消这些效应;IFI30升高与钆增强病灶存在相关。代谢因素方面,高体重指数对单核细胞代谢产生线性效应,驱动胆固醇生物合成MVD和SQLE,并增加与血脑屏障受损相关的促炎标志物FABP4和LEP。这些发现阐明了可改变危险因素参与多发性硬化病理的分子机制。数据提示风险管理的临床策略应有所区别:戒烟很可能需要完全戒断才能逆转致病性转运信号如GPR15上调,而体重指数的线性效应提示逐步减重可带来成比例的免疫获益。这些认识有力支持将生活方式干预整合为早期多发性硬化管理的核心组成部分。

基础研究 (3篇)

Annals of neurology IF 7.5 2026-11 PMID: 42799661
Gut wall physiology in multiple sclerosis (MS) and autoimmune neurologic diseases remains underexplored. This review examines gut wall dysfunctions' contribution to MS and autoimmune neurological disorder pathogenesis and progression. We discuss 3 inter-related aspects of gut physiology: intestinal barrier, enteric nervous system (ENS), and mucosal immunity. We highlight the ENS as a putative target of immune injury in selected antibody-mediated and T cell-associated neurologic diseases. Finally, we propose a unifying framework in which the gut functions as a site of immune priming and target of autoimmune injury, bridging microbiome-driven mechanisms in MS with ENS-directed autoimmunity across neurologic diseases. ANN NEUROL 2026;100:915-930.
中文摘要:多发性硬化(MS)及自身免疫性神经系统疾病中的肠壁生理仍缺乏充分探索。本综述考察肠壁功能障碍对MS及自身免疫性神经系统疾病发病机制和疾病进展的贡献。讨论肠生理三个相互关联的方面:肠道屏障、肠神经系统(ENS)和黏膜免疫。强调ENS是部分抗体介导及T细胞相关神经系统疾病中免疫损伤的假定靶点。并提出一个统一框架,认为肠道既是免疫致敏部位,也是自身免疫损伤的靶点,将MS中微生物组驱动的机制与跨神经系统疾病的ENS导向自身免疫联系起来。ANN NEUROL 2026;100:915-930。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42789917
Pediatric-onset multiple sclerosis (PedMS) provides a unique opportunity to investigate MS pathogenesis because of the short interval between environmental exposures and disease onset. This study aimed to identify differentially methylated regions (DMRs) that mediate the interplay between environmental triggers and genomic factors in the early stages of the disease. In this multicenter study, we analyzed peripheral blood DNA from 175 Italian subjects (122 PedMS patients, 53 healthy controls) using the Infinium Methylation EPIC Array v2. All patients were enrolled within 4 years of onset. The bioinformatic pipeline included batch effect correction, normalization, and differential methylation analysis adjusted for sex and inferred cell-type proportions. DMRs were detected using DMRcate. Network analysis was performed by projecting DMR-overlapping genes onto the STRING interactome using the NDEx tool, followed by pathway enrichment analysis with gProfiler. To ensure robustness, we performed an internal 1/3-2/3 validation and sensitivity analyses on treatment-naïve and low-efficacy treatment (LETA) subgroups. Our analysis revealed 55 DMRs, with 28 affecting promoter regions. Top signals involved genes such as CHI3L2, LPCAT1, CD19, PARP1, CPT1B-CHKB, and IGF2R, including several MS-associated loci. Signals mapping to CHI3L2/DENND2D and LPCAT1 were highly resilient, persisting across all validation and sensitivity subsets. Network analysis identified a subnetwork of 165 nodes where the Epstein-Barr virus (EBV) infection emerged as the top-ranked enriched pathway (p = 3.23 *10-40). High-centrality regulatory hubs included PARP1 and IGF2R, the latter overlapping with established imprinting control regions. Our findings identify a distinct epigenetic signature in early-stage PedMS, suggesting that DNA methylation changes are not stochastic but converge on high-centrality regulatory hubs. The stable association with EBV-related pathways and imprinting loci reinforces the hypothesis that epigenetic remodeling serves as a critical interface between early-life environmental exposures and genetic susceptibility in MS onset.
中文摘要:儿童期起病的多发性硬化(PedMS)从环境暴露到发病的间隔较短,为研究MS的发病机制提供了独特机会。本研究旨在识别在疾病早期介导环境触发因素与基因组因素相互作用的差异甲基化区域(DMRs)。这项多中心研究采用Infinium Methylation EPIC Array v2检测了175名意大利受试者(122例PedMS患者、53名健康对照)的外周血DNA,全部患者均在发病4年内入组。生物信息学流程包括批次效应校正、标准化,以及校正性别与推断细胞类型比例后的差异甲基化分析;DMRs由DMRcate检出。将DMR重叠基因投射至STRING相互作用组,借助NDEx工具完成网络分析,随后用gProfiler做通路富集。为检验稳健性,另做内部1/3-2/3验证,并在未治疗与低疗效治疗(LETA)亚组中开展敏感性分析。结果共检出55个DMRs,其中28个位于启动子区。最强信号涉及CHI3L2、LPCAT1、CD19、PARP1、CPT1B-CHKB与IGF2R等基因,包含若干已知MS相关位点。定位于CHI3L2/DENND2D与LPCAT1的信号高度稳定,在所有验证与敏感性亚组中均持续存在。网络分析得到含165个节点的子网络,EB病毒(EBV)感染为排名首位的富集通路(p = 3.23 *10-40)。高中心性调控枢纽包括PARP1与IGF2R,后者与已知印记控制区重叠。这些发现揭示了早期PedMS存在独特的表观遗传特征,提示DNA甲基化改变并非随机发生,而是汇聚于高中心性调控枢纽;与EBV相关通路及印记位点的稳定关联,进一步支持表观遗传重塑在MS发病中充当生命早期环境暴露与遗传易感性之间关键界面的假说。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42647759
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS whose risk and course are shaped by both genetic and environmental factors, among which the intestinal microbiota has emerged as a key, potentially modifiable contributor. People with MS frequently display altered gut microbiota, characterized by depletion of fiber-fermenting, short-chain fatty acid (SCFA)-producing commensals, and expansion of taxa associated with mucus degradation and proinflammatory metabolism. These compositional shifts are paralleled by broad changes in blood and CSF metabolites, including reduced SCFAs, tryptophan-derived aryl hydrocarbon receptor ligands, and secondary bile acids. In addition, several reports highlight the accumulation of aromatic amino acid-derived phenolic and indolic compounds and specific lipid mediators linked to neuroinflammation and neurodegeneration. In this up-to-date review, we synthesize evidence from experimental models and human studies showing how microbial metabolites can influence MS pathogenesis through converging mechanisms: modulation of gut and blood-brain barrier integrity; shaping of T-cell and B-cell responses; direct effects on microglia, astrocytes, and oligodendrocyte lineage cells after crossing into the CNS; and modulation of neural circuits, particularly those involving the vagus nerve. Finally, we highlight current gaps, including the need for longitudinal, harmonized multiomic cohorts, and mechanistic studies integrating microbiome, metabolome, and host readouts across gut, blood, and CNS. Overall, available data support a model in which coordinated disruption of the gut microbiota-metabolite axis, rather than any single pathogen, contributes to MS, opening avenues for microbiota-based and metabolite-based biomarkers and therapies aimed at restoring immune and neuroglial homeostasis.
中文摘要:多发性硬化(MS)是中枢神经系统(CNS)的慢性炎性脱髓鞘疾病,其风险和病程受遗传与环境因素共同影响,其中肠道微生物群已成为关键且可能可修饰的贡献因素。MS患者常出现肠道微生物群改变,表现为纤维发酵、产短链脂肪酸(SCFA)的共生菌耗竭,以及与黏液降解和促炎代谢相关的菌群扩增。这些组成变化伴随血液和脑脊液(CSF)代谢物的广泛改变,包括SCFA、色氨酸来源的芳香烃受体配体和次级胆汁酸减少。同时,若干报道强调与神经炎症和神经变性相关的芳香族氨基酸来源酚类和吲哚类化合物及特定脂质介质蓄积。这篇最新综述综合实验模型和人体研究的证据,显示微生物代谢物如何通过汇聚机制影响MS发病机制:调节肠道和血脑屏障完整性;塑造T细胞和B细胞反应;进入CNS后直接影响小胶质细胞、星形胶质细胞和少突胶质细胞谱系细胞;调节神经环路,尤其是涉及迷走神经的环路。当前仍存在空白,包括需要纵向、协调的多组学队列,以及整合肠道、血液和CNS的微生物组、代谢组和宿主读数的机制研究。现有数据支持一个模型:肠道微生物群-代谢物轴的协同破坏,而非任何单一病原体,促成MS,为旨在恢复免疫和神经胶质稳态的基于微生物群和代谢物的生物标志物及治疗开辟途径。

4帕金森病与运动障碍 (16篇)

临床研究 (5篇)

Nature aging IF 25.0 2026-11-04 PMID: 42983008
Parkinson's disease (PD) is a growing public health challenge as populations age. Current diagnosis relies on motor symptoms and invasive procedures, making early detection difficult. Here we present Quest2Dx, a generalized artificial intelligence model that analyzes health questionnaires to enable low-cost, non-invasive PD screening. Conventional models are built for each questionnaire, and missing responses degrade their performance. Quest2Dx uses language modeling to encode the meaning of each question and answer, allowing it to transfer across questionnaires while enhancing interpretability. On the Parkinson's Progression Markers Initiative (PPMI) Online and Fox Insight datasets, Quest2Dx achieved areas under the receiver operating characteristic curve (AUROCs) of 0.977 and 0.974, respectively, outperforming existing methods. Additionally, cross-questionnaire validation achieved AUROCs of 0.920 and 0.952, respectively, from PPMI Online to Fox Insight and vice versa. Quest2Dx also identified key predictors from the questions to provide further insights. These results indicate a promising path to PD screening in primary care.
中文摘要:帕金森病随着人口老龄化成为日益严重的公共卫生挑战。当前诊断依赖运动症状和有创操作,使早期发现困难。我们提出Quest2Dx,一种广义人工智能模型,分析健康问卷以实现低成本、无创的帕金森病筛查。传统模型针对每份问卷单独构建,缺失回答会降低其性能。Quest2Dx使用语言建模编码每个问题和答案的含义,使其能够跨问卷迁移并增强可解释性。在帕金森进展标志物计划(PPMI)Online和Fox Insight数据集上,Quest2Dx的受试者工作特征曲线下面积(AUROC)分别为0.977和0.974,优于现有方法。跨问卷验证从PPMI Online到Fox Insight及反向的AUROC分别为0.920和0.952。Quest2Dx还从问题中识别出关键预测因子以提供进一步洞见。这些结果表明在初级保健中开展帕金森病筛查的一条有前景的路径。
Annals of neurology IF 7.5 2026-11-02 PMID: 42969188
People with Parkinson's disease (PD) who carry a pathogenic GBA1 variant (PDGBA1) are at higher risk of cognitive impairment than those without the variant (PDGBA1_wildtype). To date, little is known about the pattern and evolution of cognitive decline in PDGBA1. This multicenter study characterized the cognitive profile of PDGBA, focusing on the longitudinal trajectories and the group-specific onset times among cognitive functions, as well as their clinical relevance. In this exploratory longitudinal multicohort-study (Parkinson's Precision Medicine Initiative [PPMI], Amyloid-Beta in cerebrospinal spinal fluid as a risk factor for cognitive dysfunction in Parkinson's Disease [ABC-PD], and National Centre for Excellence in Research on Parkinson's disease [NCER-PD]), comprehensive neuropsychological assessments were standardized across 546 healthy controls (follow-up years = 2.9 ± 4.3), 903 PDGBA1_wildtype (follow-up years = 4.4 ± 4.2), and 211 PDGBA1 (follow-up years = 4.8 ± 3.4). We evaluated performance across age and disease duration using generalized linear mixed effects models (GLMMs) within each cognitive domain. An exploratory latent trajectory analysis was computed to identify potential cognitive subgroups. Time-to-first-event models, assessing risks of clinically relevant performance impairment (test score z ≤ -1.5, Montreal Cognitive Assessment [MoCA] < 26), and an expanding time-window approach identified the course of cognitive impairment. PDGBA1 performed worse in executive function, attention, visuocognitive skills, and memory than PDGBA1_wildtype at baseline and exhibited a more rapid and widespread decline across these domains. The risk of developing clinically relevant cognitive impairment during the disease course was increased in PDGBA1. Processing speed and visuoperceptual showed the earliest performance impairments in PDGBA1, preceding PDGBA1_wildtype by 1.2 and 2.5 disease years, respectively. Within the PDGBA1 group, we identified a subgroup with rapidly declining cognition, who were more likely to be male patients, report depressive symptoms, and carry a severe GBA1 mutation. PDGBA1 exhibits accelerated domain-generalized and more severe cognitive decline compared to PDGBA1_wildtype. ANN NEUROL 2026.
中文摘要:携带致病性GBA1变异的帕金森病者(PDGBA1)发生认知损害的风险高于未携带该变异者(PDGBA1_wildtype)。目前对PDGBA1认知下降的模式与演变了解仍少。该多中心研究刻画PDGBA1的认知特征,关注认知功能的纵向轨迹、各认知域的组别特异性起病时间及其临床相关性。这项探索性纵向多队列研究纳入帕金森病精准医学计划(PPMI)、帕金森病认知功能障碍脑脊液淀粉样β风险因素研究(ABC-PD)和国家帕金森病卓越研究中心(NCER-PD),对546名健康对照(随访2.9±4.3年)、903名PDGBA1_wildtype(随访4.4±4.2年)和211名PDGBA1(随访4.8±3.4年)标准化实施综合神经心理评估。研究在各认知域内采用广义线性混合效应模型评估随年龄和病程的表现,并行探索性潜在轨迹分析以识别可能的认知亚组。通过首次事件时间模型评估临床相关表现损害风险(测验分数z≤-1.5,蒙特利尔认知评估MoCA<26),并结合扩展时间窗方法确定认知损害进程。PDGBA1在基线时执行功能、注意力、视认知技能和记忆表现均差于PDGBA1_wildtype,且在这些认知域出现更快速、更广泛的下降。PDGBA1在病程中发生临床相关认知损害的风险升高。PDGBA1中处理速度和视知觉表现最早受损,分别较PDGBA1_wildtype提前1.2和2.5个疾病年。PDGBA1组内识别出一个认知快速下降亚组,该亚组更可能为男性、报告抑郁症状并携带严重GBA1突变。与PDGBA1_wildtype相比,PDGBA1表现出加速的跨认知域广泛下降和更严重的认知衰退。ANN NEUROL 2026。
Annals of neurology IF 7.5 2026-11 PMID: 42671071
Hospitalized people with Parkinson's disease (PwP) face increased risks of medication errors and discharge to non-home settings, both of which are associated with adverse outcomes. This study assessed differences in medication error rates and discharge outcomes before and after implementation of a dedicated inpatient program for hospitalized PwP. During 2023, a Parkinson's disease (PD) inpatient program was implemented and refined combining: (1) an electronic health record (EHR) census for identification of hospitalized PwP; (2) inpatient monitoring and alignment of inpatient and outpatient regimens by movement-disorders-trained advanced practitioners; (3) customized EHR alerts and levodopa orders; (4) pharmacist support, and (5) staff education. Medication error rates and clinical outcomes were compared between January and June 2024 (post-implementation phase) and a pre-implementation retrospective cohort from 2018. From January to June 2024, 366 post-implementation admissions were monitored. Among those receiving contraindicated medications, the median number of doses decreased from 2 (interquartile range [IQR] = 1-6) during pre-implementation to 1 (IQR: 1-2) post-implementation (p = 0.015). Days with a levodopa dose deviation decreased from 43.1% to 38.3%, p < 0.0001, improper levodopa formulation substitutions from 18.6% to 5%, p < 0.0001, timing deviations from 72.2% to 51.8%, p < 0.00001, missed doses from 21.5% to 16.8%, p = 0.013, and discharged to non-home settings from 44.8% to 38.3%, p = 0.038. Following implementation of a multidisciplinary and proactive inpatient program, reductions in medication errors and improved discharge outcomes were observed among PwP. ANN NEUROL 2026;100:1068-1079.
中文摘要:住院帕金森病患者面临用药错误和出院后转入非家庭环境的风险增加,二者均与不良结局相关。本研究评估了为住院帕金森病患者设立专门住院项目前后,用药错误率和出院结局的差异。2023年实施并完善了一个帕金森病住院项目,包括:(1)通过电子健康档案普查识别住院帕金森病患者;(2)由接受运动障碍专科培训的高级执业人员开展住院监测,并使住院与门诊治疗方案保持一致;(3)定制电子健康档案警报和左旋多巴医嘱;(4)药师支持;(5)员工教育。研究比较了2024年1月至6月(实施后阶段)与2018年实施前回顾性队列的用药错误率和临床结局。2024年1月至6月共监测366例次实施后入院。在接受禁忌药物者中,中位剂量数从实施前的2次(四分位距[IQR]=1-6)降至实施后的1次(IQR:1-2),p=0.015。左旋多巴剂量偏差天数从43.1%降至38.3%,p<0.0001;不当左旋多巴剂型替换从18.6%降至5%,p<0.0001;给药时间偏差从72.2%降至51.8%,p<0.00001;漏服剂量从21.5%降至16.8%,p=0.013;出院至非家庭环境从44.8%降至38.3%,p=0.038。实施多学科、主动的住院项目后,帕金森病患者的用药错误减少,出院结局改善。ANN NEUROL 2026;100:1068-1079。
Molecular psychiatry IF 10.4 2026-11 PMID: 42443392
Whereas attention-deficit/hyperactive disorder (ADHD) has consistently been shown to be correlated with later risk of depression, anxiety, and substance misuse, the relationship with other adverse health endpoints, particularly somatic conditions, is uncertain. In a full-nation birth cohort study, we used a phenotype-wide approach to explore the influence, if any, of a ADHD diagnosis in childhood/adolescence on later disease and injury. Comprising 52594 children (25463 females) born in a single year with non-missing data, the 1987 Finnish Birth Cohort was generated from linkage of routinely collected data. ADHD diagnosis was captured from in- and out-patient hospital records up to age 18 years and study members continued to be surveilled for other diagnoses until 2020 (aged 33). Pre-adulthood, 0.43% (N = 228) of study members were diagnosed with ADHD. In people with ADHD, relative to population controls, there was a heightened risk of developing all of the 17 health endpoints examined. Of these associations, however, eleven were statistically significant after adjustment for age and sex, and five after further control for birth weight, family socioeconomic circumstances, study members' educational performance, and multiple testing (odds ratio; 99.7%): neurotic disorders (2.11; 1.25, 3.41); substance abuse disorder (2.26; 1.27, 3.79); poisoning (2.30; 1.02, 4.52); mood disorders (2.45; 1.49, 3.88); and epilepsy (4.55; 1.82, 9.55). Repeating the main analyses following data imputation (N = 54045) confirmed these associations with the emergence of a connection between psychotic disorders and antecedent ADHD (2.63; 1.34, 5.18). Overall, young people with ADHD in the present cohort experienced an increased future burden of psychiatric and neurological conditions but seemingly not somatic disorders.
中文摘要:注意缺陷多动障碍(ADHD)一直被发现与日后抑郁、焦虑和物质滥用的风险相关,但其与其他不良健康结局,尤其是躯体疾病的关系仍不确定。在一项全国出生队列研究中,我们采用全表型方法探讨儿童期或青少年期ADHD诊断对日后疾病和损伤是否存在影响。1987年芬兰出生队列由常规收集数据链接生成,纳入同一年出生且数据无缺失的52594名儿童(女性25463名)。ADHD诊断取自18岁前的住院和门诊医院记录,研究成员继续接受其他诊断监测至2020年(33岁)。成年之前,0.43%(N=228)的研究成员被诊断为ADHD。与人群对照相比,ADHD患者出现所检查的全部17种健康结局的风险均升高。调整年龄和性别后,其中11种关联具有统计学意义;进一步控制出生体重、家庭社会经济状况、研究成员的教育表现并校正多重检验后,5种关联仍显著(比值比;99.7%置信区间):神经症性障碍(2.11;1.25,3.41)、物质滥用障碍(2.26;1.27,3.79)、中毒(2.30;1.02,4.52)、心境障碍(2.45;1.49,3.88)和癫痫(4.55;1.82,9.55)。在数据插补后(N=54045)重复主要分析,上述关联得到确认,并出现精神病性障碍与先前ADHD之间的关联(2.63;1.34,5.18)。总体而言,本队列中患有ADHD的年轻人日后精神科和神经系统疾病负担增加,但似乎未见躯体疾病负担增加。
Annals of neurology IF 7.5 2026-10-30 PMID: 42960478
To develop and externally validate prediction models for next-year falls in Parkinson's disease (PD), and to evaluate the incremental value of imaging and fluid biomarkers. We developed models in Parkinson's Progression Markers Initiative (PPMI) to predict next-year falls with external validation in University of Pennsylvania (UPenn) cohorts. We evaluated incident falls among visits without current or prior falls and recurrent falls among visits with current falls. We calculated area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC), and development-derived risk strata. The incident model, comprising Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III, Montreal Cognitive Assessment, and Geriatric Depression Scale (GDS), was developed in 773 visit-pairs and validated in 589 visit-pairs. AUROC was 0.704 (95% confidence interval [CI] = 0.653-0.750) in PPMI and 0.630 (95% CI = 0.564-0.687) in UPenn. Incident fall risk increased from 7.1 to 18.5% across low- to high-risk groups in UPenn. The recurrent model, comprising Hoehn and Yahr (H&Y), GDS, and Symbol Digit Modalities Test, was developed in 302 visit-pairs and validated in 137 visit-pairs. AUROC was 0.683 (95% CI = 0.623-0.753) in PPMI and 0.641 (95% CI = 0.538-0.732) in UPenn. Recurrent fall rates increased from 22.2 to 65.0% across low- to high-risk groups in UPenn. Exploratory biomarker augmentation modestly improved discrimination beyond clinical models in PPMI, but not in external validation, where estimates were imprecise. Clinical measures may identify next-year fall risk in PD with moderate discrimination, although performance attenuated in external validation. Exploratory biomarkers provided modest incremental value in development but not in external validation. ANN NEUROL 2026.
中文摘要:为开发并外部验证帕金森病(PD)未来一年跌倒的预测模型,并评估影像与体液生物标志物的增量价值。研究在帕金森病进展标志物计划(PPMI)中开发模型,并在宾夕法尼亚大学(UPenn)队列中进行外部验证。在无当前或既往跌倒的访视中评估新发跌倒,在有当前跌倒的访视中评估复发性跌倒。计算受试者工作特征曲线下面积(AUROC)、精确率-召回率曲线下面积(AUPRC)及开发队列衍生的风险分层。新发跌倒模型包含运动障碍学会统一帕金森病评定量表第三部分、蒙特利尔认知评估和老年抑郁量表(GDS),在773个访视配对中开发,在589个访视配对中验证。AUROC在PPMI为0.704(95%置信区间[CI]=0.653-0.750),在UPenn为0.630(95%CI=0.564-0.687)。UPenn低风险至高危组的新发跌倒风险从7.1%升至18.5%。复发跌倒模型包含Hoehn and Yahr(H&Y)分期、GDS和符号数字模态测验,在302个访视配对中开发,在137个访视配对中验证。AUROC在PPMI为0.683(95%CI=0.623-0.753),在UPenn为0.641(95%CI=0.538-0.732)。UPenn低风险至高危组的复发跌倒率从22.2%升至65.0%。探索性生物标志物增强在PPMI中较临床模型有轻度判别改善,但在外部验证中未体现,且估计不精确。临床指标或可以中等判别度识别PD未来一年跌倒风险,但外部验证中性能下降。探索性生物标志物在开发阶段提供轻度增量价值,在外部验证中未提供。ANN NEUROL 2026。

基础研究 (11篇)

Nature biomedical engineering IF 26.3 2026-11-03 PMID: 42977739
Vagus nerve stimulation has shown promising neuroprotective and anti-inflammatory effects in progressive neurodegenerative disorders such as Parkinson's disease. However, its invasive nature introduces procedural and device-related risks. Here we introduce a magnetoelectric particulate system for oral delivery and non-invasive vagus nerve stimulation through the gut. The system comprises a magneto-responsive nickel ferrite core and a piezoelectric barium titanate shell, conjugated with capsaicin to specifically target TRPV1 receptors, ensuring effective adherence to the stomach lining after oral administration. Upon magnetic field stimulation, the particles generate electrical pulses that activate vagal afferent fibres, engaging the nucleus tractus solitarius in the brainstem via the gut-brain axis. This activation enhances norepinephrine production in the locus coeruleus and dopamine synthesis in the substantia nigra. Vagal efferent activation triggers the cholinergic anti-inflammatory pathway, mitigating both neuroinflammation and systemic inflammation. This non-invasive approach demonstrates potential for alleviating motor symptoms and non-motor anxiety in Parkinson's disease, offering valuable insights into its mechanisms and clinical applications.
中文摘要:迷走神经刺激在帕金森病等进展性神经退行性疾病中已显示出神经保护与抗炎作用的前景,但其有创性带来操作风险与器械相关风险。我们提出一种磁电颗粒系统,可口服递送并经由肠道实现无创迷走神经刺激。该系统由磁响应铁酸镍核与压电钛酸钡壳构成,并偶联辣椒素以特异性靶向TRPV1受体,从而在口服后有效黏附于胃黏膜。在磁场刺激下,颗粒产生电脉冲激活迷走传入纤维,经肠脑轴使脑干孤束核参与其中。该激活增强蓝斑去甲肾上腺素的生成以及黑质多巴胺的合成。迷走传出激活触发胆碱能抗炎通路,减轻神经炎症与全身炎症。这一无创途径显示出缓解帕金森病运动症状与非运动性焦虑的潜力,为其机制与临床应用提供了有价值的线索。
Redox biology IF 16.2 2026-11-02 PMID: 42981985
Dopaminergic neurodegeneration in the substantia nigra causes the motor symptoms of Parkinson's disease (PD). The mechanisms underlying this neurodegeneration remain unclear. Aldehydes exhibit high reactivity that can covalently modify functional proteins and cause cell damage. This study aimed to characterize protein adduction by endogenous aldehydes and investigate its role in dopaminergic neuron loss in PD. Forty free aldehydes were identified in rat models of PD induced by 6-hydroxydopamine (6-OHDA) and rotenone using chemical isotope labeling coupled with high-resolution mass spectrometry. Twenty-two aldehydes were found in the rat brain for the first time. In addition to lipid peroxidation, amine oxidation was the major source of aldehydes. Levels of 27 aldehyde-protein adducts in the substantia nigra and striatum were increased by 1- to 5-fold at 4-6 h after 6-OHDA injection. Consistently, most of these protein adducts were significantly increased in the rotenone model. Application of the trapping reagent phenelzine and the aldehyde dehydrogenase-2 activator Alda-1 reduced protein adduction by aldehydes and attenuated neuron loss induced by 6-OHDA injection. Twelve aldehydes covalently modified α-synuclein in 6-OHDA-treated rats, with the lysine residue in the GLSK peptide identified as the primary binding target. Aldehydes caused peptide crosslinking and aggregation of α-synuclein. Additive effects of covalent modification by aldehydes contributed to neuron death. Collectively, protein adduction by multiple aldehydes contributes to α-synuclein aggregation and dopaminergic neuron loss in rat models of PD. Multiple biogenic aldehydes, especially those from abnormal oxidation of amines, represent a novel class of toxic molecules that play a pathogenic role in PD.
中文摘要:黑质多巴胺能神经元变性导致帕金森病的运动症状。这种变性的机制仍不清楚。醛类反应性高,可与功能蛋白共价结合并造成细胞损伤。本研究旨在表征内源性醛类引起的蛋白加合,并探讨其在帕金森病多巴胺能神经元丢失中的作用。采用化学同位素标记结合高分辨质谱,在6-羟基多巴胺(6-OHDA)和鱼藤酮诱导的帕金森病大鼠模型中鉴定出40种游离醛类。其中22种醛类为首次在大鼠脑中发现。除脂质过氧化外,胺氧化是醛类的主要来源。6-OHDA注射后4至6小时,黑质和纹状体中27种醛-蛋白加合物的水平升高1至5倍。一致的是,这些蛋白加合物在鱼藤酮模型中大多也显著增加。给予捕获试剂苯乙肼和乙醛脱氢酶-2激活剂Alda-1可减少醛类引起的蛋白加合,并减轻6-OHDA注射诱导的神经元丢失。在6-OHDA处理大鼠中,12种醛类共价修饰α-突触核蛋白,GLSK肽段中的赖氨酸残基被确定为主要结合靶点。醛类引起肽交联和α-突触核蛋白聚集。醛类共价修饰的叠加效应促进神经元死亡。总体而言,多种醛类引起的蛋白加合促进帕金森病大鼠模型中的α-突触核蛋白聚集和多巴胺能神经元丢失。多种生物源性醛类,尤其是来自胺异常氧化的醛类,代表一类新的毒性分子,在帕金森病中发挥致病作用。
Redox biology IF 16.2 2026-11 PMID: 42843275
Protein tyrosine nitration is a post-translational modification associated with conditions of oxidative and inflammatory stress, driven by the production of reactive oxygen and nitrogen species (ROS and RNS). Once considered primarily a footprint of oxidative damage, tyrosine nitration is increasingly recognized as a selective modification that, in specific biological contexts, can alter protein structure, stability, enzymatic activity, and interaction networks. Mechanistically, nitration occurs through peroxynitrite-dependent and heme-peroxidase-dependent pathways and preferentially targets specific tyrosine residues based on local protein structure, solvent accessibility, and microenvironmental chemistry. Accumulating evidence has identified disease-specific nitration signatures across multiple pathological contexts. In neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, nitration of proteins such as tau, α-synuclein, manganese superoxide dismutase, ATP synthase, glyceraldehyde-3-phosphate dehydrogenase, heat shock proteins, and cytoskeletal components contributes to mitochondrial dysfunction, protein aggregation, metabolic failure, and neuronal loss. Similarly, in cardiovascular and pulmonary diseases, protein tyrosine nitration disrupts vascular and epithelial homeostasis by impairing endothelial signaling, fibrinolysis, lipid metabolism, and barrier integrity through modification of key regulatory proteins. By influencing phosphorylation-dependent signaling, enzymatic function, and protein-protein interactions, tyrosine nitration contributes to the connection between redox imbalance and progressive cellular and tissue dysfunction. This review summarizes current mechanistic insights into site-specific protein tyrosine nitration, highlights the emerging disease-associated nitroproteome, and discusses how advances in analytical and structural approaches are redefining nitration as a functional regulatory modification. Understanding the molecular determinants and consequences of tyrosine nitration may enable the development of targeted diagnostics and therapeutic strategies across diverse human diseases.
中文摘要:蛋白酪氨酸硝化是一种与氧化和炎症应激状态相关的翻译后修饰,由活性氧和活性氮(ROS和RNS)生成所驱动。它曾主要被视为氧化损伤的痕迹,如今越来越被认为是一种选择性修饰,在特定生物学情境中可改变蛋白质结构、稳定性、酶活性及相互作用网络。机制上,硝化通过过氧亚硝酸盐依赖性和血红素过氧化物酶依赖性途径发生,并依据局部蛋白质结构、溶剂可及性和微环境化学性质优先作用于特定酪氨酸残基。累积证据已在多种病理情境中识别出疾病特异性硝化特征。在神经退行性疾病(包括阿尔茨海默病、帕金森病和肌萎缩侧索硬化)中,tau、α-突触核蛋白、锰超氧化物歧化酶、ATP合酶、甘油醛-3-磷酸脱氢酶、热休克蛋白及细胞骨架成分等蛋白质的硝化促进线粒体功能障碍、蛋白质聚集、代谢衰竭和神经元丢失。在心血管和肺部疾病中,蛋白酪氨酸硝化通过修饰关键调控蛋白,损害内皮信号传导、纤维蛋白溶解、脂质代谢和屏障完整性,从而破坏血管和上皮稳态。酪氨酸硝化通过影响磷酸化依赖的信号传导、酶功能和蛋白质-蛋白质相互作用,参与氧化还原失衡与进行性细胞和组织功能障碍之间的联系。本综述总结关于位点特异性蛋白酪氨酸硝化的当前机制认识,突出新兴的疾病相关硝基蛋白质组,并讨论分析和结构方法的进展如何重新定义硝化作为一种功能性调控修饰。理解酪氨酸硝化的分子决定因素和后果,可能有助于在多种人类疾病中开发靶向诊断和治疗策略。
Ageing research reviews IF 15.5 2026-11 PMID: 42702294
Dopaminergic neurons constitute a heterogeneous neuronal system that regulates diverse brain functions, whereas distinct dopaminergic neuronal subpopulations exhibit unique intrinsic biological properties, selective vulnerability, and disease-specific pathological trajectories across neurodegenerative disorders. Parkinson's disease (PD) is characterized by the progressive degeneration of substantia nigra pars compacta (SNc) dopaminergic neurons, whereas Alzheimer's disease (AD) predominantly involves progressive dysfunction of ventral tegmental area (VTA)-associated dopaminergic circuits rather than widespread dopaminergic neuronal loss. This review provides a comprehensive overview of the regional heterogeneity of SNc and VTA dopaminergic neurons across multiple dimensions, including anatomical organization, electrophysiological properties, Ca²⁺ homeostasis, bioenergetics, dopamine metabolism, and proteostasis, and discusses how these cell-autonomous characteristics collectively shape the intrinsic vulnerability of distinct dopaminergic neuronal subpopulations. Furthermore, it discusses how intrinsic vulnerability interacts with disease-associated pathological processes to drive the divergent pathological trajectories of the dopaminergic system, culminating in selective neuronal degeneration in PD and progressive dysfunction of VTA-associated neural circuits in AD. Building on this evidence, this review proposes a conceptual framework in which the pathological fate of the dopaminergic system is shaped by the interplay between intrinsic vulnerability and circuit dependency. Building upon this framework, the review further discusses disease-modifying strategies and their translational implications for PD and AD. This conceptual framework provides an integrated perspective for understanding the divergent pathological trajectories of the dopaminergic system in PD and AD and establishes a foundation for future hypothesis-driven studies on neuronal subtype-specific vulnerability.
中文摘要:多巴胺能神经元构成调控多种脑功能的异质性神经元系统,不同的多巴胺能神经元亚群在神经退行性疾病中表现出独特的内在生物学特性、选择性易损性和疾病特异的病理轨迹。帕金森病(PD)以黑质致密部(SNc)多巴胺能神经元进行性变性为特征,而阿尔茨海默病(AD)主要涉及腹侧被盖区(VTA)相关多巴胺能环路的进行性功能障碍,并非广泛的多巴胺能神经元丢失。这篇综述从解剖组织、电生理特性、Ca²⁺稳态、生物能量学、多巴胺代谢和蛋白质稳态等多个维度,全面概述SNc与VTA多巴胺能神经元的区域异质性,并讨论这些细胞自主特征如何共同塑造不同多巴胺能神经元亚群的内在易损性。文章进一步讨论内在易损性如何与疾病相关病理过程相互作用,驱动多巴胺能系统走向不同的病理轨迹,最终在PD中表现为选择性神经元变性,在AD中表现为VTA相关神经环路的进行性功能障碍。基于这些证据,综述提出一个概念框架:多巴胺能系统的病理命运由内在易损性与环路依赖性之间的相互作用塑造。在这一框架下,文章进一步讨论疾病修饰策略及其对PD和AD的转化意义。该概念框架为理解PD和AD中多巴胺能系统的不同病理轨迹提供了整合视角,并为未来针对神经元亚型特异性易损性的假说驱动研究奠定基础。
Medicinal research reviews IF 13.6 2026-11 PMID: 42460688
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the pathological misfolding and aggregation of α-synuclein (α-syn), which leads to dopaminergic neuronal loss and multisystem dysfunction. Conventional clinical diagnosis is often delayed until after substantial neuronal degeneration has occurred. Recent advances in α-syn seed amplification assays (α-syn SAAs), including real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA), have revolutionized PD biomarker research. These assays exploit the prion-like seeding and propagation properties of pathological α-syn to amplify trace aggregates in biological samples with exceptional sensitivity and specificity. Here, we summarize the mechanistic principles and biophysical underpinnings of α-syn SAAs, compare their diagnostic performance across biospecimens such as cerebrospinal fluid, skin, blood, and saliva, and evaluate their potential for differential diagnosis among synucleinopathies. We further discuss the integration of SAAs with other biomarkers including α-syn oligomer ELISAs, neurofilament light chain assays, and dopaminergic PET/SPECT imaging. Emerging developments, such as same-day RT-QuIC, quantitative kinetic readouts, and peripheral blood-based assays, are accelerating clinical translation. Despite challenges in assay standardization, strain discrimination, and regulatory validation, α-syn SAAs hold transformative potential for early diagnosis, patient stratification, and monitoring of therapeutic efficacy in PD. Their convergence with artificial intelligence, organoid modeling, and multimodal biomarker frameworks promises to redefine precision medicine in PD and other synucleinopathies.
中文摘要:帕金森病(PD)是一种进行性神经退行性疾病,其特征为α-突触核蛋白(α-syn)的病理性错误折叠与聚集,进而导致多巴胺能神经元丢失和多系统功能障碍。传统临床诊断常在明显神经元变性发生后才得以确立。近年来α-syn种子扩增检测(α-syn SAAs)的进展,包括实时震动诱导转化(RT-QuIC)和蛋白错误折叠循环扩增(PMCA),改变了PD生物标志物研究。这些检测利用病理性α-syn的类朊病毒播种与传播特性,以极高灵敏度和特异性扩增生物样本中的痕量聚集体。该综述总结α-syn SAAs的机制原理与生物物理基础,比较其在脑脊液、皮肤、血液和唾液等生物样本中的诊断性能,并评估其在突触核蛋白病鉴别诊断中的潜力。进一步讨论SAAs与α-syn寡聚体ELISA、神经丝轻链检测及多巴胺能PET/SPECT显像等其他生物标志物的整合。当日RT-QuIC、定量动力学读数、基于外周血的检测等新兴发展正在加速临床转化。尽管在检测标准化、毒株区分和监管验证方面存在挑战,α-syn SAAs在PD早期诊断、患者分层和治疗疗效监测方面具有变革性潜力。其与人工智能、类器官建模和多模态生物标志物框架的融合,有望重新定义PD及其他突触核蛋白病的精准医学。
Biosensors & bioelectronics IF 11.8 2026-11-01 PMID: 42401152
Target-specific fluorescent probes are essential for biosensing and drug screening, yet their rational design remains challenging due to the intrinsic trade-off between target binding and photophysical properties. Generative artificial intelligence offers new opportunities for molecular design. However, its application to probe design remains limited as photophysical properties are not encoded during generation and resulting molecules are often chemically implausible or synthetically inaccessible. Here we present a unified generative framework in which photophysical evaluation is embedded into structure-aware molecular generation, enabling simultaneous optimization of target recognition and optical functionality during molecular construction. Furthermore, we establish a consensus-driven prioritization strategy that incorporates physics- and synthesis-constrained fragment growth, ensuring the chemical realism and synthetic accessibility of the generated molecules. As a proof-of-concept, we applied this strategy to α-synuclein fibrils, a key pathological hallmark of Parkinson's disease, and identified a fluorescent probe (CLead1) with a strong turn-on response and high selectivity against competing amyloid species. Leveraging CLead1, we developed a high-throughput screening assay and identified Dryocrassin ABBA as a neuroprotective inhibitor of α-synuclein fibrillization. This work establishes a broadly applicable generative strategy for designing target-specific fluorescent probes, bridging biosensing and therapeutic exploration.
中文摘要:靶标特异性荧光探针是生物传感与药物筛选的关键工具,但其理性设计受制于靶标结合与光物理性质之间的内在权衡。生成式人工智能为分子设计提供了新途径,然而光物理性质未在生成过程中被编码,所生成分子常出现化学不合理或难以合成的问题,使其在探针设计中的应用仍受限。本文提出一个统一的生成框架,将光物理评价嵌入结构感知的分子生成过程,在分子构建阶段同时优化靶标识别与光学功能。研究进一步建立共识驱动的优先级排序策略,结合受物理与合成约束的片段生长,保证生成分子的化学真实性与可合成性。作为概念验证,该策略被用于帕金森病关键病理标志物α-突触核蛋白纤维,获得荧光探针CLead1,其对竞争性淀粉样蛋白种类具有强开启响应与高选择性。基于CLead1建立高通量筛选方法,鉴定出Dryocrassin ABBA可作为抑制α-突触核蛋白纤维化的神经保护性抑制剂。该工作为靶标特异性荧光探针设计提供了可广泛应用的生成式策略,衔接生物传感与治疗探索。
Autophagy IF 18.6 2026-11 PMID: 42343639
Parkinson disease (PD) is closely linked to disruptions in mitochondrial quality control, a process regulated by the ubiquitin kinase PINK1 and the E3 ubiquitin ligase PRKN/parkin. Upon mitochondrial damage, PINK1 phosphorylates ubiquitin, which in turn recruits and activates PRKN. Full activation of PRKN is mediated by PINK1-dependent phosphorylation of PRKN at serine 65, which leads to widespread ubiquitination of mitochondrial substrates and amplifies the mitophagy response. Disruption of this pathway results in mitochondrial accumulation, oxidative stress, and neuronal death, all key mechanisms of PD pathogenesis. Genetic studies have shown biallelic loss-of-function mutations in PRKN are the most common cause of early-onset PD. Although the role of haploinsufficiency remains under investigation, PRKN protein becomes insoluble and inactive with aging or post-translational modifications, indicating that functional protein levels are a key determinant of disease risk. Reliable quantification of total and activated PRKN in samples has not been feasible, limiting research and clinical assessment. To address this, we developed and validated knockout (KO)-verified sandwich ELISA assays that quantify both total PRKN and PINK1-phosphorylated p-S65-PRKN. These assays provide absolute quantification of PRKN, improving functional diagnosis, and patient stratification in PD. Application of these methods established the concentration of PRKN in cells and in brain and revealed significant effects of a common genetic PRKN variant, further highlighting the importance of determining functional PRKN protein levels. The developed immunoassays complement previously established PINK1 and p-S65-Ub measurements, enhancing mechanistic insight into mitophagy and enabling effective monitoring of PD therapies and other neurodegenerative diseases.Abbreviations: AD: Alzheimer disease; CCCP: carbonyl cyanide 3-chlorophenylhydrazone; ECL: electrochemiluminescence; ELISA: enzyme-linked immunosorbent assay; IBR: In-between-RING; iPSC: induced pluripotent stem cell; KO: knockout; LoB: limit of blank; LoD: limit of detection; LoQ: limit of quantification; MSD: Meso Scale Discovery; PD: Parkinson disease; p-S65-PRKN: serine 65 phosphorylated PRKN; p-S65-Ub: serine 65 phosphorylated ubiquitin; REP: repressor element of PRKN; RING: really interesting new gene; Ub: ubiquitin; UBL: ubiquitin-like domain; VCL: vinculin; WT: wild-type.
中文摘要:帕金森病(PD)与线粒体质量控制紊乱密切相关,该过程受泛素激酶PINK1和E3泛素连接酶PRKN/parkin调控。线粒体损伤后,PINK1磷酸化泛素,进而招募并激活PRKN。PRKN的完全激活由PINK1依赖的PRKN丝氨酸65磷酸化介导,导致线粒体底物广泛泛素化并放大线粒体自噬反应。该通路受损会造成线粒体堆积、氧化应激和神经元死亡,这些均为PD发病的关键机制。遗传学研究表明,PRKN双等位基因功能缺失突变是早发性PD最常见的病因。单倍剂量不足的作用仍在研究中,但PRKN蛋白在衰老或翻译后修饰后变得不可溶且失活,提示功能性蛋白水平是疾病风险的关键决定因素。此前无法可靠定量样本中的总PRKN和活化PRKN,限制了研究与临床评估。为此,我们开发并验证了经敲除(KO)验证的夹心ELISA方法,可定量总PRKN和PINK1磷酸化的p-S65-PRKN。这些方法实现PRKN绝对定量,改善PD的功能诊断和患者分层。应用这些方法确定了细胞和脑内PRKN浓度,并揭示一种常见PRKN遗传变异具有显著影响,进一步凸显测定功能性PRKN蛋白水平的重要性。所开发的免疫分析方法补充了既有的PINK1和p-S65-Ub检测,增强对线粒体自噬机制的理解,并有助于有效监测PD及其他神经退行性疾病的治疗。
Biomaterials IF 13.6 2026-11 PMID: 42184750
The causes of Parkinson's disease (PD) so far are controversial, but its chronic nature and epidemiological studies reveal that dyshomeostasis of copper biometals is greatly responsible for the progressive dysfunctions that could fuel a vicious cycle of multiple pathogenic factors throughout PD trajectory. Unfortunately, current medication will exert non-specific removal of copper ions including biologically essential static copper pool in metalloenzyme, further exacerbating the neurotoxic effect associated with copper dyshomeostasis. Here, we reported a cascade neuroprotective therapy, which only utilized polysaccharides (i.e. thymine grafted hyaluronic acid, denoted as TgHA) to transform endogenous neurotoxic Cu(II) ions into red-emissive few-atom copper clusters while leaving the levels of essential biometals unchanged. Moreover, these copper clusters can functionally mimic three main antioxidant enzymes to protect neuronal cells from oxidative damage. In PD mouse model, about 83% of travel distance and 61% of fall latency restored back to normal mice after intraperitoneal injection of TgHA alone, clearly alleviating motor dysfunctions. We envisioned polysaccharide-mediated in vivo cascade chemistry will shift therapeutic paradigm in biometal-involved neurological disorders.
中文摘要:帕金森病(PD)的病因至今仍有争议,但其慢性病程和流行病学研究显示,铜生物金属稳态失衡是导致进行性功能障碍的重要原因,并可在PD全程推动多种致病因素形成恶性循环。现有药物会非特异性清除铜离子,包括金属酶中具有生物学意义的静态铜池,从而进一步加重与铜稳态失衡相关的神经毒性。本工作报道一种级联神经保护治疗,仅利用多糖(胸腺嘧啶接枝透明质酸,记为「TgHA」)将内源性神经毒性Cu(II)离子转化为红色发光少原子铜簇,同时不改变必需生物金属水平。这些铜簇可在功能上模拟三种主要抗氧化酶,保护神经元细胞免受氧化损伤。在PD小鼠模型中,单独腹腔注射TgHA后,约83%的行走距离和61%的跌落潜伏期恢复至正常小鼠水平,明显减轻运动功能障碍。多糖介导的体内级联化学有望转变生物金属相关神经系统疾病的治疗范式。
Ageing research reviews IF 15.5 2026-10-30 PMID: 42962772
Oxidative stress and lipid peroxidation are increasingly recognized as age-related drivers of neurodegeneration, with Parkinson's disease (PD) representing a condition of heightened vulnerability. Among lipid peroxidation products, reactive aldehydes including 4-hydroxy-2-nonenal, malondialdehyde, acrolein, 4-hydroxy-2-hexenal, and crotonaldehyde have emerged not only as biomarkers of oxidative damage, but also as active mediators of neuronal dysfunction. Owing to their electrophilic nature, these aldehydes interact with nucleophilic residues, including cysteine, lysine, and histidine, forming covalent adducts that impair proteostasis, mitochondrial function, and redox signaling. Under physiological conditions, lipid peroxidation-derived aldehydes (LPDAs) are detoxified through glutathione-dependent conjugation and oxidoreductase-mediated metabolism. However, ageing progressively impairs these protective systems, promoting aldehyde accumulation and increasing dopaminergic vulnerability. We propose that PD may reflect, at least in part, an age-dependent impairment of aldehyde detoxification in addition to increased reactive oxygen species production. Although current experimental and clinical evidence supports the pathogenic relevance of some LPDAs in PD, antioxidant-based interventions have yielded inconsistent clinical outcomes. Within this framework, antioxidant strategies can be interpreted according to their functional impact on aldehyde burden. Approaches aimed at restoring glutathione homeostasis or activating Nrf2-dependent pathways may enhance endogenous detoxification systems and thereby support aldehyde clearance. More directly targeted approaches include strategies that enhance aldehyde metabolism, such as pharmacological activation of ALDH2. Overall, shifting the therapeutic focus from radical scavenging to the modulation of aldehyde burden through combined upstream and downstream interventions represents a promising but still underexplored avenue in PD and age-related neurodegenerative disorders that warrants further validation in clinical settings.
中文摘要:氧化应激和脂质过氧化日益被视为衰老相关神经变性的驱动因素,帕金森病(PD)则是易感性升高的情形。脂质过氧化产物中,4-羟基-2-壬烯醛、丙二醛、丙烯醛、4-羟基-2-己烯醛和巴豆醛等反应性醛类不仅作为氧化损伤的生物标志物出现,也成为神经元功能障碍的主动介质。这些醛类具有亲电性,可与半胱氨酸、赖氨酸和组氨酸等亲核残基相互作用,形成共价加合物,损害蛋白质稳态、线粒体功能和氧化还原信号。生理条件下,脂质过氧化来源醛类(LPDAs)通过谷胱甘肽依赖性结合和氧化还原酶介导的代谢被解毒。衰老会逐步损害这些保护系统,促进醛类蓄积并增加多巴胺能神经元易感性。我们提出,PD至少部分反映了除活性氧产生增加之外的、年龄依赖性的醛类解毒受损。尽管现有实验和临床证据支持部分LPDAs在PD中的致病相关性,但基于抗氧化剂的干预在临床结局上并不一致。在这一框架内,抗氧化策略可按其对醛类负荷的功能影响来理解。旨在恢复谷胱甘肽稳态或激活Nrf2依赖通路的策略,可能增强内源性解毒系统,从而支持醛类清除。更直接靶向的策略包括增强醛类代谢,例如药理学激活ALDH2。整体上,将治疗重点从自由基清除转向通过上游和下游联合干预调节醛类负荷,是PD和年龄相关神经退行性疾病中有前景但仍探索不足的方向,需在临床环境中进一步验证。
Science advances IF 13.9 2026-10-30 PMID: 42962009
Chaperone-mediated autophagy (CMA), regulated by its lysosomal receptor LAMP2A, is a key pathway for αSynuclein (αSyn) clearance and a direct target of αSyn-related neurotoxicity. Rodent studies show that LAMP2A enhancement reverses neurodegeneration, whereas its deficiency accelerates pathology. To test translational relevance, we examined whether increasing LAMP2A expression in nonhuman primates could mitigate α-synucleinopathy induced by injections of Parkinson's disease patient-derived Lewy body (LB) extract. Increasing LAMP2A expression protected nigral dopaminergic neurons from LB-induced αSyn neurodegeneration, delayed the formation and release of pathology-related αSyn species, and evoked a beneficial effect on motor behavior and on cognitive functions of the primate model. Our findings provide preliminary preclinical evidence supporting CMA enhancement as a therapeutic strategy for αSynucleinopathies.
中文摘要:分子伴侣介导的自噬(CMA)受溶酶体受体LAMP2A调控,是清除α-突触核蛋白(αSyn)的关键通路,也是αSyn相关神经毒性的直接靶点。啮齿类研究显示,增强LAMP2A可逆转神经退行性变,而LAMP2A不足会加速病理进展。为检验转化意义,我们在非人灵长类中提高LAMP2A表达,观察其能否减轻注射帕金森病患者来源路易体(LB)提取物诱导的α-突触核蛋白病。提高LAMP2A表达保护黑质多巴胺能神经元免受LB诱导的αSyn神经退行性变,延缓病理相关αSyn物种的形成与释放,并对该灵长类模型的运动行为和认知功能产生有益影响。结果提供初步临床前证据,支持增强CMA作为α-突触核蛋白病的治疗策略。
Acta neuropathologica IF 10.3 2026-10-30 PMID: 42961519
A major challenge for identifying a disease-modifying cure for Parkinson's disease (PD) is creating models resembling key features of the disease including resting tremor, bradykinesia, muscle rigidity and gait disturbances. In addition, PD patients often develop cognitive symptoms that are associated with pathology in neocortical areas. Initially, PD rodent models were generated primarily by chemical neurotoxins that induce an acute loss of dopaminergic neurons. Upon discovery of familial-PD-linked genetic mutations in the SNCA gene-encoding α-synuclein (αS)-mice carrying these mutations provided deeper insight into the pathologic role of this synaptic protein throughout the brain. αS transgenic mouse models stand out for their ability to develop intraneuronal lesions that are rich in αS phospho-serine 129, a histopathological signature of the human PD brain. Recent advances in αS protein biochemistry led to the generation of mice carrying strategic amplifications of familial-PD-linked αS mutants, resulting in more pronounced neurodegeneration and progressive phenotype development. Here we review advances of αS transgenic mouse model development with a focus on strategic mutations that may have greater potential for identifying underlying disease mechanisms than classical single-mutant and wild-type αS overexpressing mice. We also present how the mice are currently used in testing drug efficacy and target engagement for PD drug discovery and outline strategies for utilizing such mice in basic and translational research.
中文摘要:识别帕金森病(PD)疾病修饰疗法的主要挑战在于建立能够再现该病关键特征的模型,这些特征包括静止性震颤、运动迟缓、肌强直和步态障碍。PD患者还常出现与大脑新皮质区病理相关的认知症状。早期PD啮齿类模型主要由化学神经毒素诱导,造成多巴胺能神经元急性丢失。随着编码α-突触核蛋白(αS)的SNCA基因中家族性PD相关突变被发现,携带这些突变的小鼠使人们更深入理解该突触蛋白在全脑中的病理作用。αS转基因小鼠模型的突出之处在于能形成富含αS磷酸化丝氨酸129的神经元内病变,而这是人PD脑组织的组织病理学标志。αS蛋白生物化学的近期进展促成了携带家族性PD相关αS突变体策略性扩增的小鼠,这些小鼠表现出更明显的神经变性和进行性表型发展。这里回顾αS转基因小鼠模型开发的进展,重点关注策略性突变,这类突变在识别潜在疾病机制方面可能比经典的单突变体和野生型αS过表达小鼠更具潜力。文中还介绍这些小鼠目前如何用于PD药物发现中的药效和靶点结合检测,并概述在基础与转化研究中利用此类小鼠的策略。

5神经重症与脑损伤 (10篇)

临床研究 (2篇)

Intensive care medicine IF 22.0 2026-11-05 PMID: 42986439
Clinical research evaluating mechanical ventilation liberation in patients with acute brain injury (ABI) shows substantial outcome heterogeneity, limiting evidence synthesis. We aimed to develop an internationally endorsed core outcome set (COS) and a hierarchical composite endpoint for ventilation trials in neurocritical care. Following COS-STAD/COS-STAP standards, we conducted a 4-round international Delphi study. Candidate outcomes were identified via a scoping review. A multidisciplinary panel from 31 countries scored outcomes using a 9-point GRADE scale. Inclusion required >70% rating as "critical" (score 7-9) and ≤15% as "not important" (1-3). Two consensus meetings were held to categorize outcomes, select representative measures, and ratify a hierarchical composite endpoint. 78 stakeholders participated in Round 1; 60 completed all rounds (23.1% attrition). Fifty-four outcomes achieved Delphi consensus. At Consensus Meeting 1, these were organized into 16 categories; the highest-scoring outcome per category was selected. Three outcomes were not ratified due to disease-specificity (NIH Stroke Scale) or lack of universal applicability (brain death, coma-free days). The final COS comprised 13 outcomes across 5 domains: respiratory function, survival, complications, functional status, and quality of life. A 3-level hierarchical composite endpoint was ratified at Consensus Meeting 2: (1) intensive care unit survival, (2) no reintubation within 72 hours, and (3) days alive without mechanical ventilation. This study establishes the first COS for ventilation weaning trials in ABI patients. Widespread adoption of these 13 outcomes and the hierarchical composite endpoint will standardize reporting, enable meaningful evidence synthesis, and facilitate clinical translation in neurocritical care. Core Outcome Measures in Effectiveness Trials (COMET) Initiative, registration number 2320.
中文摘要:针对急性脑损伤(ABI)患者机械通气撤机的临床研究结局指标差异很大,限制了证据整合。目标是建立国际认可的核心结局集(COS)以及神经重症通气试验的分层复合终点。按照COS-STAD/COS-STAP标准,开展4轮国际Delphi研究。通过范围综述识别候选结局。来自31个国家的多学科专家组采用9分GRADE量表对结局评分。纳入标准为超过70%的评分者评为「关键」(7–9分),且不超过15%评为「不重要」(1–3分)。举行两次共识会议,对结局分类、选择代表性测量指标并批准分层复合终点。第1轮有78名利益相关者参与;60名完成全部轮次(脱落率23.1%)。54个结局达到Delphi共识。第1次共识会议将其归入16个类别;每个类别选择评分最高的结局。3个结局未获批准,原因分别为疾病特异性(NIH卒中量表)或缺乏普遍适用性(脑死亡、无昏迷天数)。最终COS包含5个域的13个结局:呼吸功能、生存、并发症、功能状态和生活质量。第2次共识会议批准三级分层复合终点:(1)重症监护病房生存;(2)72小时内无再插管;(3)无机械通气存活天数。本研究建立了首个用于ABI患者通气撤机试验的COS。广泛采用这13个结局和分层复合终点将规范报告、支持有意义的证据整合,并促进神经重症的临床转化。Core Outcome Measures in Effectiveness Trials(COMET)倡议注册号2320。
JAMA network open IF 11.7 2026-11-02 PMID: 42975900
Traumatic brain injury (TBI) is highly prevalent in older adults. While there is strong and growing evidence that TBI is associated with caregiver burden and psychological health, it remains unclear whether a spouse's TBI is associated with the long-term health of the uninjured partner. To evaluate whether having a spouse who sustains an incident TBI is associated with risk of mortality, dementia, and major adverse cardiovascular events (MACE) and to assess whether associations differ by sex or survival of the injured spouse after TBI. This prospective community-based cohort of married couples was performed at 4 US centers in North Carolina, Mississippi, Minnesota, and Maryland as part of the Atherosclerosis Risk in Communities (ARIC) Study. Of 4506 baseline spousal pairs, 3281 were retained for mortality and dementia analyses and 2740 of these for MACE analyses. Participants contributed person-time from baseline (1987-1989) until incident outcome, death, loss to follow-up, divorce or separation, or administrative censoring on December 31, 2022. Analyses were conducted from November 24, 2025, through August 25, 2026. Incident spousal TBI (ascertained using self-report, hospitalization surveillance, and linked Centers for Medicare & Medicaid Services data), modeled as a 2-category time-varying exposure (spousal TBI vs no spousal TBI) and 4-category exposure incorporating spousal death. Incident all-cause mortality, dementia, and MACE. Cox proportional hazards regression shared frailty models were used to estimate associations adjusted for demographic, clinical, and behavioral characteristics. Among 3281 married pairs included in mortality and dementia analyses (among whom, 2740 pairs were included in MACE analyses), the mean (SD) age at baseline was 54.5 (5.5) years, with 3281 female and 3281 male spouses (for a total of 6562 participants). The median follow-up was 19.5 (IQR, 10.6-29.0) years. Spousal TBI was associated with increased risk of mortality (hazard ratio [HR], 1.24 [95% CI, 1.07-1.43]; P = .004) but not dementia (HR, 1.17 [95% CI, 0.88-1.56]; P = .28) or MACE (HR, 1.15 [95% CI, 0.84-1.57]; P = .40). In sex-stratified analyses, associations were similar among males and females. In models incorporating spousal death, mortality risk was higher among individuals whose spouse was alive with a TBI (HR, 1.22 [95% CI, 1.05-1.41]; P = .008), higher among those whose spouse was deceased without a TBI (HR, 1.48 [95% CI, 1.36-1.61]; P < .001), and higher among those whose spouse was deceased with a TBI (HR, 1.27 [95% CI, 1.07-1.52]; P = .006) compared with those whose spouse was alive without a TBI. Results were similar, but less precise, for dementia and MACE. In this cohort study of married pairs of participants in the ARIC Study, having a spouse who sustained a TBI was associated with a modest but significantly higher risk of mortality in the uninjured partner, whereas findings for dementia and major adverse cardiovascular events were less consistent. These findings suggest that the consequences of TBI may extend beyond injured individuals and support family- and care partner-centered approaches to care.
中文摘要:创伤性脑损伤(TBI)在老年人中很常见。已有较强且不断增加的证据显示TBI与照护者负担及心理健康相关,但配偶发生TBI是否与未受伤伴侣的长期健康相关仍不清楚。研究旨在评估配偶发生新发TBI是否与死亡、痴呆及主要不良心血管事件(MACE)风险相关,并考察这种关联是否因性别或受伤配偶TBI后存活情况而不同。该前瞻性社区队列纳入已婚夫妇,在美国北卡罗来纳州、密西西比州、明尼苏达州和马里兰州的4个中心开展,属于社区动脉粥样硬化风险(ARIC)研究的一部分。4506对基线配偶中,3281对纳入死亡和痴呆分析,其中2740对纳入MACE分析。参与者从基线(1987—1989年)贡献人时,直至发生结局、死亡、失访、离婚或分居,或2022年12月31日行政删失。分析时间为2025年11月24日至2026年8月25日。配偶新发TBI通过自我报告、住院监测及链接的医疗保险和医疗补助服务中心数据确认,分别按二分类时变暴露(配偶TBI对无配偶TBI)和纳入配偶死亡的4分类暴露建模。结局为新发全因死亡、痴呆和MACE。采用Cox比例风险回归共享脆弱模型估计关联,并校正人口学、临床和行为特征。纳入死亡和痴呆分析的3281对已婚夫妇(其中2740对纳入MACE分析)基线平均(SD)年龄为54.5(5.5)岁,包括3281名女性配偶和3281名男性配偶(共6562名参与者)。中位随访为19.5(IQR,10.6—29.0)年。配偶TBI与死亡风险升高相关(HR,1.24[95%CI,1.07—1.43];P=.004),但与痴呆(HR,1.17[95%CI,0.88—1.56];P=.28)或MACE(HR,1.15[95%CI,0.84—1.57];P=.40)无关。按性别分层分析中,男性和女性的关联相似。在纳入配偶死亡的模型中,与配偶存活且无TBI者相比,配偶存活但有TBI者死亡风险更高(HR,1.22[95%CI,1.05—1.41];P=.008),配偶死亡且无TBI者更高(HR,1.48[95%CI,1.36—1.61];P<.001),配偶死亡且有TBI者亦更高(HR,1.27[95%CI,1.07—1.52];P=.006)。痴呆和MACE的结果相似但精度较低。在这项ARIC研究已婚夫妇队列中,配偶发生TBI与未受伤伴侣死亡风险轻度但显著升高相关,而痴呆和主要不良心血管事件的结果较不一致。这些发现提示TBI的影响可能超出受伤个体本身,并支持以家庭和照护伙伴为中心的照护方式。

基础研究 (8篇)

Science advances IF 13.9 2026-11-06 PMID: 42981421
The diagnosis of traumatic brain injury (TBI) remains heavily constrained by the limitations of conventional imaging techniques in visualizing the pathological events that determine the disease progression and outcome. To address this clinical challenge, we report a manganese-doped near-infrared quantum dot (QD) to intrinsically integrate the highly sensitive optical imaging with clinical compatible magnetic resonance imaging (MRI). Taking the advantages of optical imaging powered by whole-brain clearing and cellular resolution three-dimensional (3D) panoptic imaging, in combination with the systematic in vitro cell studies on different types of cells involved in TBI, we disclosed the interpretable pathology reflected by TBI imaging through the highly sensitive fluorescence of magnetic QDs, i.e., after systemic administration, the nanoprobes were extravasated through the compromised blood-brain barrier and then selectively phagocytosed by activated microglia, which subsequently migrated into the regions rich in dead neurons and neuronal debris. This microglia-mediated tropism decodes the signal origin of MRI enhanced by the nanometer-sized contrast agent, thereby transforming the MRI from an anatomical tool into a pathological reporter. A biocompatible Fe3O4 nanoparticle of similar size was also compared with the magnetic QD mentioned above for validating the translational merits of nanoparticles in MRI diagnosis of TBI.
中文摘要:创伤性脑损伤(TBI)的诊断仍受制于常规影像技术难以显示决定疾病进展和结局的病理事件。为应对这一临床难题,我们报道了一种锰掺杂近红外量子点(QD),将高灵敏光学成像与临床兼容的磁共振成像(MRI)内在整合。借助全脑透明化与细胞分辨率三维全景成像支持的光学成像,结合对TBI涉及的不同类型细胞开展的系统体外细胞研究,我们通过磁性QD的高灵敏荧光揭示了TBI成像所反映的可解释病理,即全身给药后,纳米探针经受损血脑屏障外渗,随后被激活的小胶质细胞选择性吞噬,并迁移至富含死亡神经元和神经元碎片的区域。这种由小胶质细胞介导的趋向性解码了纳米级对比剂增强MRI的信号来源,使MRI从解剖工具转变为病理报告工具。研究还将尺寸相近的生物相容性Fe3O4纳米颗粒与上述磁性QD进行比较,以验证纳米颗粒在TBI的MRI诊断中的转化价值。
Redox biology IF 16.2 2026-11 PMID: 42822390
Traumatic brain injury (TBI) is a leading cause of mortality and morbidity and a major contributor to loss of working capacity in young adults. Current therapeutic options for TBI remain limited. This study aimed to assess the potential role and therapeutic value of ubiquitin-specific protease 18 (USP18) in TBI. A TBI model was established using the weight-drop model. Neuron-specific Usp18 knockout on the C57BL/6J background was generated by crossbreeding Usp18f/f and Thy1-Cre mice. A recombinant adeno-associated virus serotype 9 carrying Usp18 under control of the hSyn promoter was injected into wild-type mice. Mechanical stretch injury-exposed HT22 cells subjected to a well-established stretch injury model were used to simulate TBI in vitro. The underlying molecular mechanism was explored through bulk-RNA sequencing, immunoprecipitation and mass spectrometry (MS) analysis, RNA immunoprecipitation sequencing, and RNA immunoprecipitation assays. Multi-omics analysis of mouse brain and RNA-seq profiling of human brain tissues indicated that the expression of the deubiquitinating enzyme USP18 was substantially decreased in hippocampal neurons. Neuron-specific overexpression of Usp18 via recombinant adeno-associated virus 9 (AAV9) led to reduced neuronal apoptosis and improved cognitive performance in mice. The RNA-seq analysis revealed that Usp18 overexpression enhanced the homeostasis of mitochondrial dynamics, ameliorated neuronal mitochondrial dysfunction, and suppressed oxidative stress injury. These results were also confirmed in a well-established mechanical stretch injury model in HT22 cells. Moreover, compared with control mice, neuron-specific Usp18 knockout mice displayed more severe mitochondrial morphological disarray and neuronal damage after TBI. RNA sequencing, MS analysis, RNA immunoprecipitation sequencing, and RNA immunoprecipitation assays mechanistically revealed that USP18 directly interacted with DEAD-box helicase 5 (DDX5) and deubiquitinated and stabilized DDX5 at the K470 residue (via K48-linked ubiquitination) to increase the stability of the Opa1 mRNA, thereby impeding mitochondrial morphofunctional defects. Collectively, the results of this study reveal the protective effect of and molecular mechanism regulating USP18 in TBI pathology and reveal a novel neuron-specific USP18-DDX5-OPA1 axis involved in TBI. We identified a USP18-promoted mechanism that maintains the homeostasis of mitochondrial dynamics through the DDX5-OPA1 axis in a TBI model; this pathway inhibits neuronal apoptosis and improves cognitive function in mice, suggesting that USP18 activation or AAV9-Usp18 delivery represents a potential therapeutic strategy for TBI.
中文摘要:创伤性脑损伤是死亡和疾病负担的重要原因,也是年轻成年人丧失工作能力的主要因素,现有治疗选择仍有限。本研究旨在评估泛素特异性蛋白酶18在创伤性脑损伤中的潜在作用与治疗价值。研究采用重量坠落模型建立创伤性脑损伤模型,通过将Usp18f/f小鼠与Thy1-Cre小鼠杂交,在C57BL/6J背景上构建神经元特异性Usp18敲除小鼠;将携带hSyn启动子调控Usp18的重组腺相关病毒血清型9注射到野生型小鼠体内。体外采用经历机械牵张损伤的HT22细胞模拟创伤性脑损伤。通过批量RNA测序、免疫沉淀与质谱分析、RNA免疫沉淀测序以及RNA免疫沉淀实验探讨分子机制。小鼠脑多组学分析与人脑组织RNA测序谱显示,去泛素化酶USP18在海马神经元中的表达显著降低。经重组腺相关病毒9实现神经元特异性Usp18过表达后,小鼠神经元凋亡减少,认知表现改善。RNA测序分析显示,Usp18过表达增强线粒体动力学稳态,改善神经元线粒体功能障碍,并抑制氧化应激损伤;这些结果在成熟的HT22细胞机械牵张损伤模型中得到验证。与对照小鼠相比,神经元特异性Usp18敲除小鼠在创伤性脑损伤后表现出更严重的线粒体形态紊乱和神经元损伤。RNA测序、质谱分析、RNA免疫沉淀测序和RNA免疫沉淀实验从机制上显示,USP18直接与DEAD-box解旋酶5相互作用,在K470位点通过K48连接泛素化对DDX5去泛素化并稳定DDX5,从而提高Opa1 mRNA稳定性,阻止线粒体形态与功能缺陷。总体而言,本研究揭示了USP18在创伤性脑损伤病理中的保护作用及其分子调控机制,并发现参与创伤性脑损伤的神经元特异性USP18-DDX5-OPA1轴。研究识别出USP18通过DDX5-OPA1轴维持线粒体动力学稳态的机制;该通路抑制小鼠神经元凋亡并改善认知功能,提示激活USP18或递送AAV9-Usp18可能成为创伤性脑损伤的潜在治疗策略。
Nature neuroscience IF 20.3 2026-11 PMID: 42768215
Traumatic brain injury (TBI) accelerates bone healing and induces heterotopic ossification, raising the question of whether an injured brain benefits from bone. Here we reveal that dynamic compressive tibial axial loading (DCTAL), a model of tibial bone compression, increased survival and promoted motor and cognitive recovery after stroke and TBI in mice, as well as in pig TBI models. DCTAL reduced neuron loss, attenuated chronic inflammation and astrogliosis and stimulated neuronal regeneration after TBI. Deletion of the mechanosensory channel Piezo1 in osteocytes reversed these benefits, while serum from DCTAL mice recapitulated them. Osteocytes transduced mechanical signals to directly secrete factors such as IL-1R2, APOL11a and HSP70, while indirectly increasing serum levels of BDNF, PF4 and dopamine. These factors synergistically protected against TBI. Altogether, we establish a bone-brain axis in which bone endocrine function can be modulated by mechanical forces to enhance brain repair after injury.
中文摘要:创伤性脑损伤(TBI)会加速骨愈合并诱发异位骨化,由此引出一个问题:受伤的脑是否也能从骨获益。本研究发现,动态胫骨轴向加压负荷(DCTAL)这一胫骨受压模型可提高卒中和TBI小鼠的存活率,并促进其运动与认知功能恢复,在猪TBI模型中同样有效。DCTAL减少神经元丢失、减轻慢性炎症与星形胶质细胞增生,并促进TBI后的神经元再生。在骨细胞中敲除机械感受通道Piezo1可逆转上述获益,而来自DCTAL小鼠的血清能够重现这些效应。骨细胞将机械信号转导为直接分泌IL-1R2、APOL11a和HSP70等因子,同时间接提高血清中BDNF、PF4和多巴胺水平。这些因子协同发挥对TBI的保护作用。由此确立了一条骨—脑轴:骨的內分泌功能可被机械力调控,从而增强损伤后的脑修复。
Redox biology IF 16.2 2026-11 PMID: 42767162
Traumatic brain injury (TBI) is a leading cause of disability and mortality, with secondary injury mechanisms involving neuronal death and neuroinflammation, for which effective treatments remain limited. Neutrophil extracellular traps (NETs) are implicated in post-TBI neuropathology. Cuproptosis, a copper-dependent cell death pathway characterized by mitochondrial oxidative stress, dysfunction, and disrupted dynamics, has recently been implicated in neurological disorders. This study aims to investigate whether NETs exacerbate secondary brain injury by promoting neuronal cuproptosis after TBI and to elucidate the underlying molecular mechanism. We observed elevated NET levels in brain tissues from both TBI patients and mice, which correlated with poor prognosis. Single-cell RNA sequencing revealed a significant upregulation of transthyretin (Ttr) in neurons post-TBI. Mechanistically, NETs deliver lactylated S100a9 (S100a9K26la), a glycolysis-dependent lactylated protein, to neurons. S100a9K26la translocates to the nucleus and promotes Ttr transcription. Increased neuronal Ttr protein then competes with ATPase copper transporting β (Atp7b) for binding to copper metabolism MURR1 domain-containing 1 (Commd1) at the W123 residue. This competition disrupts the Commd1-Atp7b interaction, impairing copper efflux and leading to intracellular copper accumulation, mitochondrial oxidative stress, aggregation of DLAT, loss of Fe-S cluster proteins, and ultimately neuronal cuproptosis. Neuron-specific Ttr conditional knockout ameliorated neuronal death, neuroinflammation, blood-brain barrier (BBB) disruption, and neurological deficits in a TBI model. Conversely, inhibition of cuproptosis with the copper chelator tetrathiomolybdate (TTM) yielded similar protective effects. In summary, our findings elucidate a novel pathway wherein NETs, via delivery of S100a9K26la, drive neuronal Ttr overexpression. Ttr disrupts copper homeostasis by interfering with the Commd1-Atp7b axis, ultimately triggering neuronal cuproptosis and exacerbating secondary injury after TBI. This study identifies NETosis and the Ttr/Commd1/Atp7b axis as potential therapeutic targets for mitigating TBI-induced damage.
中文摘要:创伤性脑损伤(TBI)是导致残疾和死亡的主要原因之一,继发性损伤机制涉及神经元死亡和神经炎症,有效治疗仍有限。中性粒细胞胞外诱捕网(NETs)与TBI后的神经病理过程有关。铜死亡是一种铜依赖性细胞死亡途径,以线粒体氧化应激、功能障碍和动力学紊乱为特征,近期被认为与神经系统疾病相关。本研究旨在探讨NETs是否通过促进TBI后神经元铜死亡而加重继发性脑损伤,并阐明其分子机制。我们观察到TBI患者和小鼠脑组织中NET水平升高,且与不良预后相关。单细胞RNA测序显示TBI后神经元中转甲状腺素蛋白(Ttr)显著上调。机制上,NETs将糖酵解依赖的乳酰化蛋白S100a9K26la递送至神经元。S100a9K26la转位至细胞核并促进Ttr转录。神经元Ttr蛋白增多后,在W123残基处与铜代谢MURR1结构域蛋白1(Commd1)竞争结合ATP酶铜转运β(Atp7b)。这种竞争破坏Commd1-Atp7b相互作用,损害铜外排,导致细胞内铜蓄积、线粒体氧化应激、DLAT聚集、Fe-S簇蛋白丢失,最终引发神经元铜死亡。神经元特异性Ttr条件性敲除可改善TBI模型中的神经元死亡、神经炎症、血脑屏障(BBB)破坏和神经功能缺损。相反,使用铜螯合剂四硫钼酸盐(TTM)抑制铜死亡也产生类似保护作用。上述结果揭示了一条新通路:NETs通过递送S100a9K26la驱动神经元Ttr过表达,Ttr干扰Commd1-Atp7b轴而破坏铜稳态,最终触发神经元铜死亡并加重TBI后的继发性损伤。这些发现将NETosis及Ttr/Commd1/Atp7b轴确定为减轻TBI所致损伤的潜在治疗靶点。
Stroke IF 11.1 2026-11 PMID: 42751786
Metabolic and neurovascular disturbances contribute to brain injury after birth asphyxia. We previously showed that plasma feeding attenuated neuropathology after transient umbilical cord occlusion in piglets. This study explored the metabolic and molecular consequences of birth asphyxia and whether plasma feeding preserves metabolic homeostasis and brain barrier integrity. Piglets (n=89) delivered by cesarean section on gestational day 113 underwent umbilical cord occlusion (asphyxia [ASP]) or remained nonasphyxiated (control [CON]). ASP and CON piglets were randomly assigned to receive formula reconstituted with either water (vehicle-treated group) or sow plasma (plasma-treated group). Animals were euthanized at 1 hour, 24 hours, or day 4 after insult. Cerebrospinal fluid metabolites were profiled by untargeted liquid chromatography-mass spectrometry metabolomics at 24 hours. Expression of metabolite transporters and structural components of the blood-brain barrier in the caudate nucleus and the blood-cerebrospinal fluid barrier at the choroid plexus was assessed by reverse transcription quantitative polymerase chain reaction and Western blotting. The CSF/plasma Na+ ratio was assessed, and cell-specific AQP4 expression was confirmed with RNAscope. Data were analyzed using linear and linear mixed-effects models. Birth asphyxia dysregulated the CSF metabolic profile, with reductions in multiple metabolites and increases in a smaller subset, consistent with impaired amino acid and lipid metabolism. This was accompanied by reduced expression of substrate transporters, including xCT, LAT1, ASCT2, FATP1, CAV1, and MCTs. In the caudate nucleus, expression of blood-brain barrier structural proteins and ion transporters, including Na+/K+-ATPase, was reduced, whereas the choroid plexus blood-CSF barrier remained largely preserved. Plasma feeding partially restored transporter expression at both brain interfaces and increased AQP4 and ion transporter expression at the blood-brain barrier by day 4. Increased VE-cadherin (vascular endothelial cadherin) and ZO-1 (zonula occludens-1) expression and elevated CSF Na+ concentrations suggested early modulation of the integrity of the 2 brain barriers. Plasma feeding preserves metabolic homeostasis and supports brain barrier integrity after birth asphyxia, highlighting plasma-derived factors as potential therapeutic targets to reduce neurodevelopmental impairment after perinatal asphyxia.
中文摘要:代谢和神经血管紊乱参与出生窒息后的脑损伤。我们此前发现,血浆喂养可减轻仔猪短暂脐带闭塞后的神经病理改变。本研究探讨出生窒息的代谢和分子后果,以及血浆喂养能否维持代谢稳态和脑屏障完整性。妊娠第113天经剖宫产分娩的仔猪(n=89)接受脐带闭塞(窒息[ASP])或保持非窒息(对照[CON])。ASP和CON仔猪随机接受用水(溶剂处理组)或母猪血浆(血浆处理组)复溶的配方奶。动物在损伤后1小时、24小时或第4天安乐死。24小时时用非靶向液相色谱-质谱代谢组学分析脑脊液代谢物。用逆转录定量聚合酶链反应和Western blotting评估尾状核血脑屏障及脉络丛血-脑脊液屏障的代谢物转运体和结构成分表达。检测脑脊液/血浆Na+比值,并用RNAscope确认细胞特异性AQP4表达。数据采用线性和线性混合效应模型分析。出生窒息使脑脊液代谢谱失调,多种代谢物减少、少部分代谢物增加,符合氨基酸和脂质代谢受损。伴随底物转运体表达降低,包括xCT、LAT1、ASCT2、FATP1、CAV1和MCTs。尾状核中血脑屏障结构蛋白和离子转运体表达降低,包括Na+/K+-ATPase,而脉络丛血-脑脊液屏障基本保持完整。血浆喂养部分恢复两种脑屏障界面的转运体表达,并在第4天增加血脑屏障AQP4和离子转运体表达。VE-cadherin和ZO-1表达升高及脑脊液Na+浓度升高,提示两种脑屏障完整性受到早期调节。血浆喂养可维持出生窒息后的代谢稳态并支持脑屏障完整性,提示血浆来源因子是减少围产期窒息后神经发育损害的可能治疗靶点。
Ageing research reviews IF 15.5 2026-11 PMID: 42660464
Traumatic brain injury (TBI) is a major cause of mortality and persistent neurological disability and is increasingly recognized as a potential contributor to accelerated brain aging and long-term neurodegenerative processes. Beyond the immediate mechanical insult, TBI initiates dynamic secondary injury cascades involving chronic neuroinflammation, oxidative stress, mitochondrial dysfunction, synaptic and axonal degeneration, metabolic disturbances, and blood-brain barrier disruption. The persistence and temporal evolution of these molecular alterations may interact with intrinsic aging mechanisms, contributing to progressive neuronal dysfunction and increased vulnerability to age-associated neurodegenerative disorders. The marked biological and temporal heterogeneity of TBI therefore presents major challenges for conventional diagnostic, prognostic, and therapeutic approaches. Recent advances in multi-omics technologies, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, and single-cell and spatial approaches, offer unprecedented opportunities to characterize the molecular trajectories linking TBI, brain aging, and neurodegeneration. Integrative multi-omics frameworks, coupled with network biology, artificial intelligence, machine learning, and causal inference, enable the identification of molecular signatures, age-related regulatory networks, clinically relevant biomarkers, and therapeutically actionable targets. This review synthesizes emerging multi-omics insights into the molecular mechanisms through which TBI may influence brain aging and neurodegenerative progression, with particular emphasis on phase-specific molecular signatures, biomarker discovery, patient stratification, therapeutic target prioritization, and precision neurotherapeutics. We further discuss longitudinal profiling, single-cell and spatial approaches, and AI-assisted modeling for patient stratification and therapeutic optimization. Integrating multi-omics with systems biology may provide a framework for studying TBI-associated brain aging and developing personalized interventions, although prospective clinical validation remains essential.
中文摘要:创伤性脑损伤(TBI)是死亡和持续性神经功能障碍的主要原因,并日益被视为加速脑老化及长期神经退行性过程的潜在促进因素。除即刻机械性损伤外,TBI还启动动态的继发性损伤级联,涉及慢性神经炎症、氧化应激、线粒体功能障碍、突触与轴突变性、代谢紊乱及血脑屏障破坏。这些分子改变的持续存在和时间演变可能与内在衰老机制相互作用,促成进行性神经元功能障碍,并增加对年龄相关神经退行性疾病的易感性。TBI显著的生物学与时间异质性因此给传统诊断、预后和治疗策略带来重大挑战。多组学技术的最新进展,包括基因组学、表观基因组学、转录组学、蛋白质组学、代谢组学、脂质组学以及单细胞和空间方法,为刻画连接TBI、脑老化与神经退行性变的分子轨迹提供了前所未有的机会。整合多组学框架,结合网络生物学、人工智能、机器学习和因果推断,能够识别分子特征、年龄相关调控网络、具有临床相关性的生物标志物及可成药靶点。该综述综合新近多组学见解,阐述TBI可能影响脑老化与神经退行性进展的分子机制,重点关注分期特异性分子特征、生物标志物发现、患者分层、治疗靶点优先级排序及精准神经治疗。讨论还涵盖纵向分析、单细胞与空间方法以及人工智能辅助建模在患者分层和治疗优化中的应用。将多组学与系统生物学整合,可能为研究TBI相关脑老化及开发个体化干预提供框架,但前瞻性临床验证仍不可或缺。
Autophagy IF 18.6 2026-11 PMID: 42323821
Traumatic brain injury (TBI) remains a leading cause of neurological morbidity and mortality, characterized by complex pathophysiological cascades. Here, we investigate the role of the transcription factor EGR1 (early growth response 1) in modulating mitochondrial homeostasis via the HIF1A (hypoxia inducible factor 1, alpha subunit)-BNIP3 (BCL2/adenovirus E1B interacting protein 3) axis following TBI. Using integrated transcriptomic and epigenomic analyses, we identified EGR1 as a critical regulator of TBI pathology, with its expression acutely upregulated in neurons post-injury. Genetic ablation of Egr1 in mice significantly reduced neuronal apoptosis, preserved dendritic integrity, and ameliorated cognitive and sensorimotor deficits. Mechanistically, chromatin immunoprecipitation and luciferase assays revealed that EGR1 directly binds to the Hif1a promoter, repressing its transcription. Loss of EGR1 enhanced HIF1A-BNIP3-mediated mitophagy, reducing mitochondrial dysfunction and oxidative stress both in vitro and in vivo. Conversely, silencing HIF1A or BNIP3 abrogated the neuroprotective effects of EGR1 deficiency. These findings establish a novel EGR1-HIF1A-mitophagy signaling axis as a key determinant of TBI outcomes, highlighting EGR1 as a potential therapeutic target.Abbreviations: AAV: adeno-associated virus; ACTB/β-actin: actin, beta; AIF1/IBA1: allograft inflammatory factor 1; BAF: bafilomycin A1; BNIP3: BCL2/adenovirus E1B interacting protein 3; CCI: controlled cortical impact; COX8: cytochrome c oxidase subunit 8; CUT&Tag: cleavage under targets and tagmentation; DAPI: 4,'6-diamidino-2-phenylindole; DEGs: differentially expressed genes; eGFP: enhanced green fluorescent protein; EGR1: early growth response 1; GFAP: glial fibrillary acidic protein; GO: gene ontology; GSEA: gene set enrichment analysis; HCQ: hydroxychloroquine; HIF1A/HIF-1α: hypoxia inducible factor 1, alpha subunit; IGV: integrative genomics viewer; KEGG: Kyoto encyclopedia of genes and genomes; KO: knockout; LAMP1: lysosomal-associated membrane protein 1; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; Lv: lentivirus; MAP2: microtubule-associated protein 2; mCherry: monomeric cherry fluorescent protein; mRFP: monomeric red fluorescent protein; MTOR: mechanistic target of rapamycin kinase; MUT: mutant; MWM: Morris water maze; NAB1: Ngfi-A binding protein 1; NAB2: Ngfi-A binding protein 2; RBFOX3/NeuN: RNA binding protein, fox-1 homolog (C. elegans) 3; OGD: oxygen-glucose deprivation; OLIG2: oligodendrocyte transcription factor 2; PBS: phosphate-buffered saline; PECAM1/CD31: platelet/endothelial cell adhesion molecule 1; PFA: paraformaldehyde; PPI: protein-protein interaction; Puro: puromycin; ROI: region of interest; ROS: reactive oxygen species; SEM: standard error of the mean; SQSTM1/p62: sequestosome 1; TBI: traumatic brain injury; TOMM20: translocase of outer mitochondrial membrane 20; TSA: tyramide signal amplification; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling; VDAC1: voltage-dependent anion channel 1; WT: wild-type.
中文摘要:创伤性脑损伤(TBI)仍是神经病学致残和死亡的主要原因,具有复杂的病理生理级联反应。本研究探讨转录因子EGR1通过HIF1A-BNIP3轴调控TBI后线粒体稳态的作用。整合转录组与表观基因组分析显示,EGR1是TBI病理的关键调控因子,损伤后神经元中其表达急性上调。小鼠Egr1基因敲除显著减少神经元凋亡,保留树突完整性,并改善认知与感觉运动缺陷。染色质免疫沉淀和荧光素酶实验表明,EGR1直接结合Hif1a启动子并抑制其转录。EGR1缺失增强HIF1A-BNIP3介导的线粒体自噬,减轻体外和体内线粒体功能障碍与氧化应激。沉默HIF1A或BNIP3则取消EGR1缺失带来的神经保护作用。这些发现确立EGR1-HIF1A-线粒体自噬信号轴是TBI结局的关键决定因素,并提示EGR1可作为潜在治疗靶点。
Nature chemical biology IF 15.8 2026-11 PMID: 41735605
The lack of organelle-targeted neurotransmitter probes limits understanding of their intracellular roles. Here we created an organelle-targeted neurotransmitter nanoprobe using specific molecule-trapped DNA nanostructures for multiple recognition effects. In particular, we designed phenylboronic acid derivatives for chemical reaction and hydroxymethyl groups for forming hydrogen bonding with norepinephrine (NE), which were confined into tetrahedral DNA nanostructures with the optimized spatial effects, achieving the specific and rapid NE identification. Moreover, cyanine 3 providing built-in correction was designed for accurate NE quantification and the HaloTag ligand was synthesized for HaloTag protein targeting onto the organelle membrane, which were bonded to tips of the DNA nanostructure. The developed nanotrap demonstrated high selectivity, fast response (~50 ms), good stability and biocompatibility for organelle NE imaging. Using this tool, we discovered that traumatic brain injury triggers NE bursts in the endoplasmic reticulum, inducing endoplasmic reticulum (ER) stress, altering ER-mitochondrial protein regulation, promoting mitophagy and mitochondrial dysfunction and ultimately causing neuronal death.
中文摘要:缺少靶向细胞器的神经递质探针,限制了对这些递质在细胞内作用的理解。我们构建了一种靶向细胞器的神经递质纳米探针,利用特定分子捕获型DNA纳米结构实现多重识别效应。具体而言,我们设计了苯硼酸衍生物用于化学反应,并设计羟甲基用于与去甲肾上腺素(NE)形成氢键,将这些基团限制在具有优化空间效应的四面体DNA纳米结构中,从而实现对NE的特异、快速识别。我们还设计了可提供内置校正的花菁3用于NE准确定量,并合成了HaloTag配体用于将HaloTag蛋白靶向到细胞器膜上,这些元件连接在DNA纳米结构的末端。所开发的纳米陷阱对细胞器NE成像表现出高选择性、快速响应(约50 ms)、良好稳定性和生物相容性。利用该工具,我们发现创伤性脑损伤会触发内质网中的NE爆发,诱导内质网应激,改变内质网-线粒体蛋白调控,促进线粒体自噬和线粒体功能障碍,最终导致神经元死亡。

6癫痫 (8篇)

临床研究 (5篇)

Neurology and therapy IF 4.7 2026-11-03 PMID: 42975768
To evaluate adjunctive cenobamate efficacy by focal seizure subtype during the open-label extension (OLE) of a phase 3 randomized, double-blind, placebo-controlled study (C035) in Asian patients with focal seizures. Patients aged 18-70 years old with uncontrolled focal seizures despite treatment with 1-3 antiseizure medications who completed the double-blind study (n = 425) could enter the 52-week OLE, comprising a 20-week blinded conversion from placebo or 100, 200, or 400 mg/day cenobamate to a target cenobamate dose of 400 mg/day before entering a 32-week open-label maintenance phase at 300 mg/day. Percent change from double-blind baseline in 28-day seizure frequency and responder rates (e.g., ≥ 50% reduction from baseline) for focal preserved consciousness with observable manifestations (FPC), focal impaired consciousness (FIC), or focal to bilateral tonic-clonic (FBTC) seizure subtypes were assessed in the open-label maintenance phase efficacy population (OLE-EM, ≥ 1 dose of study drug and any seizure data during the open-label maintenance phase). Safety and tolerability were assessed. Among patients who entered the OLE, 357/410 (263 originally randomized to cenobamate; 94 who converted from placebo to cenobamate) were included in the OLE-EM population. Median percent seizure frequency reductions were 84.5% for FPC (n = 65), 83.0% for FIC (n = 301), and 100% for FBTC (n = 94) in the OLE-EM population. For FPC, FIC, and FBTC subtypes, ≥ 50% responder rates were 75.4%, 73.8%, and 84.0%, respectively, and 100% responder rates were 23.1%, 28.2%, and 58.5%. Among patients entering the OLE, 84.6% (347/410) completed the 52 weeks of treatment with cenobamate. The most common treatment-emergent adverse events were dizziness, somnolence, gamma-glutamyl transferase increased, and COVID-19 infection. During the C035 OLE maintenance phase, high seizure frequency reductions were seen for FPC, FIC, and FBTC focal seizure subtypes. Cenobamate was generally well tolerated, and the results were consistent with the double-blind treatment study. Graphical abstract available for this article. NCT04557085 (registered September 14, 2020).
中文摘要:评估在亚洲局灶性癫痫患者中开展的3期随机双盲安慰剂对照研究(C035)开放标签扩展(OLE)期间,辅助性cenobamate按局灶性发作亚型的疗效。18至70岁、尽管使用1至3种抗癫痫发作药物仍控制不佳的局灶性发作患者,完成双盲研究后可进入52周OLE(n=425);该阶段先经20周盲法将安慰剂或100、200、400 mg/日cenobamate转换为目标剂量400 mg/日,再进入32周开放标签维持期,剂量为300 mg/日。在开放标签维持期疗效人群(OLE-EM,至少接受1剂研究药物且开放标签维持期有任何发作数据)中,评估28天发作频率较双盲基线的百分比变化和应答率(如较基线减少≥50%),并按局灶意识保留伴可观察表现(FPC)、局灶意识受损(FIC)或局灶继发双侧强直-阵挛(FBTC)发作亚型分析。同时评估安全性和耐受性。进入OLE的患者中,357/410例纳入OLE-EM人群,其中263例原随机分配至cenobamate,94例由安慰剂转换为cenobamate。OLE-EM人群中,发作频率中位下降百分比为FPC 84.5%(n=65)、FIC 83.0%(n=301)、FBTC 100%(n=94)。FPC、FIC和FBTC亚型的≥50%应答率分别为75.4%、73.8%和84.0%,100%应答率分别为23.1%、28.2%和58.5%。进入OLE的患者中,84.6%(347/410)完成52周cenobamate治疗。最常见治疗中出现的不良事件为头晕、嗜睡、γ-谷氨酰转移酶升高和COVID-19感染。在C035 OLE维持期,FPC、FIC和FBTC局灶性发作亚型均见发作频率大幅下降。Cenobamate总体耐受性良好,结果与双盲治疗研究一致。本文提供图形摘要。NCT04557085(2020年9月14日注册)。
JAMA neurology IF 23.6 2026-11-02 PMID: 42970304
Despite the profound impact of neonatal and infantile-onset epilepsies on neurodevelopmental outcomes and mortality, consolidated global epidemiological evidence remains lacking. To estimate the global incidence and prevalence of neonatal and infantile-onset epilepsies and epilepsy syndromes and to characterize their associated etiological profiles. PubMed, Embase, Web of Science, and Scopus were searched from inception through December 18, 2025. Population-based observational studies reporting the incidence or prevalence of neonatal and infantile-onset epilepsies or epilepsy syndromes were eligible for inclusion. Two authors independently and in duplicate performed study selection, data extraction, and quality assessment of included studies using the Joanna Briggs Institute Critical Appraisal checklist for prevalence studies. Generalized linear mixed-model random-effects meta-analysis was used to pool the estimates of incidence, prevalence, and etiology. Subgroup meta-analyses were conducted by country, World Health Organization (WHO) region, World Bank income, and diagnostic criteria. Metaregression was used to investigate the association between study-level covariates and pooled incidence estimates of infantile-onset epilepsy syndromes. Cumulative incidence and prevalence of neonatal and infantile-onset epilepsies and epilepsy syndromes. A total of 86 population-based studies from 30 countries across 4 WHO regions were included. The pooled cumulative incidence of infantile-onset epilepsies within the first 2 years of life was 236.0 cases (95% CI, 164.7-338.2; 95% prediction interval [PI], 53.0-1044.3) per 100 000 live births. Among epilepsy syndrome subgroups, developmental and epileptic encephalopathies (DEEs) had the highest incidence at 67.7 cases (95% CI, 42.1-108.9; 95% PI, 7.1-636.1) per 100 000 live births. Infantile epileptic spasms syndrome (IESS) was the most incident DEE, with 31.6 cases (95% CI, 27.5-36.2; 95% PI, 13.7-72.6) per 100 000 live births. Among self-limited epilepsies, self-limited infantile epilepsy had the highest incidence at 13.0 cases (95% CI, 9.2-18.2; 95% PI, 6.4-26.4) per 100 000 live births. Subgroup analyses revealed limited geographical representativeness, with the majority of studies from high-income countries in the European Region. The findings underscore a significant global burden of neonatal and infantile-onset epilepsies, primarily driven by DEEs, specifically IESS. Given substantial between-study heterogeneity, the pooled estimates should be interpreted as broad indicators rather than precise, generalizable rates. Geographic disparities, with a lack of data from the African and Eastern Mediterranean Regions, underscore the need for population-based studies in underrepresented regions and longitudinal research on survival, remission, and functional outcomes.
中文摘要:尽管新生儿和婴儿期起病癫痫对神经发育结局和死亡率造成深远影响,全球合并的流行病学证据仍缺乏。旨在估计新生儿和婴儿期起病癫痫及癫痫综合征的全球发病率和患病率,并描述相关病因构成。检索PubMed、Embase、Web of Science和Scopus,自建库至2025年12月18日。纳入报告新生儿和婴儿期起病癫痫或癫痫综合征发病率或患病率的基于人群的观察性研究。两名作者独立并双人重复完成研究筛选、数据提取,并采用Joanna Briggs Institute患病率研究质量评价清单对纳入研究进行质量评价。采用广义线性混合模型随机效应荟萃分析合并发病率、患病率和病因估计值。按国家、世界卫生组织区域、世界银行收入水平和诊断标准进行亚组荟萃分析。采用元回归探讨研究水平协变量与婴儿期起病癫痫综合征合并发病率估计值之间的关联。累积发病率和患病率为新生儿和婴儿期起病癫痫及癫痫综合征的结局指标。共纳入来自4个WHO区域30个国家的86项基于人群的研究。婴儿期起病癫痫在生后2年内的合并累积发病率为每10万活产236.0例(95%CI 164.7-338.2;95%预测区间[PI] 53.0-1044.3)。癫痫综合征亚组中,发育性及癫痫性脑病(DEEs)发病率最高,为每10万活产67.7例(95%CI 42.1-108.9;95%PI 7.1-636.1)。婴儿癫痫性痉挛综合征(IESS)是发病率最高的DEE,为每10万活产31.6例(95%CI 27.5-36.2;95%PI 13.7-72.6)。自限性癫痫中,自限性婴儿癫痫发病率最高,为每10万活产13.0例(95%CI 9.2-18.2;95%PI 6.4-26.4)。亚组分析显示地理代表性有限,多数研究来自欧洲区域的高收入国家。这些发现强调新生儿和婴儿期起病癫痫具有显著全球负担,主要由DEEs尤其IESS驱动。鉴于研究间异质性较大,合并估计值应被视为总体指示而非精确、可外推的率。非洲区域和东地中海区域数据缺乏所体现的地理差异,提示需要在代表性不足地区开展基于人群的研究,并开展关于生存、缓解和功能结局的纵向研究。
Pharmacological research IF 12.2 2026-11 PMID: 42800573
Gain-of-function variants in SCN8A, which encodes the NaV1.6 sodium channel, lead to epilepsy syndromes ranging from drug-responsive self-limited and intermediate epilepsy to drug-resistant developmental and epileptic encephalopathy (DEE). It is currently unclear why individuals with SCN8A gain-of-function variants show variable responses to sodium channel blockers (SCBs). Here, we compared the clinical characteristics of 173 individuals with 25 different SCN8A gain-of-function variants. We found that individuals with variants altering channel activation gating were more severely affected than those with variants altering inactivation properties: They had an earlier age at onset (3 vs. 5 months, P < 0.0001), higher prevalence of DEE (75% vs. 39%; P < 0.0001), and poorer response to SCBs (20% vs. 69% seizure free; P < 0.0001). We performed pharmacological studies on representative and recurrent variants from each group: two variants (F846S and M1760I) causing hyperpolarizing shifts of the voltage-dependent activation curves, and two variants (G1475R and N1877S) causing depolarizing shifts of the voltage-dependent fast inactivation curves. Phenytoin failed to suppress neuronal firing in neurons expressing activation-related variants, but showed good suppressing effects in neurons expressing inactivation-related variants. In contrast, PRAX-330, a new SCB, which showed much faster binding rates than phenytoin, was effective for both groups of variants by markedly reducing neuronal firing through rapidly and persistently stabilizing NaV1.6 in the inactivated state. Our findings provide new pharmacogenetic insights into the mechanism of drug-resistance in SCN8A related epilepsy and support PRAX-330 and compounds with similar pharmacological properties as promising candidates for targeted therapies.
中文摘要:SCN8A 编码 NaV1.6 钠通道,其功能获得性变异可导致从药物应答良好的自限性和中间型癫痫到药物难治性发育性和癫痫性脑病(DEE)等一系列癫痫综合征。目前尚不清楚为何携带 SCN8A 功能获得性变异的个体对钠通道阻滞剂(SCBs)的反应存在差异。对 173 例携带 25 种不同 SCN8A 功能获得性变异个体的临床特征进行了比较。结果发现,改变通道激活门控的变异个体比改变失活特性的变异个体病情更重:起病年龄更早(3 个月 vs. 5 个月,P < 0.0001),DEE 患病率更高(75% vs. 39%;P < 0.0001),对 SCBs 的反应更差(无发作比例 20% vs. 69%;P < 0.0001)。研究对每组中有代表性和反复出现的变异进行了药理学研究:两个变异(F846S 和 M1760I)导致电压依赖性激活曲线向超极化方向偏移,两个变异(G1475R 和 N1877S)导致电压依赖性快速失活曲线向去极化方向偏移。苯妥英未能抑制表达激活相关变异神经元的放电,但对表达失活相关变异的神经元有良好抑制作用。相比之下,新型 SCB PRAX-330 的结合速率远快于苯妥英,通过快速且持久地将 NaV1.6 稳定在失活状态,显著降低神经元放电,对两组变异均有效。这些发现为 SCN8A 相关癫痫耐药机制提供了新的药物遗传学见解,并支持将 PRAX-330 及具有相似药理学特性的化合物作为靶向治疗的有前景候选。
Annals of neurology IF 7.5 2026-11 PMID: 42638126
Previous longitudinal neuroimaging studies suggest that epilepsy is a progressive disorder. To date, these findings have relied largely on populations from tertiary centers, resulting in ascertainment bias, as severely affected individuals are more likely to be rescanned. We aimed to determine rates of progressive brain atrophy in a prospective, population-based cohort. We analyzed longitudinal magnetic resonance imaging (MRI) data from 116 individuals with epilepsy and 89 age- and sex-matched healthy controls recruited from a prospective, longitudinal, community-based cohort in the United Kingdom. All participants underwent 2 scans 3.5 years apart, regardless of seizure status. We quantified progressive changes in cortical thickness and subcortical volumes using state-of-the-art longitudinal morphometry. People with epilepsy exhibited accelerated but modest global grey matter volume (GMV) loss compared with controls (2.7 vs 2.4 ml/year; p = 0.01). This acceleration was associated with specific phenotypes: focal epilepsy, MRI-identifiable lesions, and ongoing seizures. In contrast, generalized epilepsy and seizure-free periods were associated with more stable global trajectories. Cortical regions identified as vulnerable were characterized by markedly accelerated thinning compared to controls (5.3 vs 3.4 μm/year; p < 0.001) and were pervasive across most epilepsy phenotypes. Epilepsy is associated with progressive structural brain damage that exceeds normal aging, but the trajectory is heterogeneous. These prospective population-based data confirm that vulnerable regions show progressive atrophy, particularly in focal and lesional epilepsy and individuals with ongoing seizures. ANN NEUROL 2026;100:1028-1038.
中文摘要:此前的纵向神经影像研究提示癫痫是一种进展性疾病。迄今这些发现主要来自三级中心人群,存在 ascertainment bias,因为症状较重者更可能接受重复扫描。本研究旨在确定前瞻性人群队列中进展性脑萎缩的发生率。我们分析了来自英国一项前瞻性纵向社区队列的116例癫痫患者和89例年龄、性别匹配的健康对照的纵向磁共振成像数据。所有参与者均间隔3.5年接受2次扫描,不论其发作状态如何。我们采用先进的纵向形态学测量方法定量分析皮层厚度和皮层下体积的进展性变化。与对照相比,癫痫患者表现出加速但幅度不大的全脑灰质体积丢失(2.7 vs 2.4 ml/年;p=0.01)。这种加速与特定表型相关:局灶性癫痫、MRI可识别的病灶以及持续发作。相比之下,全面性癫痫和无发作期与更稳定的全脑变化轨迹相关。被识别为易受损的皮层区域相较对照表现出明显加速的变薄(5.3 vs 3.4 μm/年;p<0.001),且在大多数癫痫表型中普遍存在。癫痫与超出正常衰老的进展性脑结构损害相关,但其轨迹具有异质性。这些前瞻性人群数据证实,易受损区域出现进展性萎缩,尤其在局灶性和病灶性癫痫以及持续发作的个体中更为明显。ANN NEUROL 2026;100:1028-1038。
Molecular psychiatry IF 10.4 2026-10-30 PMID: 42963370
PCDH19-clustering epilepsy (PCDH19-CE) is an infantile-onset neurodevelopmental disorder characterised by clusters of seizures, typically triggered by fever. PCDH19-CE follows an unusual X-linked inheritance pattern whereby heterozygous females, and males with X-chromosome disomy or pathogenic postzygotic mosaic PCDH19 variants, are affected, while hemizygous males are spared. We aggregate published PCDH19 variants and their corresponding PCDH19-CE phenotypes to analyse phenotype-genotype correlations. Data extracted from 110 publications identified 689/735 (94%) individuals with PCDH19 variants and the typical PCDH19-CE phenotype. Three hundred seventy-three unique PCDH19 variants were identified; 195 were not recorded in ClinVar. Seizure onset prior to 12 months of age was associated with more severe intellectual disability (p < 0.001) and the presence of psychiatric morbidity (p = 0.001). There were no phenotypic differences between missense, nonsense, and frameshift variants or between individuals of different geographical backgrounds, which was assessed as a proxy for ancestry. Twenty-nine hemizygous males with constitutive PCDH19 variants did not exhibit the typical PCDH19-CE phenotype, suggesting that the identification of variants in these individuals likely results from chance or ascertainment bias. The correlation between earlier seizure onset and poorer neurodevelopmental outcomes emphasises a critical window for therapeutic intervention. The lack of phenotypic difference between variant types demonstrates that loss of PCDH19 function underpins PCDH19-CE. Moreover, the identification of PCDH19 cytoplasmic domain variants in 78 affected individuals challenges the traditional view that PCDH19-CE is caused primarily by defects in cell-cell adhesion, as variants in this domain are expected to disrupt the nuclear function(s) of PCDH19.
中文摘要:PCDH19簇集性癫痫(PCDH19-CE)是一种婴儿期起病的神经发育障碍,以成簇发作的癫痫为特征,常由发热触发。PCDH19-CE遵循一种不寻常的X连锁遗传模式:杂合女性以及具有X染色体二体或致病性体细胞嵌合PCDH19变异的男性受累,而半合子男性不受累。我们汇总已发表的PCDH19变异及其对应的PCDH19-CE表型,分析表型-基因型相关性。从110篇文献提取的数据识别出689/735(94%)携带PCDH19变异且具有典型PCDH19-CE表型的个体。共发现373个独特PCDH19变异,其中195个未收录于ClinVar。12月龄前起病与更严重的智力障碍(p < 0.001)及精神疾病共病(p = 0.001)相关。错义、无义和移码变异之间,以及不同地域背景个体之间(作为祖先背景的替代指标)未发现表型差异。29例携带构成性PCDH19变异的半合子男性未表现出典型PCDH19-CE表型,提示在这些个体中检出变异可能源于偶然或检出偏倚。起病较早与神经发育结局较差之间的相关性强调了治疗干预的关键窗口期。变异类型之间缺乏表型差异表明PCDH19功能丧失是PCDH19-CE的基础。在78例受累个体中检出PCDH19胞质结构域变异,挑战了PCDH19-CE主要由细胞间黏附缺陷所致的传统观点,因为该结构域的变异预计会破坏PCDH19的核功能。

基础研究 (3篇)

Signal transduction and targeted therapy IF 81.2 2026-11-04 PMID: 42977736
Epilepsy is one of the most prevalent and disabling neurological disorders, affecting >50 million people worldwide. Beyond recurrent seizures, it is strongly associated with cognitive impairment, psychiatric comorbidities, reduced social participation, and a markedly increased risk of premature death. Although considerable advances in neuroimaging, pharmacology, and surgical techniques have expanded therapeutic possibilities, nearly one-third of patients remain refractory to current treatments, a challenge that highlights the pressing need for deeper mechanistic insights and innovative therapeutic strategies. This review provides an integrated overview of recent progress in epilepsy research and treatment. At the molecular level, we examine how ion channel dysfunction, receptor abnormalities, and disrupted signaling pathways drive hyperexcitability. We highlight insights from genetics and acquired etiologies that illuminate disease heterogeneity. We address prevailing hypotheses of drug resistance and potential biomarkers. We also emphasize the growing recognition of epilepsy's close association with diverse comorbidities, where shared molecular pathways not only deepen our understanding of disease mechanisms but also highlight new therapeutic targets. Finally, we evaluate emerging therapeutic directions, including precision pharmacology, neuromodulation, gene and cell therapies, and metabolic approaches such as the ketogenic diet. By bridging epidemiological perspectives with mechanistic discoveries and innovative therapies, this review underscores how advances in epilepsy research are reshaping the path toward precision medicine and improved patient outcomes.
中文摘要:癫痫是最常见且致残性最强的神经系统疾病之一,全球患者超过5000万。除反复发作的痫性发作外,该病还与认知损害、精神共病、社会参与减少以及过早死亡风险显著升高密切相关。神经影像、药理学与外科技术的进步拓展了治疗可能,但仍有近三分之一患者对现有治疗难治,这一难题凸显了深入理解机制与创新治疗策略的迫切需求。本综述对癫痫研究与治疗的最新进展作整体梳理。在分子层面,分析离子通道功能异常、受体异常及信号通路紊乱如何导致神经元高兴奋性;结合遗传学与获得性病因的研究结果,说明疾病的异质性;讨论目前关于药物耐药的主要假说及潜在生物标志物;并关注癫痫与多种共病之间的密切联系,共享的分子通路既加深了对疾病机制的理解,也提示了新的治疗靶点。最后评估新兴治疗方向,包括精准药理、神经调控、基因与细胞治疗,以及生酮饮食等代谢干预。综述将流行病学视角与机制发现、创新疗法相衔接,说明癫痫研究的进展正在重塑通向精准医疗与改善患者结局的路径。
Genes & diseases IF 14.6 2026-11 PMID: 42542576
The pathophysiology of epilepsy remains poorly understood. One of the less explored areas is the role of the lung-brain axis, a sophisticated and intricate bidirectional connection between these two vital organs. Inhaled air pollutants can disrupt lung microbiome homeostasis. This disruption, analogous to gut dysbiosis implicated in neurological conditions, may contribute to epilepsy pathogenesis. Here, we review the existing evidence and theoretical foundations supporting the hypothesis that dysbiosis within the lung microbiota may play a role in the pathophysiology of epilepsy. This includes the links between environmental factors (particularly air pollution) and epilepsy susceptibility; the associations between lung-intrinsic microbiota dysregulation and neurological dysfunction; and the underlying molecular, immunological, and neural mechanisms that enable the lung-brain axis to modulate epileptogenesis. Furthermore, we outline the possible potential pathogenic mechanisms of epilepsy from the perspective of the microbiota-lung-brain axis, offer fresh perspectives on the pathophysiology of epilepsy, and explore potential new research directions related to the lung-brain axis and epilepsy. We propose that a deeper understanding of the function of the lung-brain axis will provide new insights into the etiology, diagnosis, prognosis, and treatment of epilepsy.
中文摘要:癫痫的病理生理机制仍认识不足。肺-脑轴是肺与脑这两个重要器官之间复杂而精细的双向联系,其作用属于较少被探索的领域。吸入的空气污染物可破坏肺微生物组稳态。这种破坏与神经系统疾病中涉及的肠道菌群失调类似,可能参与癫痫的发病过程。本文综述现有证据与理论基础,支持肺微生物群失调可能参与癫痫病理生理的假说,包括环境因素尤其是空气污染与癫痫易感性之间的联系、肺内微生物失调与神经功能障碍之间的关联,以及肺-脑轴调节癫痫发生的分子、免疫和神经机制。文章进一步从微生物-肺-脑轴角度概述癫痫可能的致病机制,提供认识癫痫病理生理的新视角,并探讨肺-脑轴与癫痫相关的新研究方向。作者提出,更深入理解肺-脑轴的功能将为癫痫的病因、诊断、预后和治疗提供新的见解。
Acta pharmacologica Sinica IF 10.4 2026-10-30 PMID: 42957748
Epilepsy is increasingly viewed as a systemic disorder in which recurrent seizures intersect with vascular, autonomic, respiratory, and cardiac processes to influence cardiovascular vulnerability. Seizure-related neuroinflammation involves multiple interacting mediator pathways, including HMGB1/TLR4-RAGE signaling, inflammasome/IL-1β activation, IL-6/IL-6R-gp130 signaling, albumin/TGF-β signaling following blood-brain barrier (BBB) disruption, and tumor necrosis factor-alpha (TNF-α)/TNF receptor (TNFR) signaling. Within this inflammatory network, TNF/TNFR signaling represents a mechanistically distinct and translationally relevant framework for examining how immune activation intersects with endothelial-barrier dysfunction, neurovascular unit injury, autonomic disturbance, inflammatory communication across neural and cardiovascular compartments, and cardiac vulnerability. This review integrates direct evidence from epilepsy studies with mechanistic insights from related experimental studies of BBB injury, myocardial ischemia-reperfusion injury, cardioprotection, and brain-heart communication. TNF biology is determined by ligand form, receptor subtype, cellular compartment, and disease context. Soluble TNF preferentially engages TNFR1-associated inflammatory and injury-amplifying pathways, whereas transmembrane TNF/TNFR2 signaling may support regulatory or reparative responses in selected settings. In epilepsy, seizure-associated inflammation, BBB dysfunction, glial activation, and autonomic imbalance may interact to increase susceptibility to arrhythmogenic stress, myocardial injury, adverse cardiac remodeling, and cardiorespiratory instability relevant to sudden unexpected death in epilepsy (SUDEP). However, epilepsy-specific evidence directly linking TNF/TNFR signaling to cardiovascular outcomes remains limited, and many mechanistic connections currently rely on converging evidence from neurovascular and cardiovascular research. Future studies should integrate compartment-resolved inflammatory profiling with autonomic, respiratory, electrocardiographic, and cardiac phenotyping to distinguish inflammatory signatures of disease severity from modifiable contributors to cardiovascular risk. Such approaches may enable phenotype-specific strategies to better understand and ultimately mitigate the brain-heart consequences of epilepsy.
中文摘要:癫痫日益被视为一种系统性疾病,反复发作与血管、自主神经、呼吸及心脏过程相互交织,影响心血管易感性。发作相关神经炎症涉及多条相互作用的介质通路,包括HMGB1/TLR4-RAGE信号、炎症小体/IL-1β激活、IL-6/IL-6R-gp130信号、血脑屏障(BBB)破坏后的白蛋白/TGF-β信号以及肿瘤坏死因子α(TNF-α)/TNF受体(TNFR)信号。在这一炎症网络中,TNF/TNFR信号提供了一个机制上具有独特性且具转化相关性的框架,用于考察免疫激活如何与内皮屏障功能障碍、神经血管单元损伤、自主神经紊乱、神经与心血管分区之间的炎症通讯以及心脏易感性相交汇。本综述整合癫痫研究的直接证据与BBB损伤、心肌缺血再灌注损伤、心脏保护及脑-心通讯等相关实验研究的机制认识。TNF生物学由配体形式、受体亚型、细胞分区和疾病背景决定。可溶性TNF优先激活TNFR1相关的炎症与损伤放大通路,而跨膜TNF/TNFR2信号在特定情形下可能支持调节性或修复性反应。在癫痫中,发作相关炎症、BBB功能障碍、胶质细胞激活和自主神经失衡可能相互作用,增加对致心律失常应激、心肌损伤、不良心脏重构以及与癫痫猝死(SUDEP)相关的心肺不稳定的易感性。然而,直接将TNF/TNFR信号与心血管结局联系起来的癫痫特异性证据仍有限,许多机制联系目前依赖神经血管与心血管研究的汇聚性证据。未来研究应整合分区解析的炎症谱分析与自主神经、呼吸、心电图和心脏表型评估,以区分疾病严重度的炎症特征与心血管风险的可调控因素。此类方法可能促成针对特定表型的策略,以更好地理解并最终减轻癫痫的脑-心后果。

7神经肌肉病与周围神经 (7篇)

临床研究 (3篇)

Diabetes care IF 22.6 2026-11-01 PMID: 42713876
The PDN-Sensory randomized controlled trial (RCT) evaluated the effects of high-frequency 10-kHz spinal cord stimulation (10-kHz SCS) on pain and sensory function in individuals with painful diabetic neuropathy (PDN). Participants were randomized 1:1 to conventional medical management (CMM) alone or 10-kHz SCS plus CMM. The primary and key secondary end points were the proportions of participants with pain response (≥50% lower-limb pain relief) and sensory improvement (≥3-point reduction in modified Toronto Clinical Neuropathy Score [mTCNS]). Hierarchical secondary outcomes included intraepidermal nerve fiber density (IENFD), sleep, and health- and neuropathy-related quality of life (QoL). IENFD and mTCNS assessments were allocation blinded. A total of 91 participants were randomly assigned to CMM alone (n = 50) or 10-kHz SCS plus CMM (n = 41). In a modified intention-to-treat worst-case analysis, 27 of 34 participants in the 10-kHz SCS group who underwent a temporary trial achieved the primary outcome, versus 2 of 50 CMM-alone participants (P < 0.001). Among those with 6-month data, mTCNS sensory improvement was observed in 16 of 29 (55.2%) 10-kHz SCS participants versus 12 of 48 (25.0%) CMM-alone participants (P = 0.01). The mean change in lower-calf IENFD was 0.58 fibers/mm with 10-kHz SCS versus -0.07 with CMM alone (P = 0.03). Eight of 10 hierarchical secondary end points were met (including sleep and QoL). The PDN-Sensory RCT replicated previous pain-reduction findings and showed prespecified, objective improvements in sensory function and IENFD. These 6-month findings support clinically meaningful benefit and are consistent with a potential disease-modifying effect that requires longer-term confirmation.
中文摘要:PDN-Sensory随机对照试验评估高频10 kHz脊髓电刺激(10-kHz SCS)对痛性糖尿病性周围神经病(PDN)患者疼痛与感觉功能的影响。受试者按1:1随机分配至单纯常规内科治疗(CMM)组或10-kHz SCS联合CMM组。主要终点与关键次要终点分别为疼痛应答(下肢疼痛缓解≥50%)和感觉改善(改良多伦多临床神经病变评分mTCNS降低≥3分)的受试者比例。分层次要结局包括表皮内神经纤维密度(IENFD)、睡眠以及健康相关与神经病变相关生活质量。IENFD与mTCNS评估对分组设盲。共91例受试者随机分配至单纯CMM组(n=50)或10-kHz SCS联合CMM组(n=41)。在改良意向性治疗最差情况分析中,10-kHz SCS组接受临时试验的34例中有27例达到主要终点,单纯CMM组50例中为2例(P<0.001)。在有6个月数据的受试者中,10-kHz SCS组29例有16例(55.2%)出现mTCNS感觉改善,单纯CMM组48例有12例(25.0%)(P=0.01)。小腿下段IENFD平均变化在10-kHz SCS组为0.58根/mm,单纯CMM组为-0.07根/mm(P=0.03)。10项分层次要终点中有8项达标(包括睡眠与生活质量)。PDN-Sensory随机对照试验重复了既往的疼痛缓解结果,并显示预设的客观感觉功能与IENFD改善。这些6个月结果支持具有临床意义的获益,并与可能的疾病修饰作用相一致,尚需更长疗程加以确认。
Ophthalmology IF 10.9 2026-11 PMID: 42556433
To determine whether the cup-to-disc ratio (CDR) of patients with glucagon-like peptide 1 receptor agonist (GLP-1 RA) -associated nonarteritic anterior ischemic optic neuropathy (NAION) is similar to the CDR of patients with NAION without GLP-1 RA exposure and to stratify the odds of developing NAION based on CDR. A retrospective, multicenter, case-control study of the CDR of NAION cases diagnosed between 2018 and 2024. The Disc-at-Risk Study Group included 16 neuro-ophthalmology centers that reviewed medical records of 1812 unaffected fellow eyes from 2169 consecutive patients with NAION. The control group included both eyes of 465 patients. The study compared the unaffected fellow eyes of 3 groups of patients with NAION: semaglutide users (117 eyes), nonsemaglutide GLP-1 RA users (83 eyes), and No GLP-1 RA medications (1612 eyes). Control eyes defined the distribution of CDR in the general population. The CDR of unaffected fellow eyes of patients with NAION with and without exposure to GLP-1 RA medications. The average provider-estimated CDR in unaffected fellow eyes of patients with NAION was 0.13, with no significant difference among the 3 groups. A measured CDR ≤ 0.40 was found in 94% of fellow eyes but only 56% of controls (P < 0.001). A measured CDR ≤ 0.20 was found in 54% of fellow eye photographs but only 9% of controls (P < 0.001). Eyes with a measured CDR ≤ 0.20 have the highest NAION odds (odds ratio = 46.3; 95% confidence interval, 22.9-93.4), and eyes with a CDR > 0.20 and ≤0.40 had more modest odds (odds ratio = 6.8; 95% confidence interval, 3.5-13.2) compared with eyes with a measured CDR > 0.40. Patients with NAION with and without exposure to GLP-1 RA medications have the same high prevalence of crowded optic discs. The odds of NAION are inversely proportional to CDR. Irrespective of GLP-1 RA exposure, eyes with a photo-measured CDR ≤ 0.20 have 46 times greater odds of NAION than eyes with a CDR > 0.40. Although the absolute risk of NAION is low, this quantification of NAION risk may help better inform patients concerned about NAION risk. This study does not assess whether GLP-1 RA medications are an independent risk factor for NAION. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:旨在确定胰高血糖素样肽1受体激动剂(GLP-1 RA)相关非动脉炎性前部缺血性视神经病变(NAION)患者的杯盘比(CDR)是否与未暴露于GLP-1 RA的NAION患者相似,并依据CDR分层NAION发生比值比。这是一项回顾性、多中心、病例对照研究,分析2018年至2024年诊断的NAION病例的CDR。视盘风险研究组纳入16个神经眼科中心,复习了2169例连续NAION患者中1812只未受累对侧眼的病历。对照组包括465例患者的双眼。研究比较3组NAION患者未受累对侧眼:司美格鲁肽使用者(117眼)、非司美格鲁肽GLP-1 RA使用者(83眼)和未使用GLP-1 RA药物者(1612眼)。对照眼用于定义一般人群CDR分布。分析NAION患者未受累对侧眼在暴露与未暴露GLP-1 RA药物时的CDR。NAION患者未受累对侧眼的提供者估计平均CDR为0.13,3组间无显著差异。测量CDR≤0.40见于94%的对侧眼,但仅见于56%的对照眼(P<0.001)。测量CDR≤0.20见于54%的对侧眼照片,但仅见于9%的对照眼(P<0.001)。与测量CDR>0.40的眼相比,测量CDR≤0.20的眼NAION比值比最高(比值比=46.3;95%置信区间22.9-93.4),CDR>0.20且≤0.40的眼比值比相对较低(比值比=6.8;95%置信区间3.5-13.2)。暴露与未暴露GLP-1 RA药物的NAION患者均具有同样高的拥挤视盘患病率。NAION的比值比与CDR呈反向关系。无论是否暴露于GLP-1 RA,照片测量CDR≤0.20的眼发生NAION的比值比是CDR>0.40眼的46倍。尽管NAION绝对风险较低,这种NAION风险量化可能有助于更好地告知担心NAION风险的患者。本研究未评估GLP-1 RA药物是否为NAION的独立危险因素。专有或商业披露见文末脚注与披露部分。
Annals of neurology IF 7.5 2026-11 PMID: 42528478
Behavioral impairment is common in amyotrophic lateral sclerosis (ALS) and strongly affects autonomy, caregiver burden, and outcomes, yet predictors of vulnerability remain unclear. We investigated whether premorbid regulatory traits and socio-educational exposures are associated with behavioral phenotypes in ALS within a behavioral reserve framework. We analyzed 965 consecutively assessed patients with ALS from a prospective tertiary-center cohort. Behavioral impairment was measured using the Frontal Systems Behavior Scale (FrSBe; family-rated before and after onset) and, in a subset (n = 633), the Edinburgh Cognitive and Behavioural ALS Screen-Carer Interview (ECAS-CI). Theory-driven hierarchical logistic regression models tested associations between behavioral outcomes and premorbid behavioral regulation, education, occupation, and a Social Interaction Index, including interaction effects. Prespecified sensitivity analyses addressed potential bias in premorbid estimates. Premorbid behavioral regulation showed the strongest associations with behavioral impairment across all FrSBe models. Higher combined educational attainment and social exposure were associated with lower odds of impairment, with a significant interaction across multiple behavioral domains. These patterns persisted in restricted sensitivity analyses. Reserve proxies were not significantly associated with ECAS-CI total impairment, although domain-specific effects were observed. These findings provide empirical support for a behavioral reserve framework in ALS, in which premorbid regulatory traits and socio-educational exposures are associated with behavioral vulnerability. Although causal inference is limited, reserve-related factors may contribute to non-motor heterogeneity in ALS and may inform future approaches to early behavioral risk stratification. ANN NEUROL 2026;100:934-947.
中文摘要:行为损害在肌萎缩侧索硬化(ALS)中常见,并明显影响自主性、照护者负担和结局,但其易感性的预测因素仍不清楚。我们在行为储备框架内考察病前调节特质与社会教育暴露是否与ALS的行为表型相关。研究分析了一个前瞻性三级中心队列中连续评估的965例ALS患者。行为损害采用额叶系统行为量表(FrSBe;由家属分别评定发病前和发病后)测量,并在一个子集(n=633)中使用爱丁堡认知与行为ALS筛查-照护者访谈(ECAS-CI)评估。理论驱动的分层逻辑回归模型检验行为结局与病前行为调节、教育、职业及社会互动指数之间的关联,并纳入交互效应。预设的敏感性分析用于处理病前估计中的潜在偏倚。病前行为调节在所有FrSBe模型中与行为损害的关联最强。较高的教育程度与社会暴露合并水平与较低的损害几率相关,并在多个行为领域存在显著交互。这些模式在限制性敏感性分析中仍然存在。储备代理指标与ECAS-CI总体损害无显著关联,但观察到领域特异性效应。这些发现为ALS中的行为储备框架提供了实证支持,即病前调节特质和社会教育暴露与行为脆弱性相关。尽管因果推断受限,储备相关因素可能促成ALS非运动症状的异质性,并可能为未来早期行为风险分层提供线索。《神经病学年鉴》2026;100:934-947。

基础研究 (4篇)

Plant biotechnology journal IF 12.8 2026-11 PMID: 42720300
Alfalfa (Medicago sativa) is the most widely cultivated forage crop worldwide, owing to its high protein content, balanced amino acid profile, and abundance of vitamins and minerals. However, weed infestation severely threatens alfalfa yield and quality. The lack of herbicide‑resistant cultivars, combined with the diversity of weed species, has made herbicide tolerance a key breeding objective. To address this challenge, we developed a highly optimized prime editing system and, for the first time, achieved prime editing in alfalfa by enhancing the expression efficiency of its components. Specifically, we introduced mutations in three target genes MsALS1, MsALS2 and MsACC1 to confer herbicide resistance: mutations in MsALS1 and MsALS2 were designed to confer resistance to ALS‑inhibiting herbicides (based on evidence from their rice homologs), while those in MsACC1 were targeted to confer resistance to aryloxyphenoxypropionate (APP) herbicides. Using the Csy4 nuclease system, we performed simultaneous prime editing of all three genes, ultimately generating alfalfa lines resistant to nicosulfuron and haloxyfop‑P‑methyl. This study represents the first successful multi‑gene prime editing in alfalfa, providing a novel tool and a valuable approach for alfalfa molecular breeding.
中文摘要:紫花苜蓿(Medicago sativa)因蛋白质含量高、氨基酸组成均衡且富含维生素和矿物质,是世界上种植最广泛的饲草作物。然而,杂草侵染严重威胁苜蓿产量和品质。抗除草剂品种缺乏,加之杂草种类多样,使耐除草剂性成为重要育种目标。为应对这一挑战,我们开发了高度优化的先导编辑系统,并通过提高其组分表达效率,首次在苜蓿中实现先导编辑。具体而言,我们在MsALS1、MsALS2和MsACC1三个靶基因中引入突变以赋予除草剂抗性:MsALS1和MsALS2的突变依据其水稻同源基因的证据设计,旨在赋予对ALS抑制型除草剂的抗性;MsACC1的突变则针对芳氧苯氧丙酸酯(APP)类除草剂抗性。利用Csy4核酸酶系统,我们对三个基因同时进行先导编辑,最终获得对烟嘧磺隆和高效氟吡甲禾灵具有抗性的苜蓿株系。该研究首次在苜蓿中实现多基因先导编辑,为苜蓿分子育种提供了新工具和有价值的方法。
Autophagy IF 18.6 2026-11 PMID: 42366592
Accelerated CHRN/AChR/nicotinic acetylcholine receptor internalization induced by auto-antibodies impairs neuromuscular junction transmission and contributes to myasthenia gravis (MG), a typical autoimmune disease. Although CHRN internalization is well established in MG pathogenesis, the downstream cellular events, especially those related to autophagy, remain poorly described. Here, we report that RAPSN/rapsyn, an intracellular CHRN-binding protein essential for its clustering, accumulates as aggregates in experimental autoimmune myasthenia gravis (EAMG) mice. In CHRN antibody-treated myotubes, RAPSN dissociates from internalized CHRN and forms aggregates due to exposure of its hydrophobic domains. These aggregates in turn impair the trafficking and membrane incorporation of newly synthesized CHRN, thereby exacerbating CHRN loss. Notably, the accumulation of RAPSN aggregates facilitates formation of HSPA/HSP70-BAG3 complex, which recognizes and transports the aggregates along microtubules to form perinuclear aggresomes for subsequent lysosomal degradation. Accordingly, pharmacological inhibition or knockdown of HSPA-BAG3 complex increases RAPSN aggregation, which participates in enhanced CHRN loss and worsened muscle weakness in EAMG mice. This study identifies HSPA-BAG3 aggrephagy as a protective mechanism that clears RAPSN aggregates to maintain CHRN integrity and suggests a potential therapeutic strategy for MG.Abbreviation: 3-MA: 3-methyladenine; AAV: adeno-associated virus; CASA: chaperone-assisted selective autophagy; CHRN/nicotinic acetylcholine receptor: cholinergic receptor nicotinic; CHRN-ab: CHRN antibodies; CHX: cycloheximide; CMAP: compound muscle action potential; CQ: chloroquine; EAMG: experimental autoimmune myasthenia gravis; ER: endoplasmic reticulum; GAS: gastrocnemius; MAP1LC3A/B: microtubule associated protein 1 light chain 3 alpha/beta; MG: myasthenia gravis; NMJ: neuromuscular junction; Rapa: rapamycin; RAPSN/rapsyn: receptor associated protein of the synapse; SQSTM1: sequestosome 1; TA: tibialis anterior; αBTX-A594: α-bungarotoxin-Alexa-594.
中文摘要:自身抗体诱导的CHRN/AChR/烟碱型乙酰胆碱受体加速内化会损害神经肌肉接头传递,并参与重症肌无力(MG)这一典型自身免疫病的发生。CHRN内化在MG发病机制中已较明确,其下游细胞事件特别是与自噬相关的过程仍缺乏描述。本研究报告,在实验性自身免疫性重症肌无力(EAMG)小鼠中,CHRN聚集所必需的胞内CHRN结合蛋白RAPSN/rapsyn以聚集体形式蓄积。在CHRN抗体处理过的肌管中,RAPSN与内化的CHRN解离,并因其疏水结构域暴露而形成聚集体。这些聚集体进而损害新合成CHRN的转运与膜整合,加重CHRN丢失。RAPSN聚集体的蓄积促进HSPA/HSP70-BAG3复合物形成,该复合物识别聚集体并沿微管将其运输,形成核周聚集体以便随后经溶酶体降解。相应地,药物抑制或敲低HSPA-BAG3复合物会增加RAPSN聚集,参与EAMG小鼠中CHRN丢失加重与肌无力恶化。本研究将HSPA-BAG3介导的聚集体自噬确定为清除RAPSN聚集体、维持CHRN完整性的保护机制,并提示其作为MG潜在治疗策略的可能。
Autophagy IF 18.6 2026-11 PMID: 42260986
Kaposi sarcoma-associated herpesvirus (KSHV), an oncogenic virus associated with several malignancies, including Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease, harbors a DNA replication helicase encoded by ORF44 that is crucial for viral replication and pathogenesis. In this study, we identified the host PFN1 (profilin 1), a well-known actin-binding factor, as an inhibitor of KSHV lytic replication functioning via the macroautophagy/autophagy-lysosomal degradation pathway targeting ORF44. Mechanistic analyses revealed that PFN1 interacts with ORF44, leading to enhanced polyubiquitination of PFN1. Notably, the E3 ubiquitin ligase TRIM37 (tripartite motif containing 37) facilitates the polyubiquitination of lysine residues at position 116 of PFN1, which serves as a critical recognition motif for the cargo receptor SQSTM1/p62 (sequestosome 1), which is pivotal for the subsequent autophagic degradation of ORF44. Overall, our findings revealed a previously uncharacterized antiviral function of PFN1, highlighting its potential as a novel therapeutic avenue for the treatment of KSHV-associated malignancies.Abbreviations: ALS: amyotrophic lateral sclerosis; Baf A1: bafilomycin A1; co-IP: co-immunoprecipitation; KSHV: Kaposi sarcoma-associated herpes virus; LIR: LC3-interacting region; PFN1: profilin 1; SQSTM1/p62: sequestosome 1; TRIM37: tripartite motif containing 37; UBA: ubiquitin-associated domain.
中文摘要:卡波西肉瘤相关疱疹病毒(KSHV)是一种与多种恶性肿瘤相关的致癌病毒,包括卡波西肉瘤(KS)、原发性渗出性淋巴瘤(PEL)和多中心Castleman病;其ORF44编码的DNA复制解旋酶对病毒复制和致病过程至关重要。研究识别出宿主PFN1(profilin 1,一种已知的肌动蛋白结合因子)可通过巨自噬/自噬-溶酶体降解途径靶向ORF44,抑制KSHV裂解性复制。机制分析显示,PFN1与ORF44相互作用,使PFN1多聚泛素化增强。E3泛素连接酶TRIM37(含三重基序蛋白37)促进PFN1第116位赖氨酸残基的多聚泛素化,该位点作为货物受体SQSTM1/p62(sequestosome 1)的关键识别基序,对ORF44后续的自噬降解至关重要。这些发现揭示了PFN1此前未被描述的抗病毒功能,并提示其可作为治疗KSHV相关恶性肿瘤的新治疗途径。缩写:ALS:肌萎缩侧索硬化;Baf A1:巴弗洛霉素A1;co-IP:免疫共沉淀;KSHV:卡波西肉瘤相关疱疹病毒;LIR:LC3相互作用区域;PFN1:profilin 1;SQSTM1/p62:sequestosome 1;TRIM37:含三重基序蛋白37;UBA:泛素相关结构域。
Science advances IF 13.9 2026-10-30 PMID: 42962021
Diabetic peripheral neuropathy (DPN) affects up to half of people with diabetes and lacks disease-modifying therapy. Here, we profiled MSC-EV biodistribution and multiomic programs across diabetic models, with key nerve repair established in db/db mice and corroborated in high-fat diet/streptozotocin- and methionine-choline-deficient mice. Systemically administered EVs predominantly accumulated in the liver and improved peripheral nerve structure and function, with benefits supported by glycemia-controlled or glycemia-adjusted analyses rather than being fully explained by systemic glycemic changes. EV treatment was associated with reduced circulating injury markers, attenuated spinal inflammatory responses, and improved endothelial junction integrity. Mechanistically, EV-encapsulated miR-24-3p repressed hepatic CD74, coinciding with reduced MHC II/NF-κB activity in macrophages. Hepatic CD74 overexpression promoted systemic inflammation and peripheral nerve injury, whereas pharmacologic NF-κB inhibition recapitulated EV-associated benefits. Together, these data define a liver-to-nerve causal axis and support EV-mediated restraint of hepatic CD74-NF-κB signaling as a cross-organ strategy for DPN repair.
中文摘要:糖尿病周围神经病变(DPN)影响近半数糖尿病患者,且缺乏可改变疾病进程的治疗。研究在多种糖尿病模型中描绘了间充质干细胞来源细胞外囊泡(MSC-EV)的体内分布和多组学特征,并在db/db小鼠中确立关键神经修复作用,在高脂饮食/链脲佐菌素及甲硫氨酸-胆碱缺乏小鼠中得到印证。全身给予EV主要富集于肝脏,改善外周神经结构与功能;血糖控制或血糖校正分析支持这些获益,提示其不能完全由全身血糖变化解释。EV治疗与循环损伤标志物降低、脊髓炎症反应减轻及内皮连接完整性改善相关。机制上,EV包裹的miR-24-3p抑制肝脏CD74,并与巨噬细胞中MHC II/NF-κB活性降低同时出现。肝脏CD74过表达促进全身炎症和外周神经损伤,药理抑制NF-κB可重现EV相关获益。这些数据界定了肝脏到神经的因果轴,并支持以EV限制肝脏CD74-NF-κB信号作为DPN修复的跨器官策略。

8神经遗传/影像与基础转化 (4篇)

临床研究 (1篇)

Molecular psychiatry IF 10.4 2026-11 PMID: 42286187
Brain disorders characterized by progressive neurodegeneration, such as Alzheimer's disease (AD) and frontotemporal dementia (FTD), represent an increasing medical and societal challenge. While genome‑wide studies have uncovered numerous susceptibility loci, these efforts have largely focused on common variants and leave a substantial portion of genetic liability unresolved. Variants of low frequency, often associated with stronger biological effects, remain insufficiently characterized, particularly in heterogeneous populations. Genetically isolated populations offer an effective strategy to overcome these limitations. Finland, shaped by historical demographic events, harbors a distinctive spectrum of enriched rare variants that can facilitate gene discovery. The FinnGen initiative capitalizes on this setting by combining extensive genotyping with nationwide health registry data through a coordinated network of Finnish biobanks. With half a million participants analyzed, FinnGen supports highly powered analyses across a broad array of clinical outcomes and registry data. Recent comprehensive analyses have reported thousands of significant genotype-phenotype associations, including novel protein‑altering variants. Importantly, the FinnGen cohort structure favors older individuals and hospital‑derived samples, increasing representation of brain disorders, such as AD and idiopathic normal pressure hydrocephalus (iNPH), a disorder frequently accompanied by AD‑like pathological features. In this expert review, we summarize FinnGen‑based investigations relevant to neurodegenerative diseases and iNPH, highlighting insights into genetic susceptibility, disease overlap, and protective factors, and discuss how integration with recall studies as well as biomarker and clinical data accelerates translational applications in brain disorders.
中文摘要:以进行性神经变性为特征的大脑疾病,如阿尔茨海默病(AD)和额颞叶痴呆(FTD),带来日益加重的医疗与社会负担。全基因组研究已发现众多易感位点,但这些工作多集中于常见变异,仍有相当部分遗传易感性未获解释。低频变异常伴随更强的生物学效应,其特点仍认识不足,在异质性人群中尤其如此。遗传隔离人群为克服这些局限提供了有效策略。芬兰受历史人口事件影响,携带独特的富集罕见变异谱,有助于发现新基因。FinnGen计划依托这一背景,通过芬兰生物样本库的协作网络,将大规模基因分型与全国健康登记数据结合。该计划已分析50万参与者,支持针对广泛临床结局与登记数据的高效能分析。近期综合分析报告了数千个显著的基因型-表型关联,包括新的蛋白改变变异。FinnGen队列结构偏向老年个体和医院来源样本,提高了AD以及特发性正常压力脑积水(iNPH)等脑部疾病的代表性,iNPH常伴AD样病理特征。在这篇专家综述中,我们总结与神经变性疾病和iNPH相关的FinnGen研究,阐述对遗传易感性、疾病重叠和保护因素的见解,并讨论与召回研究以及生物标志物和临床数据整合如何加速脑部疾病的转化应用。

基础研究 (3篇)

Annual review of physiology IF 20.3 2026-11-04 PMID: 42981477
Flow disturbances in the smallest blood vessels of the brain, the capillaries, have long been considered a potential cause of brain dysfunction. However, owing to the technological challenge of studying blood flow in three-dimensional capillary networks, elucidating the incidence, causes, and consequences of capillary obstructions has been difficult. Advances in optical microscopes for in vivo imaging, primarily high-spatiotemporal-resolution optical coherence tomography and two-photon microscopy, have recently enabled detailed studies of these capillary stalling events in both healthy and diseased mice. In this review, we describe these imaging approaches to quantify capillary stalling, identifying strengths and weaknesses of different methods. We then review recent findings on the incidence, molecular and cellular causes, and physiological and neurological consequences of capillary stalling across multiple mouse models of brain disease, including Alzheimer's disease, stroke, and traumatic brain injury. We conclude by suggesting necessary next steps in instrumentation and analysis for studying capillary stalling, as well as how to address key unanswered questions about underlying mechanisms for capillary stalling in the brain and how this phenomenon may impact disease progression and cognitive function.
中文摘要:脑内最小血管即毛细血管中的血流紊乱长期被视为脑功能障碍的潜在原因。然而,三维毛细血管网络内血流研究存在技术挑战,阐明毛细血管阻塞的发生率、原因和后果一直困难。活体成像光学显微镜的进展,主要是高时空分辨率光学相干断层扫描和双光子显微镜,近来使在健康和患病小鼠中详细研究这些毛细血管停滞事件成为可能。本综述介绍这些用于量化毛细血管停滞的成像方法,指出不同方法的优势与不足。随后回顾多个脑疾病小鼠模型(包括阿尔茨海默病、卒中和创伤性脑损伤)中毛细血管停滞的发生率、分子与细胞原因以及生理和神经学后果的最新发现。最后提出研究毛细血管停滞所需的仪器与分析下一步工作,并讨论如何解决关于脑内毛细血管停滞潜在机制的关键未解问题,以及这一现象可能如何影响疾病进展和认知功能。
Pharmacological research IF 12.2 2026-11 PMID: 42907296
Voltage-gated sodium (NaV) channels are critical transmembrane proteins responsible for the initiation and propagation of electrical signals in excitable tissues. They consist of a large α subunit and auxiliary β subunits. Together, the voltage sensing, ion selectivity, and rapid gating transitions regulate neuronal, muscular, and cardiac excitability. Recent cryo-electron microscopy breakthroughs have transformed the understanding of NaV structure-function relationships, revealing the asymmetric organization of voltage-sensing domains (VSD), the architecture of the DEKA selectivity filter, the mechanical coupling between S4-S5 linkers and S6 gating helices, and the allosteric mechanism by which the IFMT motif mediates fast inactivation. Across the nine human NaV isoforms, subtle structural divergences underlie distinct tissue distributions, biophysical properties, and disease susceptibilities, explaining the diverse channelopathies that range from epilepsy and cardiac arrhythmias to skeletal muscle disorders and painful neuropathies. These high-resolution structures also illuminate isoform-specific pharmacological pockets, including membrane-dependent cavities in VSD4 and dynamic fenestrations that govern state-dependent drug access, enabling the rational design of small molecules, peptide toxins, and hybrid therapeutics with improved selectivity. Advances in structural biology, biochemistry, and computation have established an integrated mechanistic model that connects NaV channel architecture to gating, inactivation, isoform-specific function, and human disease. This growing molecular atlas now supports next-generation precision therapies aimed at selectively modulating NaV channel activity in neurological, muscular, cardiac, and pain disorders.
中文摘要:电压门控钠通道(NaV)是兴奋性组织中启动和传播电信号的关键跨膜蛋白,由大型α亚基和辅助β亚基组成。电压感受、离子选择性和快速门控转换共同调控神经、肌肉与心脏兴奋性。近期冷冻电镜突破改变了对NaV结构-功能关系的认识,揭示了电压感受域的不对称组织、DEKA选择性过滤器的结构、S4-S5连接子与S6门控螺旋间的机械耦合,以及IFMT基序介导快速失活的变构机制。在九种人NaV亚型中,细微结构差异决定了组织分布、生物物理特性与疾病易感性,解释了从癫痫、心律失常到骨骼肌疾病和疼痛性神经病的多种通道病。高分辨率结构还揭示了亚型特异性药理口袋,包括VSD4中膜依赖性腔隙和调控状态依赖性药物进入的动态窗孔,为合理设计具有更好选择性的小分子、肽类毒素和混合治疗药物提供依据。结构生物学、生物化学与计算方法的进展建立了整合机制模型,将NaV通道结构与门控、失活、亚型特异性功能及人类疾病联系起来。这一不断扩展的分子图谱支持下一代精准治疗,以在神经、肌肉、心脏和疼痛疾病中选择性调控NaV通道活性。
Biomaterials IF 13.6 2026-11 PMID: 42097024
Understanding the chronic effects of intracortical microstimulation (ICMS) and device implantation on cortical function is essential for the development of stable neuroprosthetics. We chronically implanted penetrating microelectrodes into Thy1-GCaMP6s mice and conducted longitudinal mesoscopic widefield and two-photon Ca2+ imaging alongside intrinsic optical signal recordings over 12 weeks. Six ICMS frequencies (10-500 Hz) and contralateral visual LED stimuli were delivered in repeated sessions. Oxygen extraction fraction (OEF) was estimated from dual-wavelength reflectance, and hemodynamic response functions (HRFs) were derived via regularized deconvolution. Over the chronic period, 25-Hz ICMS evoked progressively larger Ca2+ responses with extending duration, while spatial spread remained stable after the first few days. Low-frequency ICMS preserved stable Ca2+ depression, whereas high-frequency ICMS and visual stimulation showed partial declines in depression magnitude and spatial extent. Two-photon imaging revealed that somatic and neuropil compartments followed distinct activation and depression trajectories, with somatic ICMS responses declining then recovering while neuropil activation tracked mesoscale trends. Concurrently, OEF reductions deepened, reflecting increased relative blood supply, and the spatial extent of OEF signals contracted in the first week before expanding by day 21. Epileptiform Ca2+ events emerged in nearly half of mice, predominantly under 25-Hz ICMS. HRF peak amplitude increased between day 0 and days 7-21, with latency decreasing. Spontaneous neural and hemodynamic activity near the probe was suppressed acutely but recovered over weeks. Chronic ICMS induces progressive potentiation of neuronal and vascular responses alongside local neurovascular uncoupling on day 0 and sustained silencing of spontaneous activity near the implant. These dynamics stabilized 6-7 weeks after implantation. The frequency-dependent epileptiform susceptibility, coupled with persistent focal neurovascular deficits, underscores the need for adaptive stimulation strategies during the pre-stabilization period and electrode designs that mitigate local suppression to ensure long-term stability of cortical neuroprostheses.
中文摘要:理解皮层内微刺激(ICMS)与器件植入对皮层功能的长期影响,对开发稳定的神经假体十分关键。我们将穿透式微电极长期植入Thy1-GCaMP6s小鼠,在12周内联合进行纵向介观宽场与双光子Ca2+成像,并记录内源光学信号。六种ICMS频率(10–500 Hz)和对侧视觉LED刺激在多次实验中被给予。由双波长反射估计氧摄取分数(OEF),并通过正则化反卷积得到血流动力学响应函数(HRF)。在长期观察期内,25 Hz ICMS诱发的Ca2+反应逐渐增大且持续时间延长,空间扩散范围在最初几天后保持稳定。低频ICMS维持稳定的Ca2+抑制,而高频ICMS与视觉刺激的抑制幅度和空间范围出现部分下降。双光子成像显示胞体与神经毡区室遵循不同的激活和抑制轨迹,胞体ICMS反应先下降后恢复,神经毡激活则跟随介观尺度趋势。同时,OEF降低加深,反映相对血供增加,OEF信号的空间范围在第一周收缩,到第21天扩大。近半数小鼠出现癫痫样Ca2+事件,主要发生在25 Hz ICMS下。HRF峰值振幅在第0天至第7–21天增加,潜伏期缩短。探针附近的自发神经与血流动力学活动在急性期受抑制,但数周内恢复。慢性ICMS引起神经元和血管反应的进行性增强,同时在第0天出现局部神经血管解耦联,并持续沉默植入物附近的自发活动。这些动态在植入后6–7周趋于稳定。频率依赖的癫痫样事件易感性,加上持续的局灶性神经血管缺陷,提示在稳定前阶段需要适应性刺激策略,并需要能减轻局部抑制的电极设计,以确保皮层神经假体的长期稳定性。

9神经退行性疾病 (4篇)

临床研究 (1篇)

MedComm IF 14.1 2026-11 PMID: 42921272
Neurodegenerative diseases are a growing cause of disability worldwide, particularly as populations age. Although these disorders differ in etiology and clinical presentation, advances in genetics, neuropathology, and biomarker research have identified shared disturbances in protein homeostasis, mitochondrial function, and immune regulation. These processes may contribute to selective neuronal vulnerability and neural circuit dysfunction. These findings are refining disease classification and diagnosis, yet effective disease-modifying therapies remain limited. Disease-specific abnormalities remain essential to clinical interpretation and treatment selection. Existing reviews often focus on individual disorders or isolated mechanisms, leaving the links between shared biology and disease-specific phenotypes insufficiently clear. We synthesize evidence on the epidemiology, risk factors, classification, and pathophysiology of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, frontotemporal dementia, Friedreich's ataxia, and multiple sclerosis. We compare their clinical manifestations and diagnostic approaches, including the evolving role of biomarkers, and critically assess established and emerging therapies. By distinguishing shared mechanisms from disease-specific abnormalities, we identify key translational gaps and explore how common biological disturbances may lead to distinct clinical trajectories. This cross-disease perspective may inform diagnostic reasoning, treatment development, and future comparative research.
中文摘要:神经退行性疾病在全球范围内是日益增长的致残原因,随着人口老龄化尤为突出。这类疾病的病因与临床表现各不相同,但遗传学、神经病理学和生物标志物研究的进展已识别出它们在蛋白稳态、线粒体功能和免疫调节方面的共同紊乱,这些过程可能促成选择性神经元易损与神经环路功能障碍。这些发现正在改进疾病分类与诊断,但有效的疾病修饰治疗仍然有限。疾病特异性异常对临床解读与治疗选择依然不可或缺。已有综述多聚焦于单一疾病或孤立机制,共同生物学基础与疾病特异性表型之间的联系尚不够清晰。本文汇总阿尔茨海默病、帕金森病、肌萎缩侧索硬化、亨廷顿病、额颞叶痴呆、弗里德赖希共济失调和多发性硬化在流行病学、危险因素、分类与病理生理学方面的证据,比较其临床表现与诊断路径,包括生物标志物作用的变化,并对已有和新兴治疗作出评价。通过区分共同机制与疾病特异性异常,指出关键的转化研究缺口,并探讨共同的生物学紊乱如何导向不同的临床轨迹。这一跨疾病视角可为诊断思路、治疗研发与未来的比较研究提供参考。

基础研究 (3篇)

Ageing research reviews IF 15.5 2026-11 PMID: 42759574
Microglia, the brain's resident immune cells, rely on histone modifications and chromatin remodeling to sculpt their identity across the trajectory from development through aging. Recent studies have identified enhancer rewiring and metabolic-epigenetic coupling-exemplified by histone lactylation-as central drivers of microglial plasticity. Disruption of this regulatory balance drives the transition from homeostatic microglia toward disease-associated microglia (DAM) in Alzheimer's and Parkinson's diseases. This Review examines emerging concepts such as trained innate immunity, state-specific enhancer landscapes, and regional heterogeneity, and posits that epigenetic reprogramming is a central mechanism governing microglial functional transitions. These insights reveal promising therapeutic targets; however, a pressing prerequisite for clinical translation is to rigorously establish the causality of these epigenetic changes across diverse model systems, sexes, and brain regions.
中文摘要:小胶质细胞是脑内常驻免疫细胞,其身份从发育到衰老依赖组蛋白修饰与染色质重塑来塑造。近期研究识别出增强子重连与代谢—表观遗传耦合,其中组蛋白乳酸化是代表性机制,这些过程是小胶质细胞可塑性的核心驱动因素。该调控平衡被破坏会促使小胶质细胞从稳态状态向阿尔茨海默病和帕金森病中的疾病相关小胶质细胞(DAM)转变。本综述讨论训练性天然免疫、状态特异性增强子景观和区域异质性等新兴概念,并提出表观遗传重编程是控制小胶质细胞功能转变的中心机制。这些认识揭示了有前景的治疗靶点;临床转化的紧迫前提是在多样模型系统、性别和脑区中严格确立这些表观遗传改变的因果关系。
Ageing research reviews IF 15.5 2026-11 PMID: 42641767
Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), and prion diseases represent a growing global health crisis. Despite significant research efforts, disease-modifying therapies remain elusive. Immunotherapy, particularly vaccination, offers a promising avenue by leveraging the body's immune system to clear pathological protein aggregates central to these disorders. This review critically analyzes the historical trajectory, current advancements, and future perspectives of vaccine development across AD, PD, and prion diseases. We highlight the evolution from first-generation pan-protein-targeting strategies to precision immunogens focusing on specific pathogenic conformers, the pivotal role of immunomodulation in balancing efficacy and safety, and the emerging landscape of novel vaccine platforms and delivery systems. A central argument advanced herein is the imperative shift from broad-spectrum immune activation to highly targeted, conformation-specific immunotherapies, coupled with early intervention strategies, to unlock the full therapeutic potential of vaccines in preventing and modifying the course of NDs. We propose that integrating lessons from diverse NDs and embracing multi-target, adaptive immunization approaches, alongside advanced biomarker identification, will be critical for achieving clinical success.
中文摘要:阿尔茨海默病(AD)、帕金森病(PD)和朊病毒病等神经退行性疾病(NDs)构成日益严峻的全球健康危机。尽管研究投入显著,改变疾病进程的疗法仍难以实现。免疫治疗,尤其是疫苗接种,通过调动机体免疫系统清除这些疾病核心的病理性蛋白聚集体,提供了有前景的途径。本综述批判性分析AD、PD和朊病毒病疫苗开发的历史脉络、当前进展与未来前景。文章强调从第一代泛蛋白靶向策略向聚焦特定致病构象的精准免疫原的演变,免疫调节在平衡疗效与安全性中的关键作用,以及新型疫苗平台和递送系统的兴起。本文提出一个核心论点:必须从广谱免疫激活转向高度靶向、构象特异性的免疫治疗,并结合早期干预策略,才能释放疫苗在预防和改变NDs病程方面的全部治疗潜力。文章认为,整合不同NDs的经验,采用多靶点、适应性免疫策略,并配合先进的生物标志物识别,对实现临床成功至关重要。
Advanced drug delivery reviews IF 21.0 2026-11 PMID: 42526715
Neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD), globally pose a significant challenge with an aging population. Despite the presence of various therapeutic agents, AD and PD treatments with small molecules currently only address the symptoms; certain biologic agents for AD have been approved for their disease-modifying effects, but the risk of intracerebral hemorrhage severely limits their use. Moreover, the bioavailability of orally administered agents in the brain is challenged by the blood-brain barrier, complicating brain-targeted drug development. Extensive efforts are currently underway to develop intranasal platforms with nanoparticles for direct nose-to-brain drug delivery. Additionally, various in vitro designs involving brain organoids, and in vivo models, such as rodents and zebrafish, have been explored to improve the efficiency and accuracy of preclinical models. Efforts to develop sophisticated computational modeling of intranasal drug delivery, including computational fluid dynamics (CFD) deposition and physiologically based pharmacokinetics (PBPK) modeling, also continue to advance the intranasal drug delivery research and potentially improve the feasibility of developing clinically relevant intranasal platforms for neurodegenerative disease.
中文摘要:随着人口老龄化,帕金森病(PD)和阿尔茨海默病(AD)等神经退行性疾病在全球范围内构成重大挑战。尽管已有多种治疗药物,AD和PD的小分子治疗目前仅能缓解症状;部分AD生物制剂已因疾病修饰作用获批,但脑出血风险严重限制其应用。口服药物在脑内的生物利用度受血脑屏障限制,使脑靶向药物开发更为复杂。目前大量工作致力于开发含纳米颗粒的鼻腔给药平台,以实现直接的鼻到脑药物递送。涉及脑类器官的多种体外设计以及啮齿类和斑马鱼等体内模型也得到探索,以提高临床前模型的效率与准确性。对鼻腔给药进行精细计算建模的工作,包括计算流体动力学(CFD)沉积建模和基于生理的药代动力学(PBPK)建模,也在持续推进鼻腔给药研究,并可能提高开发面向神经退行性疾病的临床相关鼻腔给药平台的可行性。

10神经免疫 (3篇)

临床研究 (3篇)

Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42912877
Chronic relapsing inflammatory optic neuropathy (CRION) is a steroid-dependent form of optic neuritis with incompletely understood pathophysiology. The identification of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in a substantial patient subset has challenged the diagnostic and therapeutic management. The aim of this study was to investigate clinical profiles and treatment outcomes of patients with CRION, comparing MOG-IgG-positive (MOG+) and seronegative (MOG-) subgroups. Patients from 6 European tertiary centers fulfilling diagnostic criteria for CRION were included. All underwent cell-based autoantibody testing. Clinical outcomes (visual acuity and annualized relapse rate), laboratory and imaging findings (MRI, OCT), and treatment responses were retrospectively analyzed. Sixty patients were included (median age 33 years; 70% female); 27 (45%) were MOG+. MOG+ CRION was associated with later onset, higher annualized relapse rate (ARR) before treatment (median [IQR] 2 [1-3] vs 1 [1-2], p = 0.023), and a trend toward shorter interrelapse intervals. Additional distinguishing features included higher frequencies of antinuclear antibody positivity, elevated CSF interleukin-6, and extensive enhancement of the optic nerve on MRI. Relapse burden correlated with visual acuity decline and retinal thinning. In MOG+ patients, monoclonal antibody therapy reduced the ARR (n = 21; 2 [1-3] vs 0 [0-2], p = 0.024), primarily driven by tocilizumab (n = 11; 2 [1-3] vs 0 [0-1], p = 0.023). In MOG- patients, rituximab and azathioprine showed a trend toward ARR reduction. CRION represents a heterogeneous syndrome encompassing distinct subgroups. Although MOG+ patients demonstrate higher disease activity, tocilizumab might represent a therapeutic option, though further validation is needed. Serologic testing is critical for treatment stratification and preventing relapses.
中文摘要:慢性复发性炎症性视神经病变(CRION)是一种类固醇依赖性视神经炎,病理生理机制尚未完全明确。相当一部分患者中检出髓鞘少突胶质细胞糖蛋白抗体(MOG-IgG),对诊断与治疗管理提出挑战。本研究旨在比较MOG-IgG阳性(MOG+)与血清阴性(MOG-)CRION患者的临床特征和治疗结局。纳入来自6家欧洲三级中心的符合CRION诊断标准患者,全部接受基于细胞的自身抗体检测。回顾性分析临床结局(视力和年化复发率)、实验室与影像学检查(MRI、OCT)以及治疗反应。共纳入60例患者(中位年龄33岁;女性70%);27例(45%)为MOG+。MOG+ CRION与发病年龄较晚、治疗前年化复发率较高相关(中位数[IQR] 2[1-3] vs 1[1-2],p=0.023),并有复发间期缩短趋势。其他鉴别特征包括抗核抗体阳性率较高、脑脊液白细胞介素-6升高以及MRI上视神经广泛强化。复发负担与视力下降和视网膜变薄相关。在MOG+患者中,单克隆抗体治疗降低年化复发率(n=21;2[1-3] vs 0[0-2],p=0.024),主要由托珠单抗驱动(n=11;2[1-3] vs 0[0-1],p=0.023)。在MOG-患者中,利妥昔单抗和硫唑嘌呤显示年化复发率下降趋势。CRION是一种包含不同亚组的异质性综合征。MOG+患者疾病活动度较高,托珠单抗可能成为治疗选择,但仍需进一步验证。血清学检测对治疗分层和预防复发至关重要。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42777167
Antibodies against LGI1 and CASPR2 (LGI1/CASPR2-IgG) associate with forms of autoimmune encephalitis (AE) that improve with immunotherapy but often show long-term residual disability. We aimed to investigate whether autoantibody effector functions contribute to pathogenic mechanisms and might act as prognostic biomarkers in patients with LGI1/CASPR2-AE. We included patients with LGI1/CASPR2-AE, sufficient clinical information, and 1 serum sample available. We assessed the functional profile of LGI1/CASPR2-IgG using in vitro cell-based assays for complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and antibody-dependent cellular cytotoxicity (ADCC). Outcome was measured using the modified Rankin Scale (mRS) and the Clinical Assessment Scale in AE. We enrolled 55 patients (LGI1 = 31 and CASPR2 = 24). Coexistent ADCC and ADCP (ADCC+/ADCP+) were found in 28/55 patients (10/31 with LGI1 and 18/24 with CASPR2), while an isolated ADCP (ADCC-/ADCP+) was detected in 15 patients (12 with LGI1-IgG and 3 with CASPR2-IgG), and an isolated ADCC (ADCC+/ADCP-) was detected in 2 LGI1-IgG-positive patients. Because most patients (84%) showed a combination of IgG1/IgG3 and IgG4 subclass, no specific functional profiles could be identified according to the predominant subclass. Quantitative ADCP levels showed only a moderate correlation with CASPR2/LGI1-IgG titers (rho = 0.35, p = 0.02), while ADCC showed a moderate/strong correlation (rho = 0.54, p = 0.002). None of the patients showed CDC activation. In a multivariate logistic regression model (including functional profile, rituximab treatment, relapsing course, and cognitive impairment at onset), the ADCC+/ADCP + profile was the only predictor of poor outcome (mRS > 1, OR: 10.97 [95% CI 1.96-106.9]; p = 0.014). ADCC and ADCP, but not CDC, are common effector functions of LGI1/CASPR2-IgG, and their presence correlates with long-term poor outcome, suggesting that they might represent a useful prognostic biomarker and suggest additional pathogenic mechanisms. We provide the proof- of principle for a framework that could be applied to other autoantibody-mediated disorders.
中文摘要:LGI1与CASPR2抗体(LGI1/CASPR2-IgG)与一类自身免疫性脑炎(AE)相关,这类AE经免疫治疗可改善,但常遗留长期残疾。研究拟探讨自身抗体效应功能是否参与致病机制,并可否作为LGI1/CASPR2-AE患者的预后生物标志物。纳入临床资料充分且至少有1份血清样本的LGI1/CASPR2-AE患者。采用体外细胞实验评估LGI1/CASPR2-IgG的功能特征,包括补体依赖细胞毒作用(CDC)、抗体依赖细胞吞噬作用(ADCP)和抗体依赖细胞毒作用(ADCC)。结局采用改良Rankin量表(mRS)和AE临床评估量表衡量。共纳入55例患者(LGI1=31例,CASPR2=24例)。28/55例(LGI1 10/31例,CASPR2 18/24例)同时存在ADCC和ADCP(ADCC+/ADCP+),15例(LGI1-IgG 12例,CASPR2-IgG 3例)仅检出ADCP(ADCC-/ADCP+),2例LGI1-IgG阳性患者仅检出ADCC(ADCC+/ADCP-)。多数患者(84%)呈IgG1/IgG3与IgG4亚类组合,故未能依据优势亚类识别特定功能特征。ADCP定量水平与CASPR2/LGI1-IgG滴度仅呈中度相关(rho=0.35,p=0.02),ADCC则呈中度/强相关(rho=0.54,p=0.002)。无患者显示CDC激活。在多因素logistic回归模型(纳入功能特征、利妥昔单抗治疗、复发病程和起病时认知障碍)中,ADCC+/ADCP+特征是唯一的不良结局预测因素(mRS>1,OR 10.97 [95% CI 1.96-106.9];p=0.014)。ADCC和ADCP是LGI1/CASPR2-IgG常见效应功能,CDC则否,其存在与长期不良结局相关,提示其可能是有用的预后生物标志物,并提示额外的致病机制。研究为可应用于其他自身抗体介导疾病的框架提供了概念验证。
Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42715496
To describe clinical outcomes following daratumumab therapy in severe anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis, including a literature review. We report 2 patients with severe anti-NMDAR encephalitis treated with anti-CD38 daratumumab after failure of multiple immunotherapies. Clinical data, treatments, and outcomes were analyzed retrospectively. A PubMed literature review identified 4 additional cases. Both patients (21 and 19 years) presented with severe anti-NMDAR encephalitis characterized by neuropsychiatric symptoms, seizures, abnormal movements, and dysautonomia. Modified Rankin Scale (mRS) reached rapidly 5 in both cases and required ICU transfer within the first 2 weeks of hospitalization. Despite high-dose methylprednisolone, IV immunoglobulin, plasma exchange, rituximab, and cyclophosphamide, neither patient showed improvement. Daratumumab (1800 mg s/c) was initiated 40 and 14 weeks after onset, respectively. Clinical improvement occurred within weeks after treatment initiation, with gradual recovery of cognitive and functional abilities and ultimately regained functional independence (mRS 0). Literature review identified 4 additional cases of anti-NMDAR encephalitis treated with daratumumab; most patients showed substantial neurologic improvement. These observations suggest that specific plasma cell-targeted therapy may be beneficial in severe anti-NMDAR encephalitis, potentially through reduction of pathogenic autoantibody production. However, current evidence is limited to uncontrolled reports, and further studies are needed to clarify optimal timing, efficacy, and safety.
中文摘要:报告2例重症抗NMDAR脑炎患者在接受达雷妥尤单抗治疗后的临床结局,并进行文献复习。两例患者均在多种免疫治疗失败后接受抗CD38达雷妥尤单抗治疗,对其临床资料、治疗及结局进行回顾性分析。PubMed文献复习另发现4例相关病例。两例患者分别为21岁和19岁,均表现为重症抗NMDAR脑炎,出现神经精神症状、癫痫发作、异常运动及自主神经功能障碍。两例患者改良Rankin量表(mRS)评分均迅速达到5分,并在住院前2周内转入ICU。尽管接受大剂量甲泼尼龙、静脉注射免疫球蛋白、血浆置换、利妥昔单抗和环磷酰胺治疗,两例患者均无改善。分别于起病后40周和14周开始达雷妥尤单抗1800 mg皮下注射。治疗后数周内出现临床改善,认知和功能能力逐渐恢复,最终恢复功能独立(mRS 0)。文献复习发现另外4例接受达雷妥尤单抗治疗抗NMDAR脑炎的病例,多数患者获得明显神经系统改善。这些观察提示,针对浆细胞的特异性治疗可能对重症抗NMDAR脑炎有益,机制可能在于减少致病性自身抗体产生。目前证据仅限于非对照报告,仍需进一步研究明确最佳治疗时机、疗效和安全性。

11糖尿病并发症 (2篇)

临床研究 (2篇)

Diabetologia IF 10.4 2026-11-03 PMID: 42975645
Non-healing diabetic foot ulcers are a major precursor to lower-extremity amputation (LEA) in diabetes, and gout may be an overlooked contributor. We hypothesised that individuals with both diabetes and gout have a higher risk of LEA than those with diabetes alone, with the strongest effect at more distal amputation levels. In a nationwide case-control study of 601,541 individuals with type 2 diabetes, we identified 4912 cases with LEA and 39,101 age- and sex-matched control participants. Gout exposure was determined using ICD-10 diagnoses and Anatomical Therapeutic Chemical codes for urate-lowering therapy. Associations were estimated using conditional logistic regression, adjusting for diabetes duration, peripheral arterial disease, acute myocardial infarction and late diabetes complications. Gout was associated with an increased risk of LEA (OR 1.85, 95% CI 1.69, 2.02) in unadjusted analyses, and the association remained significant after full adjustment (OR 1.53, 95% CI 1.37, 1.69). A significant trend (p=0.03) was observed across amputation levels, with potentially higher risk at more anatomically distal sites although no statistically significant differences were observed between individual amputation levels: OR 1.37 (95% CI 1.12, 1.68) for above-knee amputations, increasing to OR 1.65 (95% CI 1.32, 2.05) for toe amputations. Co-existing gout is an independent risk factor for LEA in individuals with type 2 diabetes. The risk is elevated across all amputation levels, with the most pronounced effect potentially being at distal anatomical sites. These findings highlight the need for increased awareness of gout when managing individuals with type 2 diabetes at risk of LEA.
中文摘要:不愈合的糖尿病足溃疡是糖尿病患者下肢截肢(LEA)的主要前驱病变,痛风可能是被忽视的促发因素。研究假设同时患糖尿病和痛风者比单纯糖尿病者LEA风险更高,且效应在更远端截肢水平最强。这项全国性、基于登记的病例对照研究纳入601,541例2型糖尿病个体,识别出4,912例LEA病例和39,101名按年龄、性别匹配的对照。痛风暴露依据ICD-10诊断和降尿酸治疗的ATC编码确定。采用条件logistic回归估计关联,并校正糖尿病病程、外周动脉疾病、急性心肌梗死和糖尿病晚期并发症。未校正分析中,痛风与LEA风险升高相关(OR 1.85,95% CI 1.69, 2.02),充分校正后关联仍有统计学意义(OR 1.53,95% CI 1.37, 1.69)。不同截肢水平间观察到显著趋势(p=0.03),解剖位置越远端风险可能越高,但各截肢水平之间未见统计学显著差异:膝上截肢OR 1.37(95% CI 1.12, 1.68),至足趾截肢升至OR 1.65(95% CI 1.32, 2.05)。合并痛风是2型糖尿病个体LEA的独立危险因素。各截肢水平风险均升高,远端解剖部位效应可能最明显。这些发现提示,在管理有LEA风险的2型糖尿病个体时需提高对痛风的重视。
Diabetologia IF 10.4 2026-11 PMID: 42633598
Nearly 40% of African adults with type 2 diabetes are lean (BMI <25 kg/m2). Emerging evidence suggests that type 2 diabetes in African individuals who are lean may represent a distinct phenotype driven by impaired insulin secretion rather than insulin resistance, raising concerns about treatment mismatch and divergent disease outcomes. We examined complication profiles in Africans with type 2 diabetes who are lean vs overweight/obese. We analysed harmonised, individual-level cross-sectional data from two large, well-characterised African cohorts (Africa America Diabetes Mellitus study, n=2790; Research on Obesity and Diabetes among African Migrants study, n=541; total n=3331) of adults with type 2 diabetes from Ghana, Nigeria and Kenya. Participants were classified as lean (BMI <25 kg/m2) or overweight/obese (BMI ≥25 kg/m2). Robust Poisson regression, adjusted for age, sex, education and treatment, assessed associations with retinopathy, chronic kidney disease, stroke, hypertension and 10-year cardiovascular disease risk. Cohort-specific estimates were pooled using random effects, followed by mediation analysis examining contributions of lifestyle and metabolic markers to observed differences. Type 2 diabetes in Africans who are lean was characterised by lower beta cell function and low insulin levels. Compared with individuals who are overweight/obese, adults who are lean showed a higher prevalence of retinopathy (pooled prevalence ratio [pPR] 1.36 [95% CI 1.13, 1.63]) and stroke (pPR 1.41 [95% CI 1.01, 1.99]), but lower hypertension (pPR 0.77 [95% CI 0.71, 0.85]) and 10-year cardiovascular disease risk (pPR 0.85 [95% CI 0.74, 0.97]). Chronic kidney disease prevalence did not differ between groups. Body fat percentage accounted for most differences (up to 92%). Complication patterns in Africans with type 2 diabetes who are lean vs overweight/obese follow divergent paths. In Africa, where nearly 24 million people have type 2 diabetes, two-fifths of whom are lean, our findings add to growing evidence that lean type 2 diabetes may be a distinct phenotype, underscoring the urgent need for investigation into better-targeted management for this large, potentially mistreated, population.
中文摘要:近40%的非洲2型糖尿病成人属于瘦型(BMI<25 kg/m2)。新出现的证据提示,非洲瘦型个体的2型糖尿病可能是一种由胰岛素分泌受损而非胰岛素抵抗驱动的不同表型,这引发了对治疗不匹配和疾病结局差异的担忧。我们考察了非洲瘦型与超重/肥胖2型糖尿病患者的并发症谱。我们分析了两个大型、特征明确的非洲队列(Africa America Diabetes Mellitus研究,n=2790;Research on Obesity and Diabetes among African Migrants研究,n=541;总计n=3331)中来自加纳、尼日利亚和肯尼亚的2型糖尿病成人的统一个体水平横断面数据。参与者被分为瘦型(BMI<25 kg/m2)或超重/肥胖(BMI≥25 kg/m2)。稳健泊松回归在调整年龄、性别、教育和治疗后,评估与视网膜病变、慢性肾脏病、卒中、高血压和10年心血管疾病风险的关联。各队列估计值采用随机效应模型合并,随后进行中介分析,考察生活方式和代谢指标对观察到的差异的贡献。非洲瘦型2型糖尿病的特征是β细胞功能较低和胰岛素水平低。与超重/肥胖个体相比,瘦型成人视网膜病变患病率更高(合并患病率比[pPR] 1.36 [95% CI 1.13, 1.63]),卒中患病率更高(pPR 1.41 [95% CI 1.01, 1.99]),但高血压患病率更低(pPR 0.77 [95% CI 0.71, 0.85]),10年心血管疾病风险更低(pPR 0.85 [95% CI 0.74, 0.97])。慢性肾脏病患病率在两组间无差异。体脂百分比解释了多数差异(高达92%)。非洲瘦型与超重/肥胖2型糖尿病患者的并发症模式沿不同路径发展。在非洲,近2400万人患有2型糖尿病,其中五分之二为瘦型;我们的发现进一步支持瘦型2型糖尿病可能是不同表型的证据,并强调迫切需要研究对这一庞大且可能治疗不当的人群进行更有针对性的管理。

12心血管疾病 (2篇)

临床研究 (2篇)

Circulation IF 41.3 2026-11-03 PMID: 42708217
Cardiac troponin is increasingly used for cardiovascular risk prediction. While abnormal values often reflect subclinical cardiovascular disease, they can be raised due to interference, where antibodies influence the assay or clearance of troponin from the circulation by forming macrotroponin complexes. The frequency of macrotroponins and its association with future risk are unknown. In a general population cohort, participants with both cardiac troponin I and T measurements available (n=19 499, median 49 [25th-75th percentile, 36-58] years of age, 58.3% women) were categorized into 3 groups: no myocardial injury (neither cardiac troponin I or T was elevated), suspected macrotroponin (either cardiac troponin was elevated and discordant with a >3-fold difference in concentration), and myocardial injury (either cardiac troponin was elevated without discordance). Macrotroponin complex formation was verified in a subset of samples (n=203) using immunoglobulin depletion and ultracentrifugation. Associations with future myocardial infarction, ischemic stroke, or cardiovascular death were evaluated using Cox proportional hazards models adjusted for known cardiovascular risk factors. The generalizability of our findings was determined through replication in a second general population cohort study. Elevated cardiac troponin I was present in 1% (193 of 19 499) of participants and elevated cardiac troponin T in 6% (1159 of 19 499). Among those, 48% and 57% were discordant, respectively. Biochemical testing attributed 92.5% of discordant troponin I and 15.4% of discordant troponin T to macrotroponin complexes. Participants with myocardial injury were at increased risk of future cardiovascular events compared with those without (cardiac troponin I: adjusted hazard ratio [HR], 2.90 [95% CI, 1.99-4.22]; cardiac troponin T: adjusted HR, 1.99 [95% CI, 1.63-2.42]), whereas those with suspected macrotroponin had similar risk as those without elevated values for suspected macrotroponin I (adjusted HR, 1.59 [95% CI, 0.94-2.70]) and T (adjusted HR, 1.27 [95% CI, 1.00-1.61]). Findings were similar in the replication cohort. Assay interference due to macrotroponin complex formation is common in individuals with elevated cardiac troponin concentrations in the general population, particularly for cardiac troponin I. This has important implications for the use of cardiac troponin testing for cardiovascular risk assessment in the general population.
中文摘要:心脏肌钙蛋白越来越多用于心血管风险预测。异常值常反映亚临床心血管病,但也可能因干扰而升高,即抗体影响检测,或通过形成巨肌钙蛋白复合物改变肌钙蛋白从循环中的清除。巨肌钙蛋白的出现频率及其与未来风险的关系尚不清楚。在一项一般人群队列中,同时具备心脏肌钙蛋白I和T测量值的参与者(n=19499,中位年龄49岁,25至75百分位36至58岁,女性58.3%)被分为3组:无心肌损伤(肌钙蛋白I和T均未升高)、疑似巨肌钙蛋白(任一肌钙蛋白升高且两者浓度差异超过3倍而不一致)、心肌损伤(任一肌钙蛋白升高但无不一致)。在部分样本(n=203)中通过免疫球蛋白去除和超速离心验证巨肌钙蛋白复合物形成。使用校正已知心血管危险因素的Cox比例风险模型评估其与未来心肌梗死、缺血性卒中或心血管死亡的关系。通过在第二项一般人群队列研究中复现以判断结果的普遍性。心脏肌钙蛋白I升高见于1%(193/19499)的参与者,心脏肌钙蛋白T升高见于6%(1159/19499)。其中分别有48%和57%存在不一致。生化检测将92.5%的不一致肌钙蛋白I和15.4%的不一致肌钙蛋白T归因于巨肌钙蛋白复合物。与无心肌损伤者相比,心肌损伤者未来心血管事件风险升高(心脏肌钙蛋白I:校正风险比HR 2.90,95%CI 1.99-4.22;心脏肌钙蛋白T:校正HR 1.99,95%CI 1.63-2.42);而疑似巨肌钙蛋白者的风险与无升高者相近,疑似巨肌钙蛋白I的校正HR为1.59(95%CI 0.94-2.70),疑似巨肌钙蛋白T的校正HR为1.27(95%CI 1.00-1.61)。复现队列中的结果相似。在一般人群中,心脏肌钙蛋白浓度升高者因巨肌钙蛋白复合物形成导致检测干扰较常见,尤其是心脏肌钙蛋白I。这对一般人群中使用心脏肌钙蛋白检测进行心血管风险评估具有重要意义。
European journal of preventive cardiology IF 10.0 2026-11-02 PMID: 42968334
To evaluate the association of PCSK9-targeting therapies with mortality and cardiovascular events in stable or clinically stabilized randomized trial populations. We systematically reviewed randomized trials comparing alirocumab, evolocumab or inclisiran with placebo or active control. The review was registered in PROSPERO (CRD420261395609). Treatment effects were pooled as incidence rate ratios (IRRs) using random-effects models. The primary outcome was all-cause mortality. Prespecified subgroup analyses were based on trial-level known atherosclerosis status, as defined by enrollment criteria. Thirty-two trials enrolled 77,178 participants. Individual atherosclerosis status could not be determined beyond trial-level eligibility criteria. Mortality estimates were predominantly informed by large cardiovascular outcome trials. All-cause mortality was lower with PCSK9-targeting therapy (IRR 0.88, 95% CI 0.82-0.95). Estimates favored PCSK9-targeting treatment in both trials requiring known atherosclerosis for enrollment (IRR 0.90, 95% CI 0.83-0.98) and trials without such an enrollment requirement (IRR 0.78, 95% CI 0.62-0.97; interaction p = 0.21). PCSK9-targeting treatment additionally reduced myocardial infarction, stroke, and coronary revascularization rates. Leave-one-out estimates remained directionally consistent. PCSK9-targeting therapies were associated with lower all-cause mortality and fewer ischemic events across trial populations. The predominant contribution of large cardiovascular outcome trials enrolling populations with known atherosclerosis and using PCSK9 antibodies limits the ability to infer a survival benefit in populations not selected on the basis of atherosclerosis status and across individual therapies, particularly inclisiran.
中文摘要:在稳定或临床稳定的随机试验人群中,评估靶向PCSK9治疗与死亡及心血管事件的关联。系统检索比较阿利西尤单抗、依洛尤单抗或英克司兰与安慰剂或活性对照的随机试验,方案在PROSPERO注册(CRD420261395609)。采用随机效应模型,将治疗效应合并为发病率比(IRR)。主要结局为全因死亡。预设亚组分析依据试验入组标准所定义的试验层面已知动脉粥样硬化状态。共纳入32项试验、77,178名受试者。除试验层面的入组标准外,无法确定个体动脉粥样硬化状态。死亡估计主要来自大型心血管结局试验。靶向PCSK9治疗的全因死亡率更低(IRR 0.88,95% CI 0.82-0.95)。在要求入组时已知动脉粥样硬化的试验(IRR 0.90,95% CI 0.83-0.98)与无此入组要求的试验(IRR 0.78,95% CI 0.62-0.97;交互作用p=0.21)中,估计值均支持靶向PCSK9治疗。靶向PCSK9治疗还降低心肌梗死、卒中和冠状动脉血运重建率。逐一剔除分析的估计方向保持一致。靶向PCSK9治疗与较低的全因死亡率和较少的缺血事件相关。大型心血管结局试验以已知动脉粥样硬化人群为主且使用PCSK9抗体,这一主要贡献限制了在非按动脉粥样硬化状态选择的人群中以及在各单个治疗之间推断生存获益的能力,尤其是英克司兰。

13神经遗传 (2篇)

基础研究 (2篇)

Annals of neurology IF 7.5 2026-11 PMID: 42538636
Repeat expansion mutations underlie diverse neurogenetic disorders, many involving the peripheral nervous system. Despite peripheral neuropathy being the most common neurological disorder worldwide, its contribution to repeat expansion diseases remains poorly defined, and robust preclinical models are limited. We established a translational framework to study peripheral neuropathy in spinocerebellar ataxia type 3 (SCA3), a fatal multisystem disorder caused by a pathogenic CAG expansion in ATXN3. SCA3 Knock-In Atxn3Q300/Q6 (KI) and Atxn3-/- Knock-Out (KO) mice underwent sensorimotor nerve conduction and behavioral testing. Peripheral tissues were evaluated for SCA3-related pathology, and transcriptional changes in KI dorsal root ganglia (DRG) were assessed by bulk RNA sequencing. To test therapeutic relevance, we generated a conditional "OFF" SCA3 knock-in (cKI) mouse and crossed it with Avil-Cre to selectively silence mutant ATXN3 in sensory neurons. Peripheral phenotyping was repeated in Avil-Cre; cKI mice. KI mice developed progressive sensorimotor deficits, peripheral histopathology, and RNA splicing dysregulation that parallel clinical features of SCA3. In contrast, KO mice showed normal peripheral nerve function, implicating toxic gain-of-function from mutant ATXN3 as the causative driver. Sensory neuron-specific silencing of mutant ATXN3 significantly ameliorated peripheral nerve abnormalities and DRG splicing dysregulation. These findings define a pathogenic role for repeat expansion-driven peripheral nerve degeneration in SCA3, identify sensory neurons as key therapeutic targets, and provide a preclinical platform for developing peripheral interventions in SCA3 and related repeat expansion disorders. ANN NEUROL 2026;100:1039-1054.
中文摘要:重复扩增突变是多种神经遗传病的基础,许多累及周围神经系统。周围神经病虽为全球最常见神经系统疾病,但其在重复扩增疾病中的作用仍不明确,可靠的临床前模型有限。我们建立了一个转化研究框架,用于研究脊髓小脑共济失调3型(SCA3)的周围神经病;SCA3由ATXN3致病性CAG扩增导致,是一种致死性多系统疾病。对SCA3敲入Atxn3Q300/Q6(KI)小鼠和Atxn3-/-敲除(KO)小鼠进行感觉运动神经传导和行为学检测。评估周围组织的SCA3相关病理,并用bulk RNA测序分析KI小鼠背根神经节(DRG)的转录改变。为检验治疗相关性,我们构建条件性「关闭」SCA3敲入(cKI)小鼠,并与Avil-Cre杂交,以在感觉神经元中选择性沉默突变ATXN3。在Avil-Cre; cKI小鼠中重复周围表型分析。KI小鼠出现进行性感觉运动缺陷、周围组织病理学改变和RNA剪接失调,与SCA3临床特征平行。相比之下,KO小鼠周围神经功能正常,提示突变ATXN3的毒性功能获得是致病驱动因素。感觉神经元特异性沉默突变ATXN3显著改善周围神经异常和DRG剪接失调。这些发现确定了重复扩增驱动的周围神经变性在SCA3中的致病作用,将感觉神经元确定为关键治疗靶点,并为开发SCA3及相关重复扩增疾病的周围干预提供临床前平台。ANN NEUROL 2026;100:1039-1054。
Molecular psychiatry IF 10.4 2026-11 PMID: 42410084
SCN2A encodes the voltage-gated sodium channel NaV1.2, a central regulator of action potential initiation and propagation in glutamatergic neurons, and one of the strongest single-gene risk factors for autism spectrum disorder. Premature termination codons in SCN2A are widely considered to produce uniform haploinsufficiency through nonsense-mediated mRNA decay, an assumption that underpins current mechanistic and therapeutic models. We generated two mouse lines carrying patient-derived mutations - Scn2aY84X/+ (p.Tyr84UAA; early coding sequence) and Scn2aR1627X/+ (p.Arg1627UGA; terminal coding exon). We assessed allele-specific mRNA expression, NaV1.2 protein expression, ex vivo whole-cell recordings, and behavioral phenotypes in these mice. Allele-specific RNA handling diverged by position: mRNA carrying Y84X engaged partial nonsense-mediated decay, whereas R1627X transcripts were at allelic balance. Despite this difference in RNA fate, NaV1.2 protein was comparably reduced in both lines. Both variants slowed the action potential upstroke, with a larger decrement in Scn2aY84X/+. Spike threshold was depolarized only in Scn2aY84X/+. Mutant neurons showed reduced firing near rheobase. Both lines exhibited increased grooming, but Scn2aY84X/+ alone showed greater exploration and a male-predominant rotarod learning deficit. Locomotion, sociability, and sensorimotor gating were preserved. In maximal electroshock testing, mortality was reduced in both lines without changes in seizure threshold or severity. Our results show that SCN2A premature termination codon position determines allele-specific effects on neuronal excitability and behavior, where both NMD and phenotypes of the Scn2aY84X/+ line are more penetrant. These data challenge the assumption of uniform haploinsufficiency and directly support allele-tailored mechanistic studies and therapeutic strategies.
中文摘要:SCN2A编码电压门控钠通道NaV1.2,是谷氨酸能神经元动作电位起始和传导的核心调控因子,也是孤独症谱系障碍最强的单基因风险因素之一。SCN2A的无义突变通常被认为通过无义介导的mRNA降解(NMD)产生一致的 haploinsufficiency,这一假设支撑了当前的机制与治疗模型。研究构建了携带患者来源突变的两株小鼠:Scn2aY84X/+(p.Tyr84UAA,编码序列早期)和Scn2aR1627X/+(p.Arg1627UGA,末端编码外显子)。检测了等位基因特异性mRNA表达、NaV1.2蛋白表达、离体全细胞记录和行为表型。等位基因特异性RNA处理随突变位置而不同:携带Y84X的mRNA发生部分NMD,而R1627X转录本处于等位基因平衡。尽管RNA命运不同,两株小鼠NaV1.2蛋白均 comparable 降低。两种变异均减慢动作电位上升支,Scn2aY84X/+下降更明显。尖峰阈值仅在Scn2aY84X/+中去极化。突变神经元在基强度附近放电减少。两株小鼠均表现梳理行为增加,但仅Scn2aY84X/+表现探索增加和雄性占优的转棒学习缺陷。运动、社交能力和感觉运动门控保留。最大电休克测试中,两株小鼠死亡率均降低,癫痫阈值和严重程度无变化。结果说明SCN2A无义突变位置决定其对神经元兴奋性和行为的等位基因特异性效应,其中Scn2aY84X/+的NMD和表型更具外显性。这些数据挑战了一致性 haploinsufficiency 的假设,并直接支持按等位基因定制的机制研究和治疗策略。

14神经退行病 (1篇)

基础研究 (1篇)

Translational neurodegeneration IF 19.1 2026-11-04 PMID: 42983584
Protein aggregation and impaired clearance constitute central pathological hallmarks of numerous neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia. Misfolded proteins, both extracellular and intracellular, disrupt proteostasis and contribute to synaptic dysfunction, neuroinflammation, and neuronal loss. Within the central nervous system, glial cells serve as the primary mediators of pathological protein clearance. Microglia detect, phagocytose, and degrade aggregated proteins. However, under chronic pathological stress, microglial function turns from clearing pathological proteins to paradoxically facilitating their spread. Astrocytes, which provide metabolic and homeostatic support for neurons, also participate in the clearance of aggregates through phagocytosis and glymphatic drainage. Critically, crosstalk between astrocytes and microglia enhances the clearance: microglia can recruit and process aggregates internalized by astrocytes, while astrocyte-derived signals modulate the microglial phagocytic activity. Aging, genetic risk factors, or sustained neuroinflammation may reduce the efficiency of glial removal of aggregates and accelerate disease progression. Understanding the cellular and molecular underpinnings of microglial and astrocytic clearance pathways is essential for developing therapies aimed at restoring proteostasis and mitigating neurodegeneration.
中文摘要:蛋白聚集与清除受损是多种神经退行性疾病的中心病理特征,包括阿尔茨海默病、帕金森病、肌萎缩侧索硬化症和额颞叶痴呆。细胞外和细胞内的错误折叠蛋白破坏蛋白稳态,并促成突触功能障碍、神经炎症和神经元丢失。在中枢神经系统中,胶质细胞是病理性蛋白清除的主要介导者。小胶质细胞识别、吞噬并降解聚集蛋白。然而,在慢性病理应激下,小胶质细胞的功能从清除病理性蛋白转变为反而促进其扩散。星形胶质细胞为神经元提供代谢和稳态支持,也通过吞噬作用和类淋巴引流参与聚集体清除。星形胶质细胞与小胶质细胞之间的相互作用可增强清除:小胶质细胞能够招募并处理星形胶质细胞内吞的聚集体,星形胶质细胞来源的信号则调节小胶质细胞的吞噬活性。衰老、遗传风险因素或持续存在的神经炎症可能降低胶质细胞清除聚集体的效率,并加速疾病进展。理解小胶质细胞和星形胶质细胞清除通路的细胞与分子基础,对于开发旨在恢复蛋白稳态和减轻神经退行性变的治疗策略至关重要。

15TDP-43蛋白病 (1篇)

基础研究 (1篇)

Journal of biomedical science IF 14.5 2026-11-04 PMID: 42983429
Pathological aggregation of Tar DNA-binding protein 43 (TDP-43) and disruption of neuronal protein homeostasis are defining features of amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), and related TDP-43 proteinopathies. Efficient axonal transport of proteasomes is essential for maintaining local protein quality control in neurons. Proteasome inhibitor 31 (PI31) regulates both 26S proteasome assembly and dynein-mediated transport of 20S proteasomes. Although Tankyrase 1/2 (TNKS)-mediated ADP-ribosylation of PI31 promotes 26S proteasome assembly, its role in proteasome transport and its contribution to TDP-43 pathology remain unclear. Live-cell imaging was performed to examine 20S proteasome transport in primary cortical and motor neurons from wild-type and Prp-TDP-43A315T transgenic mice. Protein interactions among TDP-43, TNKS, and PI31 were analyzed by immunoprecipitation and Förster resonance energy transfer (FRET). Insoluble protein accumulation and colocalization were assessed by RIPA/urea fractionation, Western blotting, and immunofluorescence. Proteasome assembly and activity were evaluated using native gel electrophoresis and a 20S proteasome-specific fluorogenic substrate. TDP-43 aggregation was examined by semi-denaturing detergent agarose gel electrophoresis (SDD-AGE). In cell models expressing TDP-43-FL, TDP-43-A315T, or TDP-25 and in Prp-TDP-43A315T transgenic mice, pathological TDP-43 species formed distinct aggregates, ranging from oligomers to prominent cytoplasmic aggregates, yet all reduced proteasome activity, impaired axonal proteasome transport, and caused the accumulation of polyubiquitinated proteins, PI31, 20S proteasomes, and TDP-43 in the proximal axon and cell body. Pathological TDP-43 sequestered TNKS and proteasome components into insoluble fractions, thereby limiting the availability of free and soluble TNKS for interaction with PI31 and subsequent PI31 ADP-ribosylation, ultimately impairing 19S/20S proteasome assembly. Notably, disruption of the TNKS-PI31 interaction or inhibition of TNKS activity recapitulated the proteasome dysfunction induced by pathological TDP-43, supporting a role for the aberrant TNKS-TDP-43 interaction and consequent impairment of TNKS-mediated PI31 ADP-ribosylation in TNKS/PI31/proteasome axis dysfunction. Pathological TDP-43 disrupts proteasome function by impairing the TNKS/PI31/proteasome axis, suggesting that this axis may represent a potential therapeutic target for TDP-43 proteinopathies. Selectively restoring this pathway may enhance pathological TDP-43 clearance while minimizing nonspecific proteasome activation, thereby providing a more precise and safer therapeutic strategy for ALS and FTLD.
中文摘要:TAR DNA结合蛋白43(TDP-43)的病理性聚集和神经元蛋白稳态破坏是肌萎缩侧索硬化(ALS)、额颞叶变性(FTLD)及相关TDP-43蛋白病的标志性特征。蛋白酶体的高效轴突运输对维持神经元局部蛋白质量控制至关重要。蛋白酶体抑制剂31(PI31)既调控26S蛋白酶体组装,也调控动力蛋白介导的20S蛋白酶体运输。端锚聚合酶1/2(TNKS)介导的PI31 ADP-核糖基化可促进26S蛋白酶体组装,但其在蛋白酶体运输中的作用及对TDP-43病理的贡献仍不清楚。研究采用活细胞成像检测野生型和Prp-TDP-43A315T转基因小鼠原代皮层神经元与运动神经元中的20S蛋白酶体运输。通过免疫沉淀和荧光共振能量转移(FRET)分析TDP-43、TNKS与PI31之间的蛋白相互作用。用RIPA/尿素分级、蛋白免疫印迹和免疫荧光评估不溶性蛋白蓄积与共定位。用天然凝胶电泳和20S蛋白酶体特异性荧光底物评价蛋白酶体组装与活性。用半变性去垢剂琼脂糖凝胶电泳(SDD-AGE)检测TDP-43聚集。在表达TDP-43-FL、TDP-43-A315T或TDP-25的细胞模型及Prp-TDP-43A315T转基因小鼠中,病理性TDP-43种类形成从寡聚体到明显胞质聚集体的不同聚集体,但均降低蛋白酶体活性、损害轴突蛋白酶体运输,并导致多泛素化蛋白、PI31、20S蛋白酶体和TDP-43在近端轴突与胞体中蓄积。病理性TDP-43将TNKS和蛋白酶体组分隔离至不溶性组分,限制游离且可溶性TNKS与PI31相互作用及后续PI31 ADP-核糖基化,最终损害19S/20S蛋白酶体组装。破坏TNKS-PI31相互作用或抑制TNKS活性可重现病理性TDP-43诱导的蛋白酶体功能障碍,支持异常TNKS-TDP-43相互作用及由此导致的TNKS介导PI31 ADP-核糖基化受损在TNKS/PI31/蛋白酶体轴功能障碍中发挥作用。病理性TDP-43通过损害TNKS/PI31/蛋白酶体轴破坏蛋白酶体功能,提示该轴可能是TDP-43蛋白病的潜在治疗靶点。选择性恢复该通路或可增强病理性TDP-43清除,同时尽量减少非特异性蛋白酶体激活,从而为ALS和FTLD提供更精确、更安全的治疗策略。

16房颤与卒中 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-11-04 PMID: 42978109
To characterize sex-specific differences in clinical presentation, evaluate progression through the atrial fibrillation (AF) care pathway from diagnosis to catheter ablation (CA) and assess long-term outcomes. This was a retrospective cohort study of patients with incident AF at Northwell Health between 2015 and 2024 from the ITHACA-database. Sex-specific differences in clinical presentation were examined. The AF care pathway was operationalized as a stepwise cascade, modelling conditional drop-off to identify care gaps. Sex-specific CA risk ratios were assessed via Poisson regression. Incident AF was identified among 165 563/655 459 patients (71.4 ± 11.6 years, 32% non-white, 45% female) with a recorded diagnosis of AF. Women were older (73.3 ± 10.6 vs. 69.8 ± 12.1 years, P < 0.001), had higher rates of dementia (9.1% vs. 5.2%), stroke (8.6% vs. 7.4%) and congestive heart failure (21.5% vs. 20.8%) at diagnosis. Transfer-of-care gaps [median 3.6 years follow-up, 96% retention] were identified at every level: 31.5% of women vs. 35.3% of men were evaluated by cardiology, 16.2% vs. 21.6% by electrophysiology, and 3.5% vs. 5.7% underwent CA (all P < 0.001). Women were 16% less likely to receive CA (RR 0.84 95% CI 0.77-0.91). In cause-specific Cox models, female sex was associated with incident stroke (aHR 1.24, 95% CI 1.18-1.30) and dementia (aHR 1.30, 95% CI 1.24-1.35), but modestly lower mortality after adjustment (aHR 0.96, 95% CI 0.94-0.99). In this real-world analysis, significant sex-specific differences in clinical phenotype at presentation, progression through the AF care pathway and clinical outcomes were observed.
中文摘要:旨在描述房颤患者在临床表现上的性别差异,评估从诊断到导管消融的房颤诊疗路径中的推进情况,并评价长期结局。这是一项回顾性队列研究,纳入2015年至2024年Northwell Health中ITHACA数据库的新发房颤患者。研究检查了临床表现的性别差异。房颤诊疗路径被操作化为阶梯式级联,通过建模条件性流失识别诊疗缺口。通过泊松回归评估性别特异的导管消融风险比。655 459例患者中识别出165 563例新发房颤(71.4 ± 11.6岁,32%为非白人,45%为女性)且有房颤诊断记录。女性诊断时年龄更大(73.3 ± 10.6岁对比69.8 ± 12.1岁,P < 0.001),痴呆(9.1%对比5.2%)、卒中(8.6%对比7.4%)和充血性心力衰竭(21.5%对比20.8%)比例更高。每个层级均存在诊疗转移缺口[中位随访3.6年,96%留存]:31.5%女性和35.3%男性接受心内科评估,16.2%和21.6%接受电生理评估,3.5%和5.7%接受导管消融(所有P < 0.001)。女性接受导管消融的可能性低16%(RR 0.84,95% CI 0.77-0.91)。在病因特异性Cox模型中,女性与新发卒中(aHR 1.24,95% CI 1.18-1.30)和痴呆(aHR 1.30,95% CI 1.24-1.35)相关,但校正后死亡率略低(aHR 0.96,95% CI 0.94-0.99)。在这项真实世界分析中,观察到临床表现、房颤诊疗路径推进和临床结局存在显著性别差异。

17下丘脑与代谢 (1篇)

基础研究 (1篇)

Neuron IF 16.9 2026-11-03 PMID: 42976852
Organismal physiology depends on continuous, non-hierarchical communication among cells, tissues, and organs. We argue that this communication rests on metabolic flexibility-the capacity of cells and tissues to adapt substrate use to changing energetic demands-and that the hypothalamus serves as the central hub coordinating this flexibility across the body. Using hypothalamic agouti-related protein (AgRP) and pro-opiomelanocortin (POMC) neurons as a model, we show these melanocortin neurons do more than regulate hunger and satiety: by integrating metabolic, hormonal, and immune signals, they shape reward, learning, executive function, and social behavior, while imposing coordinated metabolic states on peripheral tissues. When this flexibility is lost, as with aging or overnutrition, body-brain communication becomes rigid, driving cognitive decline, chronic inflammation, and neurodegenerative disease. We propose that signals from the body are not peripheral modifiers of brain function but fundamental determinants of it, with direct implications for hypothalamus-centered strategies to preserve brain health across the lifespan.
中文摘要:机体生理功能依赖细胞、组织和器官之间持续、非层级化的通讯。我们认为,这种通讯建立在代谢灵活性之上,即细胞和组织根据不断变化的能量需求调整底物利用的能力;下丘脑则是协调全身这种灵活性的中枢枢纽。以下丘脑刺鼠相关蛋白(AgRP)和阿片-促黑素细胞皮质素原(POMC)神经元为模型,我们表明这些黑素皮质素神经元不止调控饥饿与饱腹:它们整合代谢、激素和免疫信号,塑造奖赏、学习、执行功能和社会行为,同时对外周组织施加协调一致的代谢状态。当这种灵活性丧失时,如衰老或营养过剩,身体与大脑之间的通讯变得僵化,推动认知下降、慢性炎症和神经退行性疾病。我们提出,来自身体的信号并非脑功能的外周修饰因素,而是脑功能的基本决定因素,这对以下丘脑为中心、在生命全程维护脑健康的策略具有直接意义。

18环境神经毒理 (1篇)

基础研究 (1篇)

Environmental science & technology IF 12.2 2026-11-03 PMID: 42975484
Petroleum pollution poses a major challenge to global environmental health. Petroleum-derived naphthenic acids (NAs) are frequently detected in marine environments, yet their multidimensional toxicity and mechanisms remain poorly understood. Here, we developed an integrated toxicity framework combining bioassays, toxicity screening, computational simulations, transcriptomics, and bioinformatics to characterize NAs toxicity in marine medaka (Oryzias melastigma). A concentration gradient spanning environmentally detected levels to higher-effect concentrations (0.015-30 mg/L) revealed developmental defects, cardiac suppression, behavioral disruption, and metabolic dysfunction. CRITIC-AHP-based prioritization identified neurotoxicity as the predominant toxicity dimension, with cyclopentylpropionic acid (CPPA) and cyclohexylpropionic acid (CHPA) identified as major contributors. Mechanistically, these compounds were associated with distinct candidate pathways involving CXCR3-CXCL10 neuroinflammatory responses and DPP10-Kv4.2 ion homeostasis disruption. Their divergent toxicity profiles may be associated with differences in hydrophobicity and molecular flexibility. Rescue experiments supported these pathways, restoring swimming velocity by 60.32% and 62.09%, respectively. Furthermore, NAs induced neurobehavioral alterations and transcriptional signatures overlapping with Alzheimer's disease-associated genes, with 14 and 12 candidate genes identified for CPPA and CHPA. Collectively, this study provides a cross-scale perspective linking physicochemical properties, toxicity pathways, and adverse outcomes of NAs, offering a conceptual approach for toxicity screening and mechanism elucidation of contaminants.
中文摘要:石油污染对全球环境健康构成重大挑战。石油来源的环烷酸(NAs)在海洋环境中常被检出,其多维毒性和机制仍未充分阐明。研究构建了整合生物测定、毒性筛选、计算模拟、转录组学和生物信息学的毒性评估框架,用于表征NAs对海洋青鳉(Oryzias melastigma)的毒性。覆盖环境检出水平至较高效应浓度的梯度(0.015–30 mg/L)显示出发育缺陷、心脏抑制、行为紊乱和代谢功能障碍。基于CRITIC-AHP的优先级评估将神经毒性列为主要毒性维度,环戊基丙酸(CPPA)和环己基丙酸(CHPA)被确定为主要贡献物。机制上,这些化合物与涉及CXCR3-CXCL10神经炎症反应和DPP10-Kv4.2离子稳态破坏的候选通路相关。其毒性谱差异可能与疏水性和分子柔性差异有关。救援实验支持这些通路,分别使游动速度恢复60.32%和62.09%。NAs诱导的神经行为改变和转录特征与阿尔茨海默病相关基因存在重叠,CPPA和CHPA分别鉴定出14个和12个候选基因。该研究提供了连接NAs理化性质、毒性通路和不良结局的跨尺度视角,为污染物毒性筛选和机制阐明提供了概念性方法。

19昼夜节律调控 (1篇)

基础研究 (1篇)

Pharmacological research IF 12.2 2026-11-02 PMID: 42971417
Circadian rhythms are endogenous, approximately 24-hour oscillations that align physiology and behavior with the environmental light-dark cycle and support homeostasis. In mammals, the suprachiasmatic nucleus (SCN) serves as the central circadian pacemaker, but its neuronal projections are restricted to a relatively small set of hypothalamic targets. The hypothalamic paraventricular nucleus (PVN) is an important downstream integrative node that receives direct and indirect temporal signals from the SCN and integrates them with metabolic, visceral, stress-related, and limbic inputs. Through functionally distinct neuroendocrine, autonomic, and central-projecting neuronal populations, the PVN contributes to the temporal regulation of hypothalamic-pituitary-adrenal axis activity, glucose metabolism, feeding behavior, nociceptive sensitivity, and cardiovascular function. Cell-type-specific genetic and transcriptomic studies further indicate that PVN neuronal populations exhibit distinct clock-related molecular programs. Studies predominantly in nocturnal rodent models have linked disruption of PVN clocks or rhythmic output to aging-associated decline, metabolic dysfunction, altered tumor immunity, neurodegenerative disease, and pain-related phenotypes. Human post-mortem studies have reported heterogeneous PVN changes in Alzheimer's disease, but direct evidence of PVN clock or SCN-PVN circuit dysfunction in humans remains limited. This review integrates circuit-, cellular-, and molecular-level evidence for the PVN's role in circadian regulation, evaluates interventions spanning timed drug delivery, meal timing, light exposure, and PVN-focused experimental manipulation, and outlines the challenges of translating preclinical findings into clinical practice.
中文摘要:昼夜节律是内源性约24小时振荡,使生理和行为与环境明暗周期对齐并支持稳态。哺乳动物中视交叉上核是中枢昼夜节律起搏器,但其神经元投射仅局限于相对少量下丘脑靶区。下丘脑室旁核是重要下游整合节点,接收视交叉上核直接和间接时间信号,并与代谢、内脏、应激相关和边缘系统输入整合。室旁核通过功能不同的神经内分泌、自主神经和中枢投射神经元群体,参与下丘脑-垂体-肾上腺轴活动、糖代谢、进食行为、痛觉敏感性和心血管功能的时间调控。细胞类型特异性遗传和转录组研究进一步表明,室旁核神经元群体具有不同的钟相关分子程序。主要在夜行性啮齿动物模型中的研究将室旁核时钟或节律性输出破坏与衰老相关衰退、代谢功能障碍、肿瘤免疫改变、神经退行性疾病和疼痛相关表型联系起来。人类尸检研究报告阿尔茨海默病中室旁核改变存在异质性,但人类室旁核时钟或视交叉上核-室旁核环路功能障碍的直接证据仍有限。综述整合环路、细胞和分子层面证据,评估定时给药、进餐时间、光照暴露和聚焦室旁核的实验性干预等干预措施,并概述将临床前发现转化为临床实践的挑战。

20神经炎症 (1篇)

基础研究 (1篇)

MedComm IF 14.1 2026-11 PMID: 42898978
Astrocytes have emerged as central regulators of neuroinflammation, extending far beyond their traditional roles as structural and metabolic support cells. In neurological disorders, astrocytes undergo reactive remodeling that encompasses morphological, transcriptional, metabolic, and functional changes. Rather than fitting into a fixed A1/A2 dichotomy, reactive astrocytes exist along a disease-, region-, and stage-dependent continuum shaped by local pathology and intercellular crosstalk. This review summarizes how astrocytes contribute to neuroinflammatory processes in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, central nervous system injury, infection, multiple sclerosis, epilepsy, and autism spectrum disorder. We highlight convergent mechanisms, including cytokine and chemokine release, complement activation, glutamate and ion homeostasis disruption, oxidative stress, metabolic reprogramming, and blood-brain barrier regulation, while emphasizing disease-specific astrocytic programs. We further discuss astrocyte interactions with microglia, neurons, oligodendrocytes, endothelial cells, and peripheral immune cells, as well as key regulatory pathways, epigenetic remodeling, and lipid-dependent metabolic signaling. Finally, we evaluate current and emerging astrocyte-targeted therapeutic strategies, including metabolic modulation, receptor targeting, gene editing, nanodelivery, and gut-brain axis interventions. Defining functionally validated astrocyte states and developing biomarker-guided, stage-adaptive therapies may enable more precise intervention in neuroinflammatory and neurodegenerative diseases.
中文摘要:星形胶质细胞已成为神经炎症的核心调控者,其作用远超传统认为的结构与代谢支持细胞。在神经系统疾病中,星形胶质细胞发生反应性重塑,涉及形态、转录、代谢和功能改变。反应性星形胶质细胞并不符合固定的A1/A2二分法,而是沿疾病、区域和阶段依赖的连续谱存在,并受局部病理和细胞间交互塑造。综述总结星形胶质细胞如何参与阿尔茨海默病、帕金森病、肌萎缩侧索硬化、亨廷顿病、中枢神经系统损伤、感染、多发性硬化、癫痫和孤独症谱系障碍中的神经炎症过程。内容强调趋同机制,包括细胞因子和趋化因子释放、补体激活、谷氨酸和离子稳态破坏、氧化应激、代谢重编程以及血脑屏障调控,同时关注疾病特异的星形胶质细胞程序。进一步讨论星形胶质细胞与小胶质细胞、神经元、少突胶质细胞、内皮细胞和外周免疫细胞的相互作用,以及关键调控通路、表观遗传重塑和脂质依赖的代谢信号。当前和新兴的星形胶质细胞靶向治疗策略包括代谢调节、受体靶向、基因编辑、纳米递送和肠脑轴干预。定义经功能验证的星形胶质细胞状态,开发生物标志物引导、阶段适应性的治疗,可能实现对神经炎症和神经退行性疾病更精准的干预。

21照护者心理健康 (1篇)

临床研究 (1篇)

Clinical psychology review IF 11.2 2026-11 PMID: 42863359
We aimed to provide a comprehensive overview of the effectiveness of psychosocial interventions on informal caregivers' mental health, organized by the clinical condition(s) of the care recipient. We conducted an umbrella systematic review and random-effects meta-analyses to pool the results of the included studies for each combination of clinical condition, intervention type, comparison and outcome. We included 19 systematic reviews and 50 meta-analyses, with 26,481 participants. Several interventions improved mental health outcomes in caregivers, and across various clinical conditions of the care recipients. In dementia caregivers, multicomponent interventions significantly reduced depressive and anxiety symptoms, and caregiver burden (SMD from -0.65 to -0.19). For caregivers of people with lung cancer, psychoeducation and psychological support reduced depressive (SMD = -1.66, 95% CI -3.19 to -0.13) and anxiety symptoms (SMD = -1.37, 95% CI -2.54 to -0.21). Multicomponent interventions reduced depressive and anxiety symptoms in parents of children with cancer (SMD = -0.38, 95% CI -0.64 to -0.12; SMD = -0.89, 95% CI -1.33 to -0.45). Caregiver burden of caregivers of people with psychosis and schizophrenia decreased after psychoeducation and skills-training (SMD = -2.10, 95% CI -3.46 to -0.74; SMD = -0.94, 95% CI -1.72 to -0.17). Certainty of evidence was low to moderate, and the strength of association was overall weak. We rigorously assessed the quality, certainty of evidence, and the strength of associations. Despite the appraisals highlighting the need for further high-quality research, our results can inform policy and practice on the use of psychosocial interventions for caregivers of people with different clinical conditions.
中文摘要:本综述旨在按被照护者的临床疾病分类,全面概述心理社会干预对非正式照护者心理健康的效果。研究采用伞形系统综述与随机效应荟萃分析,按临床疾病、干预类型、对照与结局的每一种组合汇总纳入研究的结果。共纳入19篇系统综述和50项荟萃分析,涉及26481名参与者。多种干预改善了照护者的心理健康结局,覆盖被照护者的多种临床疾病。在痴呆照护者中,多成分干预显著减轻抑郁症状、焦虑症状与照护者负担(SMD为-0.65至-0.19)。对于肺癌患者的照护者,心理教育与心理支持降低了抑郁症状(SMD=-1.66,95% CI -3.19至-0.13)与焦虑症状(SMD=-1.37,95% CI -2.54至-0.21)。多成分干预减轻了癌症患儿父母的抑郁症状与焦虑症状(SMD=-0.38,95% CI -0.64至-0.12;SMD=-0.89,95% CI -1.33至-0.45)。精神病与精神分裂症患者的照护者在接受心理教育与技能训练后,照护负担下降(SMD=-2.10,95% CI -3.46至-0.74;SMD=-0.94,95% CI -1.72至-0.17)。证据确定性为低至中等,关联强度总体偏弱。研究对质量、证据确定性与关联强度作了严格评估。尽管评估结果提示仍需更多高质量研究,这些结果可为针对不同临床疾病患者照护者的心理社会干预政策与实践提供参考。

22离子通道病 (1篇)

基础研究 (1篇)

Pharmacological research IF 12.2 2026-11 PMID: 42805517
Voltage-gated sodium (NaV) channels are critical transmembrane proteins responsible for the initiation and propagation of electrical signals in excitable tissues. They consist of a large α subunit and auxiliary β subunits. Together, the voltage sensing, ion selectivity, and rapid gating transitions regulate neuronal, muscular, and cardiac excitability. Recent cryo-electron microscopy breakthroughs have transformed the understanding of NaV structure-function relationships, revealing the asymmetric organization of voltage-sensing domains (VSD), the architecture of the DEKA selectivity filter, the mechanical coupling between S4-S5 linkers and S6 gating helices, and the allosteric mechanism by which the IFMT motif mediates fast inactivation. Across the nine human NaV isoforms, subtle structural divergences underlie distinct tissue distributions, biophysical properties, and disease susceptibilities, explaining the diverse channelopathies that range from epilepsy and cardiac arrhythmias to skeletal muscle disorders and painful neuropathies. These high-resolution structures also illuminate isoform-specific pharmacological pockets, including membrane-dependent cavities in VSD4 and dynamic fenestrations that govern state-dependent drug access, enabling the rational design of small molecules, peptide toxins, and hybrid therapeutics with improved selectivity. Advances in structural biology, biochemistry, and computation have established an integrated mechanistic model that connects NaV channels architecture to gating, inactivation, isoform-specific function, and human disease. This growing molecular atlas now supports next-generation precision therapies aimed at selectively modulating NaV channels activity in neurological, muscular, cardiac, and pain disorders.
中文摘要:电压门控钠通道(NaV)是负责在可兴奋组织中启动和传播电信号的关键跨膜蛋白,由大型α亚基和辅助β亚基组成。电压感受、离子选择性和快速门控转换共同调节神经元、肌肉和心脏的兴奋性。近期冷冻电镜的突破改变了对NaV结构-功能关系的认识,揭示了电压感受域(VSD)的不对称组织、DEKA选择性过滤器的结构、S4-S5连接子与S6门控螺旋之间的机械耦合,以及IFMT基序介导快速失活的变构机制。在九种人类NaV亚型中,细微结构差异决定了组织分布、生物物理特性和疾病易感性的不同,解释了从癫痫、心律失常到骨骼肌疾病和疼痛性神经病的多种通道病。这些高分辨率结构还揭示了亚型特异性药理口袋,包括VSD4中膜依赖性腔隙和控制状态依赖性药物进入的动态窗孔,为合理设计选择性更高的小分子、肽类毒素和杂合治疗药物提供了依据。结构生物学、生物化学和计算方面的进展建立了整合机制模型,将NaV通道结构与门控、失活、亚型特异性功能及人类疾病联系起来。这一不断扩展的分子图谱支持下一代精准治疗,以在神经、肌肉、心脏和疼痛疾病中选择性调节NaV通道活性。

23消化道肿瘤 (1篇)

临床研究 (1篇)

Cancer treatment reviews IF 10.6 2026-11 PMID: 42801795
Oxaliplatin chemotherapy-induced peripheral neuropathy (CIPN) is dose-limiting, severe, and often permanent. Whether reduced oxaliplatin exposure (ROE) preserves efficacy while limiting toxicity across gastrointestinal (GI) cancers remains uncertain. We conducted a systematic review and meta-analysis of studies comparing ROE strategies versus standard-duration oxaliplatin-based therapy in GI malignancies. Random-effects meta-analyses were performed according to PRISMA guidelines. Primary endpoints were disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS). Secondary endpoints included grade 2 CIPN, grade ≥ 3 CIPN, and any grade ≥ 3 adverse events (AEs). Twenty-four studies (15 randomized trials, 9 retrospective cohorts) involving 30,395 patients were included; 13,348 received ROE and 17,047 standard therapy. In adjuvant colorectal cancer, ROE was not associated with differences in DFS [HR 1.06, 95% CI 0.97-1.17; P = 0.15] or OS (HR 0.99, 95% CI 0.90-1.09; P = 0.80). In metastatic colorectal cancer, no differences were observed in PFS (HR 1.11, 95% CI 0.99-1.25; P = 0.07) or OS (HR 1.06, 95% CI 0.92-1.23; P = 0.33). In metastatic gastroesophageal cancers, PFS (HR 0.82, 95% CI 0.34-1.99; P = 0.44) and OS (HR 0.90, 95% CI 0.67-1.21; P = 0.26) were also not statistically different. ROE reduced grade 2 CIPN (OR 0.46, 95% CI 0.25-0.84), grade ≥ 3 CIPN (OR 0.34, 95% CI 0.21-0.57), and grade ≥ 3 AEs (OR 0.67, 95% CI 0.48-0.92). ROE was not associated with statistically significant differences in survival outcomes but with reduced neurotoxicity and high-grade AEs, supporting planned limitation of oxaliplatin exposure to improve the therapeutic index across GI malignancies. The evidence was driven predominantly by colorectal cancer, while data in pancreatic and gastroesophageal cancers remain limited.
中文摘要:奥沙利铂化疗所致周围神经病变(CIPN)具有剂量限制性、严重且常不可逆。减少奥沙利铂暴露(ROE)能否在消化道恶性肿瘤中既保留疗效又限制毒性仍不确定。我们按PRISMA指南开展系统综述与荟萃分析,纳入比较ROE策略与标准疗程奥沙利铂为基础治疗的研究,采用随机效应模型。主要终点为无病生存(DFS)、无进展生存(PFS)和总生存(OS)。次要终点包括2级CIPN、≥3级CIPN和任何≥3级不良事件(AE)。共纳入24项研究(15项随机试验、9项回顾性队列),涉及30395例患者;13348例接受ROE,17047例接受标准治疗。在辅助治疗结直肠癌中,ROE与DFS(HR 1.06,95% CI 0.97-1.17;P=0.15)或OS(HR 0.99,95% CI 0.90-1.09;P=0.80)差异无关。在转移性结直肠癌中,PFS(HR 1.11,95% CI 0.99-1.25;P=0.07)和OS(HR 1.06,95% CI 0.92-1.23;P=0.33)未见差异。在转移性胃食管癌中,PFS(HR 0.82,95% CI 0.34-1.99;P=0.44)和OS(HR 0.90,95% CI 0.67-1.21;P=0.26)亦无统计学差异。ROE降低了2级CIPN(OR 0.46,95% CI 0.25-0.84)、≥3级CIPN(OR 0.34,95% CI 0.21-0.57)和≥3级AE(OR 0.67,95% CI 0.48-0.92)。ROE与生存结局无统计学显著差异,但神经毒性和高级别AE减少,支持通过计划性限制奥沙利铂暴露以改善消化道恶性肿瘤的治疗指数。证据主要来自结直肠癌,胰腺癌和胃食管癌数据仍有限。

24自身免疫病 (1篇)

基础研究 (1篇)

Redox biology IF 16.2 2026-11 PMID: 42777665
Advanced glycation end products (AGEs) and their receptor for advanced glycation end products (RAGE) have emerged as potential contributors to autoimmune pathology by linking metabolic stress, oxidative injury, and chronic inflammation. This review summarizes current mechanistic, preclinical, and clinical evidence on the role of the AGE-RAGE axis in selected autoimmune diseases, with a focus on systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, psoriasis, and multiple sclerosis. Across these conditions, increased AGE accumulation, enhanced availability of RAGE ligands, and altered soluble RAGE buffering appear to be recurring features associated with disease activity, organ damage, vascular complications, and immune dysregulation. Mechanistically, AGE-RAGE signaling amplifies nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), Janus kinase/signal transducer and activator of transcription (JAK/STAT), and reactive oxygen species (ROS)-dependent pathways, promotes pro-inflammatory immune phenotypes, and may contribute to neoepitope generation and epitope spreading. We also discuss anti-glycation strategies, including carbonyl scavengers, AGE formation inhibitors, redox-modulating agents, crosslink breakers, and RAGE-targeting interventions. Although several compounds show promising anti-inflammatory and antiglycation effects in experimental models, autoimmune-specific translational evidence remains limited, and most studies do not include validated AGE/RAGE biomarkers. Overall, the AGE-RAGE axis represents a plausible therapeutic target in autoimmunity, but establishing its therapeutic potential will require standardized biomarker panels and well-designed clinical trials.
中文摘要:晚期糖基化终产物(AGEs)及其受体RAGE通过连接代谢应激、氧化损伤和慢性炎症,已成为自身免疫病理的潜在促发因素。本综述总结AGE-RAGE轴在部分自身免疫病中作用的现有机制、临床前和临床证据,重点涉及系统性红斑狼疮、类风湿关节炎、1型糖尿病、银屑病和多发性硬化。在这些疾病中,AGE积累增加、RAGE配体可用性增强以及可溶性RAGE缓冲改变似乎是反复出现的特征,并与疾病活动度、器官损伤、血管并发症和免疫失调相关。机制上,AGE-RAGE信号放大NF-κB、MAPK、JAK/STAT和ROS依赖通路,促进促炎免疫表型,并可能参与新表位生成和表位扩展。我们还讨论抗糖基化策略,包括羰基清除剂、AGE形成抑制剂、氧化还原调节剂、交联断裂剂和RAGE靶向干预。尽管若干化合物在实验模型中显示有前景的抗炎和抗糖基化效应,自身免疫特异性的转化证据仍有限,多数研究未纳入经过验证的AGE/RAGE生物标志物。总体而言,AGE-RAGE轴是自身免疫中一个合理的治疗靶点,但确立其治疗潜力需要标准化生物标志物组合和设计良好的临床试验。

25自身免疫性脑炎 (1篇)

临床研究 (1篇)

Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42753224
Anti-leucine-rich glioma-inactivated 1 encephalitis (LGI1E) is traditionally considered as limbic encephalitis, but emerging evidence characterizes LGI1E as a whole-brain disorder. Furthermore, most neuroimaging studies have relied on cross-sectional designs and purely volumetric measures. Here, we integrate volume and fractal dimensionality (FD), a novel measure of structural complexity, to investigate cross-sectional and longitudinal brain changes in LGI1E and their associations with clinical and cognitive outcomes. This observational study included 3T MRI, clinical evaluations, and comprehensive cognitive assessments at Charité - Universitätsmedizin Berlin. Patients with LGI1E underwent up to 3 study visits at median disease durations of 10, 46, and 58 months. Disease severity was rated using the modified Rankin Scale (mRS) and the Clinical Assessment Scale in Autoimmune Encephalitis (CASE). T1-weighted MRI was processed using FreeSurfer to extract volumetric data, alongside fractal analysis to estimate FD. Dominance analysis determined the relative importance of FD and volume. Longitudinal changes were examined using linear mixed-effects models in relation to age at onset, disease duration, and relapses. We studied 34 patients with LGI1E (median age: 67 years; 29% female; 52 study visits) and 34 age-matched and sex-matched healthy controls. Patients showed clinical improvement in both mRS and CASE scores from peak illness to first study visit. Morphological analyses revealed reduced FD in fronto-temporo-parietal cortices and reduced FD and volume in subcortical areas, with FD more frequently emerging as the more important measure in affected areas. Furthermore, reduced FD in the pallidum at the first study visit was associated with less mRS improvement since peak illness, while reduced accumbens volume was linked to less CASE improvement. Reductions in both FD and volume in frontotemporal cortices and subcortical areas were associated with impaired overall cognition, with FD more frequently emerging as the dominant measure in brain-cognition associations. Finally, longer disease duration and relapses were associated with longitudinal reductions in FD and volume in subcortical areas. LGI1E is characterized by widespread morphological brain alterations beyond the limbic system, with meaningful associations to clinical outcomes, cognitive function, and longitudinal disease course. FD emerged as the more comprehensive imaging marker, capturing unique morphological brain characteristics undetected by volumetry analyses.
中文摘要:抗富亮氨酸胶质瘤失活1蛋白脑炎(LGI1E)传统上被视为边缘性脑炎,但新出现的证据将LGI1E描述为全脑疾病。多数神经影像研究采用横断面设计和纯体积测量。本研究整合体积与分形维数(FD,一种新的结构复杂性指标),探讨LGI1E的横断面与纵向脑改变及其与临床和认知结局的关联。这项观察性研究在柏林夏里特大学医院纳入3T MRI、临床评估和全面认知评估。LGI1E患者最多接受3次研究访视,中位病程分别为10、46和58个月。疾病严重程度采用改良Rankin量表(mRS)和自身免疫性脑炎临床评估量表(CASE)评分。T1加权MRI经FreeSurfer处理提取体积数据,并进行分形分析估计FD。优势分析确定FD与体积的相对重要性。采用线性混合效应模型分析纵向变化与发病年龄、病程和复发的关系。研究纳入34例LGI1E患者(中位年龄67岁;女性29%;52次研究访视)和34例年龄、性别匹配的健康对照。患者从疾病高峰至首次研究访视时mRS和CASE评分均显示临床改善。形态学分析显示额-颞-顶叶皮质FD降低,皮质下区域FD和体积降低,FD在受累区域更常成为更重要的指标。首次访视时苍白球FD降低与自疾病高峰以来mRS改善较少相关,伏隔核体积降低与CASE改善较少相关。额颞叶皮质和皮质下区域FD与体积降低均与整体认知受损相关,FD在脑-认知关联中更常成为主导指标。较长的病程和复发与皮质下区域FD和体积的纵向降低相关。LGI1E以超出边缘系统的广泛脑形态改变为特征,并与临床结局、认知功能和纵向病程存在有意义的关联。FD成为更全面的影像标志物,可捕捉体积分析未检测到的独特脑形态特征。

26多发性硬化 (1篇)

临床研究 (1篇)

Neurology(R) neuroimmunology & neuroinflammation 2026-11 PMID: 42743450
Infection with the Epstein-Barr virus is a prerequisite for the development of multiple sclerosis (MS). Recent evidence has identified an antibody response against a peptide region of the Epstein-Barr virus nuclear antigen-1 (EBNA1AE; alternative epitope, amino acid residues 381-452) that harbors cross-reactive potential against multiple autoantigens. It is currently unclear whether this antibody response is a driver of MS pathology. The presence of EBNA1-cross-reactive IgG responses in the CSF and their correlation with disease activity may provide insight into this matter. The aim of this study was to characterize the EBNA1AE response in peripheral blood and CSF of a clinically well-defined cohort of patients with MS and identify whether cross-reactive antibody responses are linked to disease characteristics. In this cross-sectional study, we quantified IgG reactivity against 4 20-mer peptides in the EBNA1AE region and their corresponding autoantigens using indirect ELISA in plasma of patients with untreated relapse-onset MS (n = 211) and healthy spouse controls (n = 63). We extended this analysis to paired serum-CSF samples from 61 patients with MS to determine intrathecal IgG responses. We observed an increased antibody response to EBNA1AE and corresponding autoantigens, supporting Epstein-Barr virus molecular mimicry in MS peripheral blood. Dimensionality reduction and clustering of 9 epitope-specific IgG responses identified 3 distinct peripheral immune signatures: EBNA1AE-high cross-reactive, EBNA1AE-high selective, and EBNA1AE-low, indicating that high EBNA1AE responses are not necessarily associated with high IgG responses against autoantigens. The cross-reactive signature, characterized by elevated reactivity to all EBNA1AE epitopes and their corresponding autoantigens, was enriched in MS. Increased IgG responses to a number of EBNA1AE epitopes were observed in patients who recently experienced a clinical relapse. The immune signatures were confirmed in the serum of the paired serum-CSF cohort. The Reiber antibody index for IgGs related to the EBNA1AE-high cross-reactive immune signature suggested intrathecal synthesis. Our findings contribute to the accumulating evidence of a role for EBNA1AE molecular mimicry in MS pathology and demonstrate heterogeneity in EBNA1AE-directed immune responses among patients with MS, differing in cross-reactivity and intrathecal enrichment.
中文摘要:EB病毒感染的EB病毒核抗原1(EBNA1)肽段381-452(EBNA1AE)存在针对多种自身抗原的交叉反应潜能,而该抗体反应是否驱动多发性硬化病理仍不清楚。检测脑脊液中EBNA1交叉反应性IgG及其与疾病活动的相关性,有助于回答这一问题。本研究在临床定义明确的多发性硬化队列中刻画外周血和脑脊液的EBNA1AE反应,并判断交叉反应性抗体反应是否与疾病特征相关。这项横断面研究用间接ELISA在未经治疗的复发起病型多发性硬化患者血浆(n=211)和健康配偶对照(n=63)中定量针对EBNA1AE区域4条20个氨基酸肽段及其对应自身抗原的IgG反应性,并将分析扩展到61例多发性硬化患者的配对血清-脑脊液样本,以判定鞘内IgG反应。结果显示,多发性硬化外周血中针对EBNA1AE及对应自身抗原的抗体反应升高,支持EB病毒分子模拟。对9种表位特异性IgG反应进行降维和聚类,识别出3种不同的外周免疫特征:EBNA1AE高交叉反应型、EBNA1AE高选择性型和EBNA1AE低型,提示高EBNA1AE反应并不必然伴随高自身抗原IgG反应。以对所有EBNA1AE表位及其对应自身抗原反应性升高为特点的交叉反应特征在多发性硬化中富集。近期发生临床复发的患者中,针对若干EBNA1AE表位的IgG反应升高。配对血清-脑脊液队列的血清中确认了这些免疫特征。与EBNA1AE高交叉反应免疫特征相关的IgG的Reiber抗体指数提示鞘内合成。这些发现为EBNA1AE分子模拟在多发性硬化病理中的作用增添了证据,并显示多发性硬化患者中针对EBNA1AE的免疫反应存在异质性,差异体现在交叉反应性和鞘内富集上。

27癌痛 (1篇)

基础研究 (1篇)

Pharmacological research IF 12.2 2026-11 PMID: 42716238
Cancer pain is increasingly recognized as an active output of tumor-nerve-immune biology rather than a passive consequence of tissue damage. Tumor-derived algogens, neurotrophic factors, stress signals and immune mediators can sensitize nociceptors, facilitate perineural invasion, remodel myeloid and lymphoid compartments and recruit central glial mechanisms that may maintain persistent pain. However, the evidence base is asymmetric: many causal circuits were defined in selected bone-metastasis, perineural-invasion, oral-cancer, sarcoma or chemotherapy-induced neuropathy models, whereas applicability to human cancer pain varies by tumor type, pain phenotype, immune contexture and treatment exposure. This critical narrative Review evaluates peripheral, central, immune and pharmacological evidence using explicit model-to-human boundaries. Recent patient studies in oral squamous cell carcinoma link pain with CGRP-positive nerve density, circulating or tissue CGRP, perineural invasion and reduced CD8-positive T-cell density, but these associations do not establish human causality; validated biomarkers of spinal glial mechanisms are still lacking. We examine druggable nodes including NGF-TrkA, SLIT2-ROBO1, CGRP-CALCRL/RAMP1, CSF1R-dependent myeloid or glial signaling, voltage-gated sodium channels and opioid-neuroimmune interactions. Clinical trial and cohort examples illustrate therapeutic paradoxes in which analgesia must be balanced against joint safety, tissue repair, host defense and potentially confounded associations with immunotherapy outcomes. We finally propose a phenotype-matched model-selection framework and a druggable circuit-state strategy for patient-stratified pharmacological development.
中文摘要:癌痛日益被视为肿瘤-神经-免疫生物学主动输出的结果,而非组织损伤的被动后果。肿瘤来源的致痛物质、神经营养因子、应激信号和免疫介质可使伤害感受器敏化,促进神经周围侵犯,重塑髓系和淋巴系细胞区室,并招募可能维持持续性疼痛的中枢胶质机制。然而证据基础并不对称:许多因果环路是在选定的骨转移、神经周围侵犯、口腔癌、肉瘤或化疗诱导的神经病变模型中确定的,而其对人类癌痛的适用性因肿瘤类型、疼痛表型、免疫背景和治疗暴露而异。本批判性叙述综述以明确的模型到人类边界评估外周、中枢、免疫和药理学证据。近期口腔鳞状细胞癌患者研究将疼痛与CGRP阳性神经密度、循环或组织CGRP、神经周围侵犯及CD8阳性T细胞密度降低联系起来,但这些关联并未确立人类因果关系;脊髓胶质机制的经验证生物标志物仍然缺乏。我们考察可成药节点,包括NGF-TrkA、SLIT2-ROBO1、CGRP-CALCRL/RAMP1、CSF1R依赖的髓系或胶质信号、电压门控钠通道及阿片-神经免疫相互作用。临床试验和队列示例说明治疗悖论:镇痛必须与关节安全性、组织修复、宿主防御以及可能与免疫治疗结局存在混杂的关联相平衡。文末提出表型匹配的模型选择框架和可成药环路状态策略,用于患者分层的药理学开发。

28前列腺癌 (1篇)

临床研究 (1篇)

JAMA internal medicine IF 26.3 2026-11-01 PMID: 42669035
Patients with prostate cancer have a high burden of cardiovascular risk factors, often suboptimally controlled, and adverse cardiovascular outcomes. To determine whether the routine referral of patients with prostate cancer to a cardiovascular specialist to implement a systematic risk factor strategy is more likely to reduce adverse cardiovascular outcomes and improve risk factor control than usual care. This randomized clinical trial included patients with prostate cancer from 55 sites in 8 countries between 2015 and 2025. Eligible patients were diagnosed with prostate cancer during the past 12 months; had received treatment with androgen deprivation therapy (ADT) for the first time within the past 6 months; or planned to start ADT in the next month. Patients taking a statin with a systolic blood pressure of 130 mm Hg or lower were ineligible. Data were analyzed from May 25 to August 7, 2026. Patients were allocated in a 1:1 ratio to receive usual care alone or usual care plus routine referral to an internist or cardiologist. The specialists provided a systematic intervention, including a target of systolic blood pressure of 130 mm Hg or lower and a statin medication, irrespective of the patient's cholesterol levels (even if not usual or guideline-driven practice); encourage smoking cessation; and provide guidance on diet and exercise. Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, suboptimal cholesterol (total cholesterol, >155 mg/dL [to convert to mmol/L, multiply by 0.0259]) and suboptimal blood pressure (systolic blood pressure, >130 mm Hg) as evaluated by the win ratio. The analysis included 2487 patients with prostate cancer (mean [SD] age, 68 [8] years). During median (IQR) follow-up of 5.8 (2.7-8.2) years, the win ratio in favor of the intervention was 1.60 (95% CI, 1.42-1.81), mostly attributable to lower cholesterol in the intervention group (mean difference, 12 mg/dL; 95% CI, 9-15 mg/dL) as a consequence of greater protocol-mandated statin use. Mean (SD) close-out systolic blood pressure values were 131.1 (16.9) mm Hg in the intervention group and 132.9 (18.3) mm Hg in the control group. There was no difference in time to cardiovascular death, myocardial infarction, stroke, or heart failure between groups (subdistribution hazard ratio, 1.08; 95% CI, 0.79-1.49). In this randomized clinical trial, routine referral of patients with prostate cancer to a cardiovascular specialist lead to improved outcomes, specifically through better cholesterol control. However, it is uncertain whether this reduced clinical cardiovascular events. ClinicalTrials.gov Identifier: NCT03127631.
中文摘要:前列腺癌患者心血管危险因素负担高,控制常不理想,心血管不良结局发生较多。该随机临床试验旨在判断,将前列腺癌患者常规转诊至心血管专科医生以实施系统性危险因素策略,是否较常规医疗更可能减少心血管不良结局并改善危险因素控制。研究于2015年至2025年在8个国家55个中心纳入前列腺癌患者。入选条件为过去12个月内诊断前列腺癌;过去6个月内首次接受雄激素剥夺治疗(ADT);或计划在下个月开始ADT。正在服用他汀且收缩压≤130 mm Hg的患者不符合入选条件。数据分析时间为2026年5月25日至8月7日。患者按1:1比例分配至单纯常规医疗组或常规医疗加常规转诊至内科或心脏科专科医生组。专科医生提供系统性干预,包括以收缩压≤130 mm Hg和他汀治疗为目标(不考虑患者胆固醇水平,即使不符合常规或指南驱动实践);鼓励戒烟;并就饮食和运动提供指导。主要结局为心血管死亡、心肌梗死、卒中、心力衰竭、胆固醇未达标(总胆固醇>155 mg/dL[换算为mmol/L需乘以0.0259])和血压未达标(收缩压>130 mm Hg)构成的层次复合结局,采用胜率比评价。分析纳入2487例前列腺癌患者(平均[SD]年龄68[8]岁)。中位(IQR)随访5.8(2.7-8.2)年期间,支持干预组的胜率比为1.60(95%CI,1.42-1.81),主要归因于干预组胆固醇较低(平均差12 mg/dL;95%CI,9-15 mg/dL),这是更多按方案使用他汀的结果。结束时平均(SD)收缩压为干预组131.1(16.9)mm Hg,对照组132.9(18.3)mm Hg。两组至心血管死亡、心肌梗死、卒中或心力衰竭的时间无差异(亚分布风险比,1.08;95%CI,0.79-1.49)。在这项随机临床试验中,将前列腺癌患者常规转诊至心血管专科医生改善了结局,具体表现为胆固醇控制更好。然而,这是否减少了临床心血管事件仍不确定。ClinicalTrials.gov注册号:NCT03127631。

29重性精神疾病 (1篇)

临床研究 (1篇)

JAMA psychiatry IF 18.0 2026-11-01 PMID: 42647034
Bipolar disorder, major depressive disorder, and schizophrenia are associated with substantial excess mortality, principally from cardiovascular disease. Identifying strategies to reduce this burden is a critical psychiatric priority. To evaluate associations between initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs sodium-glucose cotransporter-2 (SGLT2) inhibitors and all-cause mortality and major adverse cardiovascular events (MACEs) among adults with and without serious mental illness (SMI). This was a retrospective target trial emulation within the TriNetX Analytics Network, a multinational federated electronic health record network. Adults initiating GLP-1 RAs or SGLT2 inhibitors were included using a new-user, active-comparator design with propensity score matching and separate psychiatric and nonpsychiatric cohorts. The study included all available data in the TriNetX network through the most recent database refresh. Data were queried and analyzed in March 2026, with prespecified follow-up intervals of 1, 4, and 10 years. Additional subgroup analyses were conducted following peer review in May 2026. First-recorded GLP-1 RA vs SGLT2 inhibitor prescription. The primary outcome was 4-year all-cause mortality; the key secondary outcome, 1-year mortality. Additional outcomes included 3- and 5-point MACEs and individual cardiovascular end points. Sensitivity analyses included diabetes stratification, exclusion of baseline heart failure and chronic kidney disease, and censoring at crossover. Exploratory analyses examined SMI subgroups, agent-specific effects, and combination therapy. For the primary 4-year analysis, 1 528 230 adults were propensity score matched (764 115 pairs; 195 184 pairs with serious mental illness [SMI] and 568 931 pairs without SMI). The mean [SD] age in the GLP-1RA and SGLT2 inhibitor groups was 60.5 [12.0] and 60.2 [13.3] years, respectively, in the SMI cohort and 60.9 [12.2] and 60.6 [13.0] years, respectively, in the non-SMI cohort; 112 911 [57.8%], 113 488 [58.1%], 251 679 [44.2%], and 260 480 [45.8%] were female, respectively. Among participants with SMI, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (9585 of 195 184 [4.91%] vs 12 584 of 195 184 [6.45%]; hazard ratio [HR], 0.76; 95% CI, 0.74-0.78; absolute risk difference [ARD], -1.54 percentage points; 95% CI, -1.68 to -1.39; P < .001). Among participants with SMI and type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower risks of 3-point MACE (HR, 0.77; 95% CI, 0.76-0.79), 5-point MACE, myocardial infarction, stroke, heart failure, and coronary artery bypass grafting. In a separately matched 1-year SMI cohort, mortality was lower with GLP-1RA initiation than with SGLT2 inhibitor initiation (2898 of 198 065; 1.46% vs 5624 of 198 065; 2.84%; RR, 0.52; 95% CI, 0.49-0.54; ARD, -1.38 percentage points; 95% CI, -1.47 to -1.29; P < .001). In 10-year exploratory analyses among participants with type 2 diabetes, semaglutide initiation, compared with SGLT2 inhibitor initiation, was associated with lower mortality in the major depressive disorder (RR, 0.55; 95% CI, 0.53-0.56), bipolar disorder (RR, 0.57; 95% CI, 0.51-0.63), and schizophrenia (RR, 0.67; 95% CI, 0.59-0.75) groups (all P < .001). The primary mortality association persisted across prespecified sensitivity analyses. In this study, GLP-1 RA initiation was associated with lower mortality and cardiovascular events compared to SGLT2 inhibitor initiation, with greater absolute reductions in SMI. Benefits were evident within 1 year, consistent across SMI subgroups, and driven by semaglutide and tirzepatide. Prospective randomized trials are warranted.
中文摘要:双相障碍、重性抑郁障碍和精神分裂症与显著的超额死亡相关,主要死因为心血管疾病。识别减轻这一负担的策略是精神科的重要优先事项。评估在伴有和不伴有重性精神疾病(SMI)的成人中,启动胰高血糖素样肽-1受体激动剂(GLP-1 RAs)与钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂相比,与全因死亡和主要不良心血管事件(MACEs)的关联。这是一项在TriNetX Analytics Network内进行的回顾性目标试验模拟,该网络为跨国联邦电子健康记录网络。采用新使用者、活性对照设计,并结合倾向评分匹配,分别设置精神科和非精神科队列,纳入启动GLP-1 RAs或SGLT2抑制剂的成人。研究纳入TriNetX网络中截至最近一次数据库刷新时的全部可用数据。数据于2026年3月查询和分析,预设随访间期为1年、4年和10年。同行评审后于2026年5月进行了额外亚组分析。暴露为首次记录的GLP-1 RA与SGLT2抑制剂处方。主要结局为4年全因死亡;关键次要结局为1年死亡。其他结局包括3项和5项MACEs及单个心血管终点。敏感性分析包括糖尿病分层、排除基线心力衰竭和慢性肾病、以及在交叉换药时删失。探索性分析考察SMI亚组、药物特异性效应和联合治疗。主要4年分析中,1 528 230名成人经倾向评分匹配(764 115对;其中195 184对伴重性精神疾病[SMI],568 931对不伴SMI)。SMI队列中GLP-1RA组和SGLT2抑制剂组的平均[SD]年龄分别为60.5[12.0]岁和60.2[13.3]岁,非SMI队列中分别为60.9[12.2]岁和60.6[13.0]岁;女性分别为112 911[57.8%]、113 488[58.1%]、251 679[44.2%]和260 480[45.8%]。在SMI参与者中,启动GLP-1RA相比启动SGLT2抑制剂死亡更低(9585/195 184[4.91%] vs 12 584/195 184[6.45%];风险比[HR] 0.76;95% CI 0.74-0.78;绝对风险差[ARD] -1.54个百分点;95% CI -1.68至-1.39;P<.001)。在伴2型糖尿病的SMI参与者中,与启动SGLT2抑制剂相比,启动司美格鲁肽与3项MACE(HR 0.77;95% CI 0.76-0.79)、5项MACE、心肌梗死、卒中、心力衰竭和冠状动脉旁路移植术风险更低相关。在另一个匹配的1年SMI队列中,启动GLP-1RA相比启动SGLT2抑制剂死亡更低(2898/198 065;1.46% vs 5624/198 065;2.84%;RR 0.52;95% CI 0.49-0.54;ARD -1.38个百分点;95% CI -1.47至-1.29;P<.001)。在伴2型糖尿病参与者的10年探索性分析中,与启动SGLT2抑制剂相比,启动司美格鲁肽与重性抑郁障碍组(RR 0.55;95% CI 0.53-0.56)、双相障碍组(RR 0.57;95% CI 0.51-0.63)和精神分裂症组(RR 0.67;95% CI 0.59-0.75)死亡更低相关(均P<.001)。主要死亡关联在预设敏感性分析中持续存在。本研究中,与启动SGLT2抑制剂相比,启动GLP-1RA与更低的死亡和心血管事件相关,SMI中的绝对降幅更大。获益在1年内显现,在各SMI亚组中一致,并由司美格鲁肽和替尔泊肽驱动。有必要开展前瞻性随机试验。

30癫痫与痴呆 (1篇)

基础研究 (1篇)

Medical image analysis IF 14.0 2026-11 PMID: 42579974
Multi-modal learning is extensively applied to diagnose brain diseases such as epilepsy and Alzheimer's disease. However, incomplete multi-modal data, where some imaging modalities are unavailable or difficult to collect, limits the application of conventional methods. Additionally, existing approaches primarily focus on reconstructing missing imaging data but rarely enforce cross-modal semantic alignment. To address these challenges, we propose BrainCLIP, a CLIP inspired two-stage framework designed for incomplete multi-modal learning, with a focus on diagnosing representative brain diseases, i.e., epilepsy and Alzheimer's disease. The key novelty of our framework lies in its joint design of dual contrastive modality recovery and multi-modal representation learning in a two-stage pipeline. Specifically, we introduce a multi-modal contrastive learning stage that aligns text, fMRI, and DTI representations in a shared embedding space using complete samples. The recovered features are then refined through a dual contrastive recovery strategy with modality level and sample level contrastive objectives, thereby ensuring that the recovered features are semantically consistent and discriminative. For multi-modal representation learning, the recovered and available modalities are fused with fixed textual embeddings to learn task aware representations for disease classification. Extensive experiments demonstrate the effectiveness of our method in diagnosing epilepsy and Alzheimer's disease.
中文摘要:多模态学习已广泛用于癫痫和阿尔茨海默病等脑疾病的诊断。部分影像模态缺失或难以采集所造成的不完整多模态数据,限制了常规方法的应用。现有方法多集中于重建缺失影像数据,较少约束跨模态语义对齐。为应对这些问题,我们提出 BrainCLIP,一个受 CLIP 启发的两阶段框架,面向不完整多模态学习,聚焦癫痫和阿尔茨海默病这两类代表性脑疾病的诊断。该框架的新颖之处在于将双对比模态恢复与多模态表征学习联合设计为两阶段流程。具体而言,先引入多模态对比学习阶段,利用完整样本在共享嵌入空间中对齐文本、fMRI 和 DTI 表征;随后通过模态级与样本级对比目标构成的双对比恢复策略细化恢复特征,使恢复特征具有语义一致性和判别性。在多模态表征学习中,将恢复得到的模态与可用模态同固定文本嵌入融合,学习面向疾病分类的任务感知表征。大量实验表明,该方法在癫痫和阿尔茨海默病诊断中有效。

31神经影像与基础转化 (1篇)

基础研究 (1篇)

Medical image analysis IF 14.0 2026-11 PMID: 42574814
The human brain exhibits a complex and hierarchical organization that supports efficient information integration across local and global scales. Accurately characterizing such topological organization from neuroimaging data remains challenging. Conventional graph neural networks (GNNs) effectively capture local dependencies through neighborhood aggregation but often overlook higher-order topological structures that reflect the brain's small-world organization. Although Transformer architectures enable global dependency modeling, their high computational cost limits scalability for large connected brain networks. To address these challenges, we propose a Topology-Constrained Graph Transformer Network (TC-GTN) that explicitly integrates brain network topology into graph learning. TC-GTN combines two complementary modules: a cycle-constrained graph convolution, which captures localized edge aggregation and models modular brain organization, and an MST-guided Transformer, which constrains global attention along minimum spanning tree (MST) pathways to efficiently model long-range dependencies while reducing redundant communication. Moreover, we introduce cycle-based edge positional encodings (CEPE) that provide a topological coordinate system for distinguishing edges with similar local structures but different cycle-level contexts. We evaluate TC-GTN on both structural and functional brain networks, extracted from diffusion-weighted imaging (DWI) and functional MRI (fMRI) respectively, using large-scale datasets, including UK Biobank (38557 participants; 18100 females/20457 males; age 40-70 years) and ABCD (7684 participants; 3782 females/3902 males; age 9-10 years). Experiments on sex classification and brain-age estimation demonstrate that TC-GTN consistently outperforms state-of-the-art graph network approaches, achieving superior accuracy, interpretability, and generalizability. Clinical significance analysis further demonstrates that the model accurately characterizes neuroanatomical divergence across pathological states. Using the brain age gap (BAG) as a biomarker, systemic accelerated aging is identified in multiple sclerosis and dementia, alongside heterogeneous structural alterations in stroke and Parkinson's disease. Our code is available at https://github.com/bieqa/TC-GTN.
中文摘要:人脑具有复杂的层级组织结构,支撑局部与全局尺度上高效的信息整合。从神经影像数据中准确刻画这种拓扑组织仍具挑战。传统图神经网络(GNN)通过邻域聚合有效捕捉局部依赖,却常忽略反映脑小世界组织的高阶拓扑结构。Transformer 架构虽能建模全局依赖,但其高计算代价限制了对大规模连接脑网络的可扩展性。为应对上述问题,我们提出拓扑约束图 Transformer 网络(TC-GTN),将脑网络拓扑显式融入图学习。TC-GTN 组合两个互补模块:循环约束图卷积,捕捉局部边聚合并建模脑的模块化组织;最小生成树(MST)引导的 Transformer,沿 MST 路径约束全局注意力,从而高效建模长程依赖并减少冗余通信。我们还引入基于循环的边位置编码(CEPE),提供拓扑坐标系,用以区分局部结构相似但循环层级上下文不同的边。我们在结构与功能脑网络上评估 TC-GTN,二者分别由扩散加权成像(DWI)与功能 MRI(fMRI)提取,使用大规模数据集,包括 UK Biobank(38557 名参与者;18100 名女性/20457 名男性;年龄 40-70 岁)与 ABCD(7684 名参与者;3782 名女性/3902 名男性;年龄 9-10 岁)。性别分类与脑龄估计实验表明,TC-GTN 持续优于最先进的图网络方法,在准确性、可解释性与泛化性上均有提升。临床意义分析进一步显示,该模型能准确刻画不同病理状态下的神经解剖差异。以脑龄差(BAG)为生物标志物,在多发性硬化与痴呆中识别出系统性加速老化,同时在卒中与帕金森病中观察到异质性结构改变。代码见 https://github.com/bieqa/TC-GTN。

32卒中与运动障碍 (1篇)

临床研究 (1篇)

Annals of neurology IF 7.5 2026-11 PMID: 42558032
The human neuroanatomy for gait dysfunction remains unclear. We sought (1) to identify a brain circuit for gait impairment post stroke, (2) to identify a brain circuit for gait changes after subthalamic deep brain stimulation (DBS) for Parkinson's disease (PD), and (3) to test for convergence between these 2 circuits. This cross-sectional retrospective study used data from 4 independent datasets including 109 individuals with stroke and 125 PD patients who received subthalamic DBS. Gait impairment post-stroke was measured using the Combined Walking Index. Gait changes after DBS were measured using the gait subscore on the Unified Parkinson Disease Rating Scale part III. Connectivity between lesion locations or DBS sites and 2 a priori locomotor regions (pedunculopontine nucleus and cerebellar locomotor region) was computed using a large normative connectome. We repeated this analysis in a data-driven fashion to identify additional connections. Connectivity between lesion locations and a priori regions were associated with gait impairment post-stroke (p < 0.05), along with connectivity to a distributed circuit of other brain regions. Connectivity between DBS sites and our a priori gait regions and connectivity between DBS sites and our lesion-based gait circuit were all associated with gait changes post DBS (p < 10-3). Data-driven gait circuits derived from lesions and DBS showed similar topography and converged on a common brain circuit (spatial r = 0.68, p = 0.0063, 10,000 permutations). Lesion locations impairing gait and DBS sites modulating gait converge on a common brain circuit. ANN NEUROL 2026;100:1089-1103.
中文摘要:人步态功能障碍的神经解剖基础仍不清楚。研究目的为:(1)识别卒中后步态损害相关的脑环路;(2)识别帕金森病丘脑底核脑深部电刺激(DBS)后步态变化相关的脑环路;(3)检验这两个环路是否汇聚。这项横断面回顾性研究使用4个独立数据集,包括109例卒中患者和125例接受丘脑底核DBS的帕金森病患者。卒中后步态损害用综合步行指数评估;DBS后步态变化用统一帕金森病评定量表第Ⅲ部分的步态分项评估。利用大型常模连接组计算病灶位置或DBS位点与两个预设运动区域(脚桥核和小脑运动区)之间的连接。以数据驱动方式重复该分析,以识别其他连接。病灶位置与预设区域的连接与卒中后步态损害相关(p<0.05),与另一分布式的其他脑区环路之间的连接也相关。DBS位点与预设步态区域之间的连接、DBS位点与基于病灶的步态环路之间的连接,均与DBS后步态变化相关(p<10-3)。由病灶和DBS得到的数据驱动步态环路具有相似的空间分布,并汇聚于共同的脑环路(空间r=0.68,p=0.0063,10 000次置换)。损害步态的病灶位置与调节步态的DBS位点汇聚于共同的脑环路。ANN NEUROL 2026;100:1089-1103。

33运动神经元病 (1篇)

临床研究 (1篇)

Annals of neurology IF 7.5 2026-11 PMID: 42479906
Amyotrophic lateral sclerosis (ALS) has a markedly distinctive clinical and neuroradiological signature, with the preferential involvement of specific brain networks and the apparent sparing of others. The molecular underpinnings of the strikingly selective anatomical vulnerability have not been fully elucidated to date despite the potential therapeutic relevance of characterizing neurotransmitter receptor-defined susceptibility to degeneration. A large neuroimaging study was undertaken with 258 participants to systematically evaluate topological associations between neurodegeneration and neurotransmitter expression distributions. Patients were stratified based on their genetic profile into sporadic and C90rf72 hexanucleotide repeat expansion carriers. Anatomical associations were evaluated between patterns of atrophy and topological neurotransmitter receptor distributions. Cross-sectional and longitudinal trends were comprehensively evaluated over 4 consecutive timepoints. Our analyses reveal topological associations between neurodegeneration in sporadic ALS and GABA-A receptor α5-selective component (GABAa5), serotonin 1a receptor, and kappa opioid receptor expression maps. In addition to these networks, neuronal loss in patients with GGGGCC hexanucleotide repeat expansions exhibit predilection to glutamatergic, endocannabinoid, and microglial systems. Our multi-timepoint longitudinal analyses reveal dynamic temporal associations between focal volume loss and neurotransmitter expression with increasing spatial associations with noradrenaline transporter and GABAa5, but high attrition rates preclude definite longitudinal inferences. Our data suggest the preferential vulnerability of GABAergic, serotonergic, kappa opioid mediated networks in sporadic ALS. In C9orf72-assocaited ALS, glutamatergic, endocannabinoid circuits are also susceptible and microglia-mediated neuroinflammation is also implicated. The comprehensive evaluation of neurotransmitter-receptor associations not only offer academic insights regarding pathophysiological processes in ALS, but may inform targeted therapy development strategies. ANN NEUROL 2026;100:948-961.
中文摘要:肌萎缩侧索硬化(ALS)具有鲜明的临床与神经影像学特征,特定脑网络优先受累,另一些网络则似乎相对保留。这种显著选择性解剖易损性的分子基础迄今尚未完全阐明,而刻画由神经递质受体定义的退化易感性可能具有治疗相关性。一项纳入258名参与者的大型神经影像研究系统评估了神经退化与神经递质表达分布之间的拓扑关联。患者按遗传背景分为散发性ALS与C9orf72六核苷酸重复扩增携带者。研究评估了萎缩模式与神经递质受体拓扑分布之间的解剖关联,并在连续4个时间点全面评价横断面与纵向趋势。分析显示,散发性ALS的神经退化与GABA-A受体α5选择性成分(GABAa5)、5-羟色胺1a受体及κ阿片受体表达图谱存在拓扑关联。在这些网络之外,携带GGGGCC六核苷酸重复扩增患者的神经元丢失还表现出对谷氨酸能、内源性大麻素能及小胶质细胞系统的偏向。多时间点纵向分析显示,局灶性体积丢失与神经递质表达之间存在动态时间关联,与去甲肾上腺素转运体及GABAa5的空间关联随时间增强,但高脱落率使纵向推断难以确定。数据提示散发性ALS中GABA能、5-羟色胺能及κ阿片介导网络存在优先易损性。在C9orf72相关ALS中,谷氨酸能、内源性大麻素回路同样易感,小胶质细胞介导的神经炎症亦被涉及。对神经递质受体关联的系统评估不仅为ALS病理生理过程提供学术见解,也可能为靶向治疗开发策略提供信息。ANN NEUROL 2026;100:948-961。

34神经变性病 (1篇)

基础研究 (1篇)

Molecular psychiatry IF 10.4 2026-11 PMID: 42410083
Depression is one of the most common and disabling neuropsychiatric complications of neurodegenerative diseases. In Alzheimer's disease (AD) and Parkinson's disease (PD), depressive syndromes affect more than one-third of patients and are associated with accelerated cognitive decline, reduced quality of life, and increased healthcare utilisation. Despite this burden, current antidepressant treatments show little or no efficacy in these populations, suggesting that depression arising in the context of neurodegeneration may reflect distinct underlying neurobiological mechanisms. Emerging evidence from molecular imaging, neuropathology, and cognitive neuroscience indicates disease-specific disruption of monoaminergic, glutamatergic, inflammatory, and reward-related circuits in AD and PD. These alterations may undermine the mechanisms of action of standard antidepressants and contribute to treatment resistance. Yet patients with cognitive impairment are routinely excluded from antidepressant trials, and few high-quality studies have evaluated novel therapies in neurodegenerative disease. In this narrative review, we synthesise current evidence on the neurobiological mechanisms underpinning depression in AD and PD and critically evaluate emerging pharmacological and neuromodulatory therapies targeting glutamatergic, serotonergic, dopaminergic, immune, and circuit-level dysfunction. Here, we highlight that depression in neurodegenerative disease offers a unique and underutilised model for mechanistically guided antidepressant development. We identify how interventions including glutamate modulators, dopaminergic agents, kappa opioid antagonists, immune-modulating therapies, and next-generation brain stimulation approaches may offer therapeutic promise. By aligning treatment development with disease-specific circuit and molecular pathology, this framework may improve outcomes for this neglected population while advancing precision psychiatry more broadly.
中文摘要:抑郁是神经退行性疾病最常见且致残性最强的神经精神并发症之一。在阿尔茨海默病(AD)和帕金森病(PD)中,抑郁综合征影响超过三分之一的患者,并与认知下降加速、生活质量下降和医疗资源使用增加相关。尽管负担沉重,现有抗抑郁治疗在这些人群中疗效很小或没有疗效,提示神经退行性背景下的抑郁可能反映不同的潜在神经生物学机制。来自分子影像、神经病理学和认知神经科学的新证据表明,AD和PD中存在疾病特异性的单胺能、谷氨酸能、炎症和奖赏相关环路紊乱。这些改变可能削弱标准抗抑郁药的作用机制,并促成治疗抵抗。然而,认知受损患者常被排除在抗抑郁药试验之外,评估神经退行性疾病中新疗法的优质研究很少。在这篇叙述性综述中,我们综合关于AD和PD抑郁神经生物学机制的当前证据,并批判性评估针对谷氨酸能、5-羟色胺能、多巴胺能、免疫及环路水平功能障碍的新兴药物和神经调控治疗。我们强调,神经退行性疾病中的抑郁为机制导向的抗抑郁药开发提供了独特且利用不足的模型。我们指出,谷氨酸调节剂、多巴胺能药物、κ阿片受体拮抗剂、免疫调节治疗和下一代脑刺激方法等干预可能具有治疗前景。通过使治疗开发与疾病特异性环路和分子病理相匹配,这一框架可能改善这一被忽视人群的结局,同时更广泛地推进精准精神病学。

35精神疾病 (1篇)

基础研究 (1篇)

Molecular psychiatry IF 10.4 2026-11 PMID: 42362769
Neurexin (nrxn) genes encode synaptic cell-adhesion molecules that have been repetitively associated with neurodevelopmental and mental disorders. While the zebrafish animal model offers tremendous advantages for dissecting neural development/function, no complete loss-of-function (LOF) nrxn zebrafish models are currently available. In this study, we generated the first collection of zebrafish knockout lines for each nrxn gene, with mutations ranging from transmembrane domain- to full genomic locus-deletions. Surprisingly, all homozygous lines developed normally, presenting no gross neurodevelopmental or obvious early behavioural abnormalities. However, this absence of early phenotypes translated into profound, paralog-specific behavioural alterations emerging during later developmental stages. All neurexin knockouts affected mating behaviour, complicating the generation and maintenance of homozygous lines. Except for this shared behavioural alteration, nrxn1, but not nrxn2 or nrxn3, led to marked changes in affiliative social behaviour and aggression. In contrast, nrxn2 mutants exhibited severe anxiety-like behaviours, including bottom-dwelling and repetitive freezing/seizure events. Strikingly, nrxn1 full-locus deletion mutants showed opposing behaviour, spending most of their time near the surface. The two also displayed opposite responses to open/closed field transitions; confinement alleviated nrxn2 anxiety but enhanced nrxn1 surface-dwelling. Meanwhile, nrxn3 mutants behaved normally in all our initial tests. In summary, our study introduces a complete set of zebrafish mutants covering the whole nrxn gene family, presenting striking adult behavioural alterations despite the absence of noticeable early defects; echoing the delayed onset of human psychiatric disorders such as schizophrenia. This work confirms the value of zebrafish to study mental disorders and unlock a novel platform to unravel the pathogenic contribution of neurexins and associated subtle neurodevelopmental changes/timing that drive the emergence of mental illnesses.
中文摘要:Neurexin(nrxn)基因编码突触细胞黏附分子,与神经发育障碍和精神疾病反复相关。斑马鱼模型在解析神经发育与功能方面优势明显,但目前尚无完整的nrxn基因功能缺失(LOF)斑马鱼模型。该工作构建了覆盖每个nrxn基因的首批斑马鱼敲除品系,突变范围从跨膜结构域到完整基因组位点缺失。出乎意料的是,所有纯合品系均发育正常,未见大体神经发育异常或明显早期行为异常。早期表型的缺失在较晚发育阶段转化为深刻且旁系同源基因特异的行为改变。所有neurexin敲除均影响交配行为,使纯合品系的建立与维持变得困难。除这一共同改变外,nrxn1而非nrxn2或nrxn3导致亲和性社会行为和攻击性显著改变。nrxn2突变体表现出严重焦虑样行为,包括底栖和重复性僵直/发作事件。nrxn1全位点缺失突变体表现相反,大部分时间停留在水面附近。两者对开阔/封闭场转换也呈相反反应;限制空间缓解nrxn2焦虑,却增强nrxn1的水面停留。nrxn3突变体在初步测试中行为正常。该工作提供覆盖整个nrxn基因家族的完整斑马鱼突变体集合,在缺乏明显早期缺陷的情况下出现显著的成年行为改变,呼应精神分裂症等人类精神障碍的延迟起病。这项工作确认斑马鱼研究精神疾病的价值,并建立新平台以揭示neurexins及相关细微神经发育改变/时序在驱动精神疾病发生中的致病作用。

36脑老化与代谢 (1篇)

临床研究 (1篇)

Molecular psychiatry IF 10.4 2026-11 PMID: 42337012
Accelerated brain aging is increasingly recognized as a transdiagnostic risk factor for neuropsychiatric and neurodegenerative disorders, yet its metabolic underpinnings remain poorly understood. Here we integrated multimodal neuroimaging (MRI), plasma metabolomics, and genomic data from the UK Biobank to identify metabolic markers of brain aging and evaluate their causal relevance. Using 1079 imaging-derived phenotypes (IDPs) from 4333 healthy participants, we trained and validated machine learning models for brain age prediction, with a least absolute shrinkage and selection operator (LASSO) regression model achieving the best performance (mean absolute error = 3.26 years, R² = 0.68). Brain age gap (BAG) was then estimated in 37,458 participants. Association analyses in 21,780 individuals identified nine plasma metabolites significantly linked to BAG after Bonferroni correction, with glucose showing the strongest effect (β = 0.32, P = 9.90 × 10⁻¹²). Genome-wide association studies (GWAS) identified 392 BAG-associated single-nucleotide polymorphisms (SNPs) (P < 5 × 10⁻⁸), and two-sample Mendelian randomization (MR) provided evidence supporting a potential causal role of glucose in accelerating brain aging. Clinically, elevated plasma glucose was positively associated with seven brain disorders, including all-cause dementia, Alzheimer's disease, vascular dementia, Parkinson's disease, stroke, depression, and anxiety, and negatively associated with cognitive performance, movement function, and mental health outcomes. Higher glucose concentrations were also associated with reduced regional brain volumes across 80 cortical, subcortical, and cerebellar regions. These findings implicate glucose metabolism as a modifiable pathway in brain aging, with implications for early intervention strategies aimed at preserving brain health across the lifespan.
中文摘要:加速脑老化日益被视为神经精神疾病和神经退行性疾病的跨诊断风险因素,但其代谢基础仍不清楚。本研究整合英国生物银行的多模态神经影像(MRI)、血浆代谢组学和基因组数据,识别脑老化的代谢标志物并评估其因果相关性。利用4333名健康参与者中的1079个影像衍生表型(IDP),训练并验证脑龄预测机器学习模型,最小绝对收缩和选择算子(LASSO)回归模型表现最佳(平均绝对误差=3.26年,R²=0.68)。随后在37458名参与者中估计脑龄差(BAG)。在21780人中的关联分析经Bonferroni校正后识别出9种与BAG显著相关的血浆代谢物,葡萄糖效应最强(β=0.32,P=9.90×10⁻¹²)。全基因组关联研究(GWAS)识别出392个与BAG相关的单核苷酸多态性(SNP)(P<5×10⁻⁸),两样本孟德尔随机化(MR)提供了支持葡萄糖在加速脑老化中潜在因果作用的证据。临床上,血浆葡萄糖升高与七种脑疾病呈正相关,包括全因痴呆、阿尔茨海默病、血管性痴呆、帕金森病、卒中、抑郁和焦虑,并与认知表现、运动功能和心理健康结局呈负相关。较高葡萄糖浓度还与80个皮层、皮层下和小脑区域的脑体积降低相关。这些发现提示葡萄糖代谢是脑老化中可修饰的通路,对旨在终生维护脑健康的早期干预策略具有意义。

37痴呆与脑损伤 (1篇)

基础研究 (1篇)

Medicinal research reviews IF 13.6 2026-11 PMID: 42288958
The present review describes the current knowledge on phosphonates designed for brain disease therapeutics, a less explored aspect of the studies on their medicinal chemistry. Because of their structural similarity with phosphates and of the ubiquitous presence of phosphate-dependent processes in the brain, phosphonate compounds are able to influence brain chemistry, interfering with neurotransmission and phosphorous-dependent bioprocesses. One of the main applications for phosphonates in the brain is Alzheimer's disease, for which they can be new drug candidates and/or afford innovative strategies for diagnostics. Such applications are described in the first section of this review, which includes a large number of reports on phosphonates with cholinesterase-inhibiting activity, some recent studies exploring phosphonates for inhibiting the interaction between amyloid-β protein and alcohol dehydrogenases, and phosphonate-based materials used in proteomics-based investigative and diagnosis platforms for the different stages of development of Alzheimer's disease. The second section of the review is dedicated to ischemic brain injury and to the development of phosphonates for active against NMDA and AMPA receptors with the purpose of reducing brain damage caused by glutamate excitotoxicity. Furthermore, agonists targeting the mGlu-4 receptor suggest potential for promoting neuroregeneration. The review concludes by emphasizing the relevance of phosphonate stability, versatility, and ability to mimic natural phosphate groups in the development of new therapeutic agents for brain disorders, weighing the advantages against the gaps in knowledge in order to set future directions of research in brain health.
中文摘要:该综述描述用于脑病治疗的膦酸酯类化合物的现有认识,这是其药物化学研究中较少被探索的一面。由于与磷酸盐结构相似,且脑内磷酸盐依赖过程广泛存在,膦酸酯化合物能够影响脑化学,干扰神经传递和磷依赖的生物过程。膦酸酯在脑内的主要应用之一是阿尔茨海默病,它们可作为新的候选药物和/或提供创新的诊断策略。综述第一部分介绍此类应用,包括大量关于具有胆碱酯酶抑制活性的膦酸酯的报道、近期探索膦酸酯抑制β-淀粉样蛋白与醇脱氢酶相互作用的研究,以及用于阿尔茨海默病不同发展阶段、基于蛋白质组学的检查与诊断平台的膦酸酯材料。第二部分聚焦缺血性脑损伤,以及开发针对NMDA和AMPA受体、旨在减轻谷氨酸兴奋毒性所致脑损伤的膦酸酯。靶向mGlu-4受体的激动剂也显示出促进神经再生的潜力。文末强调膦酸酯稳定性、多功能性及模拟天然磷酸基团的能力在脑部疾病新治疗药物开发中的意义,并权衡优势与知识空白,以确定脑健康研究的未来方向。

38神经发育障碍 (1篇)

基础研究 (1篇)

Medicinal research reviews IF 13.6 2026-11 PMID: 42272247
Voltage-gated ion channels play important physiological roles by regulating the electrical activity of a range of different cell types through maintaining the gradients of different ions. Among these, voltage-gated calcium channels mediate various cellular activities, including muscle contraction, gene regulation, and neurotransmission. A sub-type of calcium channels are T-type calcium channels that play a critical role in regulating neuronal excitability and are essential for neurodevelopment. Mutations in genes encoding T-type calcium channels, including CACNA1G, CACNA1H, and CACNA1I can lead to altered channel activity, resulting in disrupted calcium entry, calcium signaling, synaptic plasticity, and neuronal differentiation. They have been implicated in a range of neurodevelopmental disorders, such as epilepsy, autism spectrum disorder, and intellectual disability. There has been considerable interest in developing blockers against T-type calcium channels to restore the dysregulated calcium homeostasis in neuronal disorders. T-type calcium channel blockers, originally developed for cardiovascular diseases, have emerged as potential therapeutic agents for neurodevelopmental disorders by targeting aberrant calcium signaling. This review explores the molecular mechanisms underlying T-type channel dysfunction caused by genetic mutations and evaluates the current evidence on the therapeutic efficacy of T-type calcium channel blockers in neurodevelopmental disorders. Although preclinical studies show promise, translating these findings into effective clinical therapies presents significant challenges. Future research focusing on optimizing blocker specificity and understanding the broader impact of channel modulation is necessary for developing targeted treatments for neurological pathologies.
中文摘要:电压门控离子通道通过维持不同离子的梯度,调节多种细胞类型的电活动,具有重要生理作用。电压门控钙通道介导肌肉收缩、基因调控和神经传递等多种细胞活动。T型钙通道是钙通道的一个亚型,在调节神经元兴奋性中起关键作用,并对神经发育必不可少。编码T型钙通道的基因CACNA1G、CACNA1H和CACNA1I发生突变可导致通道活性改变,进而破坏钙内流、钙信号、突触可塑性和神经元分化。这些通道与癫痫、孤独症谱系障碍和智力障碍等一系列神经发育障碍有关。开发T型钙通道阻滞剂以恢复神经疾病中失调的钙稳态受到广泛关注。最初为心血管疾病开发的T型钙通道阻滞剂通过靶向异常钙信号,已成为神经发育障碍的潜在治疗药物。基因突变导致T型通道功能异常的分子机制,以及T型钙通道阻滞剂在神经发育障碍中治疗疗效的现有证据,在此一并评估。尽管临床前研究显示出希望,将这些发现转化为有效的临床治疗仍面临重大挑战。未来研究需聚焦优化阻滞剂特异性并理解通道调控的更广泛影响,以开发针对神经病理的靶向治疗。

39先天性巨结肠 (1篇)

基础研究 (1篇)

Gastroenterology IF 29.7 2026-11 PMID: 42250889
Hirschsprung disease (HSCR) is a congenital enteric neuropathy with distal aganglionosis and dysmotility. Germline mutations explain many familial cases, but most sporadic cases lack a molecular explanation. We sought noncanonical mechanisms and blood-accessible biomarkers. We performed RNA-sequencing (RNA-seq) on paired aganglionic and ganglionic colon biopsy specimens from 103 sporadic HSCR patients, with control colon samples (n = 22). Blood whole-genome sequencing (WGS) was available for 41 patients with RNA-seq profiles. We assessed PR/SET domain 9 (PRDM9) in patient tissues, perturbed prdm9 in zebrafish and mice, and performed mechanistic profiling in PRDM9-knockout human-induced pluripotent stem cell-derived enteric neural crest cells. Mosaic promoter deletions (MPDs) were called from colon WGS (n = 30; matched blood, n = 27) and summarized as a blood MPD score in blood WGS cohorts (discovery: 89 HSCR and 43 controls; validation: 165 HSCR and 42 controls), alone and combined with the polygenic risk score. A predominant subgroup (79.6% [82 of 103]) showed coordinated repression of neurogenesis programs. Promoter motif enrichment implicated PRDM9, which we localized to normal enteric nervous system but found down-regulated in aganglionic tissue with promoter hypermethylation. Prdm9 perturbation reduced HuC/D-positive differentiated enteric neurons and impaired motility in zebrafish and mice. In enteric neural crest cells, PRDM9 loss redistributed DNA double-strand breaks toward promoters and enhancers, generated MPDs at neurogenesis loci, and correlated with transcriptional repression and impaired neuronal differentiation. Blood MPD score discriminated HSCR from controls in a discovery cohort (area under the receiver operating characteristic curve [AUROC], 0.78) and an independent validation cohort (AUROC, 0.82), and improved with polygenic risk score (AUROC, 0.89 and 0.91, respectively). PRDM9 deficiency links ectopic DNA breaks to MPDs and impaired enteric neuronal differentiation in a predominant molecular subgroup within sporadic HSCR and enables complementary, noninvasive molecular stratification.
中文摘要:先天性巨结肠(HSCR)是一种先天性肠神经系统病变,表现为远端无神经节细胞和肠动力障碍。胚系突变可解释许多家族性病例,但多数散发病例缺乏分子层面的解释。研究寻找非经典机制与可经血液检测的生物标志物。对103例散发性HSCR患者配对的無神经节细胞与有神经节细胞结肠活检标本行RNA测序(RNA-seq),另设对照结肠样本(n=22)。其中41例有RNA-seq图谱的患者具备血液全基因组测序(WGS)数据。在患者组织中检测PR/SET结构域9(PRDM9),在斑马鱼和小鼠中干扰prdm9,并在PRDM9敲除的人诱导多能干细胞来源肠神经嵴细胞中做机制分析。嵌合启动子缺失(MPD)由结肠WGS判定(n=30,配对血液n=27),在血液WGS队列(发现队列:89例HSCR与43例对照;验证队列:165例HSCR与42例对照)中汇总为血液MPD评分,分别单独及联合多基因风险评分进行分析。一个占主导的亚组(79.6%,103例中82例)显示神经发生程序的协同抑制。启动子基序富集提示PRDM9参与,该蛋白定位于正常肠神经系统,在无神经节细胞组织中表达下调并伴启动子高甲基化。干扰Prdm9使斑马鱼和小鼠HuC/D阳性的分化肠神经元减少、运动功能受损。在肠神经嵴细胞中,PRDM9缺失使DNA双链断裂重新分布至启动子和增强子,在神经发生位点产生MPD,并与转录抑制及神经元分化受损相关。血液MPD评分可在发现队列(受试者工作特征曲线下面积AUROC 0.78)与独立验证队列(AUROC 0.82)中区分HSCR与对照,联合多基因风险评分后进一步提高(分别为0.89和0.91)。PRDM9缺陷将异位DNA断裂与MPD及肠神经元分化受损联系起来,存在于散发性HSCR中占主导的分子亚组,并支持互补的无创分子分层。

40神经调控 (1篇)

基础研究 (1篇)

Nature protocols IF 18.4 2026-11 PMID: 42204340
Neuromodulation approaches can target specific brain functional circuits to treat various brain disorders, and resting-state functional magnetic resonance imaging is increasingly being used to map functional circuits in individual patients for target localization. However, this strategy faces three major hurdles for clinical translation: time-intensive resting-state functional magnetic resonance imaging processing, insufficient robustness for clinical use and a lack of automated targeting solutions. Here we cover the use of a generic, rapid, robust and automated platform for personalized functional circuit-guided target planning across different neuromodulation techniques, termed Unified Platform for Neuromodulation with Individualized Target Estimation (UNITE). UNITE is computationally efficiency and robust and uses DeepPrep, a recently developed end-to-end preprocessing pipeline that achieves a tenfold speedup and improved robustness compared with state-of-the-art clinical pipeline. Using DeepPrep's preprocessed data, UNITE maps functional circuits and localizes personalized targets through automated targeting algorithms. Currently, UNITE offers three built-in transcranial magnetic stimulation-targeting algorithms for post-stroke functional rehabilitation and one focused ultrasound stimulation-targeting algorithm for Parkinson's disease. Notably, it is designed to be adapted for other brain disorders and neuromodulation applications. To ensure quality and usability, UNITE generates a data quality control report and a visual verification report of the identified targets, with target coordinates exported in multiple formats for compatibility with different neuronavigation systems. Overall, this platform enables personalized neuromodulation target localization within 30 min on a local graphics processing unit-equipped workstation. A basic level of computer science proficiency, along with neuroimaging experience, is sufficient for its use.
中文摘要:神经调控方法可靶向特定脑功能环路以治疗多种脑部疾病,静息态功能磁共振成像正越来越多地用于在个体患者中绘制功能环路并定位靶点。该策略在临床转化中面临三大障碍:静息态功能磁共振成像处理耗时、临床使用稳健性不足、缺乏自动化靶点规划方案。本文介绍一个通用、快速、稳健且自动化的平台,用于跨不同神经调控技术开展个体化功能环路引导的靶点规划,称为UNITE(Unified Platform for Neuromodulation with Individualized Target Estimation,个体化靶点估计神经调控统一平台)。UNITE计算高效且稳健,采用新近开发的端到端预处理流程DeepPrep,与当前先进的临床流程相比实现十倍加速并提高稳健性。利用DeepPrep预处理后的数据,UNITE通过自动化靶点算法绘制功能环路并定位个体化靶点。目前UNITE内置三种经颅磁刺激靶点算法,用于卒中后功能康复,并内置一种聚焦超声刺激靶点算法,用于帕金森病。该平台设计上可适配其他脑部疾病与神经调控应用。为保证质量与可用性,UNITE生成数据质量控制报告和所识别靶点的可视化验证报告,靶点坐标以多种格式导出,以兼容不同神经导航系统。整体上,该平台可在配备图形处理器的本地工作站上于30分钟内完成个体化神经调控靶点定位。使用者具备基础计算机科学能力并具有神经影像经验即可使用。

41头痛与疼痛 (1篇)

临床研究 (1篇)

Neurology and therapy IF 4.7 2026-10-30 PMID: 42961629
Migraine is a highly prevalent and disabling neurological disorder that imposes a substantial health, social, and economic burden, including significant impacts on workforce participation and productivity. Despite advances in treatment and increased recognition of its burden, migraine remains underdiagnosed, undertreated, and insufficiently prioritized in many health systems. Barriers across the patient journey continue to limit timely diagnosis, effective management, and equitable access to care. This Global Migraine narrative review and expert perspective seek to promote international alignment on the burden of migraine and provide evidence-informed guidance to improve care, workplace support, and policy development worldwide. A two-stage methodology was applied. First, a structured non-systematic literature review synthesized evidence on migraine epidemiology, socioeconomic burden, quality of life, workplace productivity, policies, access to care, and the patient journey. Second, findings were validated and refined through consultations with international experts representing diverse geographies, healthcare systems, and levels of migraine policy development. Two virtual expert panel meetings were held in December 2025 and March 2026, respectively, supported by offline reviews and follow-up consultations. Six key areas of unmet need were identified: diagnosis and disease recognition; knowledge and education; social and psychological impact; access to care; availability and affordability; and treatment quality. Migraine remains largely absent from national health strategies, contributing to fragmented care and inadequate resource allocation. The call-to-action outlines priority recommendations, key stakeholders, and implementation considerations to address these gaps across different health system contexts. Migraine should be recognized as a public health and economic priority. Coordinated strategies are needed to improve diagnosis, care pathways, treatment access, and productivity outcomes, while strengthening global collaboration and policy alignment.
中文摘要:偏头痛是一种患病率高、致残性强的神经系统疾病,带来沉重的健康、社会和经济负担,并显著影响劳动参与和生产力。尽管治疗取得进展,其负担也受到更多关注,偏头痛在许多卫生系统中仍存在诊断不足、治疗不足和优先级不够的问题。患者旅程中的多重障碍持续限制及时诊断、有效管理和公平获得照护。这项全球偏头痛叙事综述与专家观点旨在促进国际社会对偏头痛负担形成一致认识,并提供循证指导,以改善全球照护、工作场所支持和政策制定。研究采用两阶段方法。第一阶段为结构化的非系统性文献综述,汇总偏头痛流行病学、社会经济负担、生活质量、工作场所生产力、政策、照护可及性和患者旅程方面的证据。第二阶段通过咨询来自不同地区、不同卫生体系和不同偏头痛政策发展水平的国际专家,对结果进行验证和完善。两次线上专家小组会议分别于2025年12月和2026年3月举行,并以线下审阅和后续咨询提供支持。研究识别出六个关键未满足需求领域:诊断与疾病识别;知识与教育;社会和心理影响;照护可及性;可获得性与可负担性;治疗质量。偏头痛仍基本未纳入国家卫生战略,导致照护碎片化和资源配置不足。行动呼吁提出优先建议、关键利益相关方及实施考虑,以在不同卫生体系背景下弥补这些缺口。偏头痛应被视为公共卫生和经济优先事项。需要协调策略改善诊断、照护路径、治疗可及性和生产力结局,同时加强全球合作和政策协同。